0001104659-21-101081.txt : 20210806 0001104659-21-101081.hdr.sgml : 20210806 20210806070058 ACCESSION NUMBER: 0001104659-21-101081 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 68 CONFORMED PERIOD OF REPORT: 20210630 FILED AS OF DATE: 20210806 DATE AS OF CHANGE: 20210806 FILER: COMPANY DATA: COMPANY CONFORMED NAME: IRADIMED CORP CENTRAL INDEX KEY: 0001325618 STANDARD INDUSTRIAL CLASSIFICATION: SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841] IRS NUMBER: 731408526 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 001-36534 FILM NUMBER: 211150502 BUSINESS ADDRESS: STREET 1: 1025 WILLA SPRINGS DR. CITY: WINTER SPRINGS STATE: FL ZIP: 32708 BUSINESS PHONE: 4076778022 MAIL ADDRESS: STREET 1: 1025 WILLA SPRINGS DR. CITY: WINTER SPRINGS STATE: FL ZIP: 32708 10-Q 1 irmd-20210630x10q.htm FORM 10Q

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10-Q

⌧

QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the Quarterly Period Ended June 30, 2021

◻

TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from to

Commission File No.: 001-36534

IRADIMED CORPORATION

(Exact name of Registrant as specified in its charter)


Delaware		73-1408526
(State or other jurisdiction of incorporation or organization)		(I.R.S. Employer Identification Number

1025 Willa Springs Drive Winter Springs, Florida		32708
(Address of principal executive offices)		(Zip Code)

(407) 677-8022

(Registrant’s telephone number, including area code)

N/A

(Former Name, former address and former fiscal year, if changed since last report)

Securities registered pursuant to Section 12(b) of the Act:


Title of each class:	Trading Symbol	Name of each exchange on which registered:
Common stock, par value $0.0001	IRMD	NASDAQ Capital Market

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐

Indicate by check mark whether the registrant has submitted electronically pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒ No ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer or a smaller reporting company. See definitions of “large accelerated filer,” “accelerated filer” and “smaller reporting company” as defined in Rule 12b-2 of the Exchange Act.


Large accelerated filer ☐		Accelerated filer ☐
Non-accelerated filer ☒		Smaller reporting company ☒
		Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. Yes ☐ No ☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No ☒

The registrant had 12,318,027 shares of common stock, par value $0.0001 per share, outstanding as of August 1, 2021.

Table of Contents

IRADIMED CORPORATION

Table of Contents


			Page
Cautionary Note Regarding Forward-Looking Statements			3

Part I	Financial Information		5

	Item 1	Condensed Financial Statements	5

		(a) Condensed Balance Sheets as of June 30, 2021 (Unaudited) and December 31, 2020	5

		(b) Condensed Statements of Operations for the Three and Six Months Ended June 30, 2021 and 2020 (Unaudited)	6

		(c) Condensed Statements of Comprehensive Income for the Three and Six Months Ended June 30, 2021 and 2020 (Unaudited)	7

		(d) Condensed Statements of Stockholders’ Equity for the Three and Six Months Ended June 30, 2021 and 2020 (Unaudited)	8

		(e) Condensed Statements of Cash Flows for the Six Months Ended June 30, 2021 and 2020 (Unaudited)	9

		(f) Notes to Unaudited Condensed Financial Statements	10

	Item 2	Management’s Discussion and Analysis of Financial Condition and Results of Operations	19

	Item 3	Quantitative and Qualitative Disclosures About Market Risk	26

	Item 4	Controls and Procedures	26

Part II	Other Information		27

	Item 1	Legal Proceedings	27

	Item 1A	Risk Factors	27

	Item 2	Unregistered Sale of Equity Securities and Use of Proceeds	27

	Item 3	Default Upon Senior Securities	27

	Item 4	Mine Safety Disclosures	27

	Item 5	Other Information	27

	Item 6	Exhibits	28

Signatures			29

Table of Contents

CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS

This Quarterly Report on Form 10-Q contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended (the “Securities Act”), and Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), that involve substantial risks and uncertainties. The forward-looking statements are contained principally in the sections entitled “Business,” “Risk Factors” and “Management’s Discussion and Analysis and Results of Operations.” In some cases, you can identify forward-looking statements by the following words: “may,” “will,” “could,” “would,” “should,” “expect,” “intend,” “plan,” “anticipate,” “believe,” “estimate,” “predict,” “project,” “potential,” “continue,” “ongoing” or the negative of these terms or other comparable terminology, although not all forward-looking statements contain these words. These statements relate to future events or our future financial performance or condition and involve known and unknown risks, uncertainties and other factors that could cause our actual results, levels of activity, performance or achievement to differ materially from those expressed or implied by these forward-looking statements. These forward-looking statements include, but are not limited to, statements about:

●

our ability to respond and adapt to unexpected hospital, legal and regulatory changes resulting from the ongoing COVID-19 pandemic, such as changes in hospital treatment and financial practices, shelter-in-place orders, travel, social distancing and quarantine policies, curtailment of trade, and other business restrictions affecting our ability to assemble and sell our products;

●

our ability to receive 510(k) clearance for our products and product candidates, complete inspections conducted by the FDA or other regulatory bodies resulting in favorable outcomes, additional actions by or requests from the U.S. Food & Drug Administration (“FDA”), including a request to cease domestic distribution of products, or other regulatory bodies and unanticipated costs or delays associated with the resolution of these matters;

●

the timing and likelihood of regulatory approvals or clearances from the FDA or other regulatory bodies and regulatory actions on our product candidates and product marketing activities;

●

unexpected costs, expenses and diversion of management attention resulting from actions or requests posed to us by the FDA or other regulatory bodies;

●

our primary reliance on a limited number of products;

●

our ability to retain the continued service of our key professionals and to identify, hire and retain additional qualified professionals;

●

our expectations regarding the sales and marketing of our products, product candidates and services;

●

our expectations regarding the integrity of our supply chain for our products;

●

the potential for adverse application of environmental, health and safety and other laws and regulations of any jurisdiction on our operations;

●

our expectations for market acceptance of our new products;

●

the potential for our marketed products to be withdrawn due to recalls, patient adverse events or deaths;

●

our ability to establish and maintain intellectual property on our products and our ability to successfully defend these in cases of infringement;

●

the implementation of our business strategies;

●

the potential for exposure to product liability claims;

●

our financial performance expectations and interpretations thereof by securities analysts and investors;

●

our ability to compete in the development and marketing of our products and product candidates with other companies in our industry;

Table of Contents

●

difficulties or delays in the development, production, manufacturing and marketing of new or existing products and services, including difficulties or delays associated with obtaining requisite regulatory approvals or clearances associated with those activities;

●

changes in laws and regulations or in the interpretation or application of laws or regulations, as well as possible failures to comply with applicable laws or regulations as a result of possible misinterpretations or misapplications;

●

cost-containment efforts of our customers, purchasing groups, third-party payers and governmental organizations;

●

costs associated with protecting our trade secrets and enforcing our patent, copyright and trademark rights, and successful challenges to the validity of our patents, copyrights or trademarks;

●

actions of regulatory bodies and other government authorities, including the FDA and foreign counterparts, that could delay, limit or suspend product development, manufacturing or sales or result in recalls, seizures, consent decrees, injunctions and monetary sanctions;

●

costs or claims resulting from potential errors or defects in our manufacturing that may injure persons or damage property or operations, including costs from remediation efforts or recalls;

●

the results, consequences, effects or timing of any commercial disputes, patent infringement claims or other legal proceedings or any government investigations;

●

interruption in our ability to manufacture our products or an inability to obtain key components or raw materials or increased costs in such key components or raw materials;

●

uncertainties in our industry due to the effects of government-driven or mandated healthcare reform;

●

competitive pressures in the markets in which we operate;

●

the loss of, or default by, one or more key customers or suppliers; and

●

unfavorable changes to the terms of key customer or supplier relationships.

Forward-looking statements are not guarantees of future performance and are subject to substantial risks and uncertainties that could cause the actual results to differ materially from those that we predicted in the forward-looking statements. Investors should carefully review the information contained under the caption "Risk Factors" contained in Part II, Item 1A for a description of risks and uncertainties that could cause actual results to differ from those that we predicted. All forward-looking statements are based on information available to us on the date hereof, and we assume no obligation to update forward-looking statements, except as required by Federal Securities laws.

Unless expressly indicated or the context requires otherwise, references in this Quarterly Report to “IRADIMED,” the “Company,” “we,” “our,” and “us” refer to IRADIMED CORPORATION.

Table of Contents

PART I. FINANCIAL INFORMATION

Item 1. Condensed Financial Statements

IRADIMED CORPORATION

CONDENSED BALANCE SHEETS


	June 30,		December 31,
	2021		2020
	(unaudited)
ASSETS
Current assets:
Cash and cash equivalents	$	55,159,661	$	50,068,728
Investments		948,958		1,909,368
Accounts receivable, net of allowance for doubtful accounts of $45,578 as of June 30, 2021 and $46,484 as of December 31, 2020		3,884,704		4,574,932
Inventory, net		4,468,115		3,933,987
Prepaid expenses and other current assets		1,230,033		771,666
Prepaid income taxes		2,945,799		2,477,211
Total current assets		68,637,270		63,735,892
Property and equipment, net		2,092,224		2,120,148
Intangible assets, net		1,010,073		960,885
Operating lease right-of-use asset, net		2,614,351		2,715,030
Deferred income taxes, net		992,996		1,272,672
Other assets		232,685		261,993
Total assets	$	75,579,599	$	71,066,620
LIABILITIES AND STOCKHOLDERS’ EQUITY
Current liabilities:
Accounts payable	$	667,882	$	657,054
Accrued payroll and benefits		2,010,074		1,714,782
Other accrued taxes		122,452		103,981
Warranty reserve		108,528		90,054
Deferred revenue		2,973,334		1,949,259
Current portion of operating lease liability		268,488		255,698
Other current liabilities		146,435		146,435
Total current liabilities		6,297,193		4,917,263
Deferred revenue		2,034,429		2,305,413
Operating lease liability, less current portion		2,345,863		2,459,332
Total liabilities		10,677,485		9,682,008
Stockholders’ equity:
Common stock; $0.0001 par value; 31,500,000 shares authorized; 12,317,036 shares issued and outstanding as of June 30, 2021 and 12,308,432 shares issued and outstanding as of December 31, 2020		1,232		1,231
Additional paid-in capital		24,350,709		23,676,843
Retained earnings		40,525,994		37,669,451
Accumulated other comprehensive income		24,179		37,087
Total stockholders’ equity		64,902,114		61,384,612
Total liabilities and stockholders’ equity	$	75,579,599	$	71,066,620

See accompanying notes to unaudited condensed financial statements.

Table of Contents

IRADIMED CORPORATION

CONDENSED STATEMENTS OF OPERATIONS

(Unaudited)


	For the Three Months Ended					For the Six Months Ended
	June 30,					June 30,
	2021		2020		2021		2020
Revenue	$	9,810,423	$	6,794,692	$	19,034,419	$	15,472,233
Cost of revenue		2,478,122		1,864,587		4,639,802		4,078,317
Gross profit		7,332,301		4,930,105		14,394,617		11,393,916
Operating expenses:
General and administrative		2,564,619		5,002,427		4,994,988		7,865,154
Sales and marketing		2,469,777		2,374,134		4,848,901		4,807,701
Research and development		453,679		482,654		929,496		912,936
Total operating expenses		5,488,075		7,859,215		10,773,385		13,585,791
Income (loss) from operations		1,844,226		(2,929,110)		3,621,232		(2,191,875)
Other income, net		13,195		17,852		7,532		116,354
Income (loss) before provision for income taxes		1,857,421		(2,911,258)		3,628,764		(2,075,521)
Provision for income tax expense (benefit)		387,727		(798,988)		772,221		(1,732,462)
Net income (loss)	$	1,469,694	$	(2,112,270)	$	2,856,543	$	(343,059)
Net income (loss) per share:
Basic	$	0.12	$	(0.17)	$	0.23	$	(0.03)
Diluted	$	0.12	$	(0.17)	$	0.23	$	(0.03)
Weighted average shares outstanding:
Basic		12,313,563		12,076,399		12,312,078		11,983,913
Diluted		12,554,828		12,076,399		12,539,483		11,983,913

See accompanying notes to unaudited condensed financial statements.

Table of Contents

IRADIMED CORPORATION

CONDENSED STATEMENTS OF COMPREHENSIVE INCOME

(Unaudited)


	For the Three Months Ended				For the Six Months Ended
	June 30,				June 30,
	2021		2020		2021		2020
Net income (loss)	$	1,469,694	$	(2,112,270)	$	2,856,543	$	(343,059)
Other comprehensive (loss) income:
Change in fair value of available-for-sale securities, net of tax expense (benefit) of $5,772 and $4,227 for the three months ended June 30, 2021 and 2020, respectively, and $(7,331) and $7,669 for the six months ended June 30, 2021 and 2020, respectively		1,790		19,797		(3,079)		30,230
Realized gain on available-for-sale securities reclassified to net income, net of tax expense of $3,176 and $2,199 for the three months ended June 30, 2021 and 2020, respectively, and $3,176 and $2,199 for the six months ended June 30, 2021 and 2020, respectively		(9,829)		(6,662)		(9,829)		(6,662)
Other comprehensive (loss) income		(8,039)		13,135		(12,908)		23,568
Comprehensive income (loss)	$	1,461,655	$	(2,099,135)	$	2,843,635	$	(319,491)

See accompanying notes to unaudited condensed financial statements.

Table of Contents

IRADIMED CORPORATION

CONDENSED STATEMENTS OF STOCKHOLDERS’ EQUITY

(Unaudited)


								Accumulated
				Additional				Other
	Common Stock			Paid-in		Retained		Comprehensive		Stockholders’
	Shares	Amount		Capital		Earnings		Income		Equity
Balances, December 31, 2020	12,308,432	$	1,231	$	23,676,843	$	37,669,451	$	37,087	$	61,384,612
Net income	—		—		—		1,386,849		—		1,386,849
Other comprehensive loss	—		—		—		—		(4,869)		(4,869)
Stock-based compensation expense	—		—		347,741		—		—		347,741
Net share settlement of restricted stock units	3,502		—		(38,707)		—		—		(38,707)
Exercise of stock options	250		—		2,460		—		—		2,460
Balances, March 31, 2021	12,312,184	$	1,231	$	23,988,337	$	39,056,300	$	32,218	$	63,078,086
Net income	—		—		—		1,469,694		—		1,469,694
Other comprehensive loss	—		—		—		—		(8,039)		(8,039)
Stock-based compensation expense	—		—		358,012		—		—		358,012
Net share settlement of restricted stock units	2,727		1		(15,875)		—		—		(15,874)
Exercise of stock options	2,125		—		20,235		—		—		20,235
Balances, June 30, 2021	12,317,036	$	1,232	$	24,350,709	$	40,525,994	$	24,179	$	64,902,114


								Accumulated
				Additional				Other
	Common Stock			Paid-in		Retained		Comprehensive		Stockholders’
	Shares	Amount		Capital		Earnings		Income		Equity
Balances, December 31, 2019	11,765,875	$	1,177	$	19,192,394	$	36,300,450	$	30,374	$	55,524,395
Net income	—		—		—		1,769,211		—		1,769,211
Other comprehensive income	—		—		—		—		10,433		10,433
Stock-based compensation expense	—		—		568,958		—		—		568,958
Net share settlement of restricted stock units	14,521		1		(133,873)		—		—		(133,872)
Exercise of stock options	190,541		19		322,160		—		—		322,179
Balances, March 31, 2020	11,970,937	$	1,197	$	19,949,639	$	38,069,661	$	40,807	$	58,061,304
Net loss	—		—		—		(2,112,270)		—		(2,112,270)
Other comprehensive income	—		—		—		—		13,135		13,135
Stock-based compensation expense	—		—		2,658,632		—		—		2,658,632
Net share settlement of restricted stock units	76,381		8		(725,393)		—		—		(725,385)
Exercise of stock options	150,519		15		468,795		—		—		468,810
Balances, June 30, 2020	12,197,837	$	1,220	$	22,351,673	$	35,957,391	$	53,942	$	58,364,226

See accompanying notes to unaudited condensed financial statements.

Table of Contents

IRADIMED CORPORATION

CONDENSED STATEMENTS OF CASH FLOWS

(Unaudited)


	Six Months Ended
	June 30,
	2021		2020
Operating activities:
Net income (loss)	$	2,856,543	$	(343,059)
Adjustments to reconcile net income (loss) to net cash provided by operating activities:
Change in allowance for doubtful accounts		(879)		40,029
Change in provision for excess and obsolete inventory		52,978		35,376
Depreciation and amortization		680,091		668,823
Stock-based compensation		705,753		3,227,590
Deferred income taxes, net		290,183		(834,179)
Gain on maturities of investments		(13,005)		(8,861)
Changes in operating assets and liabilities:
Accounts receivable		691,107		2,747,675
Inventory		(493,488)		(1,360,074)
Prepaid expenses and other current assets		(1,473,503)		(674,047)
Other assets		30,425		(26,402)
Accounts payable		(79,060)		(319,583)
Accrued payroll and benefits		295,292		(472,705)
Other accrued taxes		18,471		(88,451)
Warranty reserve		18,474		6,611
Deferred revenue		1,402,978		255,298
Other current liability		—		31,141
Prepaid income taxes		(468,588)		(897,951)
Net cash provided by operating activities		4,513,772		1,987,231
Investing activities:
Proceeds from maturity of investments		950,000		480,000
Purchases of property and equipment		(240,543)		(300,558)
Capitalized intangible assets		(100,410)		(122,534)
Net cash provided by investing activities		609,047		56,908
Financing activities:
Proceeds from exercises of stock options		22,695		790,989
Taxes paid related to the net share settlement of equity awards		(54,581)		(859,257)
Net cash used in financing activities		(31,886)		(68,268)
Net increase in cash and cash equivalents		5,090,933		1,975,871
Cash and cash equivalents, beginning of period		50,068,728		43,481,781
Cash and cash equivalents, end of period	$	55,159,661	$	45,457,652
Supplemental disclosure of cash flow information:
Cash paid for income taxes	$	963,722	$	—
Right-of-use asset recognized in exchange for a new lease obligation		27,713		—
Operating and short-term lease payments recorded within cash flow provided by operating activities	$	238,982	$	214,877

See accompanying notes to unaudited condensed financial statements.

Table of Contents

IRADIMED CORPORATION

Notes to Unaudited Condensed Financial Statements

1 — Basis of Presentation

The accompanying interim condensed financial statements of IRADIMED CORPORATION (“IRADIMED”, the “Company”, “we”, “our”) have been prepared pursuant to the rules and regulations of the SEC. Certain information and footnote disclosures normally presented in annual financial statements prepared in accordance with U.S. generally accepted accounting principles ("GAAP") have been condensed or omitted pursuant to such rules and regulations. The interim financial information is unaudited, but reflects all normal adjustments that are, in the opinion of management, necessary for the fair presentation of our financial position, results of operations and cash flows for the interim periods presented. Operating results for the three and six months ended June 30, 2021 are not necessarily indicative of the results that may be expected for the year ending December 31, 2021.

These accompanying interim condensed financial statements should be read with the financial statements and related footnotes to financial statements included in our Annual Report on Form 10-K for the year ended December 31, 2020. The accounting policies followed in the preparation of these interim condensed financial statements, except as described in Note 1, are consistent in all material respects with those described in Note 1 of our Form 10-K.

We operate in one reportable segment which is the development, manufacture and sale of MRI compatible medical devices, related accessories, disposables and service for use by hospitals and acute care facilities during MRI procedures.

Certain Significant Risks and Uncertainties

We market our products to end users in the U.S. and to distributors internationally. Sales to end users in the U.S. are generally made on open credit terms. Management maintains an allowance for potential credit losses.

We have deposited our cash and cash equivalents with various financial institutions. Our cash and cash equivalents balances exceed federally insured limits throughout the year. We have not incurred any losses related to these balances.

Our products require clearance from the Food and Drug Administration and international regulatory agencies prior to commercialized sales. Our future products may not receive required approvals. If we were denied such approvals, or if such approvals were revoked or delayed or if we were unable to timely renew certain approvals for existing products, it would have a materially adverse impact on our business, results of operations and financial condition.

Certain key components of our products essential to their functionality are sole-sourced. Any disruption in the availability of these components would have a materially adverse impact on our business, results of operations and financial condition.

COVID-19 Considerations

The COVID-19 pandemic continues to cause disruption in global supply and distribution channels and dramatically changed the way companies do business. From the beginning of this global health crisis, our first priority has been the safety and well-being of our employees.

We continue to monitor the developments associated with the COVID-19 pandemic and its effects on our employees, customers, supply chain and distribution channels. The ongoing impact of the pandemic depends on a number of factors including the severity and duration of the pandemic and the extent and severity of the impact on our customers, which is uncertain and unpredictable. Our future results of operations and cash flows may suffer adverse effects from delays in payments on outstanding accounts receivable, potential manufacturing, distribution and supply chain disruptions, uncertain demand for our products, and effects of any actions we may take to address financial and operational challenges our customers may face. Our future results will be heavily determined by timely rollout of the vaccines, effectiveness of the vaccines, the duration of the pandemic, its geographic spread, further business disruptions and the overall impact on the global economy. Other risks and uncertainties that we face include, but are not limited to:

●

postponement or cancellation of MRI medical procedures and their uncertain return which adversely impacts our business;

Table of Contents

●

disruptions in our supply chain that may limit our ability to procure materials necessary to manufacture our products;

●

potential temporary or prolonged closure of our office and production facility;

●

the health of our employees and ability to meet staffing needs;

●

potential new or continued governmental actions that may limit employees’ ability to work;

●

civil unrest relating to government, corporate and societal responses to the pandemic;

●

volatility in economic conditions and the financial markets, and

●

other unanticipated effects that remain unknown.

We are actively managing our response to the COVID-19 pandemic and working with our customers, distributors, vendors, and suppliers and assessing the potential effects to our financial position, results of operations and cash flows. As of the date of the issuance of these financial statements, the extent to which COVID-19 may materially impact our financial condition, liquidity, or results of operations in future periods remains uncertain.

Recent Accounting Pronouncements

Recently Issued Accounting Pronouncements to be Implemented

In June 2016, the Financial Accounting Standards Board (“FASB”) issued Accounting Standard Update (“ASU”) 2016-13, Financial Instruments - Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments, which requires the Company to measure and recognize expected credit losses for financial assets held and not accounted for at fair value through net income. In November 2018, April 2019 and May 2019, the FASB issued ASU 2018-19, Codification Improvements to Topic 326, Financial Instruments - Credit Losses, ASU 2019-04, Codification Improvements to Topic 326, Financial Instruments - Credit Losses and ASU 2019-05, Financial Instruments - Credit Losses (Topic 326): Targeted Transition Relief, which provided additional implementation guidance on ASU 2016-03. The previously mentioned ASUs are effective for fiscal years beginning after December 15, 2022, with early adoption permitted. We do not expect the adoption of these ASUs to have a material impact on our financial condition, results of operations or cash flows.

Accounting Pronouncements Implemented in 2021

In December 2019, the FASB issued ASU No. 2019-12, Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes. ASU 2019-12 will be effective for fiscal years, and interim periods within those years, beginning after December 15, 2020. We adopted ASU 2019-12 on January 1, 2021, and the adoption did not have an impact on our financial condition, results of operations or cash flows.

Table of Contents

2 — Revenue Recognition

Disaggregation of Revenue

We disaggregate revenue from contracts with customers by geographic region and revenue type as we believe it best depicts the nature, amount, timing and uncertainty of our revenue and cash flow.

Revenue information by geographic region is as follows:


	Three Months Ended				Six Months Ended
	June 30,				June 30,
	2021		2020		2021		2020

	(unaudited)				(unaudited)
United States	$	8,043,156	$	4,642,916	$	15,315,986	$	10,965,022
International		1,767,267		2,151,776		3,718,433		4,507,211
Total revenue	$	9,810,423	$	6,794,692	$	19,034,419	$	15,472,233

Revenue information by type is as follows:


	Three Months Ended				Six Months Ended
	June 30,				June 30,
	2021		2020		2021		2020

	(unaudited)				(unaudited)
Devices:
MRI Compatible IV Infusion Pump Systems	$	2,456,767	$	1,875,159	$	5,960,114	$	4,539,993
MRI Compatible Patient Vital Signs Monitoring Systems		3,377,719		1,927,473		5,981,549		4,546,988
Total Devices revenue		5,834,486		3,802,632		11,941,663		9,086,981
Disposables, services and other		3,490,969		2,535,548		6,126,435		5,467,449
Amortization of extended warranty agreements		484,968		456,512		966,321		917,803
Total revenue	$	9,810,423	$	6,794,692	$	19,034,419	$	15,472,233

Contract Liabilities

Our contract liabilities consist of:


	June 30,		December 31,
	2021		2020
	(unaudited)
Advance payments from customers	$	484,354	$	85,590
Shipments in-transit		649,887		35,013
Extended warranty agreements		3,873,522		4,134,069
Total	$	5,007,763	$	4,254,672

Changes in the contract liabilities during the periods presented are as follows:


	Deferred
	Revenue
Contract liabilities, December 31, 2020	$	4,254,672
Increases due to cash received from customers		2,426,575
Decreases due to recognition of revenue		(1,673,484)
Contract liabilities, June 30, 2021	$	5,007,763

Table of Contents


	Deferred
	Revenue
Contract liabilities, December 31, 2019	$	4,301,887
Increases due to cash received from customers		1,236,658
Decreases due to recognition of revenue		(1,048,380)
Contract liabilities, June 30, 2020	$	4,490,165

Capitalized Contract Costs

Our capitalized contract costs totaled $353,942 and $384,367 as of June 30, 2021 and December 31, 2020, respectively.

3 — Basic and Diluted Net Income per Share

Basic net income per share is based upon the weighted-average number of common shares outstanding during the period. Diluted net income per share reflects the potential dilution that could occur if securities or other contracts to issue common stock were exercised or converted into common stock. Stock options and restricted stock units granted by us represent the only dilutive effect reflected in diluted weighted-average shares outstanding.

The following table presents the computation of basic and diluted net income per share:


	Three Months Ended June 30,				Six Months Ended June 30,
	2021		2020		2021		2020

	(unaudited)				(unaudited)
Net income (loss)	$	1,469,694	$	(2,112,270)	$	2,856,543	$	(343,059)
Weighted-average shares outstanding — Basic		12,313,563		12,076,399		12,312,078		11,983,913
Effect of dilutive securities:
Stock options		194,419		—		192,347		—
Restricted stock units		46,846		—		35,058		—
Weighted-average shares outstanding — Diluted		12,554,828		12,076,399		12,539,483		11,983,913
Basic net income (loss) per share	$	0.12	$	(0.17)	$	0.23	$	(0.03)
Diluted net income (loss) per share	$	0.12	$	(0.17)	$	0.23	$	(0.03)

Stock options and restricted stock units excluded from the calculation of diluted net income per share because the effect would have been anti-dilutive are as follows:


	Three Months Ended		Six Months Ended
	June 30,		June 30,
	2021	2020	2021	2020

	(unaudited)		(unaudited)
Anti-dilutive stock options and restricted stock units	1,500	399,772	1,635	479,499

4 — Inventory

Inventory consists of:


	June 30,		December 31,
	2021		2020
	(unaudited)
Raw materials	$	3,528,442	$	3,210,815
Work in process		264,868		207,807
Finished goods		865,456		653,038
Inventory before allowance for excess and obsolete		4,658,766		4,071,660
Allowance for excess and obsolete		(190,651)		(137,673)
Total	$	4,468,115	$	3,933,987

Table of Contents

5 — Property and Equipment

Property and equipment consist of:


	June 30,		December 31,
	2021		2020
	(unaudited)
Computer software and hardware	$	783,690	$	705,811
Furniture and fixtures		1,233,749		1,226,113
Leasehold improvements		230,351		230,351
Machinery and equipment		2,044,479		1,823,835
Tooling in-process		395,782		470,446
		4,688,051		4,456,556
Accumulated depreciation		(2,595,827)		(2,336,408)
Total	$	2,092,224	$	2,120,148

Depreciation expense of property and equipment was $137,598 and $127,945 for the three months ended June 30, 2021 and 2020, respectively, and $264,737 and $254,253 for the six months ended June 30, 2021 and 2020, respectively.

Property and equipment, net, information by geographic region is as follows:


	June 30,		December 31,
	2021		2020
	(unaudited)
United States	$	1,839,405	$	1,832,894
International		252,819		287,254
Total property and equipment, net	$	2,092,224	$	2,120,148

Long-lived assets held outside of the United States consist principally of tooling and machinery and equipment, which are components of property and equipment, net.

6 — Intangible Assets

The following table summarizes the components of intangible asset balances:


	June 30,		December 31,
	2021		2020
	(unaudited)
Patents — in use	$	372,502	$	362,162
Patents — in process		78,123		69,733
Internally developed software — in use		872,218		872,253
Internally developed software — in process		342,887		261,622
Trademarks		27,697		27,247
		1,693,427		1,593,017
Accumulated amortization		(683,354)		(632,132)
Total	$	1,010,073	$	960,885

Amortization expense of intangible assets was $25,104 and $22,999 for the three months ended June 30, 2021 and 2020, respectively, and $51,222 and $45,490 for the six months ended June 30, 2021 and 2020, respectively.

Table of Contents

Expected annual amortization expense for the remaining portion of 2021 and the next five years related to intangible assets is as follows (excludes in process intangible assets):


Six months ending December 31, 2021	$	50,513
2022	$	100,308
2023	$	99,797
2024	$	99,395
2025	$	96,225
2026	$	84,508

7 — Investments

Our investments consist of bonds that we have classified as available-for-sale and are summarized in the following tables:


	June 30, 2021
			Gross		Gross
			Unrealized		Unrealized		Fair
	Cost		Gains		Losses		Value
U.S. corporate bonds	$	926,387	$	22,571	$	—	$	948,958


	December 31, 2020
			Gross		Gross
			Unrealized		Unrealized		Fair
	Cost		Gains		Losses		Value
U.S. corporate bonds	$	1,863,382	$	45,986	$	—	$	1,909,368

8 — Fair Value Measurements

The fair values of cash equivalents, accounts receivables, net and accounts payable approximate their carrying amounts due to their short duration.

The fair value of our assets and liabilities subject to recurring fair value measurements are as follows:

Fair Value at June 30, 2021

Quoted Prices

Significant

in Active

Other

Significant

Market for

Observable

Unobservable

Fair

Identical Assets

Inputs

Value

(Level 1)

(Level 2)

(Level 3)

U.S. corporate bonds

948,958

—

948,958

—

Fair Value at December 31, 2020

Quoted Prices

Significant

in Active

Other

Significant

Market for

Observable

Unobservable

Fair

Identical Assets

Inputs

Value

(Level 1)

(Level 2)

(Level 3)

U.S. corporate bonds

1,909,368

—

1,909,368

—

Our corporate bonds are valued by a third-party custodian at closing prices from secondary exchanges or pricing vendors on the valuation date.

There were no transfers into or out of any Levels during the six months ended June 30, 2021 or the year ended December 31, 2020.

Table of Contents

9 — Accumulated Other Comprehensive Income

The components of accumulated other comprehensive income, net of tax, for the three months ended June 30, 2021 and 2020 are as follows:


	Unrealized (Losses)
	Gains on
	Available-For-Sale
	Securities
Balance at March 31, 2021	$	32,218
Gain on available-for-sale securities, net		1,790
Reclassification realized in net earnings		(9,829)
Balance at June 30, 2021	$	24,179

Balance at March 31, 2020	$	40,807
Gains on available-for-sale securities, net		19,797
Reclassification realized in net earnings		(6,662)
Balance at June 30, 2020	$	53,942

The components of accumulated other comprehensive income, net of tax, for the six months ended June 30, 2021 and 2020 are as follows:


	Unrealized (Losses)
	Gains on
	Available-For-Sale
	Securities
Balance at December 31, 2020	$	37,087
Loss on available-for-sale securities, net		(3,079)
Reclassification realized in net earnings		(9,829)
Balance at June 30, 2021	$	24,179

Balance at December 31, 2019	$	30,374
Gains on available-for-sale securities, net		30,230
Reclassification realized in net earnings		(6,662)
Balance at June 30, 2020	$	53,942

10 — Stock-Based Compensation

Stock-based compensation was recognized as follows in the Condensed Statements of Operations:


	Three Months Ended				Six Months Ended
	June 30,				June 30,
	2021		2020		2021		2020

	(unaudited)				(unaudited)
Cost of revenue	$	54,937	$	58,253	$	109,148	$	116,507
General and administrative		180,854		2,500,634		361,058		2,862,786
Sales and marketing		91,360		77,572		173,295		208,527
Research and development		30,861		22,173		62,252		39,770
Total	$	358,012	$	2,658,632	$	705,753	$	3,227,590

As of June 30, 2021, we had $2,527,686 of unrecognized compensation cost related to unvested restricted stock units, which is expected to be recognized over a weighted-average period of 2.5 years. As of June 30, 2021, we had $224,090 of unrecognized compensation cost related to unvested PSUs, which is expected to be recognized over a weighted-average period of 2.4 years.

Table of Contents

The following table presents a summary of our stock-based compensation activity for the six months ended June 30, 2021 (shares):


			Performance
			Based
	Stock	Restricted	Restricted
	Options	Stock Units	Stock Units
Outstanding beginning of period	230,510	151,139	11,891
Awards granted	—	8,920	—
Awards exercised/vested	(2,375)	(8,443)	—
Awards canceled	—	(9,549)	(2,546)
Outstanding end of period	228,135	142,067	9,345

11 — Income Taxes

For the three and six months ended June 30, 2021, we recorded a provision for income tax expense of $387,727 and $772,221, respectively. Our effective tax rate was 20.9 percent and 21.3 percent, respectively, and differed from the U.S. Federal statutory rate primarily due to U.S. state income tax expense, partially offset by benefits from foreign derived intangible income and research and development tax credits.

For the three and six months ended June 30, 2020, we recorded a provision for income tax benefit of $(798,988) and $(1,732,462), respectively. Our effective tax rate was 27.4 percent and 83.5 percent, respectively, and differed from the U.S. Federal statutory rate primarily due to discrete items related to tax benefits associated with stock-based compensation and a U.S. state tax benefit, partially offset by a limitation on the deductibility of certain executive compensation associated with the separation of our former Chief Executive Officer. Additionally, we recognized a benefit in our effective tax rate resulting from the Coronavirus Aid, Relief, and Economic Security Act, which allowed us to carryback net operating losses to years prior to the enactment of the Tax Cuts and Jobs Act.

As of June 30, 2021, and December 31, 2020, we had not identified or accrued for any uncertain tax positions. We are currently unaware of any uncertain tax positions that could result in significant payments, accruals or other material deviations in this estimate over the next 12 months. We believe that our tax positions comply in all material respects with applicable tax law. However, tax law is subject to interpretation, and interpretations by taxing authorities could be different from ours, which could result in the imposition of additional taxes and penalties.

We file tax returns in the United States Federal jurisdiction and many U.S. state jurisdictions. Our returns are not currently under examination by the Internal Revenue Service. The Company remains subject to income tax examinations for our United States Federal and certain U.S. state income taxes for 2017 and subsequent years and various other U.S. state income taxes for 2016 and subsequent years.

12 — Leases

We have entered into operating lease contracts for our office and various office equipment.

We have one material lease contract outstanding. In January 2014, we entered into a non-cancelable operating lease, commencing July 1, 2014, for our manufacturing and headquarters facility in Winter Springs, Florida owned by Susi, LLC, an entity controlled by our President, Chief Executive Officer, and Chairman of the Board, Roger Susi. Pursuant to the terms of our lease for this property, the monthly base rent is $34,133, adjusted annually for changes in the consumer price index. Under the terms of the lease, we are responsible for property taxes, insurance and maintenance expenses. Prior to May 31, 2019, the expiration date of the initial lease term, and pursuant to the terms of the lease contract, we renewed the lease for an additional five years, resulting in a new lease expiration date of May 31, 2024. Unless advance written notice of termination is timely provided, the lease will automatically renew for one additional successive term of five years beginning in 2024, and thereafter, will be renewed for successive terms of one year each.We concluded that we would exercise the remaining five-year option, resulting in a remaining lease term of 7.9 years as of June 30, 2021. This lease agreement does not contain any residual value guarantee or material restrictive covenants.

Table of Contents

Operating lease cost recognized in the Condensed Statements of Operations is as follows:


	Three Months Ended					Six Months Ended
	June 30,				June 30,
	2021		2020		2021		2020

		(unaudited)				(unaudited)
Cost of revenue	$	51,094	$	46,535	$	102,189	$	93,070
General and administrative		53,406		46,044		103,962		92,088
Sales and marketing		2,860		2,603		5,719		5,208
Research and development		7,923		7,215		15,845		14,430
Total	$	115,283	$	102,397	$	227,715	$	204,796

Lease costs for short-term leases were immaterial for the three and six months ended June 30, 2021 and 2020.

Maturity of our operating lease liability as of June 30, 2021 is as follows:


Six months ending December 31, 2021	$	207,647
2022		415,294
2023		415,294
2024		415,294
2025		415,294
Thereafter		1,400,876
Total lease payments		3,269,699
Imputed interest		(655,348)
Present value of lease liability	$	2,614,351

13 — Commitments and Contingencies

Purchase commitments. We had various purchase orders for goods or services totaling $4,819,367 and $3,089,103 as of June 30, 2021 and December 31, 2020, respectively. No amounts related to these purchase orders have been recognized in our balance sheet.

Legal matters. We may from time to time become party to various legal proceedings or claims that arise in the ordinary course of business.

Table of Contents

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations

The following discussion and analysis should be read in conjunction with our condensed financial statements and the related notes to those statements included in this Quarterly Report, the discussion of certain risks and uncertainties contained in Part II, Item 1A of this Quarterly Report, the discussion under “Management’s Discussion and Analysis of Financial Condition and Results of Operations” and “Business” included in our Annual Report filed on Form 10-K for the fiscal year ended December 31, 2020 and the cautionary information regarding forward-looking statements at the beginning of this Quarterly Report.

Our Business

We develop, manufacture, market and distribute Magnetic Resonance Imaging (“MRI”) compatible medical devices and accessories and services relating to them.

We are a leader in the development of innovative MRI compatible medical devices. We are the only known provider of a non-magnetic intravenous (“IV”) infusion pump system that is specifically designed to be safe for use during MRI procedures. We were the first to develop an infusion delivery system that largely eliminates many of the dangers and problems present during MRI procedures. Standard infusion pumps contain magnetic and electronic components which can create radio frequency interference and are dangerous to operate in the presence of the powerful magnet that drives an MRI system. Our patented MRidium® MRI compatible IV infusion pump system has been designed with a non-magnetic ultrasonic motor, uniquely designed non-ferrous parts and other special features to safely and predictably deliver anesthesia and other IV fluids during various MRI procedures. Our pump solution provides a seamless approach that enables accurate, safe and dependable fluid delivery before, during and after an MRI scan, which is important to critically ill patients who cannot be removed from their vital medications, and children and infants who must generally be sedated to remain immobile during an MRI scan.

Each IV infusion pump system consists of an MRidium® MRI compatible IV infusion pump, non-magnetic mobile stand, proprietary disposable IV tubing sets and many of these systems contain additional optional upgrade accessories.

Our 3880 MRI compatible patient vital signs monitoring system has been designed with non-magnetic components and other special features to safely and accurately monitor a patient’s vital signs during various MRI procedures. The IRADIMED 3880 system operates dependably in magnetic fields up to 30,000 gauss, which means it can operate virtually anywhere in the MRI scanner room. The IRADIMED 3880 has a compact, lightweight design allowing it to travel with the patient from their critical care unit, to the MRI and back, resulting in increased patient safety through uninterrupted vital signs monitoring and decreasing the amount of time critically ill patients are away from critical care units. The features of the IRADIMED 3880 include: wireless ECG with dynamic gradient filtering; wireless SpO2 using Masimo® algorithms; non-magnetic respiratory CO2; invasive and non-invasive blood pressure; patient temperature, and; optional advanced multi-gas anesthetic agent unit featuring continuous Minimum Alveolar Concentration measurements. The IRADIMED 3880 MRI compatible patient vital signs monitoring system has an easy-to-use design and allows for the effective communication of patient vital signs information to clinicians.

We generate revenue from the sale of MRI compatible medical devices and accessories, extended warranty agreements, services related to maintaining our products and the sale of disposable products used with our devices. The principal customers for our MRI compatible products include hospitals and acute care facilities, both in the U.S. and internationally.

Selling cycles for our devices have varied widely and have historically ranged between three and six months in duration with more recent trends lengthening beyond this historical range due to the COVID-19 pandemic. We also enter into agreements with healthcare supply contracting companies, commonly referred to as Group Purchasing Organizations (“GPOs”), in the U.S., which facilitates our ability to sell and distribute our products to their member hospitals. Under these agreements, we are required to pay these GPOs a fee of three percent of the sales of our products to their member hospitals.

Financial Highlights

Beginning in the second quarter 2020, our business was significantly impacted by the COVID-19 pandemic, which negatively impacted our operations and financial results. Additionally, during that second quarter, we recognized $2.8 million of general and administrative expense related to the separation of our former CEO.

For the second quarter ended June 30, 2021, our revenue increased $3.0 million, or 44.4 percent, to $9.8 million, compared to $6.8 million for the second quarter last year. Income before the provision for income taxes was $1.9 million for the second quarter 2021, compared to a loss before the provision for income taxes of $(2.9) million for the second quarter last year. Net income was $1.5

Table of Contents

million, or $0.12 per diluted share in the second quarter ended June 30, 2021, compared to a net loss of $(2.1) million, or $(0.17) per share in the second quarter last year.

Effects of the COVID-19 Pandemic

●

postponement or cancellation of MRI medical procedures and their uncertain return which adversely impacts our business;

●

disruptions in our supply chain that may limit our ability to procure materials necessary to manufacture our products;

●

potential temporary or prolonged closure of our office and production facility;

●

the health of our employees and ability to meet staffing needs;

●

potential new or continued governmental actions that may limit employees’ ability to work;

●

civil unrest relating to government, corporate and societal responses to the pandemic;

●

volatility in economic conditions and the financial markets, and

●

other unanticipated effects that remain unknown.

Application of Critical Accounting Policies

We prepare our financial statements in conformity with GAAP. The preparation of these financial statements requires us to make estimates and use assumptions that affect the reported amounts of assets, liabilities and related disclosures at the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. Actual results could differ from those estimates.

We believe that the following critical accounting policies require the use of significant estimates, assumptions, and judgments:

●

Revenue recognition;

●

Accounts receivable and allowance for doubtful accounts;

●

Inventory carried at the lower of cost or net realizable value;

Table of Contents

●

Stock-based compensation; and

●

Income taxes.

These critical accounting policies are described in more detail in our Annual Report filed on Form 10-K, under Management’s Discussion and Analysis and Results of Operations. Except as disclosed in Note 1 to the unaudited condensed financial statements contained herein related to the adoption of recent accounting pronouncements, there have been no changes to these policies during the three and six months ended June 30, 2021.

The use of different estimates, assumptions, and judgments could have a material effect on the reported amounts of assets, liabilities and related disclosures as of the date of the financial statements and revenue and expenses during the reporting period.

Results of Operations

The following table sets forth selected statements of operations data as a percentage of total revenue for the periods indicated. Our historical operating results are not necessarily indicative of the results for any future period.


	Percent of Revenue				Percent of Revenue
	Three Months				Six Months
	Ended June 30,				Ended June 30,
	2021		2020		2021		2020
Revenue	100.0	%	100.0	%	100.0	%	100.0	%
Cost of revenue	25.3		27.4		24.4		26.4
Gross profit	74.7		72.6		75.6		73.6
Operating expenses:
General and administrative	26.1		73.6		26.2		50.8
Sales and marketing	25.2		34.9		25.5		31.1
Research and development	4.6		7.1		4.9		5.9
Total operating expenses	55.9		115.7		56.6		87.8
Income (loss) from operations	18.8		(43.1)		19.0		(14.2)
Other income, net	0.1		0.3		0.0		0.8
Income (loss) before provision for income taxes	18.9		(42.8)		19.1		(13.4)
Provision for income tax expense (benefit)	4.0		(11.8)		4.1		(11.2)
Net income (loss)	15.0	%	(31.1)	%	15.0	%	(2.2)	%

Three and Six Months Ended June 30, 2021 and 2020

Revenue by Geographic Region


	Three Months Ended				Six Months Ended
	June 30,				June 30,
	2021		2020		2021		2020
United States	$	8,043,156	$	4,642,916	$	15,315,986	$	10,965,022
International		1,767,267		2,151,776		3,718,433		4,507,211
Total revenue	$	9,810,423	$	6,794,692	$	19,034,419	$	15,472,233

Table of Contents

Revenue by Type


	Three Months Ended				Six Months Ended
	June 30,				June 30,
	2021		2020		2021		2020
Devices:
MRI Compatible IV Infusion Pump Systems	$	2,456,767	$	1,875,159	$	5,960,114	$	4,539,993
MRI Compatible Patient Vital Signs Monitoring Systems		3,377,719		1,927,473		5,981,549		4,546,988
Total Devices revenue		5,834,486		3,802,632		11,941,663		9,086,981
Disposables, services and other		3,490,969		2,535,548		6,126,435		5,467,449
Amortization of extended warranty agreements		484,968		456,512		966,321		917,803
Total revenue	$	9,810,423	$	6,794,692	$	19,034,419	$	15,472,233

For the three months ended June 30, 2021, revenue increased $3.0 million, or 44.4 percent, to $9.8 million from $6.8 million for the same period in 2020.

Revenue from sales in the U.S. increased $3.4 million, or 73.2 percent, to $8.0 million for the second quarter 2021, from $4.6 million for the second quarter 2020. Revenue from sales internationally decreased $(0.4) million, or (17.9) percent, to $1.8 million for the second quarter 2021, from $2.2 million for the second quarter 2020. Domestic sales accounted for 82.0 percent of revenue for the second quarter 2021, compared to 68.3 percent for the second quarter 2020.

Revenue from sales of devices increased $2.0 million, or 53.4 percent, to $5.8 million for the three months ended June 30, 2021, from $3.8 million for the same period in 2020.

The average selling price of our MRI compatible IV infusion pump system during the three months ended June 30, 2021 was approximately $41,600, compared to approximately $30,200 for the same period in 2020. The increase in ASP is the result of a favorable product and geographic sales mix when compared to the same period in 2020.

The average selling price of our MRI compatible patient vital signs monitoring system during the three months ended June 30, 2021 was approximately $39,700, compared to approximately $30,600 for the same period in 2020. The increase in ASP relates to a favorable product and geographic sales mix when compared to the same period in 2020.

Revenue from sales of our disposables, service and other increased $1.0 million, or 37.7 percent, to $3.5 million for the three months ended June 30, 2021, from $2.5 million for the same period in 2020. Revenue from the amortization of extended maintenance contracts was consistent at $0.5 million for the three months ended June 30, 2021 and 2020.

For the six months ended June 30, 2021, revenue increased $3.5 million, or 23.0 percent, to $19.0 million from $15.5 million for the same period in 2020.

Revenue from sales in the U.S. increased $4.3 million, or 39.7 percent, to $15.3 million for the six months ended June 30, 2021, from $11.0 million for the same period in 2020. Revenue from sales internationally decreased $(0.8) million, or (17.5) percent, to $3.7 million for the six months ended June 30, 2021, from $4.5 million for the same period in 2020. Domestic sales accounted for 80.5 percent of revenue for the six months ended June 30, 2021, compared to 70.9 percent for the same period in 2020.

Revenue from sales of devices increased $2.8 million, or 31.4 percent, to $11.9 million for the six months ended June 30, 2021, from $9.1 million for the same period in 2020.

The average selling price of our MRI compatible IV infusion pump system during the six months ended June 30, 2021 was approximately $35,900, compared to approximately $30,100 for the same period in 2020. The increase in ASP relates to a favorable product and geographic sales mix when compared to the same period in 2020.

The average selling price of our MRI compatible patient vital signs monitoring system during the six months ended June 30, 2021 was approximately $39,100, compared to approximately $33,100 for the same period in 2020. The increase in ASP relates to favorable product and geographic sales mix when compared to the same period in 2020.

Revenue from sales of our disposables, service and other increased $0.6 million, or 12.1 percent, to $6.1 million for the six months ended June 30, 2021, from $5.5 million for the same period in 2020. Revenue from the amortization of extended maintenance

Table of Contents

contracts increased $0.1 million, or 5.3 percent, to $1.0 million for the six months ended June 30, 2021, from $0.9 million for the same period in 2020.

Cost of Revenue and Gross Profit


	Three Months Ended						Six Months Ended
	June 30,						June 30,
	2021			2020			2021			2020
Revenue	$	9,810,423		$	6,794,692		$	19,034,419		$	15,472,233
Cost of revenue		2,478,122			1,864,587			4,639,802			4,078,317
Gross profit	$	7,332,301		$	4,930,105		$	14,394,617		$	11,393,916
Gross profit percentage		74.7	%		72.6	%		75.6	%		73.6	%

For the three months ended June 30, 2021, cost of revenue increased $0.6 million, or 32.9 percent, to $2.5 million from $1.9 million for the same period last year. Gross profit increased $2.4 million, or 48.7 percent, to $7.3 million for the second quarter 2021 from $4.9 million for the same period in 2020. Gross profit margin was 74.7 percent for second quarter 2021, compared to 72.6 percent for the second quarter 2020. The increase in gross profit and gross profit margin is primarily due to a favorable geographic sales mix, partially offset by unfavorable inventory reserve adjustments and overhead variances.

For the six months ended June 30, 2021, cost of revenue increased $0.5 million, or 13.8 percent, to $4.6 million from $4.1 million for the same period last year. Gross profit increased $3.0 million, or 26.3 percent, to $14.4 million for the six months ended June 30, 2021 from $11.4 million for the same period in 2020. Gross profit margin was 75.6 percent for six months ended June 30, 2021, compared to 73.6 percent for the same period in 2020. The increase in gross profit and gross profit margin is primarily due to a favorable geographic sales mix, partially offset by unfavorable inventory reserve adjustments and overhead variances.

Operating Expenses


	Three Months Ended						Six Months Ended
	June 30,						June 30,
	2021			2020			2021			2020
General and administrative	$	2,564,619		$	5,002,427		$	4,994,988		$	7,865,154
Percentage of revenue		26.1	%		73.6	%		26.2	%		50.8	%
Sales and marketing	$	2,469,777		$	2,374,134		$	4,848,901		$	4,807,701
Percentage of revenue		25.2	%		34.9	%		25.5	%		31.1	%
Research and development	$	453,679		$	482,654		$	929,496		$	912,936
Percentage of revenue		4.6	%		7.1	%		4.9	%		5.9	%

General and Administrative

For the three months ended June 30, 2021, general and administrative expense decreased $(2.4) million, or (48.7) percent, to $2.6 million from $5.0 million for the same period last year. This decrease is primarily due to stock and cash compensation expenses incurred during the second quarter 2020 related to the separation of our former Chief Executive Officer.

For the six months ended June 30, 2021, general and administrative expense decreased $(2.9) million, or (36.5) percent, to $5.0 million from $7.9 million for the same period last year. This decrease is primarily due to stock and cash compensation expenses incurred during the second quarter 2020 related to the separation of our former Chief Executive Officer.

Sales and Marketing

For the three months ended June 30, 2021, sales and marketing expense increased $0.1 million, 4.0 percent, to $2.5 million from $2.4 million for the same period last year. This is primarily the result of higher sales commissions and sales activities expenses, partially offset by lower payroll and benefits expenses.

For the six months ended June 30, 2021 and 2020, sales and marketing expense was consistent at $4.8 million. This is primarily the result of higher sales commissions and consulting services, offset by lower payroll and benefits expenses.

Table of Contents

Research and Development

For the three months ended June 30, 2021, research and development expense was consistent at $0.5 million. For the six months ended June 30, 2021, research and development expense was consistent at $0.9 million. There were no significant changes in these accounts during the three and six months ended June 30, 2021, compared to the same periods last year.

Other Income, Net

Other income, net consists of interest income, foreign currency gains and losses, and other miscellaneous income. For the three months ended June 30, 2021, we reported other income of approximately $13,000, compared to $18,000 for the three months ended June 30, 2020. There were no significant changes in these accounts during the three months ended June 30, 2021, compared to the same quarter last year.

For the six months ended June 30, 2021, we reported other income of approximately $8,000, compared to $116,000 for the six months ended June 30, 2020. This decrease is primarily due to lower interest income during the six months ended June 30, 2021.

Income Taxes

Liquidity and Capital Resources

Our principal sources of liquidity have historically been our cash and cash equivalents balances, our investments, cash flow from operations and access to the financial markets. Our principal uses of cash are operating expenses, working capital requirements and capital expenditures.

As of June 30, 2021, we had cash and investments of $56.1 million, stockholders’ equity of $64.9 million, and working capital of $62.3 million. As of December 31, 2020, we had cash and investments of $52.0 million, stockholders’ equity of $61.4 million, and working capital of $58.8 million.

Table of Contents

We believe that our current cash, investments and any cash generated from operations will be sufficient to meet our ongoing operating requirements for at least the next 12 months. We do not anticipate requiring additional capital; however, if required or desirable, we may seek to obtain a credit facility, raise debt or issue additional equity in private or public markets.


	Six Months Ended
	June 30,
	2021		2020
Net cash provided by operating activities	$	4,513,772	$	1,987,231
Net cash provided by investing activities		609,047		56,908
Net cash used in financing activities		(31,886)		(68,268)

Cash provided by operating activities increased $2.5 million, to $4.5 million for the six months ended June 30, 2021, compared to $2.0 million for the same period in 2020. During the six months ended June 30, 2021, cash provided by operations was positively impacted by cash inflows from deferred revenue, and negatively impacted by cash outflows from prepaid expenses and inventory purchases.

Cash provided by investing activities increased $0.5 million, to $0.6 million for the six months ended June 30, 2021, compared to $0.1 million for the same period in 2020. During the six months ended June 30, 2021, cash provided by investing activities was positively impacted by cash inflows from maturities of securities, and negatively impacted by capital expenditures and capitalized intangible assets.

Cash used in financing activities was approximately $(32,000) for the six months ended June 30, 2021, compared to approximately $(68,000) for the same period in 2020. This increase is primarily due to lower cash outflows for the net share settlement of restricted stock units and lower cash inflows from the exercise of stock options during the six months ended June 30, 2021.

Our manufacturing and headquarters facility has been leased from Susi, LLC, an entity controlled by our Chairman of the Board and Chief Executive Officer, Roger Susi. Pursuant to the terms of our lease, the monthly base rent is $34,133, adjusted annually for changes in the consumer price index.

Off-Balance Sheet Arrangements

As of June 30, 2021 and December 31, 2020, we did not have any off-balance sheet arrangements, as such term is defined under Item 303 of Regulation S-K, that have or are reasonably likely to have a current or future effect on our financial condition, changes in financial condition, revenues or expenses, results of operations, liquidity, capital expenditures or capital resources that is material to investors.

Contractual Obligations

There have been no material changes outside the ordinary course of business to our contractual obligations and commercial commitments since December 31, 2020.

Recent Accounting Pronouncements

See Note 1 to the unaudited condensed financial statements contained herein for a full description of recent accounting pronouncements including the respective expected dates of adoption and status of evaluation of expected effects on results of our operations and financial condition.

Table of Contents

Item 3. Quantitative and Qualitative Disclosures about Market Risk

Foreign Currency Exchange Risk

We have foreign currency risks related to our revenue and operating expenses denominated in currencies other than the U.S. Dollar, principally the Japanese yen (“Yen”). The volatility of the Yen depends on many factors that we cannot forecast with reliable accuracy. We have experienced and will continue to experience fluctuations in our net income because of transaction gains (losses) related to revaluing Yen denominated accounts payable balances. In the event our Yen denominated accounts payable or expenses increase, our operating results may be affected by fluctuations in the Yen exchange rate. If the U.S. Dollar uniformly increased or decreased in strength by 10 percent relative to the Yen, our net income would have correspondingly increased or decreased by an immaterial amount for the three and six months ended June 30, 2021 and 2020.

Interest Rate Risk

When able, we invest excess cash in bank money-market funds, corporate debt securities or discrete short-term investments. The fair value of our cash equivalents and short-term investments is sensitive to changes in the general level of interest rates in the U.S., and the fair value of these investments will decline if market interest rates increase. As of June 30, 2021, we had $0.9 million in corporate bonds, all of which are maturing in less than 1 year. These corporate bonds have fixed interest rates and semi-annual interest payment dates. If market interest rates were to change by 100 basis points from levels at June 30, 2021, we expect the corresponding change in fair value of our investments would be immaterial. This is based on sensitivity analyses performed on our financial position as of June 30, 2021. Actual results may differ as our analysis of the effects of changes in interest rates does not account for, among other things, sales of securities prior to maturity and repurchase of replacement securities, the change in mix or quality of the investments in the portfolio, and changes in the relationship between short-term and long-term interest rates.

Item 4. Controls and Procedures

Evaluation of Disclosure Controls and Procedures

Disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e)) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), are designed to ensure that: (1) information required to be disclosed in reports filed or submitted under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in SEC rules and forms; and (2) such information is accumulated and communicated to management, including the principal executive officer and principal financial officer, as appropriate to allow timely decisions regarding required disclosures. There are inherent limitations to the effectiveness of any system of disclosure controls and procedures, including the possibility of human error and the circumvention or overriding of controls and procedures. Accordingly, even effective disclosure controls and procedures can only provide reasonable assurance of achieving their control objectives.

Our management, including our Chief Executive Officer and Chief Financial and Operating Officer, evaluated the effectiveness of the design and operation of our disclosure controls and procedures as of June 30, 2021. Our Chief Executive Officer and Chief Financial and Operating Officer have concluded that our disclosure controls and procedures as of June 30, 2021 were effective.

Changes in Internal Control Over Financial Reporting

There was no change in our internal control over financial reporting identified in connection with the evaluation required by Rule 13a-15(d) and 15d-15(d) of the Exchange Act that occurred during the period covered by this Quarterly Report on Form 10-Q that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.

Table of Contents

PART II. OTHER INFORMATION

Item 1. Legal Proceedings

We may from time to time become party to various legal proceedings or claims that arise in the ordinary course of business. Our management reviews these matters if and when they arise and believes that the resolution of any such matters currently known will not have a material effect on our results of operations or financial position.

Item 1A. Risk Factors

We operate in a rapidly changing environment that involves a number of risks that could materially affect our business, financial condition or future results, some of which are beyond our control. The occurrence of any of these risks could harm our business, financial condition, results of operations and/or growth prospects or cause our actual results to differ materially from those contained in forward-looking statements we have made in this report and those we may make from time to time. In evaluating the Company and its business, you should carefully consider the information included in this Quarterly Report on Form 10-Q and the factors discussed under Part I, Item 1A “Risk Factors” in our Annual Report on Form 10-K for the fiscal year ended December 31, 2020, as well as in other documents we file with the SEC. Except as described below, there have been no material changes to the risk factors previously disclosed in our Annual Report on Form 10-K for the fiscal year ended December 31, 2020.

Item 2. Unregistered Sale of Equity Securities and Use of Proceeds

None.

Item 3. Default Upon Senior Securities

Not Applicable.

Item 4. Mine Safety Disclosures.

Not Applicable.

Item 5. Other Information

None.

Table of Contents

Item 6. Exhibits


Exhibit Number		Description of Document
31.1		Certification of Chief Executive Officer pursuant to Exchange Act Rule, 13a-14(a) and 15d-14(a), as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
31.2		Certification of Chief Financial Officer pursuant to Exchange Act Rule, 13a-14(a) and 15d-14(a), as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
32.1*		Certifications of Chief Executive Officer and Chief Financial Officer pursuant to 18 I.S.C Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
101.INS**		XBRL Instance Document
101.SCH**		XBRL Taxonomy Extension Schema Document
101.CAL**		XBRL Taxonomy Extension Calculation Linkbase Document
101.DEF**		XBRL Taxonomy Extension Definition Linkbase Document
101.LAB**		XBRL Taxonomy Extension Label Linkbase Document
101.PRE**		XBRL Taxonomy Extension Presentation Linkbase Document
104**		Inline XBRL for the cover page of this Quarterly Report on Form 10-Q, included as part of this Exhibit 101 inline XBRL Document set

This exhibit shall not be deemed “filed” for purposes of Section 18 of the Exchange Act or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act or the Exchange Act, whether made before or after the date hereof and irrespective of any general incorporation language in any filings.

**	In accordance with Rule 402 of Regulation S-T, this interactive data file is deemed not filed or part of this Quarterly Report on Form 10-Q for purposes of Sections 11 or 12 of the Securities Act or Section 18 of the Exchange Act and otherwise is not subject to liability under these sections.

Table of Contents

IRADIMED CORPORATION

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.


	IRADIMED CORPORATION

Dated: August 6, 2021	/s/ Roger Susi
	By:	Roger Susi
	Its:	Chief Executive Officer and President (Principal Executive Officer and Authorized Officer)

	/s/ Chris Scott
	By:	Chris Scott
	Its:	Chief Financial and Operating Officer and Secretary (Principal Financial and Accounting Officer)

EX-31.1 2 irmd-20210630xex31d1.htm EXHIBIT 31.1

Exhibit 31.1

Certification of Chief Executive Officer pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002

I, Roger Susi, certify that:

1.	I have reviewed this quarterly report on Form 10-Q of IRADIMED CORPORATION;

2.	Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3.	Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

(a)

Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant is made known to us by others within those entities, particularly during the period in which this report is being prepared;

(b)

Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

(c)

Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

(d)

Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5.	The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

(a)

All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

(b)

Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date: August 6, 2021

/s/ Roger Susi
By: Roger Susi
Chief Executive Officer and President
(Principal Executive Officer)

EX-31.2 3 irmd-20210630xex31d2.htm EXHIBIT 31.2

Exhibit 31.2

Certification of Chief Financial Officer pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002

I, Chris Scott, certify that:

1.	I have reviewed this quarterly report on Form 10-Q of IRADIMED CORPORATION;

2.	Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3.	Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

(a)

(b)

(c)

(d)

5.	The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

(a)

(b)

Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date: August 6, 2021

/s/ Chris Scott
By: Chris Scott
Chief Financial and Operating Officer and Secretary
(Principal Financial and Accounting Officer)

EX-32.1 4 irmd-20210630xex32d1.htm EXHIBIT 32.1

Exhibit 32.1

Certification of Chief Executive Officer and Chief Financial Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002

In connection with the quarterly report of IRADIMED CORPORATION (the “Company”) on Form 10-Q for the quarter ending June 30, 2021, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), each of the undersigned, in the capacities and on the date indicated below, hereby certifies, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to his knowledge:

(1)

The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

(2)

The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

/s/ Roger Susi
By: Roger Susi
Chief Executive Officer and President
(Principal Executive Officer)
August 6, 2021


/s/ Chris Scott
By: Chris Scott
Chief Financial and Operating Officer and Secretary
(Principal Financial and Accounting Officer)
August 6, 2021

EX-101.SCH 5 irmd-20210630.xsd XBRL TAXONOMY EXTENSION SCHEMA 00100 - Statement - CONDENSED BALANCE SHEETS link:presentationLink link:calculationLink link:definitionLink 00200 - Statement - CONDENSED STATEMENTS OF OPERATIONS link:presentationLink link:calculationLink link:definitionLink 00300 - Statement - CONDENSED STATEMENTS OF COMPREHENSIVE INCOME link:presentationLink link:calculationLink link:definitionLink 00500 - Statement - CONDENSED STATEMENTS OF CASH FLOWS link:presentationLink link:calculationLink link:definitionLink 40202 - Disclosure - Revenue Recognition - Information by Type (Details) link:presentationLink link:calculationLink link:definitionLink 40203 - Disclosure - Revenue Recognition - Contract Liabilities (Details) link:presentationLink link:calculationLink link:definitionLink 40301 - Disclosure - Basic and Diluted Net Income per Share (Details) link:presentationLink link:calculationLink link:definitionLink 40401 - Disclosure - Inventory (Details) link:presentationLink link:calculationLink link:definitionLink 40501 - Disclosure - Property and Equipment (Details) link:presentationLink link:calculationLink link:definitionLink 40601 - Disclosure - Intangible Assets (Details) link:presentationLink link:calculationLink link:definitionLink 41203 - Disclosure - Leases - Maturity of Lease Liabilities (Details) link:presentationLink link:calculationLink link:definitionLink 41203 - Disclosure - Leases - Maturity of lease liabilities (Details) Calc 2 link:presentationLink link:calculationLink link:definitionLink 00090 - Document - Document and Entity Information link:presentationLink link:calculationLink link:definitionLink 00105 - Statement - CONDENSED BALANCE SHEETS (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 00305 - Statement - CONDENSED STATEMENTS OF COMPREHENSIVE INCOME (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 00400 - Statement - CONDENSED STATEMENTS OF STOCKHOLDERS' EQUITY link:presentationLink link:calculationLink link:definitionLink 10301 - Disclosure - Basic and Diluted Net Income per Share link:presentationLink link:calculationLink link:definitionLink 10401 - Disclosure - Inventory link:presentationLink link:calculationLink link:definitionLink 10501 - Disclosure - Property and Equipment link:presentationLink link:calculationLink link:definitionLink 10601 - Disclosure - Intangible Assets link:presentationLink link:calculationLink link:definitionLink 10701 - Disclosure - Investments link:presentationLink link:calculationLink link:definitionLink 10801 - Disclosure - Fair Value Measurements link:presentationLink link:calculationLink link:definitionLink 10901 - Disclosure - Accumulated Other Comprehensive Income link:presentationLink link:calculationLink link:definitionLink 11001 - Disclosure - Stock-Based Compensation link:presentationLink link:calculationLink link:definitionLink 11101 - Disclosure - Income Taxes link:presentationLink link:calculationLink link:definitionLink 11301 - Disclosure - Commitments and Contingencies link:presentationLink link:calculationLink link:definitionLink 20102 - Disclosure - Basis of Presentation (Policies) link:presentationLink link:calculationLink link:definitionLink 30303 - Disclosure - Basic and Diluted Net Income per Share (Tables) link:presentationLink link:calculationLink link:definitionLink 30403 - Disclosure - Inventory (Tables) link:presentationLink link:calculationLink link:definitionLink 30503 - Disclosure - Property and Equipment (Tables) link:presentationLink link:calculationLink link:definitionLink 30603 - Disclosure - Intangible Assets (Tables) link:presentationLink link:calculationLink link:definitionLink 30703 - Disclosure - Investments (Tables) link:presentationLink link:calculationLink link:definitionLink 30803 - Disclosure - Fair Value Measurements (Tables) link:presentationLink link:calculationLink link:definitionLink 30903 - Disclosure - Accumulated Other Comprehensive Income (Loss) (Tables) link:presentationLink link:calculationLink link:definitionLink 31003 - Disclosure - Stock-Based Compensation (Tables) link:presentationLink link:calculationLink link:definitionLink 40201 - Disclosure - Revenue Recognition - Information by geographic region (Details) link:presentationLink link:calculationLink link:definitionLink 40204 - Disclosure - Revenue Recognition - Capitalized Contract Costs (Details) link:presentationLink link:calculationLink link:definitionLink 40502 - Disclosure - Property and Equipment - Geographic information (Details) link:presentationLink link:calculationLink link:definitionLink 40701 - Disclosure - Investments (Details) link:presentationLink link:calculationLink link:definitionLink 40801 - Disclosure - Fair Value Measurements (Details) link:presentationLink link:calculationLink link:definitionLink 40901 - Disclosure - Accumulated Other Comprehensive Income (Details) link:presentationLink link:calculationLink link:definitionLink 41001 - Disclosure - Stock-Based Compensation (Details) link:presentationLink link:calculationLink link:definitionLink 41002 - Disclosure - Stock-Based Compensation - Stock Options and Restricted Stock Units Activity (Details) link:presentationLink link:calculationLink link:definitionLink 41101 - Disclosure - Income Taxes (Details) link:presentationLink link:calculationLink link:definitionLink 41201 - Disclosure - Leases (Details) link:presentationLink link:calculationLink link:definitionLink 41202 - Disclosure - Leases - Operating Lease Cost (Details) link:presentationLink link:calculationLink link:definitionLink 41301 - Disclosure - Commitments and Contingencies (Details) link:presentationLink link:calculationLink link:definitionLink 10101 - Disclosure - Basis of Presentation link:presentationLink link:calculationLink link:definitionLink 10201 - Disclosure - Revenue Recognition link:presentationLink link:calculationLink link:definitionLink 11201 - Disclosure - Leases link:presentationLink link:calculationLink link:definitionLink 30203 - Disclosure - Revenue Recognition (Tables) link:presentationLink link:calculationLink link:definitionLink 31203 - Disclosure - Leases (Tables) link:presentationLink link:calculationLink link:definitionLink 40101 - Disclosure - Basis of Presentation (Details) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 6 irmd-20210630_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE EX-101.DEF 7 irmd-20210630_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE EX-101.LAB 8 irmd-20210630_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Document and Entity Information Document Information [Table] Document Information [Line Items] Entity Registrant Name Entity Central Index Key Document Type Document Period End Date Amendment Flag Document Quarterly Report Document Transition Report Entity File Number Entity Incorporation, State or Country Code Entity Tax Identification Number Entity Address, Address Line One Entity Address, City or Town Entity Address, State or Province Entity Address, Postal Zip Code City Area Code Local Phone Number Current Fiscal Year End Date Entity Current Reporting Status Entity Filer Category Trading Symbol Title of 12(b) Security Security Exchange Name Entity Common Stock, Shares Outstanding Entity Small Business Entity Emerging Growth Company Entity Shell Company Entity Interactive Data Current Document Fiscal Year Focus Document Fiscal Period Focus CONDENSED BALANCE SHEETS Statement [Table] Statement [Line Items] Statement Assets [Abstract] ASSETS Assets, Current [Abstract] Current assets: Cash and Cash Equivalents, at Carrying Value Cash and cash equivalents Debt Securities, Current Investments Accounts Receivable, Net, Current Accounts receivable, net of allowance for doubtful accounts of $45,578 as of June 30, 2021 and $46,484 as of December 31, 2020 Inventory, Net Inventory, net Total Prepaid Expense and Other Assets, Current Prepaid expenses and other current assets Prepaid Taxes Prepaid income taxes Assets, Current Total current assets Property, Plant and Equipment, Net Property and equipment, net Total Total property and equipment, net Finite-Lived Intangible Assets, Net Intangible assets, net Total Operating Lease, Right-of-Use Asset Operating lease right-of-use asset, net Deferred Income Tax Assets, Net Deferred income taxes, net Other Assets, Noncurrent Other assets Assets Total assets Liabilities and Equity [Abstract] LIABILITIES AND STOCKHOLDERS' EQUITY Liabilities, Current [Abstract] Current liabilities: Accounts Payable, Current Accounts payable Employee-related Liabilities, Current Accrued payroll and benefits Accrual for Taxes Other than Income Taxes, Current Other accrued taxes Product Warranty Accrual, Current Warranty reserve Contract with Customer, Liability, Current Deferred revenue Operating Lease, Liability, Current Current portion of operating lease liability Other Liabilities, Current Other current liabilities Liabilities, Current Total current liabilities Contract with Customer, Liability, Noncurrent Deferred revenue Operating Lease, Liability, Noncurrent Operating lease liability, less current portion Liabilities Total liabilities Stockholders' Equity Attributable to Parent [Abstract] Stockholders' equity: Common Stock, Value, Issued Common stock; $0.0001 par value; 31,500,000 shares authorized; 12,317,036 shares issued and outstanding as of June 30, 2021 and 12,308,432 shares issued and outstanding as of December 31, 2020 Additional Paid in Capital Additional paid-in capital Retained Earnings (Accumulated Deficit) Retained earnings Accumulated Other Comprehensive Income (Loss), Net of Tax Balance at the end Balance at the beginning Accumulated other comprehensive income Stockholders' Equity Attributable to Parent Balances Balances Total stockholders' equity Liabilities and Equity Total liabilities and stockholders' equity Allowance for Doubtful Accounts Receivable, Current Accounts receivable, allowance for doubtful accounts Common Stock, Par or Stated Value Per Share Common stock, par value (in dollars per share) Common Stock, Shares Authorized Common stock, shares authorized Common Stock, Shares, Issued Common stock, shares issued Common Stock, Shares, Outstanding Common stock, shares outstanding CONDENSED STATEMENTS OF OPERATIONS Revenues Revenue Cost of Revenue. Cost of revenue Gross Profit Gross profit Operating Expenses [Abstract] Operating expenses: General and Administrative Expense General and administrative Selling and Marketing Expense Sales and marketing Research and Development Expense Research and development Operating Expenses Total operating expenses Operating Income (Loss) Income (loss) from operations Nonoperating Income (Expense) Other income, net Income (Loss) from Continuing Operations before Income Taxes, Extraordinary Items, Noncontrolling Interest Income (loss) before provision for income taxes Income Tax Expense (Benefit) Provision for income tax expense (benefit) Net Income (Loss) Attributable to Parent Net income (loss) Net income (loss) Earnings Per Share, Basic [Abstract] Net income (loss) per share: Earnings Per Share, Basic Basic net income (loss) per share (in dollars per share) Basic (in dollars per share) Earnings Per Share, Diluted Diluted net income (loss) per share (in dollars per share) Diluted (in dollars per share) Weighted Average Number of Shares Outstanding, Diluted [Abstract] Weighted average shares outstanding: Weighted Average Number of Shares Outstanding, Basic Weighted-average shares outstanding - Basic (in shares) Basic (in shares) Weighted Average Number of Shares Outstanding, Diluted Weighted-average shares outstanding - Diluted (in shares) Diluted (in shares) CONDENSED STATEMENTS OF COMPREHENSIVE INCOME Accumulated Other Comprehensive Income Other comprehensive income: Other Comprehensive Income (Loss), Available-for-sale Securities Adjustment, Net of Tax, Portion Attributable to Parent Change in fair value of available-for-sale securities, net of tax expense (benefit) of $5,772 and $4,227 for the three months ended June 30, 2021 and 2020, respectively, and $(7,331) and $7,669 for the six months ended June 30, 2021 and 2020, respectively Gains (Loss) on available-for-sale securities, net Other Comprehensive Income (Loss), Reclassification Adjustment from AOCI for Sale of Securities, Net of Tax Realized gain on available-for-sale securities reclassified to net income, net of tax expense of $3,176 and $2,199 for the three months ended June 30, 2021 and 2020, respectively, and $3,176 and $2,199 for the six months ended June 30, 2021 and 2020, respectively Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent Other comprehensive income Comprehensive Income (Loss), Net of Tax, Attributable to Parent Comprehensive income (loss) Other Comprehensive Income (Loss), Available-for-sale Securities, Tax, Portion Attributable to Parent Change in fair value of available-for-sale securities, net of tax expense Other Comprehensive Income (Loss), Reclassification Adjustment from AOCI for Sale of Securities, Tax Realized gain on available-for-sale securities reclassified to net income, net of tax expense (benefit) CONDENSED STATEMENTS OF STOCKHOLDERS' EQUITY Increase (Decrease) in Stockholders' Equity Shares, Outstanding Balance (in shares) Balance (in shares) Other Comprehensive Income (Loss), Net of Tax Other comprehensive income (loss) Adjustments to Additional Paid in Capital, Share-based Compensation, Requisite Service Period Recognition Stock-based compensation expense Restricted Stock, Value, Shares Issued Net of Tax Withholdings Net share settlement of restricted stock units Restricted Stock, Shares Issued Net of Shares for Tax Withholdings Net share settlement of restricted stock units (in shares) Stock Issued During Period, Value, Stock Options Exercised Exercise of stock options Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period Options exercised (in shares) Exercise of stock options (in Shares) CONDENSED STATEMENTS OF CASH FLOWS Net Cash Provided by (Used in) Operating Activities, Continuing Operations [Abstract] Operating activities: Net Income (Loss), Including Portion Attributable to Noncontrolling Interest Net income (loss) Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract] Adjustments to reconcile net income (loss) to net cash provided by operating activities: Provision for Doubtful Accounts Change in allowance for doubtful accounts Inventory Write-down Change in provision for excess and obsolete inventory Depreciation, Depletion and Amortization Depreciation and amortization Share-based Compensation Stock-based compensation Increase (Decrease) in Deferred Income Taxes Deferred income taxes, net Realized Investment Gains (Losses) Gain on maturities of investments Increase (Decrease) in Operating Capital [Abstract] Changes in operating assets and liabilities: Increase (Decrease) in Accounts Receivable Accounts receivable Increase (Decrease) in Inventories Inventory Increase (Decrease) in Prepaid Expense and Other Assets Prepaid expenses and other current assets Increase (Decrease) in Other Operating Assets Other assets Increase (Decrease) in Accounts Payable Accounts payable Increase (Decrease) in Employee Related Liabilities Accrued payroll and benefits Increase (Decrease) in Property and Other Taxes Payable Other accrued taxes Represents the increase (decrease) during the period in the carrying amount (including both current and noncurrent portions of the accrual) of the liability pertaining to warranty reserve. Increase Decrease in Warranty Reserve Warranty reserve Increase (Decrease) in Other Current Liabilities Other current liability Increase (Decrease) in Contract with Customer, Liability Deferred revenue Increase (Decrease) in Income Taxes Payable Prepaid income taxes Net Cash Provided by (Used in) Operating Activities, Continuing Operations Net cash provided by operating activities Net Cash Provided by (Used in) Investing Activities, Continuing Operations [Abstract] Investing activities: Proceeds from Sale, Maturity and Collection of Investments Proceeds from maturity of investments Payments to Acquire Property, Plant, and Equipment Purchases of property and equipment Payments to Acquire Other Productive Assets Capitalized intangible assets Net Cash Provided by (Used in) Investing Activities Net cash provided by investing activities Net Cash Provided by (Used in) Financing Activities, Continuing Operations [Abstract] Financing activities: Proceeds from Stock Options Exercised Proceeds from exercises of stock options Payments Related to Tax Withholding for Share-based Compensation Taxes paid related to the net share settlement of equity awards Net Cash Provided by (Used in) Financing Activities, Continuing Operations Net cash used in financing activities Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect Net increase in cash and cash equivalents Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents Cash and cash equivalents, end of period Cash and cash equivalents, beginning of period Supplemental Cash Flow Information [Abstract] Supplemental disclosure of cash flow information: Income Taxes Paid, Net Cash paid for income taxes Right-of-Use Asset Obtained in Exchange for Operating Lease Liability Right-of-use asset recognized in exchange for a new lease obligation Operating Lease, Payments Operating and short-term lease payments recorded within cash flow provided by operating activities Basis of Presentation Organization, Consolidation and Presentation of Financial Statements Disclosure and Significant Accounting Policies [Text Block] Basis of Presentation Revenue Recognition Revenue from Contract with Customer [Text Block] Revenue Recognition Basic and Diluted Net Income per Share Earnings Per Share [Text Block] Basic and Diluted Net Income per Share Inventory Inventory Disclosure [Text Block] Inventory Property and Equipment Property, Plant and Equipment Disclosure [Text Block] Property and Equipment Intangible Assets Intangible Assets Disclosure [Text Block] Intangible Assets Investments Investments in Debt and Marketable Equity Securities (and Certain Trading Assets) Disclosure [Text Block] Investments Fair Value Measurements Fair Value Disclosures [Text Block] Fair Value Measurements Comprehensive Income (Loss) Note [Text Block] Accumulated Other Comprehensive Income Stock-Based Compensation Disclosure of Compensation Related Costs, Share-based Payments [Text Block] Stock-Based Compensation Income Taxes Income Tax Disclosure [Text Block] Income Taxes Leases Lessee, Operating Leases [Text Block] Leases Commitments and Contingencies Commitments and Contingencies Disclosure [Text Block] Commitments and Contingencies Concentration Risk, Credit Risk, Policy [Policy Text Block] Certain Significant Risks and Uncertainties New Accounting Pronouncements, Policy [Policy Text Block] Recent Accounting Pronouncements Disaggregation of Revenue [Table Text Block] Schedule of disaggregation of revenue by geographic region and revenue type Contract with Customer, Asset and Liability [Table Text Block] Schedule of contract liabilities and changes in the contract liabilities Schedule of Earnings Per Share, Basic and Diluted [Table Text Block] Schedule of computation of basic and diluted net income per share Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block] Schedule of stock options and restricted stock units excluded from the calculation of diluted net income per share Schedule of Inventory, Current [Table Text Block] Schedule of inventory Property, Plant and Equipment [Table Text Block] Schedule of property and equipment Long-lived Assets by Geographic Areas [Table Text Block] Schedule of property and equipment, net, information by geographic region Schedule of Finite-Lived Intangible Assets [Table Text Block] Summary of the components of intangible asset balances Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block] Schedule of expected annual amortization expense related to intangible assets (excludes in process intangible assets) Debt Securities, Available-for-sale [Table Text Block] Summary of available-for-sale securities Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block] Schedule of the fair value of assets and liabilities subject to recurring fair value measurements Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block] Schedule of components of accumulated other comprehensive loss, net of tax Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table Text Block] Schedule of stock-based compensation Schedule of Share-based Compensation, Activity [Table Text Block] Summary of stock options and restricted stock units activity Lease, Cost [Table Text Block] Schedule of operating lease cost Lessee, Operating Lease, Liability, Maturity [Table Text Block] Schedule of maturity of operating lease liability Number of Reportable Segments Number of reportable segment EX-101.PRE 9 irmd-20210630_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE XML 10 irmd-20210630x10q_htm.xml IDEA: XBRL DOCUMENT 0001325618 us-gaap:EmployeeStockOptionMember 2021-01-01 2021-06-30 0001325618 us-gaap:RetainedEarningsMember 2021-06-30 0001325618 us-gaap:AdditionalPaidInCapitalMember 2021-06-30 0001325618 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-06-30 0001325618 us-gaap:RetainedEarningsMember 2021-03-31 0001325618 us-gaap:AdditionalPaidInCapitalMember 2021-03-31 0001325618 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-03-31 0001325618 us-gaap:RetainedEarningsMember 2020-12-31 0001325618 us-gaap:AdditionalPaidInCapitalMember 2020-12-31 0001325618 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-12-31 0001325618 us-gaap:RetainedEarningsMember 2020-06-30 0001325618 us-gaap:AdditionalPaidInCapitalMember 2020-06-30 0001325618 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-06-30 0001325618 us-gaap:RetainedEarningsMember 2020-03-31 0001325618 us-gaap:AdditionalPaidInCapitalMember 2020-03-31 0001325618 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-03-31 0001325618 us-gaap:RetainedEarningsMember 2019-12-31 0001325618 us-gaap:AdditionalPaidInCapitalMember 2019-12-31 0001325618 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-12-31 0001325618 us-gaap:CommonStockMember 2021-06-30 0001325618 us-gaap:CommonStockMember 2021-03-31 0001325618 us-gaap:CommonStockMember 2020-12-31 0001325618 us-gaap:CommonStockMember 2020-06-30 0001325618 us-gaap:CommonStockMember 2020-03-31 0001325618 us-gaap:CommonStockMember 2019-12-31 0001325618 us-gaap:EmployeeStockOptionMember 2021-06-30 0001325618 us-gaap:RestrictedStockUnitsRSUMember 2020-12-31 0001325618 us-gaap:EmployeeStockOptionMember 2020-12-31 0001325618 irmd:PerformanceBasedRestrictedStockUnitsMember 2020-12-31 0001325618 irmd:InternationalMember 2021-04-01 2021-06-30 0001325618 country:US 2021-04-01 2021-06-30 0001325618 irmd:InternationalMember 2021-01-01 2021-06-30 0001325618 country:US 2021-01-01 2021-06-30 0001325618 irmd:InternationalMember 2020-04-01 2020-06-30 0001325618 country:US 2020-04-01 2020-06-30 0001325618 irmd:InternationalMember 2020-01-01 2020-06-30 0001325618 country:US 2020-01-01 2020-06-30 0001325618 us-gaap:CommonStockMember 2021-04-01 2021-06-30 0001325618 us-gaap:CommonStockMember 2021-01-01 2021-03-31 0001325618 us-gaap:CommonStockMember 2020-04-01 2020-06-30 0001325618 us-gaap:CommonStockMember 2020-01-01 2020-03-31 0001325618 irmd:InternationalMember 2021-06-30 0001325618 country:US 2021-06-30 0001325618 irmd:InternationalMember 2020-12-31 0001325618 country:US 2020-12-31 0001325618 us-gaap:MachineryAndEquipmentMember 2021-06-30 0001325618 us-gaap:LeaseholdImprovementsMember 2021-06-30 0001325618 us-gaap:FurnitureAndFixturesMember 2021-06-30 0001325618 irmd:ToolingInProcessMember 2021-06-30 0001325618 irmd:ComputerSoftwareAndHardwareMember 2021-06-30 0001325618 us-gaap:MachineryAndEquipmentMember 2020-12-31 0001325618 us-gaap:LeaseholdImprovementsMember 2020-12-31 0001325618 us-gaap:FurnitureAndFixturesMember 2020-12-31 0001325618 irmd:ToolingInProcessMember 2020-12-31 0001325618 irmd:ComputerSoftwareAndHardwareMember 2020-12-31 0001325618 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-04-01 2021-06-30 0001325618 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-01-01 2021-03-31 0001325618 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-04-01 2020-06-30 0001325618 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-01-01 2020-03-31 0001325618 us-gaap:RetainedEarningsMember 2021-04-01 2021-06-30 0001325618 us-gaap:RetainedEarningsMember 2021-01-01 2021-03-31 0001325618 us-gaap:RetainedEarningsMember 2020-04-01 2020-06-30 0001325618 us-gaap:RetainedEarningsMember 2020-01-01 2020-03-31 0001325618 irmd:WinterSpringsFloridaFacilityMember irmd:SusiLLCMember 2021-06-30 0001325618 us-gaap:TrademarksMember 2021-06-30 0001325618 irmd:SoftwareDevelopmentInUseMember 2021-06-30 0001325618 irmd:SoftwareDevelopmentInProcessMember 2021-06-30 0001325618 irmd:PatentsInUseMember 2021-06-30 0001325618 irmd:PatentsInProcessMember 2021-06-30 0001325618 us-gaap:TrademarksMember 2020-12-31 0001325618 irmd:SoftwareDevelopmentInUseMember 2020-12-31 0001325618 irmd:SoftwareDevelopmentInProcessMember 2020-12-31 0001325618 irmd:PatentsInUseMember 2020-12-31 0001325618 irmd:PatentsInProcessMember 2020-12-31 0001325618 us-gaap:RestrictedStockUnitsRSUMember 2021-06-30 0001325618 irmd:PerformanceBasedRestrictedStockUnitsMember 2021-06-30 0001325618 us-gaap:RestrictedStockUnitsRSUMember 2021-01-01 2021-06-30 0001325618 irmd:PerformanceBasedRestrictedStockUnitsMember 2021-01-01 2021-06-30 0001325618 us-gaap:DomesticCorporateDebtSecuritiesMember 2021-01-01 2021-06-30 0001325618 us-gaap:DomesticCorporateDebtSecuritiesMember 2020-01-01 2020-12-31 0001325618 us-gaap:DomesticCorporateDebtSecuritiesMember 2021-06-30 0001325618 us-gaap:DomesticCorporateDebtSecuritiesMember 2020-12-31 0001325618 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:DomesticCorporateDebtSecuritiesMember 2021-06-30 0001325618 us-gaap:FairValueMeasurementsRecurringMember us-gaap:DomesticCorporateDebtSecuritiesMember 2021-06-30 0001325618 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:DomesticCorporateDebtSecuritiesMember 2020-12-31 0001325618 us-gaap:FairValueMeasurementsRecurringMember us-gaap:DomesticCorporateDebtSecuritiesMember 2020-12-31 0001325618 us-gaap:SellingAndMarketingExpenseMember 2021-04-01 2021-06-30 0001325618 us-gaap:ResearchAndDevelopmentExpenseMember 2021-04-01 2021-06-30 0001325618 us-gaap:GeneralAndAdministrativeExpenseMember 2021-04-01 2021-06-30 0001325618 us-gaap:CostOfSalesMember 2021-04-01 2021-06-30 0001325618 us-gaap:SellingAndMarketingExpenseMember 2021-01-01 2021-06-30 0001325618 us-gaap:ResearchAndDevelopmentExpenseMember 2021-01-01 2021-06-30 0001325618 us-gaap:GeneralAndAdministrativeExpenseMember 2021-01-01 2021-06-30 0001325618 us-gaap:CostOfSalesMember 2021-01-01 2021-06-30 0001325618 us-gaap:SellingAndMarketingExpenseMember 2020-04-01 2020-06-30 0001325618 us-gaap:ResearchAndDevelopmentExpenseMember 2020-04-01 2020-06-30 0001325618 us-gaap:GeneralAndAdministrativeExpenseMember 2020-04-01 2020-06-30 0001325618 us-gaap:CostOfSalesMember 2020-04-01 2020-06-30 0001325618 us-gaap:SellingAndMarketingExpenseMember 2020-01-01 2020-06-30 0001325618 us-gaap:ResearchAndDevelopmentExpenseMember 2020-01-01 2020-06-30 0001325618 us-gaap:GeneralAndAdministrativeExpenseMember 2020-01-01 2020-06-30 0001325618 us-gaap:CostOfSalesMember 2020-01-01 2020-06-30 0001325618 us-gaap:AdditionalPaidInCapitalMember 2021-04-01 2021-06-30 0001325618 us-gaap:AdditionalPaidInCapitalMember 2021-01-01 2021-03-31 0001325618 2021-01-01 2021-03-31 0001325618 us-gaap:AdditionalPaidInCapitalMember 2020-04-01 2020-06-30 0001325618 us-gaap:AdditionalPaidInCapitalMember 2020-01-01 2020-03-31 0001325618 2020-01-01 2020-03-31 0001325618 2021-03-31 0001325618 2020-06-30 0001325618 2020-03-31 0001325618 2019-12-31 0001325618 irmd:MRICompatiblePatientVitalSignsMonitoringSystemsMember 2021-04-01 2021-06-30 0001325618 irmd:MRICompatibleIVInfusionPumpsMember 2021-04-01 2021-06-30 0001325618 irmd:MRICompatiblePatientVitalSignsMonitoringSystemsMember 2021-01-01 2021-06-30 0001325618 irmd:MRICompatibleIVInfusionPumpsMember 2021-01-01 2021-06-30 0001325618 irmd:MRICompatiblePatientVitalSignsMonitoringSystemsMember 2020-04-01 2020-06-30 0001325618 irmd:MRICompatibleIVInfusionPumpsMember 2020-04-01 2020-06-30 0001325618 irmd:MRICompatiblePatientVitalSignsMonitoringSystemsMember 2020-01-01 2020-06-30 0001325618 irmd:MRICompatibleIVInfusionPumpsMember 2020-01-01 2020-06-30 0001325618 irmd:WinterSpringsFloridaFacilityMember irmd:SusiLLCMember 2014-01-31 0001325618 irmd:WinterSpringsFloridaFacilityMember irmd:SusiLLCMember 2014-01-01 2014-01-31 0001325618 2021-04-01 2021-06-30 0001325618 2020-04-01 2020-06-30 0001325618 2020-01-01 2020-06-30 0001325618 2021-06-30 0001325618 2020-12-31 0001325618 2021-08-01 0001325618 2021-01-01 2021-06-30 shares iso4217:USD irmd:item pure iso4217:USD shares irmd:segment 0 0

false

0001325618 --12-31 2021 Q2 false

true

12317036

12308432

10-Q true 2021-06-30 false 001-36534 IRADIMED CORP DE 73-1408526 1025 Willa Springs Drive Winter Springs FL 32708 407 677-8022 Common stock, par value $0.0001 IRMD NASDAQ Yes Yes Non-accelerated Filer true false false 12318027

55159661

50068728

948958

1909368

45578

46484

3884704

4574932

4468115

3933987

1230033

771666

2945799

2477211

68637270

63735892

2092224

2120148

1010073

960885

2614351

2715030

992996

1272672

232685

261993

75579599

71066620

667882

657054

2010074

1714782

122452

103981

108528

90054

2973334

1949259

268488

255698

146435

6297193

4917263

2034429

2305413

2345863

2459332

10677485

9682008

0.0001

31500000

12317036

1232

1231

24350709

23676843

40525994

37669451

24179

37087

64902114

61384612

75579599

71066620

9810423

6794692

19034419

15472233

2478122

1864587

4639802

4078317

7332301

4930105

14394617

11393916

2564619

5002427

4994988

7865154

2469777

2374134

4848901

4807701

453679

482654

929496

912936

5488075

7859215

10773385

13585791

1844226

-2929110

3621232

-2191875

13195

17852

7532

116354

1857421

-2911258

3628764

-2075521

387727

-798988

772221

-1732462

1469694

-2112270

2856543

-343059

0.12

-0.17

0.23

-0.03

0.12

-0.17

0.23

-0.03

12313563

12076399

12312078

11983913

12554828

12076399

12539483

11983913

1469694

-2112270

2856543

-343059

5772

4227

-7331

7669

1790

19797

-3079

30230

3176

2199

3176

2199

9829

6662

9829

6662

-8039

13135

-12908

23568

1461655

-2099135

2843635

-319491

12308432

1231

23676843

37669451

37087

61384612

1386849

-4869

347741

3502

-38707

250

2460

12312184

1231

23988337

39056300

32218

63078086

1469694

-8039

358012

2727

-15875

-15874

2125

20235

12317036

1232

24350709

40525994

24179

64902114

11765875

1177

19192394

36300450

30374

55524395

1769211

10433

568958

14521

-133873

-133872

190541

322160

322179

11970937

1197

19949639

38069661

40807

58061304

-2112270

13135

2658632

76381

-725393

-725385

150519

468795

468810

12197837

1220

22351673

35957391

53942

58364226

2856543

-343059

-879

40029

52978

35376

680091

668823

705753

3227590

-290183

834179

13005

8861

-691107

-2747675

493488

1360074

1473503

674047

-30425

26402

-79060

-319583

295292

-472705

18471

-88451

18474 6611

1402978

255298

31141

-468588

-897951

4513772

1987231

950000

480000

240543

300558

100410

122534

609047

56908

22695

790989

54581

859257

-31886

-68268

5090933

1975871

50068728

43481781

55159661

45457652

963722

27713

238982

214877

IRADIMED CORPORATIONNotes to Unaudited Condensed Financial Statements1 — Basis of PresentationThe accompanying interim condensed financial statements of IRADIMED CORPORATION (“IRADIMED”, the “Company”, “we”, “our”) have been prepared pursuant to the rules and regulations of the SEC. Certain information and footnote disclosures normally presented in annual financial statements prepared in accordance with U.S. generally accepted accounting principles ("GAAP") have been condensed or omitted pursuant to such rules and regulations. The interim financial information is unaudited, but reflects all normal adjustments that are, in the opinion of management, necessary for the fair presentation of our financial position, results of operations and cash flows for the interim periods presented. Operating results for the three and six months ended June 30, 2021 are not necessarily indicative of the results that may be expected for the year ending December 31, 2021.These accompanying interim condensed financial statements should be read with the financial statements and related footnotes to financial statements included in our Annual Report on Form 10-K for the year ended December 31, 2020. The accounting policies followed in the preparation of these interim condensed financial statements, except as described in Note 1, are consistent in all material respects with those described in Note 1 of our Form 10-K. We operate in one reportable segment which is the development, manufacture and sale of MRI compatible medical devices, related accessories, disposables and service for use by hospitals and acute care facilities during MRI procedures.Certain Significant Risks and UncertaintiesWe market our products to end users in the U.S. and to distributors internationally. Sales to end users in the U.S. are generally made on open credit terms. Management maintains an allowance for potential credit losses. We have deposited our cash and cash equivalents with various financial institutions. Our cash and cash equivalents balances exceed federally insured limits throughout the year. We have not incurred any losses related to these balances.Our products require clearance from the Food and Drug Administration and international regulatory agencies prior to commercialized sales. Our future products may not receive required approvals. If we were denied such approvals, or if such approvals were revoked or delayed or if we were unable to timely renew certain approvals for existing products, it would have a materially adverse impact on our business, results of operations and financial condition.Certain key components of our products essential to their functionality are sole-sourced. Any disruption in the availability of these components would have a materially adverse impact on our business, results of operations and financial condition.COVID-19 ConsiderationsThe COVID-19 pandemic continues to cause disruption in global supply and distribution channels and dramatically changed the way companies do business. From the beginning of this global health crisis, our first priority has been the safety and well-being of our employees.We continue to monitor the developments associated with the COVID-19 pandemic and its effects on our employees, customers, supply chain and distribution channels. The ongoing impact of the pandemic depends on a number of factors including the severity and duration of the pandemic and the extent and severity of the impact on our customers, which is uncertain and unpredictable. Our future results of operations and cash flows may suffer adverse effects from delays in payments on outstanding accounts receivable, potential manufacturing, distribution and supply chain disruptions, uncertain demand for our products, and effects of any actions we may take to address financial and operational challenges our customers may face. Our future results will be heavily determined by timely rollout of the vaccines, effectiveness of the vaccines, the duration of the pandemic, its geographic spread, further business disruptions and the overall impact on the global economy. Other risks and uncertainties that we face include, but are not limited to:<table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:54pt;"/><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">●</td><td style="padding:0pt;">postponement or cancellation of MRI medical procedures and their uncertain return which adversely impacts our business;</td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:54pt;"/><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">●</td><td style="padding:0pt;">disruptions in our supply chain that may limit our ability to procure materials necessary to manufacture our products;</td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:54pt;"/><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">●</td><td style="padding:0pt;">potential temporary or prolonged closure of our office and production facility;</td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:54pt;"/><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">●</td><td style="padding:0pt;">the health of our employees and ability to meet staffing needs;</td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:54pt;"/><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">●</td><td style="padding:0pt;">potential new or continued governmental actions that may limit employees’ ability to work;</td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:54pt;"/><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">●</td><td style="padding:0pt;">civil unrest relating to government, corporate and societal responses to the pandemic;</td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:54pt;"/><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">●</td><td style="padding:0pt;">volatility in economic conditions and the financial markets, and</td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:54pt;"/><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">●</td><td style="padding:0pt;">other unanticipated effects that remain unknown.</td></tr></table><div style="margin-top:10pt;"/>We are actively managing our response to the COVID-19 pandemic and working with our customers, distributors, vendors, and suppliers and assessing the potential effects to our financial position, results of operations and cash flows. As of the date of the issuance of these financial statements, the extent to which COVID-19 may materially impact our financial condition, liquidity, or results of operations in future periods remains uncertain.Recent Accounting PronouncementsRecently Issued Accounting Pronouncements to be ImplementedIn June 2016, the Financial Accounting Standards Board (“FASB”) issued Accounting Standard Update (“ASU”) 2016-13, Financial Instruments - Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments, which requires the Company to measure and recognize expected credit losses for financial assets held and not accounted for at fair value through net income. In November 2018, April 2019 and May 2019, the FASB issued ASU 2018-19, Codification Improvements to Topic 326, Financial Instruments - Credit Losses, ASU 2019-04, Codification Improvements to Topic 326, Financial Instruments - Credit Losses and ASU 2019-05, Financial Instruments - Credit Losses (Topic 326): Targeted Transition Relief, which provided additional implementation guidance on ASU 2016-03. The previously mentioned ASUs are effective for fiscal years beginning after December 15, 2022, with early adoption permitted. We do not expect the adoption of these ASUs to have a material impact on our financial condition, results of operations or cash flows.Accounting Pronouncements Implemented in 2021In December 2019, the FASB issued ASU No. 2019-12, Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes. ASU 2019-12 will be effective for fiscal years, and interim periods within those years, beginning after December 15, 2020. We adopted ASU 2019-12 on January 1, 2021, and the adoption did not have an impact on our financial condition, results of operations or cash flows.

Certain Significant Risks and UncertaintiesWe market our products to end users in the U.S. and to distributors internationally. Sales to end users in the U.S. are generally made on open credit terms. Management maintains an allowance for potential credit losses. We have deposited our cash and cash equivalents with various financial institutions. Our cash and cash equivalents balances exceed federally insured limits throughout the year. We have not incurred any losses related to these balances.Our products require clearance from the Food and Drug Administration and international regulatory agencies prior to commercialized sales. Our future products may not receive required approvals. If we were denied such approvals, or if such approvals were revoked or delayed or if we were unable to timely renew certain approvals for existing products, it would have a materially adverse impact on our business, results of operations and financial condition.Certain key components of our products essential to their functionality are sole-sourced. Any disruption in the availability of these components would have a materially adverse impact on our business, results of operations and financial condition.COVID-19 ConsiderationsThe COVID-19 pandemic continues to cause disruption in global supply and distribution channels and dramatically changed the way companies do business. From the beginning of this global health crisis, our first priority has been the safety and well-being of our employees.We continue to monitor the developments associated with the COVID-19 pandemic and its effects on our employees, customers, supply chain and distribution channels. The ongoing impact of the pandemic depends on a number of factors including the severity and duration of the pandemic and the extent and severity of the impact on our customers, which is uncertain and unpredictable. Our future results of operations and cash flows may suffer adverse effects from delays in payments on outstanding accounts receivable, potential manufacturing, distribution and supply chain disruptions, uncertain demand for our products, and effects of any actions we may take to address financial and operational challenges our customers may face. Our future results will be heavily determined by timely rollout of the vaccines, effectiveness of the vaccines, the duration of the pandemic, its geographic spread, further business disruptions and the overall impact on the global economy. Other risks and uncertainties that we face include, but are not limited to:<table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:54pt;"/><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">●</td><td style="padding:0pt;">postponement or cancellation of MRI medical procedures and their uncertain return which adversely impacts our business;</td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:54pt;"/><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">●</td><td style="padding:0pt;">disruptions in our supply chain that may limit our ability to procure materials necessary to manufacture our products;</td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:54pt;"/><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">●</td><td style="padding:0pt;">potential temporary or prolonged closure of our office and production facility;</td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:54pt;"/><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">●</td><td style="padding:0pt;">the health of our employees and ability to meet staffing needs;</td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:54pt;"/><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">●</td><td style="padding:0pt;">potential new or continued governmental actions that may limit employees’ ability to work;</td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:54pt;"/><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">●</td><td style="padding:0pt;">civil unrest relating to government, corporate and societal responses to the pandemic;</td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:54pt;"/><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">●</td><td style="padding:0pt;">volatility in economic conditions and the financial markets, and</td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:54pt;"/><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">●</td><td style="padding:0pt;">other unanticipated effects that remain unknown.</td></tr></table><div style="margin-top:10pt;"/>We are actively managing our response to the COVID-19 pandemic and working with our customers, distributors, vendors, and suppliers and assessing the potential effects to our financial position, results of operations and cash flows. As of the date of the issuance of these financial statements, the extent to which COVID-19 may materially impact our financial condition, liquidity, or results of operations in future periods remains uncertain.

2 — Revenue RecognitionDisaggregation of RevenueWe disaggregate revenue from contracts with customers by geographic region and revenue type as we believe it best depicts the nature, amount, timing and uncertainty of our revenue and cash flow.Revenue information by geographic region is as follows:<table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:43.21%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.51%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.51%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.51%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td></tr><tr><td style="vertical-align:bottom;width:43.21%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:25.88%;margin:0pt;padding:0pt;">Three Months Ended </td><td style="vertical-align:bottom;white-space:nowrap;width:2.51%;margin:0pt;padding:0pt;"></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:25.87%;margin:0pt;padding:0pt;">Six Months Ended</td></tr><tr><td style="vertical-align:bottom;width:43.21%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:25.88%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">June 30, </td><td style="vertical-align:bottom;white-space:nowrap;width:2.51%;margin:0pt;padding:0pt;"></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:25.87%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">June 30,</td></tr><tr><td style="vertical-align:bottom;width:43.21%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">2021</td><td style="vertical-align:bottom;white-space:nowrap;width:2.51%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">2020</td><td style="vertical-align:bottom;white-space:nowrap;width:2.51%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">2021</td><td style="vertical-align:bottom;white-space:nowrap;width:2.51%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">2020</td></tr><tr style="height:0pt;visibility:hidden;"><td colspan="13" style="padding:0pt;"/></tr><tr><td style="vertical-align:bottom;width:43.21%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:25.88%;margin:0pt;padding:0pt;">(unaudited)</td><td style="vertical-align:bottom;white-space:nowrap;width:2.51%;margin:0pt;padding:0pt;"></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:25.87%;margin:0pt;padding:0pt;">(unaudited)</td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:43.21%;margin:0pt;padding:0pt;">United States </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;">$</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.1%;margin:0pt;padding:0pt;"> 8,043,156</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.51%;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;">$</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.1%;margin:0pt;padding:0pt;"> 4,642,916</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.51%;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;">$</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.1%;margin:0pt;padding:0pt;"> 15,315,986</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.51%;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;">$</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.08%;margin:0pt;padding:0pt;"> 10,965,022</td></tr><tr><td style="vertical-align:bottom;width:43.21%;margin:0pt;padding:0pt;">International </td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 1,767,267</td><td style="vertical-align:bottom;white-space:nowrap;width:2.51%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2,151,776</td><td style="vertical-align:bottom;white-space:nowrap;width:2.51%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 3,718,433</td><td style="vertical-align:bottom;white-space:nowrap;width:2.51%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 4,507,211</td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:43.21%;margin:0pt;padding:0pt;">Total revenue </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.58%;border-bottom:3px double #000000;margin:0pt;padding:0pt;">$</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.1%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 9,810,423</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.51%;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.58%;border-bottom:3px double #000000;margin:0pt;padding:0pt;">$</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.1%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 6,794,692</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.51%;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.58%;border-bottom:3px double #000000;margin:0pt;padding:0pt;">$</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.1%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 19,034,419</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.51%;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.58%;border-bottom:3px double #000000;margin:0pt;padding:0pt;">$</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.08%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 15,472,233</td></tr></table>Revenue information by type is as follows:<table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:48.07%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.17%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.19%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.47%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.47%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td></tr><tr><td style="vertical-align:bottom;width:48.07%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.41%;margin:0pt;padding:0pt;">Three Months Ended </td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:24%;margin:0pt;padding:0pt;">Six Months Ended </td></tr><tr><td style="vertical-align:bottom;width:48.07%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">June 30, </td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">June 30, </td></tr><tr><td style="vertical-align:bottom;width:48.07%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">2021</td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">2020</td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.87%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">2021</td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.87%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">2020</td></tr><tr style="height:0pt;visibility:hidden;"><td colspan="13" style="padding:0pt;"/></tr><tr><td style="vertical-align:bottom;width:48.07%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.41%;margin:0pt;padding:0pt;">(unaudited)</td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:24%;margin:0pt;padding:0pt;">(unaudited)</td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:48.07%;margin:0pt;padding:0pt;">Devices:</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.17%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.19%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.47%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.47%;margin:0pt;padding:0pt;"></td></tr><tr><td style="vertical-align:bottom;width:48.07%;margin:0pt;padding:0pt;">MRI Compatible IV Infusion Pump Systems</td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:9.17%;margin:0pt;padding:0pt;"> 2,456,767</td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:9.19%;margin:0pt;padding:0pt;"> 1,875,159</td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:9.47%;margin:0pt;padding:0pt;"> 5,960,114</td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:9.47%;margin:0pt;padding:0pt;"> 4,539,993</td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:48.07%;margin:0pt;padding:0pt;">MRI Compatible Patient Vital Signs Monitoring Systems</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 3,377,719</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 1,927,473</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 5,981,549</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 4,546,988</td></tr><tr><td style="vertical-align:bottom;width:48.07%;margin:0pt;padding:0pt;">Total Devices revenue</td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.17%;margin:0pt;padding:0pt;"> 5,834,486</td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.19%;margin:0pt;padding:0pt;"> 3,802,632</td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.47%;margin:0pt;padding:0pt;"> 11,941,663</td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.47%;margin:0pt;padding:0pt;"> 9,086,981</td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:48.07%;margin:0pt;padding:0pt;">Disposables, services and other</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.17%;margin:0pt;padding:0pt;"> 3,490,969</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.19%;margin:0pt;padding:0pt;"> 2,535,548</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.47%;margin:0pt;padding:0pt;"> 6,126,435</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.47%;margin:0pt;padding:0pt;"> 5,467,449</td></tr><tr><td style="vertical-align:bottom;width:48.07%;margin:0pt;padding:0pt;">Amortization of extended warranty agreements</td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 484,968</td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 456,512</td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 966,321</td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 917,803</td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:48.07%;margin:0pt;padding:0pt;">Total revenue</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.39%;border-bottom:3px double #000000;margin:0pt;padding:0pt;">$</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.17%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 9,810,423</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.39%;border-bottom:3px double #000000;margin:0pt;padding:0pt;">$</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.19%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 6,794,692</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.39%;border-bottom:3px double #000000;margin:0pt;padding:0pt;">$</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.47%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 19,034,419</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.4%;border-bottom:3px double #000000;margin:0pt;padding:0pt;">$</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.47%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 15,472,233</td></tr></table>Contract LiabilitiesOur contract liabilities consist of:<table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:60.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.51%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:14.09%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.51%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:14.09%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td></tr><tr><td style="vertical-align:bottom;width:60.37%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:3.51%;margin:0pt;padding:0pt;"></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.29%;margin:0pt;padding:0pt;">June 30, </td><td style="vertical-align:bottom;white-space:nowrap;width:3.51%;margin:0pt;padding:0pt;"></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.29%;margin:0pt;padding:0pt;">December 31, </td></tr><tr><td style="vertical-align:bottom;width:60.37%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:3.51%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">2021</td><td style="vertical-align:bottom;white-space:nowrap;width:3.51%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">2020</td></tr><tr><td style="vertical-align:bottom;width:60.37%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:3.51%;margin:0pt;padding:0pt;"></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.29%;margin:0pt;padding:0pt;">(unaudited)</td><td style="vertical-align:bottom;white-space:nowrap;width:3.51%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:14.09%;margin:0pt;padding:0pt;"></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:60.37%;margin:0pt;padding:0pt;">Advance payments from customers </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.51%;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;">$</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:14.09%;margin:0pt;padding:0pt;"> 484,354</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.51%;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;">$</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:14.09%;margin:0pt;padding:0pt;"> 85,590</td></tr><tr><td style="vertical-align:bottom;width:60.37%;margin:0pt;padding:0pt;">Shipments in-transit </td><td style="vertical-align:bottom;white-space:nowrap;width:3.51%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:14.09%;margin:0pt;padding:0pt;"> 649,887</td><td style="vertical-align:bottom;white-space:nowrap;width:3.51%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:14.09%;margin:0pt;padding:0pt;"> 35,013</td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:60.37%;margin:0pt;padding:0pt;">Extended warranty agreements </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.51%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:14.09%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 3,873,522</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.51%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:14.09%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 4,134,069</td></tr><tr><td style="vertical-align:bottom;width:60.37%;margin:0pt;padding:0pt;">Total </td><td style="vertical-align:bottom;white-space:nowrap;width:3.51%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;border-bottom:3px double #000000;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:14.09%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 5,007,763</td><td style="vertical-align:bottom;white-space:nowrap;width:3.51%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;border-bottom:3px double #000000;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:14.09%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 4,254,672</td></tr></table>Changes in the contract liabilities during the periods presented are as follows:<table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:83.43%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td></tr><tr><td style="vertical-align:bottom;width:83.43%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.95%;margin:0pt;padding:0pt;">Deferred </td></tr><tr><td style="vertical-align:bottom;width:83.43%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.95%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">Revenue</td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:83.43%;margin:0pt;padding:0pt;">Contract liabilities, December 31, 2020</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;">$</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.33%;margin:0pt;padding:0pt;"> 4,254,672</td></tr><tr><td style="vertical-align:bottom;width:83.43%;margin:0pt;padding:0pt;">Increases due to cash received from customers </td><td style="vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:12.33%;margin:0pt;padding:0pt;"> 2,426,575</td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:83.43%;margin:0pt;padding:0pt;">Decreases due to recognition of revenue </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.33%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (1,673,484)</td></tr><tr><td style="vertical-align:bottom;width:83.43%;margin:0pt;padding:0pt;">Contract liabilities, June 30, 2021</td><td style="vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;border-bottom:3px double #000000;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:12.33%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 5,007,763</td></tr></table><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:83.43%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td></tr><tr><td style="vertical-align:bottom;width:83.43%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.95%;margin:0pt;padding:0pt;">Deferred </td></tr><tr><td style="vertical-align:bottom;width:83.43%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.95%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">Revenue</td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:83.43%;margin:0pt;padding:0pt;">Contract liabilities, December 31, 2019</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;">$</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.33%;margin:0pt;padding:0pt;"> 4,301,887</td></tr><tr><td style="vertical-align:bottom;width:83.43%;margin:0pt;padding:0pt;">Increases due to cash received from customers</td><td style="vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.33%;margin:0pt;padding:0pt;"> 1,236,658</td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:83.43%;margin:0pt;padding:0pt;">Decreases due to recognition of revenue</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.33%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (1,048,380)</td></tr><tr><td style="vertical-align:bottom;width:83.43%;margin:0pt;padding:0pt;">Contract liabilities, June 30, 2020</td><td style="vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;border-bottom:3px double #000000;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:12.33%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 4,490,165</td></tr></table>Capitalized Contract CostsOur capitalized contract costs totaled $353,942 and $384,367 as of June 30, 2021 and December 31, 2020, respectively.

Revenue information by geographic region is as follows:<table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:43.21%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.51%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.51%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.51%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td></tr><tr><td style="vertical-align:bottom;width:43.21%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:25.88%;margin:0pt;padding:0pt;">Three Months Ended </td><td style="vertical-align:bottom;white-space:nowrap;width:2.51%;margin:0pt;padding:0pt;"></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:25.87%;margin:0pt;padding:0pt;">Six Months Ended</td></tr><tr><td style="vertical-align:bottom;width:43.21%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:25.88%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">June 30, </td><td style="vertical-align:bottom;white-space:nowrap;width:2.51%;margin:0pt;padding:0pt;"></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:25.87%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">June 30,</td></tr><tr><td style="vertical-align:bottom;width:43.21%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">2021</td><td style="vertical-align:bottom;white-space:nowrap;width:2.51%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">2020</td><td style="vertical-align:bottom;white-space:nowrap;width:2.51%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">2021</td><td style="vertical-align:bottom;white-space:nowrap;width:2.51%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">2020</td></tr><tr style="height:0pt;visibility:hidden;"><td colspan="13" style="padding:0pt;"/></tr><tr><td style="vertical-align:bottom;width:43.21%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:25.88%;margin:0pt;padding:0pt;">(unaudited)</td><td style="vertical-align:bottom;white-space:nowrap;width:2.51%;margin:0pt;padding:0pt;"></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:25.87%;margin:0pt;padding:0pt;">(unaudited)</td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:43.21%;margin:0pt;padding:0pt;">United States </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;">$</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.1%;margin:0pt;padding:0pt;"> 8,043,156</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.51%;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;">$</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.1%;margin:0pt;padding:0pt;"> 4,642,916</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.51%;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;">$</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.1%;margin:0pt;padding:0pt;"> 15,315,986</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.51%;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;">$</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.08%;margin:0pt;padding:0pt;"> 10,965,022</td></tr><tr><td style="vertical-align:bottom;width:43.21%;margin:0pt;padding:0pt;">International </td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 1,767,267</td><td style="vertical-align:bottom;white-space:nowrap;width:2.51%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2,151,776</td><td style="vertical-align:bottom;white-space:nowrap;width:2.51%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 3,718,433</td><td style="vertical-align:bottom;white-space:nowrap;width:2.51%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 4,507,211</td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:43.21%;margin:0pt;padding:0pt;">Total revenue </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.58%;border-bottom:3px double #000000;margin:0pt;padding:0pt;">$</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.1%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 9,810,423</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.51%;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.58%;border-bottom:3px double #000000;margin:0pt;padding:0pt;">$</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.1%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 6,794,692</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.51%;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.58%;border-bottom:3px double #000000;margin:0pt;padding:0pt;">$</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.1%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 19,034,419</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.51%;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.58%;border-bottom:3px double #000000;margin:0pt;padding:0pt;">$</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.08%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 15,472,233</td></tr></table>Revenue information by type is as follows:<table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:48.07%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.17%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.19%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.47%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.47%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td></tr><tr><td style="vertical-align:bottom;width:48.07%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.41%;margin:0pt;padding:0pt;">Three Months Ended </td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:24%;margin:0pt;padding:0pt;">Six Months Ended </td></tr><tr><td style="vertical-align:bottom;width:48.07%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">June 30, </td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">June 30, </td></tr><tr><td style="vertical-align:bottom;width:48.07%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">2021</td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">2020</td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.87%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">2021</td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.87%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">2020</td></tr><tr style="height:0pt;visibility:hidden;"><td colspan="13" style="padding:0pt;"/></tr><tr><td style="vertical-align:bottom;width:48.07%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.41%;margin:0pt;padding:0pt;">(unaudited)</td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:24%;margin:0pt;padding:0pt;">(unaudited)</td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:48.07%;margin:0pt;padding:0pt;">Devices:</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.17%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.19%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.47%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.47%;margin:0pt;padding:0pt;"></td></tr><tr><td style="vertical-align:bottom;width:48.07%;margin:0pt;padding:0pt;">MRI Compatible IV Infusion Pump Systems</td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:9.17%;margin:0pt;padding:0pt;"> 2,456,767</td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:9.19%;margin:0pt;padding:0pt;"> 1,875,159</td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:9.47%;margin:0pt;padding:0pt;"> 5,960,114</td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:9.47%;margin:0pt;padding:0pt;"> 4,539,993</td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:48.07%;margin:0pt;padding:0pt;">MRI Compatible Patient Vital Signs Monitoring Systems</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 3,377,719</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 1,927,473</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 5,981,549</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 4,546,988</td></tr><tr><td style="vertical-align:bottom;width:48.07%;margin:0pt;padding:0pt;">Total Devices revenue</td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.17%;margin:0pt;padding:0pt;"> 5,834,486</td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.19%;margin:0pt;padding:0pt;"> 3,802,632</td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.47%;margin:0pt;padding:0pt;"> 11,941,663</td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.47%;margin:0pt;padding:0pt;"> 9,086,981</td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:48.07%;margin:0pt;padding:0pt;">Disposables, services and other</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.17%;margin:0pt;padding:0pt;"> 3,490,969</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.19%;margin:0pt;padding:0pt;"> 2,535,548</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.47%;margin:0pt;padding:0pt;"> 6,126,435</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.47%;margin:0pt;padding:0pt;"> 5,467,449</td></tr><tr><td style="vertical-align:bottom;width:48.07%;margin:0pt;padding:0pt;">Amortization of extended warranty agreements</td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 484,968</td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 456,512</td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 966,321</td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 917,803</td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:48.07%;margin:0pt;padding:0pt;">Total revenue</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.39%;border-bottom:3px double #000000;margin:0pt;padding:0pt;">$</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.17%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 9,810,423</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.39%;border-bottom:3px double #000000;margin:0pt;padding:0pt;">$</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.19%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 6,794,692</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.39%;border-bottom:3px double #000000;margin:0pt;padding:0pt;">$</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.47%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 19,034,419</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.4%;border-bottom:3px double #000000;margin:0pt;padding:0pt;">$</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.47%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 15,472,233</td></tr></table>

8043156

4642916

15315986

10965022

1767267

2151776

3718433

4507211

9810423

6794692

19034419

15472233

2456767 1875159 5960114 4539993 3377719 1927473 5981549 4546988 5834486 3802632 11941663 9086981 3490969 2535548 6126435 5467449 484968 456512 966321 917803

9810423

6794692

19034419

15472233

Our contract liabilities consist of:<table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:60.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.51%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:14.09%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.51%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:14.09%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td></tr><tr><td style="vertical-align:bottom;width:60.37%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:3.51%;margin:0pt;padding:0pt;"></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.29%;margin:0pt;padding:0pt;">June 30, </td><td style="vertical-align:bottom;white-space:nowrap;width:3.51%;margin:0pt;padding:0pt;"></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.29%;margin:0pt;padding:0pt;">December 31, </td></tr><tr><td style="vertical-align:bottom;width:60.37%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:3.51%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">2021</td><td style="vertical-align:bottom;white-space:nowrap;width:3.51%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">2020</td></tr><tr><td style="vertical-align:bottom;width:60.37%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:3.51%;margin:0pt;padding:0pt;"></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.29%;margin:0pt;padding:0pt;">(unaudited)</td><td style="vertical-align:bottom;white-space:nowrap;width:3.51%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:14.09%;margin:0pt;padding:0pt;"></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:60.37%;margin:0pt;padding:0pt;">Advance payments from customers </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.51%;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;">$</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:14.09%;margin:0pt;padding:0pt;"> 484,354</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.51%;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;">$</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:14.09%;margin:0pt;padding:0pt;"> 85,590</td></tr><tr><td style="vertical-align:bottom;width:60.37%;margin:0pt;padding:0pt;">Shipments in-transit </td><td style="vertical-align:bottom;white-space:nowrap;width:3.51%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:14.09%;margin:0pt;padding:0pt;"> 649,887</td><td style="vertical-align:bottom;white-space:nowrap;width:3.51%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:14.09%;margin:0pt;padding:0pt;"> 35,013</td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:60.37%;margin:0pt;padding:0pt;">Extended warranty agreements </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.51%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:14.09%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 3,873,522</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.51%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:14.09%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 4,134,069</td></tr><tr><td style="vertical-align:bottom;width:60.37%;margin:0pt;padding:0pt;">Total </td><td style="vertical-align:bottom;white-space:nowrap;width:3.51%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;border-bottom:3px double #000000;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:14.09%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 5,007,763</td><td style="vertical-align:bottom;white-space:nowrap;width:3.51%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;border-bottom:3px double #000000;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:14.09%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 4,254,672</td></tr></table>Changes in the contract liabilities during the periods presented are as follows:<table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:83.43%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td></tr><tr><td style="vertical-align:bottom;width:83.43%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.95%;margin:0pt;padding:0pt;">Deferred </td></tr><tr><td style="vertical-align:bottom;width:83.43%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.95%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">Revenue</td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:83.43%;margin:0pt;padding:0pt;">Contract liabilities, December 31, 2020</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;">$</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.33%;margin:0pt;padding:0pt;"> 4,254,672</td></tr><tr><td style="vertical-align:bottom;width:83.43%;margin:0pt;padding:0pt;">Increases due to cash received from customers </td><td style="vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:12.33%;margin:0pt;padding:0pt;"> 2,426,575</td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:83.43%;margin:0pt;padding:0pt;">Decreases due to recognition of revenue </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.33%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (1,673,484)</td></tr><tr><td style="vertical-align:bottom;width:83.43%;margin:0pt;padding:0pt;">Contract liabilities, June 30, 2021</td><td style="vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;border-bottom:3px double #000000;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:12.33%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 5,007,763</td></tr></table><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:83.43%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td></tr><tr><td style="vertical-align:bottom;width:83.43%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.95%;margin:0pt;padding:0pt;">Deferred </td></tr><tr><td style="vertical-align:bottom;width:83.43%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.95%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">Revenue</td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:83.43%;margin:0pt;padding:0pt;">Contract liabilities, December 31, 2019</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;">$</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.33%;margin:0pt;padding:0pt;"> 4,301,887</td></tr><tr><td style="vertical-align:bottom;width:83.43%;margin:0pt;padding:0pt;">Increases due to cash received from customers</td><td style="vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.33%;margin:0pt;padding:0pt;"> 1,236,658</td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:83.43%;margin:0pt;padding:0pt;">Decreases due to recognition of revenue</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.33%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (1,048,380)</td></tr><tr><td style="vertical-align:bottom;width:83.43%;margin:0pt;padding:0pt;">Contract liabilities, June 30, 2020</td><td style="vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;border-bottom:3px double #000000;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:12.33%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 4,490,165</td></tr></table>

484354 85590 649887 35013

3873522

4134069

5007763

4254672

2426575 1673484

5007763

4301887

1236658 1048380

4490165

353942

384367

3 — Basic and Diluted Net Income per ShareBasic net income per share is based upon the weighted-average number of common shares outstanding during the period. Diluted net income per share reflects the potential dilution that could occur if securities or other contracts to issue common stock were exercised or converted into common stock. Stock options and restricted stock units granted by us represent the only dilutive effect reflected in diluted weighted-average shares outstanding.The following table presents the computation of basic and diluted net income per share:<table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:52.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.47%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.47%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.47%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.47%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td></tr><tr><td style="vertical-align:bottom;width:52.48%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:22.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">Three Months Ended June 30, </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:22.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">Six Months Ended June 30, </td></tr><tr><td style="vertical-align:bottom;width:52.48%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">2021</td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">2020</td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">2021</td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">2020</td></tr><tr style="height:0pt;visibility:hidden;"><td colspan="13" style="padding:0pt;"/></tr><tr><td style="vertical-align:bottom;width:52.48%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:22.27%;margin:0pt;padding:0pt;">(unaudited)</td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:22.27%;margin:0pt;padding:0pt;">(unaudited)</td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:52.48%;margin:0pt;padding:0pt;">Net income (loss)</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:3px double #000000;margin:0pt;padding:0pt;">$</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.47%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 1,469,694</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:3px double #000000;margin:0pt;padding:0pt;">$</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.47%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> (2,112,270)</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:3px double #000000;margin:0pt;padding:0pt;">$</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.47%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 2,856,543</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:3px double #000000;margin:0pt;padding:0pt;">$</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.47%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> (343,059)</td></tr><tr><td style="vertical-align:bottom;width:52.48%;margin:0pt;padding:0pt;">Weighted-average shares outstanding — Basic</td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.47%;margin:0pt;padding:0pt;"> 12,313,563</td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.47%;margin:0pt;padding:0pt;"> 12,076,399</td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.47%;margin:0pt;padding:0pt;"> 12,312,078</td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.47%;margin:0pt;padding:0pt;"> 11,983,913</td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:52.48%;margin:0pt;padding:0pt;">Effect of dilutive securities:</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.47%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.47%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.47%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.47%;margin:0pt;padding:0pt;"></td></tr><tr><td style="vertical-align:bottom;width:52.48%;margin:0pt;padding:0pt;">Stock options</td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:9.47%;margin:0pt;padding:0pt;"> 194,419</td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:9.47%;margin:0pt;padding:0pt;">—</td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:9.47%;margin:0pt;padding:0pt;"> 192,347</td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:9.47%;margin:0pt;padding:0pt;">—</td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:52.48%;margin:0pt;padding:0pt;">Restricted stock units</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 46,846</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">—</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 35,058</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">—</td></tr><tr><td style="vertical-align:bottom;width:52.48%;margin:0pt;padding:0pt;">Weighted-average shares outstanding — Diluted</td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.47%;margin:0pt;padding:0pt;"> 12,554,828</td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.47%;margin:0pt;padding:0pt;"> 12,076,399</td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.47%;margin:0pt;padding:0pt;"> 12,539,483</td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.47%;margin:0pt;padding:0pt;"> 11,983,913</td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:52.48%;margin:0pt;padding:0pt;">Basic net income (loss) per share</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:3px double #000000;margin:0pt;padding:0pt;">$</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.47%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 0.12</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:3px double #000000;margin:0pt;padding:0pt;">$</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.47%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> (0.17)</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:3px double #000000;margin:0pt;padding:0pt;">$</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.47%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 0.23</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:3px double #000000;margin:0pt;padding:0pt;">$</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.47%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> (0.03)</td></tr><tr><td style="vertical-align:bottom;width:52.48%;margin:0pt;padding:0pt;">Diluted net income (loss) per share</td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:3px double #000000;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:9.47%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 0.12</td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:3px double #000000;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:9.47%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> (0.17)</td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:3px double #000000;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:9.47%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 0.23</td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:3px double #000000;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:9.47%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> (0.03)</td></tr></table>Stock options and restricted stock units excluded from the calculation of diluted net income per share because the effect would have been anti-dilutive are as follows:<table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:61.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.68%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.67%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.67%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.63%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td></tr><tr><td style="vertical-align:bottom;width:61.64%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:17.27%;margin:0pt;padding:0pt;">Three Months Ended </td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:17.23%;margin:0pt;padding:0pt;">Six Months Ended</td></tr><tr><td style="vertical-align:bottom;width:61.64%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:17.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">June 30, </td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:17.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">June 30,</td></tr><tr><td style="vertical-align:bottom;width:61.64%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">2021</td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">2020</td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">2021</td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">2020</td></tr><tr style="height:0pt;visibility:hidden;"><td colspan="9" style="padding:0pt;"/></tr><tr><td style="vertical-align:bottom;width:61.64%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:17.27%;margin:0pt;padding:0pt;">(unaudited)</td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:17.23%;margin:0pt;padding:0pt;">(unaudited)</td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:61.64%;margin:0pt;padding:0pt;">Anti-dilutive stock options and restricted stock units</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.68%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 1,500</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.67%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 399,772</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.67%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 1,635</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.63%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 479,499</td></tr></table>

<table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:52.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.47%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.47%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.47%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.47%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td></tr><tr><td style="vertical-align:bottom;width:52.48%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:22.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">Three Months Ended June 30, </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:22.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">Six Months Ended June 30, </td></tr><tr><td style="vertical-align:bottom;width:52.48%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">2021</td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">2020</td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">2021</td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">2020</td></tr><tr style="height:0pt;visibility:hidden;"><td colspan="13" style="padding:0pt;"/></tr><tr><td style="vertical-align:bottom;width:52.48%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:22.27%;margin:0pt;padding:0pt;">(unaudited)</td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:22.27%;margin:0pt;padding:0pt;">(unaudited)</td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:52.48%;margin:0pt;padding:0pt;">Net income (loss)</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:3px double #000000;margin:0pt;padding:0pt;">$</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.47%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 1,469,694</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:3px double #000000;margin:0pt;padding:0pt;">$</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.47%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> (2,112,270)</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:3px double #000000;margin:0pt;padding:0pt;">$</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.47%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 2,856,543</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:3px double #000000;margin:0pt;padding:0pt;">$</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.47%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> (343,059)</td></tr><tr><td style="vertical-align:bottom;width:52.48%;margin:0pt;padding:0pt;">Weighted-average shares outstanding — Basic</td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.47%;margin:0pt;padding:0pt;"> 12,313,563</td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.47%;margin:0pt;padding:0pt;"> 12,076,399</td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.47%;margin:0pt;padding:0pt;"> 12,312,078</td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.47%;margin:0pt;padding:0pt;"> 11,983,913</td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:52.48%;margin:0pt;padding:0pt;">Effect of dilutive securities:</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.47%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.47%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.47%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.47%;margin:0pt;padding:0pt;"></td></tr><tr><td style="vertical-align:bottom;width:52.48%;margin:0pt;padding:0pt;">Stock options</td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:9.47%;margin:0pt;padding:0pt;"> 194,419</td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:9.47%;margin:0pt;padding:0pt;">—</td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:9.47%;margin:0pt;padding:0pt;"> 192,347</td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:9.47%;margin:0pt;padding:0pt;">—</td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:52.48%;margin:0pt;padding:0pt;">Restricted stock units</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 46,846</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">—</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 35,058</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">—</td></tr><tr><td style="vertical-align:bottom;width:52.48%;margin:0pt;padding:0pt;">Weighted-average shares outstanding — Diluted</td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.47%;margin:0pt;padding:0pt;"> 12,554,828</td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.47%;margin:0pt;padding:0pt;"> 12,076,399</td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.47%;margin:0pt;padding:0pt;"> 12,539,483</td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.47%;margin:0pt;padding:0pt;"> 11,983,913</td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:52.48%;margin:0pt;padding:0pt;">Basic net income (loss) per share</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:3px double #000000;margin:0pt;padding:0pt;">$</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.47%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 0.12</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:3px double #000000;margin:0pt;padding:0pt;">$</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.47%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> (0.17)</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:3px double #000000;margin:0pt;padding:0pt;">$</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.47%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 0.23</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:3px double #000000;margin:0pt;padding:0pt;">$</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.47%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> (0.03)</td></tr><tr><td style="vertical-align:bottom;width:52.48%;margin:0pt;padding:0pt;">Diluted net income (loss) per share</td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:3px double #000000;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:9.47%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 0.12</td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:3px double #000000;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:9.47%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> (0.17)</td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:3px double #000000;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:9.47%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 0.23</td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:3px double #000000;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:9.47%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> (0.03)</td></tr></table>

1469694

-2112270

2856543

-343059

12313563

12076399

12312078

11983913

194419

192347

46846 35058

12554828

12076399

12539483

11983913

0.12

-0.17

0.23

-0.03

0.12

-0.17

0.23

-0.03

1500

399772

1635

479499

4 — InventoryInventory consists of:<table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:72.61%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.68%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.68%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td></tr><tr><td style="vertical-align:bottom;width:72.61%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.84%;margin:0pt;padding:0pt;">June 30, </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.84%;margin:0pt;padding:0pt;">December 31, </td></tr><tr><td style="vertical-align:bottom;width:72.61%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">2021</td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">2020</td></tr><tr><td style="vertical-align:bottom;width:72.61%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.84%;margin:0pt;padding:0pt;">(unaudited)</td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.84%;margin:0pt;padding:0pt;"></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:72.61%;margin:0pt;padding:0pt;">Raw materials </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;">$</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.68%;margin:0pt;padding:0pt;"> 3,528,442</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;">$</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.68%;margin:0pt;padding:0pt;"> 3,210,815</td></tr><tr><td style="vertical-align:bottom;width:72.61%;margin:0pt;padding:0pt;">Work in process </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.68%;margin:0pt;padding:0pt;"> 264,868</td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.68%;margin:0pt;padding:0pt;"> 207,807</td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:72.61%;margin:0pt;padding:0pt;">Finished goods </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 865,456</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 653,038</td></tr><tr><td style="vertical-align:bottom;width:72.61%;margin:0pt;padding:0pt;">Inventory before allowance for excess and obsolete</td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:10.68%;margin:0pt;padding:0pt;"> 4,658,766</td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:10.68%;margin:0pt;padding:0pt;"> 4,071,660</td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:72.61%;margin:0pt;padding:0pt;">Allowance for excess and obsolete</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (190,651)</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (137,673)</td></tr><tr><td style="vertical-align:bottom;width:72.61%;margin:0pt;padding:0pt;">Total </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:3px double #000000;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:10.68%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 4,468,115</td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:3px double #000000;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:10.68%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 3,933,987</td></tr></table>

3528442

3210815

264868

207807

865456

653038

4658766

4071660

190651

137673

4468115

3933987

5 — Property and EquipmentProperty and equipment consist of:<table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:71.2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.38%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.38%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:71.2%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.54%;margin:0pt;padding:0pt;">June 30, </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.54%;margin:0pt;padding:0pt;">December 31, </td></tr><tr><td style="vertical-align:bottom;width:71.2%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">2021</td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">2020</td></tr><tr><td style="vertical-align:bottom;width:71.2%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.54%;margin:0pt;padding:0pt;">(unaudited)</td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.54%;margin:0pt;padding:0pt;"></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:71.2%;margin:0pt;padding:0pt;">Computer software and hardware </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;">$</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.38%;margin:0pt;padding:0pt;"> 783,690</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;">$</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.38%;margin:0pt;padding:0pt;"> 705,811</td></tr><tr><td style="vertical-align:bottom;width:71.2%;margin:0pt;padding:0pt;">Furniture and fixtures </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.38%;margin:0pt;padding:0pt;"> 1,233,749</td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.38%;margin:0pt;padding:0pt;"> 1,226,113</td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:71.2%;margin:0pt;padding:0pt;">Leasehold improvements </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.38%;margin:0pt;padding:0pt;"> 230,351</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.38%;margin:0pt;padding:0pt;"> 230,351</td></tr><tr><td style="vertical-align:bottom;width:71.2%;margin:0pt;padding:0pt;">Machinery and equipment </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.38%;margin:0pt;padding:0pt;"> 2,044,479</td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.38%;margin:0pt;padding:0pt;"> 1,823,835</td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:71.2%;margin:0pt;padding:0pt;">Tooling in-process </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 395,782</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 470,446</td></tr><tr><td style="vertical-align:bottom;width:71.2%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.38%;margin:0pt;padding:0pt;"> 4,688,051</td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.38%;margin:0pt;padding:0pt;"> 4,456,556</td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:71.2%;margin:0pt;padding:0pt;">Accumulated depreciation </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (2,595,827)</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (2,336,408)</td></tr><tr><td style="vertical-align:bottom;width:71.2%;margin:0pt;padding:0pt;">Total </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:3px double #000000;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:11.38%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 2,092,224</td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:3px double #000000;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:11.38%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 2,120,148</td></tr></table>Depreciation expense of property and equipment was $137,598 and $127,945 for the three months ended June 30, 2021 and 2020, respectively, and $264,737 and $254,253 for the six months ended June 30, 2021 and 2020, respectively.Property and equipment, net, information by geographic region is as follows:<table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:72.61%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.68%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.68%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td></tr><tr><td style="vertical-align:bottom;width:72.61%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.84%;margin:0pt;padding:0pt;">June 30, </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.84%;margin:0pt;padding:0pt;">December 31, </td></tr><tr><td style="vertical-align:bottom;width:72.61%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">2021</td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">2020</td></tr><tr><td style="vertical-align:bottom;width:72.61%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.84%;margin:0pt;padding:0pt;">(unaudited)</td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.84%;margin:0pt;padding:0pt;"></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:72.61%;margin:0pt;padding:0pt;">United States</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;">$</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.68%;margin:0pt;padding:0pt;"> 1,839,405</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;">$</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.68%;margin:0pt;padding:0pt;"> 1,832,894</td></tr><tr><td style="vertical-align:bottom;width:72.61%;margin:0pt;padding:0pt;">International</td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 252,819</td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 287,254</td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:72.61%;margin:0pt;padding:0pt;">Total property and equipment, net</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:3px double #000000;margin:0pt;padding:0pt;">$</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.68%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 2,092,224</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:3px double #000000;margin:0pt;padding:0pt;">$</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.68%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 2,120,148</td></tr></table>Long-lived assets held outside of the United States consist principally of tooling and machinery and equipment, which are components of property and equipment, net.

783690

705811

1233749

1226113

230351

2044479

1823835

395782

470446

4688051

4456556

2595827

2336408

2092224

2120148

137598

127945

264737

254253

<table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:72.61%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.68%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.68%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td></tr><tr><td style="vertical-align:bottom;width:72.61%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.84%;margin:0pt;padding:0pt;">June 30, </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.84%;margin:0pt;padding:0pt;">December 31, </td></tr><tr><td style="vertical-align:bottom;width:72.61%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">2021</td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">2020</td></tr><tr><td style="vertical-align:bottom;width:72.61%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.84%;margin:0pt;padding:0pt;">(unaudited)</td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.84%;margin:0pt;padding:0pt;"></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:72.61%;margin:0pt;padding:0pt;">United States</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;">$</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.68%;margin:0pt;padding:0pt;"> 1,839,405</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;">$</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.68%;margin:0pt;padding:0pt;"> 1,832,894</td></tr><tr><td style="vertical-align:bottom;width:72.61%;margin:0pt;padding:0pt;">International</td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 252,819</td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 287,254</td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:72.61%;margin:0pt;padding:0pt;">Total property and equipment, net</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:3px double #000000;margin:0pt;padding:0pt;">$</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.68%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 2,092,224</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:3px double #000000;margin:0pt;padding:0pt;">$</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.68%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 2,120,148</td></tr></table>

1839405

1832894

252819

287254

2092224

2120148

6 — Intangible AssetsThe following table summarizes the components of intangible asset balances:<table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:70.76%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.68%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.68%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td></tr><tr><td style="vertical-align:bottom;width:70.76%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.84%;margin:0pt;padding:0pt;">June 30, </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.84%;margin:0pt;padding:0pt;">December 31, </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"></td></tr><tr><td style="vertical-align:bottom;width:70.76%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">2021</td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">2020</td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:70.76%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.84%;margin:0pt;padding:0pt;">(unaudited)</td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.84%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:70.76%;margin:0pt;padding:0pt;">Patents — in use</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;">$</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.68%;margin:0pt;padding:0pt;"> 372,502</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;">$</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.68%;margin:0pt;padding:0pt;"> 362,162</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"></td></tr><tr><td style="vertical-align:bottom;width:70.76%;margin:0pt;padding:0pt;">Patents — in process</td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.68%;margin:0pt;padding:0pt;"> 78,123</td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.68%;margin:0pt;padding:0pt;"> 69,733</td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:70.76%;margin:0pt;padding:0pt;">Internally developed software — in use</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.68%;margin:0pt;padding:0pt;"> 872,218</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.68%;margin:0pt;padding:0pt;"> 872,253</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"></td></tr><tr><td style="vertical-align:bottom;width:70.76%;margin:0pt;padding:0pt;">Internally developed software — in process</td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:10.68%;margin:0pt;padding:0pt;"> 342,887</td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:10.68%;margin:0pt;padding:0pt;"> 261,622</td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:70.76%;margin:0pt;padding:0pt;">Trademarks</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 27,697</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 27,247</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"></td></tr><tr><td style="vertical-align:bottom;width:70.76%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.68%;margin:0pt;padding:0pt;"> 1,693,427</td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.68%;margin:0pt;padding:0pt;"> 1,593,017</td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:70.76%;margin:0pt;padding:0pt;">Accumulated amortization </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (683,354)</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (632,132)</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"></td></tr><tr><td style="vertical-align:bottom;width:70.76%;margin:0pt;padding:0pt;">Total </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:3px double #000000;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:10.68%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 1,010,073</td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:3px double #000000;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:10.68%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 960,885</td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"></td></tr></table>Amortization expense of intangible assets was $25,104 and $22,999 for the three months ended June 30, 2021 and 2020, respectively, and $51,222 and $45,490 for the six months ended June 30, 2021 and 2020, respectively. Expected annual amortization expense for the remaining portion of 2021 and the next five years related to intangible assets is as follows (excludes in process intangible assets):<table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:79.99%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:85.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:85.1%;margin:0pt;padding:0pt;">Six months ending December 31, 2021</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;">$</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"> 50,513</td></tr><tr><td style="vertical-align:bottom;width:85.1%;margin:0pt;padding:0pt;">2022</td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"> 100,308</td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:85.1%;margin:0pt;padding:0pt;">2023</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;">$</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"> 99,797</td></tr><tr><td style="vertical-align:bottom;width:85.1%;margin:0pt;padding:0pt;">2024</td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"> 99,395</td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:85.1%;margin:0pt;padding:0pt;">2025</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;">$</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"> 96,225</td></tr><tr><td style="vertical-align:bottom;width:85.1%;margin:0pt;padding:0pt;">2026</td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"> 84,508</td></tr></table>

372502

362162

78123

69733

872218

872253

342887

261622

27697

27247

1693427

1593017

683354

632132

1010073

960885

25104

22999

51222

45490

50513

100308

99797

99395

96225

84508

7 — InvestmentsOur investments consist of bonds that we have classified as available-for-sale and are summarized in the following tables:<table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:79.99%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:43.2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.51%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.09%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.52%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.52%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.52%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td></tr><tr><td style="vertical-align:bottom;width:43.2%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.51%;margin:0pt;padding:0pt;"></td><td colspan="11" style="vertical-align:bottom;white-space:nowrap;width:54.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">June 30, 2021</td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:43.2%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.51%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:10.09%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.52%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.69%;margin:0pt;padding:0pt;">Gross</td><td style="vertical-align:bottom;white-space:nowrap;width:2.52%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.69%;margin:0pt;padding:0pt;">Gross</td><td style="vertical-align:bottom;white-space:nowrap;width:2.52%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.08%;margin:0pt;padding:0pt;"></td></tr><tr><td style="vertical-align:bottom;width:43.2%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.51%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:10.09%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.52%;margin:0pt;padding:0pt;"></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.69%;margin:0pt;padding:0pt;">Unrealized</td><td style="vertical-align:bottom;white-space:nowrap;width:2.52%;margin:0pt;padding:0pt;"></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.69%;margin:0pt;padding:0pt;">Unrealized</td><td style="vertical-align:bottom;white-space:nowrap;width:2.52%;margin:0pt;padding:0pt;"></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.66%;margin:0pt;padding:0pt;">Fair</td></tr><tr><td style="vertical-align:bottom;width:43.2%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.51%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">Cost</td><td style="vertical-align:bottom;white-space:nowrap;width:2.52%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">Gains</td><td style="vertical-align:bottom;white-space:nowrap;width:2.52%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">Losses</td><td style="vertical-align:bottom;white-space:nowrap;width:2.52%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">Value</td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:43.2%;margin:0pt;padding:0pt;">U.S. corporate bonds</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.51%;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.57%;border-bottom:3px double #000000;margin:0pt;padding:0pt;">$</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.09%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 926,387</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.52%;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.58%;border-bottom:3px double #000000;margin:0pt;padding:0pt;">$</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.1%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 22,571</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.52%;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.58%;border-bottom:3px double #000000;margin:0pt;padding:0pt;">$</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.1%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> —</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.52%;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.58%;border-bottom:3px double #000000;margin:0pt;padding:0pt;">$</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.08%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 948,958</td></tr></table><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:43.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.68%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.98%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.68%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td></tr><tr><td style="vertical-align:bottom;width:43.1%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"></td><td colspan="11" style="vertical-align:bottom;white-space:nowrap;width:54.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">December 31, 2020</td></tr><tr><td style="vertical-align:bottom;width:43.1%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:10.68%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.45%;margin:0pt;padding:0pt;">Gross</td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.48%;margin:0pt;padding:0pt;">Gross</td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:10.68%;margin:0pt;padding:0pt;"></td></tr><tr><td style="vertical-align:bottom;width:43.1%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:10.68%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.45%;margin:0pt;padding:0pt;">Unrealized</td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.48%;margin:0pt;padding:0pt;">Unrealized</td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.16%;margin:0pt;padding:0pt;">Fair</td></tr><tr><td style="vertical-align:bottom;width:43.1%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">Cost</td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">Gains</td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">Losses</td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">Value</td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:43.1%;margin:0pt;padding:0pt;">U.S. corporate bonds</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.46%;border-bottom:3px double #000000;margin:0pt;padding:0pt;">$</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.68%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 1,863,382</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.46%;border-bottom:3px double #000000;margin:0pt;padding:0pt;">$</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.98%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 45,986</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;">$</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> —</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;">$</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.68%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 1,909,368</td></tr></table>

<table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:79.99%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:43.2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.51%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.09%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.52%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.52%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.52%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td></tr><tr><td style="vertical-align:bottom;width:43.2%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.51%;margin:0pt;padding:0pt;"></td><td colspan="11" style="vertical-align:bottom;white-space:nowrap;width:54.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">June 30, 2021</td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:43.2%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.51%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:10.09%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.52%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.69%;margin:0pt;padding:0pt;">Gross</td><td style="vertical-align:bottom;white-space:nowrap;width:2.52%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.69%;margin:0pt;padding:0pt;">Gross</td><td style="vertical-align:bottom;white-space:nowrap;width:2.52%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.08%;margin:0pt;padding:0pt;"></td></tr><tr><td style="vertical-align:bottom;width:43.2%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.51%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:10.09%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.52%;margin:0pt;padding:0pt;"></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.69%;margin:0pt;padding:0pt;">Unrealized</td><td style="vertical-align:bottom;white-space:nowrap;width:2.52%;margin:0pt;padding:0pt;"></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.69%;margin:0pt;padding:0pt;">Unrealized</td><td style="vertical-align:bottom;white-space:nowrap;width:2.52%;margin:0pt;padding:0pt;"></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.66%;margin:0pt;padding:0pt;">Fair</td></tr><tr><td style="vertical-align:bottom;width:43.2%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.51%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">Cost</td><td style="vertical-align:bottom;white-space:nowrap;width:2.52%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">Gains</td><td style="vertical-align:bottom;white-space:nowrap;width:2.52%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">Losses</td><td style="vertical-align:bottom;white-space:nowrap;width:2.52%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">Value</td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:43.2%;margin:0pt;padding:0pt;">U.S. corporate bonds</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.51%;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.57%;border-bottom:3px double #000000;margin:0pt;padding:0pt;">$</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.09%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 926,387</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.52%;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.58%;border-bottom:3px double #000000;margin:0pt;padding:0pt;">$</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.1%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 22,571</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.52%;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.58%;border-bottom:3px double #000000;margin:0pt;padding:0pt;">$</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.1%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> —</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.52%;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.58%;border-bottom:3px double #000000;margin:0pt;padding:0pt;">$</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.08%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 948,958</td></tr></table><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:43.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.68%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.98%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.68%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td></tr><tr><td style="vertical-align:bottom;width:43.1%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"></td><td colspan="11" style="vertical-align:bottom;white-space:nowrap;width:54.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">December 31, 2020</td></tr><tr><td style="vertical-align:bottom;width:43.1%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:10.68%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.45%;margin:0pt;padding:0pt;">Gross</td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.48%;margin:0pt;padding:0pt;">Gross</td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:10.68%;margin:0pt;padding:0pt;"></td></tr><tr><td style="vertical-align:bottom;width:43.1%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:10.68%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.45%;margin:0pt;padding:0pt;">Unrealized</td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.48%;margin:0pt;padding:0pt;">Unrealized</td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.16%;margin:0pt;padding:0pt;">Fair</td></tr><tr><td style="vertical-align:bottom;width:43.1%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">Cost</td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">Gains</td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">Losses</td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">Value</td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:43.1%;margin:0pt;padding:0pt;">U.S. corporate bonds</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.46%;border-bottom:3px double #000000;margin:0pt;padding:0pt;">$</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.68%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 1,863,382</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.46%;border-bottom:3px double #000000;margin:0pt;padding:0pt;">$</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.98%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 45,986</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;">$</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> —</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;">$</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.68%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 1,909,368</td></tr></table>

926387

22571

948958

1863382

45986

1909368

8 — Fair Value MeasurementsThe fair values of cash equivalents, accounts receivables, net and accounts payable approximate their carrying amounts due to their short duration.The fair value of our assets and liabilities subject to recurring fair value measurements are as follows:<table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:79.99%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:43.14%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.45%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.45%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.71%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.45%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.45%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.01%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td></tr><tr><td style="vertical-align:bottom;width:43.14%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.45%;margin:0pt;padding:0pt;"></td><td colspan="11" style="vertical-align:bottom;white-space:nowrap;width:54.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">Fair Value at June 30, 2021</td></tr><tr><td style="vertical-align:bottom;width:43.14%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.45%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.45%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.4%;margin:0pt;padding:0pt;">Quoted Prices</td><td style="vertical-align:bottom;white-space:nowrap;width:2.45%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.54%;margin:0pt;padding:0pt;">Significant</td><td style="vertical-align:bottom;white-space:nowrap;width:2.45%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:10.01%;margin:0pt;padding:0pt;"></td></tr><tr><td style="vertical-align:bottom;width:43.14%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.45%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.45%;margin:0pt;padding:0pt;"></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.4%;margin:0pt;padding:0pt;">in Active</td><td style="vertical-align:bottom;white-space:nowrap;width:2.45%;margin:0pt;padding:0pt;"></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.54%;margin:0pt;padding:0pt;">Other</td><td style="vertical-align:bottom;white-space:nowrap;width:2.45%;margin:0pt;padding:0pt;"></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.52%;margin:0pt;padding:0pt;">Significant</td></tr><tr><td style="vertical-align:bottom;width:43.14%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.45%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.45%;margin:0pt;padding:0pt;"></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.4%;margin:0pt;padding:0pt;">Market for</td><td style="vertical-align:bottom;white-space:nowrap;width:2.45%;margin:0pt;padding:0pt;"></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.54%;margin:0pt;padding:0pt;">Observable</td><td style="vertical-align:bottom;white-space:nowrap;width:2.45%;margin:0pt;padding:0pt;"></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.52%;margin:0pt;padding:0pt;">Unobservable</td></tr><tr><td style="vertical-align:bottom;width:43.14%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.45%;margin:0pt;padding:0pt;"></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.54%;margin:0pt;padding:0pt;">Fair</td><td style="vertical-align:bottom;white-space:nowrap;width:2.45%;margin:0pt;padding:0pt;"></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.4%;margin:0pt;padding:0pt;">Identical Assets</td><td style="vertical-align:bottom;white-space:nowrap;width:2.45%;margin:0pt;padding:0pt;"></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.54%;margin:0pt;padding:0pt;">Inputs</td><td style="vertical-align:bottom;white-space:nowrap;width:2.45%;margin:0pt;padding:0pt;"></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.52%;margin:0pt;padding:0pt;">Inputs</td></tr><tr><td style="vertical-align:bottom;width:43.14%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.45%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">Value</td><td style="vertical-align:bottom;white-space:nowrap;width:2.45%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">(Level 1)</td><td style="vertical-align:bottom;white-space:nowrap;width:2.45%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">(Level 2)</td><td style="vertical-align:bottom;white-space:nowrap;width:2.45%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">(Level 3)</td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:43.14%;margin:0pt;padding:0pt;">U.S. corporate bonds</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.45%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.51%;border-bottom:3px double #000000;margin:0pt;padding:0pt;">$</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 948,958</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.45%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.68%;border-bottom:3px double #000000;margin:0pt;padding:0pt;">$</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.71%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> —</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.45%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.51%;border-bottom:3px double #000000;margin:0pt;padding:0pt;">$</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 948,958</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.45%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.51%;border-bottom:3px double #000000;margin:0pt;padding:0pt;">$</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.01%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> —</td></tr></table><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:42.99%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.68%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.71%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.68%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.76%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td></tr><tr><td style="vertical-align:bottom;width:42.99%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"></td><td colspan="11" style="vertical-align:bottom;white-space:nowrap;width:54.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">Fair Value at December 31, 2020</td></tr><tr><td style="vertical-align:bottom;width:42.99%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:10.68%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.4%;margin:0pt;padding:0pt;">Quoted Prices</td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.06%;margin:0pt;padding:0pt;">Significant</td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:9.76%;margin:0pt;padding:0pt;"></td></tr><tr><td style="vertical-align:bottom;width:42.99%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:10.68%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.4%;margin:0pt;padding:0pt;">in Active</td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.06%;margin:0pt;padding:0pt;">Other</td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.25%;margin:0pt;padding:0pt;">Significant</td></tr><tr><td style="vertical-align:bottom;width:42.99%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:10.68%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.4%;margin:0pt;padding:0pt;">Market for</td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.06%;margin:0pt;padding:0pt;">Observable</td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.25%;margin:0pt;padding:0pt;">Unobservable</td></tr><tr><td style="vertical-align:bottom;width:42.99%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.04%;margin:0pt;padding:0pt;">Fair</td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.4%;margin:0pt;padding:0pt;">Identical Assets</td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.06%;margin:0pt;padding:0pt;">Inputs</td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.25%;margin:0pt;padding:0pt;">Inputs</td></tr><tr><td style="vertical-align:bottom;width:42.99%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">Value</td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">(Level 1)</td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">(Level 2)</td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">(Level 3)</td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:42.99%;margin:0pt;padding:0pt;">U.S. corporate bonds</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.36%;border-bottom:3px double #000000;margin:0pt;padding:0pt;">$</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.68%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 1,909,368</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.68%;border-bottom:3px double #000000;margin:0pt;padding:0pt;">$</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.71%;border-bottom:3px double #000000;margin:0pt;padding:0pt;">—</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.37%;border-bottom:3px double #000000;margin:0pt;padding:0pt;">$</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.68%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 1,909,368</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;">$</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.76%;border-bottom:3px double #000000;margin:0pt;padding:0pt;">—</td></tr></table>Our corporate bonds are valued by a third-party custodian at closing prices from secondary exchanges or pricing vendors on the valuation date.There were no transfers into or out of any Levels during the six months ended June 30, 2021 or the year ended December 31, 2020.

<table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:79.99%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:43.14%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.45%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.45%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.71%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.45%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.45%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.01%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td></tr><tr><td style="vertical-align:bottom;width:43.14%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.45%;margin:0pt;padding:0pt;"></td><td colspan="11" style="vertical-align:bottom;white-space:nowrap;width:54.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">Fair Value at June 30, 2021</td></tr><tr><td style="vertical-align:bottom;width:43.14%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.45%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.45%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.4%;margin:0pt;padding:0pt;">Quoted Prices</td><td style="vertical-align:bottom;white-space:nowrap;width:2.45%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.54%;margin:0pt;padding:0pt;">Significant</td><td style="vertical-align:bottom;white-space:nowrap;width:2.45%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:10.01%;margin:0pt;padding:0pt;"></td></tr><tr><td style="vertical-align:bottom;width:43.14%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.45%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.45%;margin:0pt;padding:0pt;"></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.4%;margin:0pt;padding:0pt;">in Active</td><td style="vertical-align:bottom;white-space:nowrap;width:2.45%;margin:0pt;padding:0pt;"></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.54%;margin:0pt;padding:0pt;">Other</td><td style="vertical-align:bottom;white-space:nowrap;width:2.45%;margin:0pt;padding:0pt;"></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.52%;margin:0pt;padding:0pt;">Significant</td></tr><tr><td style="vertical-align:bottom;width:43.14%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.45%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.45%;margin:0pt;padding:0pt;"></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.4%;margin:0pt;padding:0pt;">Market for</td><td style="vertical-align:bottom;white-space:nowrap;width:2.45%;margin:0pt;padding:0pt;"></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.54%;margin:0pt;padding:0pt;">Observable</td><td style="vertical-align:bottom;white-space:nowrap;width:2.45%;margin:0pt;padding:0pt;"></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.52%;margin:0pt;padding:0pt;">Unobservable</td></tr><tr><td style="vertical-align:bottom;width:43.14%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.45%;margin:0pt;padding:0pt;"></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.54%;margin:0pt;padding:0pt;">Fair</td><td style="vertical-align:bottom;white-space:nowrap;width:2.45%;margin:0pt;padding:0pt;"></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.4%;margin:0pt;padding:0pt;">Identical Assets</td><td style="vertical-align:bottom;white-space:nowrap;width:2.45%;margin:0pt;padding:0pt;"></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.54%;margin:0pt;padding:0pt;">Inputs</td><td style="vertical-align:bottom;white-space:nowrap;width:2.45%;margin:0pt;padding:0pt;"></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.52%;margin:0pt;padding:0pt;">Inputs</td></tr><tr><td style="vertical-align:bottom;width:43.14%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.45%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">Value</td><td style="vertical-align:bottom;white-space:nowrap;width:2.45%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">(Level 1)</td><td style="vertical-align:bottom;white-space:nowrap;width:2.45%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">(Level 2)</td><td style="vertical-align:bottom;white-space:nowrap;width:2.45%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">(Level 3)</td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:43.14%;margin:0pt;padding:0pt;">U.S. corporate bonds</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.45%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.51%;border-bottom:3px double #000000;margin:0pt;padding:0pt;">$</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 948,958</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.45%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.68%;border-bottom:3px double #000000;margin:0pt;padding:0pt;">$</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.71%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> —</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.45%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.51%;border-bottom:3px double #000000;margin:0pt;padding:0pt;">$</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 948,958</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.45%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.51%;border-bottom:3px double #000000;margin:0pt;padding:0pt;">$</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.01%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> —</td></tr></table><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:42.99%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.68%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.71%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.68%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.76%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td></tr><tr><td style="vertical-align:bottom;width:42.99%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"></td><td colspan="11" style="vertical-align:bottom;white-space:nowrap;width:54.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">Fair Value at December 31, 2020</td></tr><tr><td style="vertical-align:bottom;width:42.99%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:10.68%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.4%;margin:0pt;padding:0pt;">Quoted Prices</td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.06%;margin:0pt;padding:0pt;">Significant</td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:9.76%;margin:0pt;padding:0pt;"></td></tr><tr><td style="vertical-align:bottom;width:42.99%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:10.68%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.4%;margin:0pt;padding:0pt;">in Active</td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.06%;margin:0pt;padding:0pt;">Other</td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.25%;margin:0pt;padding:0pt;">Significant</td></tr><tr><td style="vertical-align:bottom;width:42.99%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:10.68%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.4%;margin:0pt;padding:0pt;">Market for</td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.06%;margin:0pt;padding:0pt;">Observable</td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.25%;margin:0pt;padding:0pt;">Unobservable</td></tr><tr><td style="vertical-align:bottom;width:42.99%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.04%;margin:0pt;padding:0pt;">Fair</td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.4%;margin:0pt;padding:0pt;">Identical Assets</td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.06%;margin:0pt;padding:0pt;">Inputs</td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.25%;margin:0pt;padding:0pt;">Inputs</td></tr><tr><td style="vertical-align:bottom;width:42.99%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">Value</td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">(Level 1)</td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">(Level 2)</td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">(Level 3)</td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:42.99%;margin:0pt;padding:0pt;">U.S. corporate bonds</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.36%;border-bottom:3px double #000000;margin:0pt;padding:0pt;">$</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.68%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 1,909,368</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.68%;border-bottom:3px double #000000;margin:0pt;padding:0pt;">$</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.71%;border-bottom:3px double #000000;margin:0pt;padding:0pt;">—</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.37%;border-bottom:3px double #000000;margin:0pt;padding:0pt;">$</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.68%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 1,909,368</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;">$</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.76%;border-bottom:3px double #000000;margin:0pt;padding:0pt;">—</td></tr></table>

948958

1909368

0 0

9 — Accumulated Other Comprehensive IncomeThe components of accumulated other comprehensive income, net of tax, for the three months ended June 30, 2021 and 2020 are as follows:<table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:81.67%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:14.3%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td></tr><tr><td style="vertical-align:bottom;width:81.67%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.94%;margin:0pt;padding:0pt;">Unrealized (Losses) </td></tr><tr><td style="vertical-align:bottom;width:81.67%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.94%;margin:0pt;padding:0pt;">Gains on</td></tr><tr><td style="vertical-align:bottom;width:81.67%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.94%;margin:0pt;padding:0pt;">Available-For-Sale</td></tr><tr><td style="vertical-align:bottom;width:81.67%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">Securities</td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:81.67%;margin:0pt;padding:0pt;">Balance at March 31, 2021</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;">$</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:14.3%;margin:0pt;padding:0pt;"> 32,218</td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:81.67%;margin:0pt;padding:0pt;">Gain on available-for-sale securities, net</td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:14.3%;margin:0pt;padding:0pt;"> 1,790</td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:81.67%;margin:0pt;padding:0pt;">Reclassification realized in net earnings</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:14.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (9,829)</td></tr><tr><td style="vertical-align:bottom;width:81.67%;margin:0pt;padding:0pt;">Balance at June 30, 2021</td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;border-bottom:3px double #000000;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:14.3%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 24,179</td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:81.67%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:14.3%;margin:0pt;padding:0pt;"></td></tr><tr><td style="vertical-align:bottom;width:81.67%;margin:0pt;padding:0pt;">Balance at March 31, 2020</td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:14.3%;margin:0pt;padding:0pt;"> 40,807</td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:81.67%;margin:0pt;padding:0pt;">Gains on available-for-sale securities, net</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:14.3%;margin:0pt;padding:0pt;"> 19,797</td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:81.67%;margin:0pt;padding:0pt;">Reclassification realized in net earnings</td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:14.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (6,662)</td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:81.67%;margin:0pt;padding:0pt;">Balance at June 30, 2020</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;border-bottom:3px double #000000;margin:0pt;padding:0pt;">$</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:14.3%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 53,942</td></tr></table>The components of accumulated other comprehensive income, net of tax, for the six months ended June 30, 2021 and 2020 are as follows:<table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:81.67%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:14.3%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td></tr><tr><td style="vertical-align:bottom;width:81.67%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.94%;margin:0pt;padding:0pt;">Unrealized (Losses) </td></tr><tr><td style="vertical-align:bottom;width:81.67%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.94%;margin:0pt;padding:0pt;">Gains on</td></tr><tr><td style="vertical-align:bottom;width:81.67%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.94%;margin:0pt;padding:0pt;">Available-For-Sale</td></tr><tr><td style="vertical-align:bottom;width:81.67%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">Securities</td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:81.67%;margin:0pt;padding:0pt;">Balance at December 31, 2020</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;">$</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:14.3%;margin:0pt;padding:0pt;"> 37,087</td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:81.67%;margin:0pt;padding:0pt;">Loss on available-for-sale securities, net</td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:14.3%;margin:0pt;padding:0pt;"> (3,079)</td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:81.67%;margin:0pt;padding:0pt;">Reclassification realized in net earnings</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:14.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (9,829)</td></tr><tr><td style="vertical-align:bottom;width:81.67%;margin:0pt;padding:0pt;">Balance at June 30, 2021</td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;border-bottom:3px double #000000;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:14.3%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 24,179</td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:81.67%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:14.3%;margin:0pt;padding:0pt;"></td></tr><tr><td style="vertical-align:bottom;width:81.67%;margin:0pt;padding:0pt;">Balance at December 31, 2019</td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:14.3%;margin:0pt;padding:0pt;"> 30,374</td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:81.67%;margin:0pt;padding:0pt;">Gains on available-for-sale securities, net</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:14.3%;margin:0pt;padding:0pt;"> 30,230</td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:81.67%;margin:0pt;padding:0pt;">Reclassification realized in net earnings</td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:14.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (6,662)</td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:81.67%;margin:0pt;padding:0pt;">Balance at June 30, 2020</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;border-bottom:3px double #000000;margin:0pt;padding:0pt;">$</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:14.3%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 53,942</td></tr></table>

The components of accumulated other comprehensive income, net of tax, for the three months ended June 30, 2021 and 2020 are as follows:<table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:81.67%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:14.3%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td></tr><tr><td style="vertical-align:bottom;width:81.67%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.94%;margin:0pt;padding:0pt;">Unrealized (Losses) </td></tr><tr><td style="vertical-align:bottom;width:81.67%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.94%;margin:0pt;padding:0pt;">Gains on</td></tr><tr><td style="vertical-align:bottom;width:81.67%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.94%;margin:0pt;padding:0pt;">Available-For-Sale</td></tr><tr><td style="vertical-align:bottom;width:81.67%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">Securities</td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:81.67%;margin:0pt;padding:0pt;">Balance at March 31, 2021</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;">$</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:14.3%;margin:0pt;padding:0pt;"> 32,218</td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:81.67%;margin:0pt;padding:0pt;">Gain on available-for-sale securities, net</td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:14.3%;margin:0pt;padding:0pt;"> 1,790</td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:81.67%;margin:0pt;padding:0pt;">Reclassification realized in net earnings</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:14.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (9,829)</td></tr><tr><td style="vertical-align:bottom;width:81.67%;margin:0pt;padding:0pt;">Balance at June 30, 2021</td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;border-bottom:3px double #000000;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:14.3%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 24,179</td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:81.67%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:14.3%;margin:0pt;padding:0pt;"></td></tr><tr><td style="vertical-align:bottom;width:81.67%;margin:0pt;padding:0pt;">Balance at March 31, 2020</td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:14.3%;margin:0pt;padding:0pt;"> 40,807</td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:81.67%;margin:0pt;padding:0pt;">Gains on available-for-sale securities, net</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:14.3%;margin:0pt;padding:0pt;"> 19,797</td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:81.67%;margin:0pt;padding:0pt;">Reclassification realized in net earnings</td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:14.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (6,662)</td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:81.67%;margin:0pt;padding:0pt;">Balance at June 30, 2020</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;border-bottom:3px double #000000;margin:0pt;padding:0pt;">$</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:14.3%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 53,942</td></tr></table>The components of accumulated other comprehensive income, net of tax, for the six months ended June 30, 2021 and 2020 are as follows:<table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:81.67%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:14.3%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td></tr><tr><td style="vertical-align:bottom;width:81.67%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.94%;margin:0pt;padding:0pt;">Unrealized (Losses) </td></tr><tr><td style="vertical-align:bottom;width:81.67%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.94%;margin:0pt;padding:0pt;">Gains on</td></tr><tr><td style="vertical-align:bottom;width:81.67%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.94%;margin:0pt;padding:0pt;">Available-For-Sale</td></tr><tr><td style="vertical-align:bottom;width:81.67%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">Securities</td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:81.67%;margin:0pt;padding:0pt;">Balance at December 31, 2020</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;">$</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:14.3%;margin:0pt;padding:0pt;"> 37,087</td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:81.67%;margin:0pt;padding:0pt;">Loss on available-for-sale securities, net</td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:14.3%;margin:0pt;padding:0pt;"> (3,079)</td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:81.67%;margin:0pt;padding:0pt;">Reclassification realized in net earnings</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:14.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (9,829)</td></tr><tr><td style="vertical-align:bottom;width:81.67%;margin:0pt;padding:0pt;">Balance at June 30, 2021</td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;border-bottom:3px double #000000;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:14.3%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 24,179</td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:81.67%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:14.3%;margin:0pt;padding:0pt;"></td></tr><tr><td style="vertical-align:bottom;width:81.67%;margin:0pt;padding:0pt;">Balance at December 31, 2019</td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:14.3%;margin:0pt;padding:0pt;"> 30,374</td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:81.67%;margin:0pt;padding:0pt;">Gains on available-for-sale securities, net</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:14.3%;margin:0pt;padding:0pt;"> 30,230</td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:81.67%;margin:0pt;padding:0pt;">Reclassification realized in net earnings</td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:14.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (6,662)</td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:81.67%;margin:0pt;padding:0pt;">Balance at June 30, 2020</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;border-bottom:3px double #000000;margin:0pt;padding:0pt;">$</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:14.3%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 53,942</td></tr></table>

32218

1790

9829

24179

40807

19797

6662

53942

37087

-3079

9829

24179

30374

30230

6662

53942

10 — Stock-Based CompensationStock-based compensation was recognized as follows in the Condensed Statements of Operations:<table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:58.65%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.54%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.54%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td></tr><tr><td style="vertical-align:bottom;width:58.65%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:19.03%;margin:0pt;padding:0pt;">Three Months Ended</td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:19.27%;margin:0pt;padding:0pt;">Six Months Ended </td></tr><tr><td style="vertical-align:bottom;width:58.65%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:19.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">June 30, </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:19.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">June 30, </td></tr><tr><td style="vertical-align:bottom;width:58.65%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">2021</td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">2020</td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">2021</td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">2020</td></tr><tr style="height:0pt;visibility:hidden;"><td colspan="13" style="padding:0pt;"/></tr><tr><td style="vertical-align:bottom;width:58.65%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:19.03%;margin:0pt;padding:0pt;">(unaudited)</td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:19.27%;margin:0pt;padding:0pt;">(unaudited)</td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:58.65%;margin:0pt;padding:0pt;">Cost of revenue </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;">$</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.15%;margin:0pt;padding:0pt;"> 54,937</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;">$</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.54%;margin:0pt;padding:0pt;"> 58,253</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;">$</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.15%;margin:0pt;padding:0pt;"> 109,148</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;">$</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.54%;margin:0pt;padding:0pt;"> 116,507</td></tr><tr><td style="vertical-align:bottom;width:58.65%;margin:0pt;padding:0pt;">General and administrative </td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.15%;margin:0pt;padding:0pt;"> 180,854</td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.54%;margin:0pt;padding:0pt;"> 2,500,634</td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.15%;margin:0pt;padding:0pt;"> 361,058</td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.54%;margin:0pt;padding:0pt;"> 2,862,786</td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:58.65%;margin:0pt;padding:0pt;">Sales and marketing </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.15%;margin:0pt;padding:0pt;"> 91,360</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.54%;margin:0pt;padding:0pt;"> 77,572</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.15%;margin:0pt;padding:0pt;"> 173,295</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.54%;margin:0pt;padding:0pt;"> 208,527</td></tr><tr><td style="vertical-align:bottom;width:58.65%;margin:0pt;padding:0pt;">Research and development </td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 30,861</td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 22,173</td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 62,252</td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 39,770</td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:58.65%;margin:0pt;padding:0pt;">Total</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:3px double #000000;margin:0pt;padding:0pt;">$</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.15%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 358,012</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:3px double #000000;margin:0pt;padding:0pt;">$</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.54%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 2,658,632</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.16%;border-bottom:3px double #000000;margin:0pt;padding:0pt;">$</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.15%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 705,753</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:3px double #000000;margin:0pt;padding:0pt;">$</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.54%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 3,227,590</td></tr></table>As of June 30, 2021, we had $2,527,686 of unrecognized compensation cost related to unvested restricted stock units, which is expected to be recognized over a weighted-average period of 2.5 years. As of June 30, 2021, we had $224,090 of unrecognized compensation cost related to unvested PSUs, which is expected to be recognized over a weighted-average period of 2.4 years.The following table presents a summary of our stock-based compensation activity for the six months ended June 30, 2021 (shares):<table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:64.74%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.58%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.58%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.55%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td></tr><tr><td style="vertical-align:bottom;width:64.74%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:9.58%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:9.58%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:9.55%;margin:0pt;padding:0pt;">Performance</td></tr><tr><td style="vertical-align:bottom;width:64.74%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:9.58%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:9.58%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:9.55%;margin:0pt;padding:0pt;">Based</td></tr><tr><td style="vertical-align:bottom;width:64.74%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:9.58%;margin:0pt;padding:0pt;">Stock</td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:9.58%;margin:0pt;padding:0pt;">Restricted</td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:9.55%;margin:0pt;padding:0pt;">Restricted</td></tr><tr><td style="vertical-align:bottom;width:64.74%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">Options</td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">Stock Units</td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">Stock Units</td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:64.74%;margin:0pt;padding:0pt;">Outstanding beginning of period</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.58%;margin:0pt;padding:0pt;"> 230,510</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.58%;margin:0pt;padding:0pt;"> 151,139</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.55%;margin:0pt;padding:0pt;"> 11,891</td></tr><tr><td style="vertical-align:bottom;width:64.74%;margin:0pt;padding:0pt;">Awards granted</td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:9.58%;margin:0pt;padding:0pt;"> —</td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:9.58%;margin:0pt;padding:0pt;"> 8,920</td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:9.55%;margin:0pt;padding:0pt;">—</td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:64.74%;margin:0pt;padding:0pt;">Awards exercised/vested</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.58%;margin:0pt;padding:0pt;"> (2,375)</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.58%;margin:0pt;padding:0pt;"> (8,443)</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.55%;margin:0pt;padding:0pt;">—</td></tr><tr><td style="vertical-align:bottom;width:64.74%;margin:0pt;padding:0pt;">Awards canceled</td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:9.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">—</td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:9.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (9,549)</td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:9.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (2,546)</td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:64.74%;margin:0pt;padding:0pt;">Outstanding end of period</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.58%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 228,135</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.58%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 142,067</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.55%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 9,345</td></tr></table>

54937

58253

109148

116507

180854

2500634

361058

2862786

91360

77572

173295

208527

30861

22173

62252

39770

358012

2658632

705753

3227590

2527686

P2Y6M

224090

P2Y4M24D

The following table presents a summary of our stock-based compensation activity for the six months ended June 30, 2021 (shares):<table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:64.74%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.58%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.58%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.55%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td></tr><tr><td style="vertical-align:bottom;width:64.74%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:9.58%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:9.58%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:9.55%;margin:0pt;padding:0pt;">Performance</td></tr><tr><td style="vertical-align:bottom;width:64.74%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:9.58%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:9.58%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:9.55%;margin:0pt;padding:0pt;">Based</td></tr><tr><td style="vertical-align:bottom;width:64.74%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:9.58%;margin:0pt;padding:0pt;">Stock</td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:9.58%;margin:0pt;padding:0pt;">Restricted</td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:9.55%;margin:0pt;padding:0pt;">Restricted</td></tr><tr><td style="vertical-align:bottom;width:64.74%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">Options</td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">Stock Units</td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">Stock Units</td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:64.74%;margin:0pt;padding:0pt;">Outstanding beginning of period</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.58%;margin:0pt;padding:0pt;"> 230,510</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.58%;margin:0pt;padding:0pt;"> 151,139</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.55%;margin:0pt;padding:0pt;"> 11,891</td></tr><tr><td style="vertical-align:bottom;width:64.74%;margin:0pt;padding:0pt;">Awards granted</td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:9.58%;margin:0pt;padding:0pt;"> —</td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:9.58%;margin:0pt;padding:0pt;"> 8,920</td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:9.55%;margin:0pt;padding:0pt;">—</td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:64.74%;margin:0pt;padding:0pt;">Awards exercised/vested</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.58%;margin:0pt;padding:0pt;"> (2,375)</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.58%;margin:0pt;padding:0pt;"> (8,443)</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.55%;margin:0pt;padding:0pt;">—</td></tr><tr><td style="vertical-align:bottom;width:64.74%;margin:0pt;padding:0pt;">Awards canceled</td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:9.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">—</td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:9.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (9,549)</td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:9.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (2,546)</td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:64.74%;margin:0pt;padding:0pt;">Outstanding end of period</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.58%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 228,135</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.58%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 142,067</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.55%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 9,345</td></tr></table>

230510

151139

11891

8920

2375

8443

9549

2546

228135

142067

9345

11 — Income TaxesFor the three and six months ended June 30, 2021, we recorded a provision for income tax expense of $387,727 and $772,221, respectively. Our effective tax rate was 20.9 percent and 21.3 percent, respectively, and differed from the U.S. Federal statutory rate primarily due to U.S. state income tax expense, partially offset by benefits from foreign derived intangible income and research and development tax credits.For the three and six months ended June 30, 2020, we recorded a provision for income tax benefit of $(798,988) and $(1,732,462), respectively. Our effective tax rate was 27.4 percent and 83.5 percent, respectively, and differed from the U.S. Federal statutory rate primarily due to discrete items related to tax benefits associated with stock-based compensation and a U.S. state tax benefit, partially offset by a limitation on the deductibility of certain executive compensation associated with the separation of our former Chief Executive Officer. Additionally, we recognized a benefit in our effective tax rate resulting from the Coronavirus Aid, Relief, and Economic Security Act, which allowed us to carryback net operating losses to years prior to the enactment of the Tax Cuts and Jobs Act.As of June 30, 2021, and December 31, 2020, we had not identified or accrued for any uncertain tax positions. We are currently unaware of any uncertain tax positions that could result in significant payments, accruals or other material deviations in this estimate over the next 12 months. We believe that our tax positions comply in all material respects with applicable tax law. However, tax law is subject to interpretation, and interpretations by taxing authorities could be different from ours, which could result in the imposition of additional taxes and penalties.We file tax returns in the United States Federal jurisdiction and many U.S. state jurisdictions. Our returns are not currently under examination by the Internal Revenue Service. The Company remains subject to income tax examinations for our United States Federal and certain U.S. state income taxes for 2017 and subsequent years and various other U.S. state income taxes for 2016 and subsequent years.

387727

772221

0.209

0.213

-798988

-1732462

0.274

0.835

12 — LeasesWe have entered into operating lease contracts for our office and various office equipment.We have one material lease contract outstanding. In January 2014, we entered into a non-cancelable operating lease, commencing July 1, 2014, for our manufacturing and headquarters facility in Winter Springs, Florida owned by Susi, LLC, an entity controlled by our President, Chief Executive Officer, and Chairman of the Board, Roger Susi. Pursuant to the terms of our lease for this property, the monthly base rent is $34,133, adjusted annually for changes in the consumer price index. Under the terms of the lease, we are responsible for property taxes, insurance and maintenance expenses. Prior to May 31, 2019, the expiration date of the initial lease term, and pursuant to the terms of the lease contract, we renewed the lease for an additional five years, resulting in a new lease expiration date of May 31, 2024. Unless advance written notice of termination is timely provided, the lease will automatically renew for one additional successive term of five years beginning in 2024, and thereafter, will be renewed for successive terms of one year each.We concluded that we would exercise the remaining five-year option, resulting in a remaining lease term of 7.9 years as of June 30, 2021. This lease agreement does not contain any residual value guarantee or material restrictive covenants. Operating lease cost recognized in the Condensed Statements of Operations is as follows:<table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:55.71%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.21%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td></tr><tr><td style="vertical-align:bottom;width:55.71%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:20.29%;margin:0pt;padding:0pt;">Three Months Ended</td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"></td><td colspan="4" style="vertical-align:bottom;white-space:nowrap;width:19.36%;margin:0pt;padding:0pt;">Six Months Ended</td></tr><tr><td style="vertical-align:bottom;width:55.71%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:20.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">June 30, </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:20.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">June 30, </td></tr><tr><td style="vertical-align:bottom;width:55.71%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">2021</td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">2020</td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">2021</td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">2020</td></tr><tr style="height:0pt;visibility:hidden;"><td colspan="13" style="padding:0pt;"/></tr><tr><td style="vertical-align:bottom;width:55.71%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;margin:0pt;padding:0pt;"></td><td colspan="4" style="vertical-align:bottom;white-space:nowrap;width:19.23%;margin:0pt;padding:0pt;">(unaudited)</td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"></td><td colspan="4" style="vertical-align:bottom;white-space:nowrap;width:19.36%;margin:0pt;padding:0pt;">(unaudited)</td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:55.71%;margin:0pt;padding:0pt;">Cost of revenue</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.05%;margin:0pt;padding:0pt;">$</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.21%;margin:0pt;padding:0pt;"> 51,094</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;">$</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.24%;margin:0pt;padding:0pt;"> 46,535</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;">$</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.22%;margin:0pt;padding:0pt;"> 102,189</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;">$</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.22%;margin:0pt;padding:0pt;"> 93,070</td></tr><tr><td style="vertical-align:bottom;width:55.71%;margin:0pt;padding:0pt;">General and administrative</td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.21%;margin:0pt;padding:0pt;"> 53,406</td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:8.24%;margin:0pt;padding:0pt;"> 46,044</td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:8.22%;margin:0pt;padding:0pt;"> 103,962</td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:8.22%;margin:0pt;padding:0pt;"> 92,088</td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:55.71%;margin:0pt;padding:0pt;">Sales and marketing</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.05%;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.21%;margin:0pt;padding:0pt;"> 2,860</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.24%;margin:0pt;padding:0pt;"> 2,603</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.22%;margin:0pt;padding:0pt;"> 5,719</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.22%;margin:0pt;padding:0pt;"> 5,208</td></tr><tr><td style="vertical-align:bottom;width:55.71%;margin:0pt;padding:0pt;">Research and development</td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 7,923</td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:8.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 7,215</td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:8.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 15,845</td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:8.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 14,430</td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:55.71%;margin:0pt;padding:0pt;">Total</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.05%;border-bottom:3px double #000000;margin:0pt;padding:0pt;">$</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.21%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 115,283</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.06%;border-bottom:3px double #000000;margin:0pt;padding:0pt;">$</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.24%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 102,397</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.06%;border-bottom:3px double #000000;margin:0pt;padding:0pt;">$</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.22%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 227,715</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.06%;border-bottom:3px double #000000;margin:0pt;padding:0pt;">$</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.22%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 204,796</td></tr></table>Lease costs for short-term leases were immaterial for the three and six months ended June 30, 2021 and 2020.Maturity of our operating lease liability as of June 30, 2021 is as follows: <table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:83.43%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:83.43%;margin:0pt;padding:0pt;">Six months ending December 31, 2021</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;">$</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.33%;margin:0pt;padding:0pt;"> 207,647</td></tr><tr><td style="vertical-align:bottom;width:83.43%;margin:0pt;padding:0pt;">2022</td><td style="vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:12.33%;margin:0pt;padding:0pt;"> 415,294</td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:83.43%;margin:0pt;padding:0pt;">2023</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.33%;margin:0pt;padding:0pt;"> 415,294</td></tr><tr><td style="vertical-align:bottom;width:83.43%;margin:0pt;padding:0pt;">2024</td><td style="vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.33%;margin:0pt;padding:0pt;"> 415,294</td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:83.43%;margin:0pt;padding:0pt;">2025</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.33%;margin:0pt;padding:0pt;"> 415,294</td></tr><tr><td style="vertical-align:bottom;width:83.43%;margin:0pt;padding:0pt;">Thereafter</td><td style="vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.33%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 1,400,876</td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:83.43%;margin:0pt;padding:0pt;">Total lease payments</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.33%;margin:0pt;padding:0pt;"> 3,269,699</td></tr><tr><td style="vertical-align:bottom;width:83.43%;margin:0pt;padding:0pt;">Imputed interest</td><td style="vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.33%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (655,348)</td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:83.43%;margin:0pt;padding:0pt;">Present value of lease liability</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.62%;border-bottom:3px double #000000;margin:0pt;padding:0pt;">$</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.33%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 2,614,351</td></tr></table>

1 34133 P5Y 1 P5Y P1Y

P7Y10M24D

51094

46535

102189

93070

53406

46044

103962

92088

2860

2603

5719

5208

7923

7215

15845

14430

115283

102397

227715

204796

207647

415294

1400876

3269699

655348

2614351

13 — Commitments and ContingenciesPurchase commitments. We had various purchase orders for goods or services totaling $4,819,367 and $3,089,103 as of June 30, 2021 and December 31, 2020, respectively. No amounts related to these purchase orders have been recognized in our balance sheet.Legal matters. We may from time to time become party to various legal proceedings or claims that arise in the ordinary course of business.

4819367

3089103

XML 11 R1.htm IDEA: XBRL DOCUMENT

Document and Entity Information - shares	6 Months Ended
Document and Entity Information - shares	Jun. 30, 2021	Aug. 01, 2021
Document and Entity Information
Entity Registrant Name	IRADIMED CORP
Entity Central Index Key	0001325618
Document Type	10-Q
Document Period End Date	Jun. 30, 2021
Amendment Flag	false
Document Quarterly Report	true
Document Transition Report	false
Entity File Number	001-36534
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	73-1408526
Entity Address, Address Line One	1025 Willa Springs Drive
Entity Address, City or Town	Winter Springs
Entity Address, State or Province	FL
Entity Address, Postal Zip Code	32708
City Area Code	407
Local Phone Number	677-8022
Current Fiscal Year End Date	--12-31
Entity Current Reporting Status	Yes
Entity Filer Category	Non-accelerated Filer
Trading Symbol	IRMD
Title of 12(b) Security	Common stock, par value $0.0001
Security Exchange Name	NASDAQ
Entity Common Stock, Shares Outstanding		12,318,027
Entity Small Business	true
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Interactive Data Current	Yes
Document Fiscal Year Focus	2021
Document Fiscal Period Focus	Q2

XML 12 R2.htm IDEA: XBRL DOCUMENT

CONDENSED BALANCE SHEETS - USD ($)	Jun. 30, 2021	Dec. 31, 2020
Current assets:
Cash and cash equivalents	$ 55,159,661	$ 50,068,728
Investments	948,958	1,909,368
Accounts receivable, net of allowance for doubtful accounts of $45,578 as of June 30, 2021 and $46,484 as of December 31, 2020	3,884,704	4,574,932
Inventory, net	4,468,115	3,933,987
Prepaid expenses and other current assets	1,230,033	771,666
Prepaid income taxes	2,945,799	2,477,211
Total current assets	68,637,270	63,735,892
Property and equipment, net	2,092,224	2,120,148
Intangible assets, net	1,010,073	960,885
Operating lease right-of-use asset, net	2,614,351	2,715,030
Deferred income taxes, net	992,996	1,272,672
Other assets	232,685	261,993
Total assets	75,579,599	71,066,620
Current liabilities:
Accounts payable	667,882	657,054
Accrued payroll and benefits	2,010,074	1,714,782
Other accrued taxes	122,452	103,981
Warranty reserve	108,528	90,054
Deferred revenue	2,973,334	1,949,259
Current portion of operating lease liability	268,488	255,698
Other current liabilities	146,435	146,435
Total current liabilities	6,297,193	4,917,263
Deferred revenue	2,034,429	2,305,413
Operating lease liability, less current portion	2,345,863	2,459,332
Total liabilities	10,677,485	9,682,008
Stockholders' equity:
Common stock; $0.0001 par value; 31,500,000 shares authorized; 12,317,036 shares issued and outstanding as of June 30, 2021 and 12,308,432 shares issued and outstanding as of December 31, 2020	1,232	1,231
Additional paid-in capital	24,350,709	23,676,843
Retained earnings	40,525,994	37,669,451
Accumulated other comprehensive income	24,179	37,087
Total stockholders' equity	64,902,114	61,384,612
Total liabilities and stockholders' equity	$ 75,579,599	$ 71,066,620

XML 13 R3.htm IDEA: XBRL DOCUMENT

CONDENSED BALANCE SHEETS (Parenthetical) - USD ($)	Jun. 30, 2021	Dec. 31, 2020
CONDENSED BALANCE SHEETS
Accounts receivable, allowance for doubtful accounts	$ 45,578	$ 46,484
Common stock, par value (in dollars per share)	$ 0.0001	$ 0.0001
Common stock, shares authorized	31,500,000	31,500,000
Common stock, shares issued	12,317,036	12,308,432
Common stock, shares outstanding	12,317,036	12,308,432

XML 14 R4.htm IDEA: XBRL DOCUMENT

CONDENSED STATEMENTS OF OPERATIONS - USD ($)	3 Months Ended		6 Months Ended
CONDENSED STATEMENTS OF OPERATIONS - USD ($)	Jun. 30, 2021	Jun. 30, 2020	Jun. 30, 2021	Jun. 30, 2020
CONDENSED STATEMENTS OF OPERATIONS
Revenue	$ 9,810,423	$ 6,794,692	$ 19,034,419	$ 15,472,233
Cost of revenue	2,478,122	1,864,587	4,639,802	4,078,317
Gross profit	7,332,301	4,930,105	14,394,617	11,393,916
Operating expenses:
General and administrative	2,564,619	5,002,427	4,994,988	7,865,154
Sales and marketing	2,469,777	2,374,134	4,848,901	4,807,701
Research and development	453,679	482,654	929,496	912,936
Total operating expenses	5,488,075	7,859,215	10,773,385	13,585,791
Income (loss) from operations	1,844,226	(2,929,110)	3,621,232	(2,191,875)
Other income, net	13,195	17,852	7,532	116,354
Income (loss) before provision for income taxes	1,857,421	(2,911,258)	3,628,764	(2,075,521)
Provision for income tax expense (benefit)	387,727	(798,988)	772,221	(1,732,462)
Net income (loss)	$ 1,469,694	$ (2,112,270)	$ 2,856,543	$ (343,059)
Net income (loss) per share:
Basic (in dollars per share)	$ 0.12	$ (0.17)	$ 0.23	$ (0.03)
Diluted (in dollars per share)	$ 0.12	$ (0.17)	$ 0.23	$ (0.03)
Weighted average shares outstanding:
Basic (in shares)	12,313,563	12,076,399	12,312,078	11,983,913
Diluted (in shares)	12,554,828	12,076,399	12,539,483	11,983,913

XML 15 R5.htm IDEA: XBRL DOCUMENT

CONDENSED STATEMENTS OF COMPREHENSIVE INCOME - USD ($)	3 Months Ended		6 Months Ended
CONDENSED STATEMENTS OF COMPREHENSIVE INCOME - USD ($)	Jun. 30, 2021	Jun. 30, 2020	Jun. 30, 2021	Jun. 30, 2020
CONDENSED STATEMENTS OF COMPREHENSIVE INCOME
Net income (loss)	$ 1,469,694	$ (2,112,270)	$ 2,856,543	$ (343,059)
Other comprehensive income:
Change in fair value of available-for-sale securities, net of tax expense (benefit) of $5,772 and $4,227 for the three months ended June 30, 2021 and 2020, respectively, and $(7,331) and $7,669 for the six months ended June 30, 2021 and 2020, respectively	1,790	19,797	(3,079)	30,230
Realized gain on available-for-sale securities reclassified to net income, net of tax expense of $3,176 and $2,199 for the three months ended June 30, 2021 and 2020, respectively, and $3,176 and $2,199 for the six months ended June 30, 2021 and 2020, respectively	(9,829)	(6,662)	(9,829)	(6,662)
Other comprehensive income	(8,039)	13,135	(12,908)	23,568
Comprehensive income (loss)	$ 1,461,655	$ (2,099,135)	$ 2,843,635	$ (319,491)

- Definition

The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1A
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=121641772&loc=SL7669619-108580

Reference 2: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 31
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8924-108599

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 11
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(22))
-URI http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 11
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (f)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 7
-URI http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22595-107794

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1B
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=121641772&loc=SL7669625-108580

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599

Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(18))
-URI http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263

Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(20))
-URI http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227

Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-URI http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (b)(2)
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 9
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22663-107794

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 28
-Subparagraph (f)
-URI http://asc.fasb.org/extlink&oid=75031198&loc=d3e14064-108612

Reference 17: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 30
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599

Reference 18: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22583-107794

Reference 19: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(g)(1)(ii))
-URI http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690

Reference 20: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 60B
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=121326447&loc=SL5780133-109256

Reference 21: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 323
-SubTopic 10
-Section 50
-Paragraph 3
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571

Reference 22: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599

Reference 23: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22658-107794

+ Details

XML 16 R6.htm IDEA: XBRL DOCUMENT

CONDENSED STATEMENTS OF COMPREHENSIVE INCOME (Parenthetical) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2021	Jun. 30, 2020	Jun. 30, 2021	Jun. 30, 2020
CONDENSED STATEMENTS OF COMPREHENSIVE INCOME
Change in fair value of available-for-sale securities, net of tax expense	$ 5,772	$ 4,227	$ (7,331)	$ 7,669
Realized gain on available-for-sale securities reclassified to net income, net of tax expense (benefit)	$ 3,176	$ 2,199	$ 3,176	$ 2,199

XML 17 R7.htm IDEA: XBRL DOCUMENT

CONDENSED STATEMENTS OF STOCKHOLDERS' EQUITY - USD ($)	Common Stock	Additional Paid-in Capital	Retained Earnings	Accumulated Other Comprehensive (Loss) Income	Total
Balances at Dec. 31, 2019	$ 1,177	$ 19,192,394	$ 36,300,450	$ 30,374	$ 55,524,395
Balance (in shares) at Dec. 31, 2019	11,765,875
Increase (Decrease) in Stockholders' Equity
Net income (loss)			1,769,211		1,769,211
Other comprehensive income (loss)				10,433	10,433
Stock-based compensation expense		568,958			568,958
Net share settlement of restricted stock units	$ 1	(133,873)			(133,872)
Net share settlement of restricted stock units (in shares)	14,521
Exercise of stock options	$ 19	322,160			322,179
Exercise of stock options (in Shares)	190,541
Balances at Mar. 31, 2020	$ 1,197	19,949,639	38,069,661	40,807	58,061,304
Balance (in shares) at Mar. 31, 2020	11,970,937
Balances at Dec. 31, 2019	$ 1,177	19,192,394	36,300,450	30,374	55,524,395
Balance (in shares) at Dec. 31, 2019	11,765,875
Increase (Decrease) in Stockholders' Equity
Net income (loss)					(343,059)
Balances at Jun. 30, 2020	$ 1,220	22,351,673	35,957,391	53,942	58,364,226
Balance (in shares) at Jun. 30, 2020	12,197,837
Balances at Mar. 31, 2020	$ 1,197	19,949,639	38,069,661	40,807	58,061,304
Balance (in shares) at Mar. 31, 2020	11,970,937
Increase (Decrease) in Stockholders' Equity
Net income (loss)			(2,112,270)		(2,112,270)
Other comprehensive income (loss)				13,135	13,135
Stock-based compensation expense		2,658,632			2,658,632
Net share settlement of restricted stock units	$ 8	(725,393)			(725,385)
Net share settlement of restricted stock units (in shares)	76,381
Exercise of stock options	$ 15	468,795			468,810
Exercise of stock options (in Shares)	150,519
Balances at Jun. 30, 2020	$ 1,220	22,351,673	35,957,391	53,942	58,364,226
Balance (in shares) at Jun. 30, 2020	12,197,837
Balances at Dec. 31, 2020	$ 1,231	23,676,843	37,669,451	37,087	61,384,612
Balance (in shares) at Dec. 31, 2020	12,308,432
Increase (Decrease) in Stockholders' Equity
Net income (loss)			1,386,849		1,386,849
Other comprehensive income (loss)				(4,869)	(4,869)
Stock-based compensation expense		347,741			347,741
Net share settlement of restricted stock units		(38,707)			(38,707)
Net share settlement of restricted stock units (in shares)	3,502
Exercise of stock options		2,460			2,460
Exercise of stock options (in Shares)	250
Balances at Mar. 31, 2021	$ 1,231	23,988,337	39,056,300	32,218	63,078,086
Balance (in shares) at Mar. 31, 2021	12,312,184
Balances at Dec. 31, 2020	$ 1,231	23,676,843	37,669,451	37,087	61,384,612
Balance (in shares) at Dec. 31, 2020	12,308,432
Increase (Decrease) in Stockholders' Equity
Net income (loss)					2,856,543
Balances at Jun. 30, 2021	$ 1,232	24,350,709	40,525,994	24,179	64,902,114
Balance (in shares) at Jun. 30, 2021	12,317,036
Balances at Mar. 31, 2021	$ 1,231	23,988,337	39,056,300	32,218	63,078,086
Balance (in shares) at Mar. 31, 2021	12,312,184
Increase (Decrease) in Stockholders' Equity
Net income (loss)			1,469,694		1,469,694
Other comprehensive income (loss)				(8,039)	(8,039)
Stock-based compensation expense		358,012			358,012
Net share settlement of restricted stock units	$ 1	(15,875)			(15,874)
Net share settlement of restricted stock units (in shares)	2,727
Exercise of stock options		20,235			20,235
Exercise of stock options (in Shares)	2,125
Balances at Jun. 30, 2021	$ 1,232	$ 24,350,709	$ 40,525,994	$ 24,179	$ 64,902,114
Balance (in shares) at Jun. 30, 2021	12,317,036

XML 18 R8.htm IDEA: XBRL DOCUMENT

CONDENSED STATEMENTS OF CASH FLOWS - USD ($)	6 Months Ended
CONDENSED STATEMENTS OF CASH FLOWS - USD ($)	Jun. 30, 2021	Jun. 30, 2020
Operating activities:
Net income (loss)	$ 2,856,543	$ (343,059)
Adjustments to reconcile net income (loss) to net cash provided by operating activities:
Change in allowance for doubtful accounts	(879)	40,029
Change in provision for excess and obsolete inventory	52,978	35,376
Depreciation and amortization	680,091	668,823
Stock-based compensation	705,753	3,227,590
Deferred income taxes, net	290,183	(834,179)
Gain on maturities of investments	(13,005)	(8,861)
Changes in operating assets and liabilities:
Accounts receivable	691,107	2,747,675
Inventory	(493,488)	(1,360,074)
Prepaid expenses and other current assets	(1,473,503)	(674,047)
Other assets	30,425	(26,402)
Accounts payable	(79,060)	(319,583)
Accrued payroll and benefits	295,292	(472,705)
Other accrued taxes	18,471	(88,451)
Warranty reserve	18,474	6,611
Other current liability		31,141
Deferred revenue	1,402,978	255,298
Prepaid income taxes	(468,588)	(897,951)
Net cash provided by operating activities	4,513,772	1,987,231
Investing activities:
Proceeds from maturity of investments	950,000	480,000
Purchases of property and equipment	(240,543)	(300,558)
Capitalized intangible assets	(100,410)	(122,534)
Net cash provided by investing activities	609,047	56,908
Financing activities:
Proceeds from exercises of stock options	22,695	790,989
Taxes paid related to the net share settlement of equity awards	54,581	859,257
Net cash used in financing activities	(31,886)	(68,268)
Net increase in cash and cash equivalents	5,090,933	1,975,871
Cash and cash equivalents, beginning of period	50,068,728	43,481,781
Cash and cash equivalents, end of period	55,159,661	45,457,652
Supplemental disclosure of cash flow information:
Cash paid for income taxes	963,722
Right-of-use asset recognized in exchange for a new lease obligation	27,713
Operating and short-term lease payments recorded within cash flow provided by operating activities	$ 238,982	$ 214,877

XML 19 R9.htm IDEA: XBRL DOCUMENT

Basis of Presentation

6 Months Ended

Jun. 30, 2021

Basis of Presentation

Basis of Presentation

IRADIMED CORPORATION

Notes to Unaudited Condensed Financial Statements

1 — Basis of Presentation

Certain Significant Risks and Uncertainties

COVID-19 Considerations

●

postponement or cancellation of MRI medical procedures and their uncertain return which adversely impacts our business;

●

disruptions in our supply chain that may limit our ability to procure materials necessary to manufacture our products;

●

potential temporary or prolonged closure of our office and production facility;

●

the health of our employees and ability to meet staffing needs;

●

potential new or continued governmental actions that may limit employees’ ability to work;

●

civil unrest relating to government, corporate and societal responses to the pandemic;

●

volatility in economic conditions and the financial markets, and

●

other unanticipated effects that remain unknown.

Recent Accounting Pronouncements

Recently Issued Accounting Pronouncements to be Implemented

Accounting Pronouncements Implemented in 2021

XML 20 R10.htm IDEA: XBRL DOCUMENT

Revenue Recognition

6 Months Ended

Jun. 30, 2021

Revenue Recognition

Revenue Recognition

2 — Revenue Recognition

Disaggregation of Revenue

We disaggregate revenue from contracts with customers by geographic region and revenue type as we believe it best depicts the nature, amount, timing and uncertainty of our revenue and cash flow.

Revenue information by geographic region is as follows:


	Three Months Ended				Six Months Ended
	June 30,				June 30,
	2021		2020		2021		2020

	(unaudited)				(unaudited)
United States	$	8,043,156	$	4,642,916	$	15,315,986	$	10,965,022
International		1,767,267		2,151,776		3,718,433		4,507,211
Total revenue	$	9,810,423	$	6,794,692	$	19,034,419	$	15,472,233

Revenue information by type is as follows:


	Three Months Ended				Six Months Ended
	June 30,				June 30,
	2021		2020		2021		2020

	(unaudited)				(unaudited)
Devices:
MRI Compatible IV Infusion Pump Systems	$	2,456,767	$	1,875,159	$	5,960,114	$	4,539,993
MRI Compatible Patient Vital Signs Monitoring Systems		3,377,719		1,927,473		5,981,549		4,546,988
Total Devices revenue		5,834,486		3,802,632		11,941,663		9,086,981
Disposables, services and other		3,490,969		2,535,548		6,126,435		5,467,449
Amortization of extended warranty agreements		484,968		456,512		966,321		917,803
Total revenue	$	9,810,423	$	6,794,692	$	19,034,419	$	15,472,233

Contract Liabilities

Our contract liabilities consist of:


	June 30,		December 31,
	2021		2020
	(unaudited)
Advance payments from customers	$	484,354	$	85,590
Shipments in-transit		649,887		35,013
Extended warranty agreements		3,873,522		4,134,069
Total	$	5,007,763	$	4,254,672

Changes in the contract liabilities during the periods presented are as follows:


	Deferred
	Revenue
Contract liabilities, December 31, 2020	$	4,254,672
Increases due to cash received from customers		2,426,575
Decreases due to recognition of revenue		(1,673,484)
Contract liabilities, June 30, 2021	$	5,007,763


	Deferred
	Revenue
Contract liabilities, December 31, 2019	$	4,301,887
Increases due to cash received from customers		1,236,658
Decreases due to recognition of revenue		(1,048,380)
Contract liabilities, June 30, 2020	$	4,490,165

Capitalized Contract Costs

Our capitalized contract costs totaled $353,942 and $384,367 as of June 30, 2021 and December 31, 2020, respectively.

- Definition

The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-URI http://asc.fasb.org/topic&trid=49130388

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 10
-URI http://asc.fasb.org/extlink&oid=121604090&loc=SL49130551-203045

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 13
-Subparagraph (b)(2)
-URI http://asc.fasb.org/extlink&oid=121604090&loc=SL49130556-203045

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 12
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=121604090&loc=SL49130554-203045

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 9
-URI http://asc.fasb.org/extlink&oid=121604090&loc=SL49130550-203045

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 12
-Subparagraph (e)
-URI http://asc.fasb.org/extlink&oid=121604090&loc=SL49130554-203045

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 12
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=121604090&loc=SL49130554-203045

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 12
-Subparagraph (d)
-URI http://asc.fasb.org/extlink&oid=121604090&loc=SL49130554-203045

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 15
-URI http://asc.fasb.org/extlink&oid=121604090&loc=SL49130558-203045

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 12
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=121604090&loc=SL49130554-203045

+ Details

XML 21 R11.htm IDEA: XBRL DOCUMENT

Basic and Diluted Net Income per Share

6 Months Ended

Jun. 30, 2021

Basic and Diluted Net Income per Share

Basic and Diluted Net Income per Share

3 — Basic and Diluted Net Income per Share

The following table presents the computation of basic and diluted net income per share:


	Three Months Ended June 30,				Six Months Ended June 30,
	2021		2020		2021		2020

	(unaudited)				(unaudited)
Net income (loss)	$	1,469,694	$	(2,112,270)	$	2,856,543	$	(343,059)
Weighted-average shares outstanding — Basic		12,313,563		12,076,399		12,312,078		11,983,913
Effect of dilutive securities:
Stock options		194,419		—		192,347		—
Restricted stock units		46,846		—		35,058		—
Weighted-average shares outstanding — Diluted		12,554,828		12,076,399		12,539,483		11,983,913
Basic net income (loss) per share	$	0.12	$	(0.17)	$	0.23	$	(0.03)
Diluted net income (loss) per share	$	0.12	$	(0.17)	$	0.23	$	(0.03)

Stock options and restricted stock units excluded from the calculation of diluted net income per share because the effect would have been anti-dilutive are as follows:


	Three Months Ended		Six Months Ended
	June 30,		June 30,
	2021	2020	2021	2020

	(unaudited)		(unaudited)
Anti-dilutive stock options and restricted stock units	1,500	399,772	1,635	479,499

XML 22 R12.htm IDEA: XBRL DOCUMENT

Inventory

6 Months Ended

Jun. 30, 2021

Inventory

Inventory

4 — Inventory

Inventory consists of:


	June 30,		December 31,
	2021		2020
	(unaudited)
Raw materials	$	3,528,442	$	3,210,815
Work in process		264,868		207,807
Finished goods		865,456		653,038
Inventory before allowance for excess and obsolete		4,658,766		4,071,660
Allowance for excess and obsolete		(190,651)		(137,673)
Total	$	4,468,115	$	3,933,987

XML 23 R13.htm IDEA: XBRL DOCUMENT

Property and Equipment

6 Months Ended

Jun. 30, 2021

Property and Equipment

Property and Equipment

5 — Property and Equipment

Property and equipment consist of:


	June 30,		December 31,
	2021		2020
	(unaudited)
Computer software and hardware	$	783,690	$	705,811
Furniture and fixtures		1,233,749		1,226,113
Leasehold improvements		230,351		230,351
Machinery and equipment		2,044,479		1,823,835
Tooling in-process		395,782		470,446
		4,688,051		4,456,556
Accumulated depreciation		(2,595,827)		(2,336,408)
Total	$	2,092,224	$	2,120,148

Property and equipment, net, information by geographic region is as follows:


	June 30,		December 31,
	2021		2020
	(unaudited)
United States	$	1,839,405	$	1,832,894
International		252,819		287,254
Total property and equipment, net	$	2,092,224	$	2,120,148

Long-lived assets held outside of the United States consist principally of tooling and machinery and equipment, which are components of property and equipment, net.

XML 24 R14.htm IDEA: XBRL DOCUMENT

Intangible Assets

6 Months Ended

Jun. 30, 2021

Intangible Assets

Intangible Assets

6 — Intangible Assets

The following table summarizes the components of intangible asset balances:


	June 30,		December 31,
	2021		2020
	(unaudited)
Patents — in use	$	372,502	$	362,162
Patents — in process		78,123		69,733
Internally developed software — in use		872,218		872,253
Internally developed software — in process		342,887		261,622
Trademarks		27,697		27,247
		1,693,427		1,593,017
Accumulated amortization		(683,354)		(632,132)
Total	$	1,010,073	$	960,885

Expected annual amortization expense for the remaining portion of 2021 and the next five years related to intangible assets is as follows (excludes in process intangible assets):


Six months ending December 31, 2021	$	50,513
2022	$	100,308
2023	$	99,797
2024	$	99,395
2025	$	96,225
2026	$	84,508

XML 25 R15.htm IDEA: XBRL DOCUMENT

Investments

6 Months Ended

Jun. 30, 2021

Investments

Investments

7 — Investments

Our investments consist of bonds that we have classified as available-for-sale and are summarized in the following tables:


	June 30, 2021
			Gross		Gross
			Unrealized		Unrealized		Fair
	Cost		Gains		Losses		Value
U.S. corporate bonds	$	926,387	$	22,571	$	—	$	948,958


	December 31, 2020
			Gross		Gross
			Unrealized		Unrealized		Fair
	Cost		Gains		Losses		Value
U.S. corporate bonds	$	1,863,382	$	45,986	$	—	$	1,909,368

XML 26 R16.htm IDEA: XBRL DOCUMENT

Fair Value Measurements

6 Months Ended

Jun. 30, 2021

Fair Value Measurements

Fair Value Measurements

8 — Fair Value Measurements

The fair values of cash equivalents, accounts receivables, net and accounts payable approximate their carrying amounts due to their short duration.

The fair value of our assets and liabilities subject to recurring fair value measurements are as follows:

Fair Value at June 30, 2021

Quoted Prices

Significant

in Active

Other

Significant

Market for

Observable

Unobservable

Fair

Identical Assets

Inputs

Value

(Level 1)

(Level 2)

(Level 3)

U.S. corporate bonds

948,958

—

948,958

—

Fair Value at December 31, 2020

Quoted Prices

Significant

in Active

Other

Significant

Market for

Observable

Unobservable

Fair

Identical Assets

Inputs

Value

(Level 1)

(Level 2)

(Level 3)

U.S. corporate bonds

1,909,368

—

1,909,368

—

Our corporate bonds are valued by a third-party custodian at closing prices from secondary exchanges or pricing vendors on the valuation date.

There were no transfers into or out of any Levels during the six months ended June 30, 2021 or the year ended December 31, 2020.

- Definition

The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.

+ References + Details

XML 27 R17.htm IDEA: XBRL DOCUMENT

Accumulated Other Comprehensive Income

6 Months Ended

Jun. 30, 2021

Accumulated Other Comprehensive Income

Accumulated Other Comprehensive Income

9 — Accumulated Other Comprehensive Income

The components of accumulated other comprehensive income, net of tax, for the three months ended June 30, 2021 and 2020 are as follows:


	Unrealized (Losses)
	Gains on
	Available-For-Sale
	Securities
Balance at March 31, 2021	$	32,218
Gain on available-for-sale securities, net		1,790
Reclassification realized in net earnings		(9,829)
Balance at June 30, 2021	$	24,179

Balance at March 31, 2020	$	40,807
Gains on available-for-sale securities, net		19,797
Reclassification realized in net earnings		(6,662)
Balance at June 30, 2020	$	53,942

The components of accumulated other comprehensive income, net of tax, for the six months ended June 30, 2021 and 2020 are as follows:


	Unrealized (Losses)
	Gains on
	Available-For-Sale
	Securities
Balance at December 31, 2020	$	37,087
Loss on available-for-sale securities, net		(3,079)
Reclassification realized in net earnings		(9,829)
Balance at June 30, 2021	$	24,179

Balance at December 31, 2019	$	30,374
Gains on available-for-sale securities, net		30,230
Reclassification realized in net earnings		(6,662)
Balance at June 30, 2020	$	53,942

XML 28 R18.htm IDEA: XBRL DOCUMENT

Stock-Based Compensation

6 Months Ended

Jun. 30, 2021

Stock-Based Compensation

Stock-Based Compensation

10 — Stock-Based Compensation

Stock-based compensation was recognized as follows in the Condensed Statements of Operations:


	Three Months Ended				Six Months Ended
	June 30,				June 30,
	2021		2020		2021		2020

	(unaudited)				(unaudited)
Cost of revenue	$	54,937	$	58,253	$	109,148	$	116,507
General and administrative		180,854		2,500,634		361,058		2,862,786
Sales and marketing		91,360		77,572		173,295		208,527
Research and development		30,861		22,173		62,252		39,770
Total	$	358,012	$	2,658,632	$	705,753	$	3,227,590

The following table presents a summary of our stock-based compensation activity for the six months ended June 30, 2021 (shares):


			Performance
			Based
	Stock	Restricted	Restricted
	Options	Stock Units	Stock Units
Outstanding beginning of period	230,510	151,139	11,891
Awards granted	—	8,920	—
Awards exercised/vested	(2,375)	(8,443)	—
Awards canceled	—	(9,549)	(2,546)
Outstanding end of period	228,135	142,067	9,345

XML 29 R19.htm IDEA: XBRL DOCUMENT

Income Taxes

6 Months Ended

Jun. 30, 2021

Income Taxes

Income Taxes

11 — Income Taxes

- Definition

The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.

+ References + Details

XML 30 R20.htm IDEA: XBRL DOCUMENT

Leases

6 Months Ended

Jun. 30, 2021

Leases

Leases

12 — Leases

We have entered into operating lease contracts for our office and various office equipment.

Operating lease cost recognized in the Condensed Statements of Operations is as follows:


	Three Months Ended					Six Months Ended
	June 30,				June 30,
	2021		2020		2021		2020

		(unaudited)				(unaudited)
Cost of revenue	$	51,094	$	46,535	$	102,189	$	93,070
General and administrative		53,406		46,044		103,962		92,088
Sales and marketing		2,860		2,603		5,719		5,208
Research and development		7,923		7,215		15,845		14,430
Total	$	115,283	$	102,397	$	227,715	$	204,796

Lease costs for short-term leases were immaterial for the three and six months ended June 30, 2021 and 2020.

Maturity of our operating lease liability as of June 30, 2021 is as follows:


Six months ending December 31, 2021	$	207,647
2022		415,294
2023		415,294
2024		415,294
2025		415,294
Thereafter		1,400,876
Total lease payments		3,269,699
Imputed interest		(655,348)
Present value of lease liability	$	2,614,351

XML 31 R21.htm IDEA: XBRL DOCUMENT

Commitments and Contingencies

6 Months Ended

Jun. 30, 2021

Commitments and Contingencies

Commitments and Contingencies

13 — Commitments and Contingencies

Legal matters. We may from time to time become party to various legal proceedings or claims that arise in the ordinary course of business.

XML 32 R22.htm IDEA: XBRL DOCUMENT

Basis of Presentation (Policies)

6 Months Ended

Jun. 30, 2021

Basis of Presentation

Certain Significant Risks and Uncertainties

COVID-19 Considerations

●

postponement or cancellation of MRI medical procedures and their uncertain return which adversely impacts our business;

●

disruptions in our supply chain that may limit our ability to procure materials necessary to manufacture our products;

●

potential temporary or prolonged closure of our office and production facility;

●

the health of our employees and ability to meet staffing needs;

●

potential new or continued governmental actions that may limit employees’ ability to work;

●

civil unrest relating to government, corporate and societal responses to the pandemic;

●

volatility in economic conditions and the financial markets, and

●

other unanticipated effects that remain unknown.

Recent Accounting Pronouncements

Recently Issued Accounting Pronouncements to be Implemented

Accounting Pronouncements Implemented in 2021

XML 33 R23.htm IDEA: XBRL DOCUMENT

Revenue Recognition (Tables)

6 Months Ended

Jun. 30, 2021

Revenue Recognition

Schedule of disaggregation of revenue by geographic region and revenue type

Revenue information by geographic region is as follows:


	Three Months Ended				Six Months Ended
	June 30,				June 30,
	2021		2020		2021		2020

	(unaudited)				(unaudited)
United States	$	8,043,156	$	4,642,916	$	15,315,986	$	10,965,022
International		1,767,267		2,151,776		3,718,433		4,507,211
Total revenue	$	9,810,423	$	6,794,692	$	19,034,419	$	15,472,233

Revenue information by type is as follows:


	Three Months Ended				Six Months Ended
	June 30,				June 30,
	2021		2020		2021		2020

	(unaudited)				(unaudited)
Devices:
MRI Compatible IV Infusion Pump Systems	$	2,456,767	$	1,875,159	$	5,960,114	$	4,539,993
MRI Compatible Patient Vital Signs Monitoring Systems		3,377,719		1,927,473		5,981,549		4,546,988
Total Devices revenue		5,834,486		3,802,632		11,941,663		9,086,981
Disposables, services and other		3,490,969		2,535,548		6,126,435		5,467,449
Amortization of extended warranty agreements		484,968		456,512		966,321		917,803
Total revenue	$	9,810,423	$	6,794,692	$	19,034,419	$	15,472,233

Schedule of contract liabilities and changes in the contract liabilities

Our contract liabilities consist of:


	June 30,		December 31,
	2021		2020
	(unaudited)
Advance payments from customers	$	484,354	$	85,590
Shipments in-transit		649,887		35,013
Extended warranty agreements		3,873,522		4,134,069
Total	$	5,007,763	$	4,254,672

Changes in the contract liabilities during the periods presented are as follows:


	Deferred
	Revenue
Contract liabilities, December 31, 2020	$	4,254,672
Increases due to cash received from customers		2,426,575
Decreases due to recognition of revenue		(1,673,484)
Contract liabilities, June 30, 2021	$	5,007,763


	Deferred
	Revenue
Contract liabilities, December 31, 2019	$	4,301,887
Increases due to cash received from customers		1,236,658
Decreases due to recognition of revenue		(1,048,380)
Contract liabilities, June 30, 2020	$	4,490,165

XML 34 R24.htm IDEA: XBRL DOCUMENT

Basic and Diluted Net Income per Share (Tables)

6 Months Ended

Jun. 30, 2021

Basic and Diluted Net Income per Share

Schedule of computation of basic and diluted net income per share


	Three Months Ended June 30,				Six Months Ended June 30,
	2021		2020		2021		2020

	(unaudited)				(unaudited)
Net income (loss)	$	1,469,694	$	(2,112,270)	$	2,856,543	$	(343,059)
Weighted-average shares outstanding — Basic		12,313,563		12,076,399		12,312,078		11,983,913
Effect of dilutive securities:
Stock options		194,419		—		192,347		—
Restricted stock units		46,846		—		35,058		—
Weighted-average shares outstanding — Diluted		12,554,828		12,076,399		12,539,483		11,983,913
Basic net income (loss) per share	$	0.12	$	(0.17)	$	0.23	$	(0.03)
Diluted net income (loss) per share	$	0.12	$	(0.17)	$	0.23	$	(0.03)

Schedule of stock options and restricted stock units excluded from the calculation of diluted net income per share


	Three Months Ended		Six Months Ended
	June 30,		June 30,
	2021	2020	2021	2020

	(unaudited)		(unaudited)
Anti-dilutive stock options and restricted stock units	1,500	399,772	1,635	479,499

XML 35 R25.htm IDEA: XBRL DOCUMENT

Inventory (Tables)

6 Months Ended

Jun. 30, 2021

Inventory

Schedule of inventory


	June 30,		December 31,
	2021		2020
	(unaudited)
Raw materials	$	3,528,442	$	3,210,815
Work in process		264,868		207,807
Finished goods		865,456		653,038
Inventory before allowance for excess and obsolete		4,658,766		4,071,660
Allowance for excess and obsolete		(190,651)		(137,673)
Total	$	4,468,115	$	3,933,987

XML 36 R26.htm IDEA: XBRL DOCUMENT

Property and Equipment (Tables)

6 Months Ended

Jun. 30, 2021

Property and Equipment

Schedule of property and equipment


	June 30,		December 31,
	2021		2020
	(unaudited)
Computer software and hardware	$	783,690	$	705,811
Furniture and fixtures		1,233,749		1,226,113
Leasehold improvements		230,351		230,351
Machinery and equipment		2,044,479		1,823,835
Tooling in-process		395,782		470,446
		4,688,051		4,456,556
Accumulated depreciation		(2,595,827)		(2,336,408)
Total	$	2,092,224	$	2,120,148

Schedule of property and equipment, net, information by geographic region


	June 30,		December 31,
	2021		2020
	(unaudited)
United States	$	1,839,405	$	1,832,894
International		252,819		287,254
Total property and equipment, net	$	2,092,224	$	2,120,148

XML 37 R27.htm IDEA: XBRL DOCUMENT

Intangible Assets (Tables)

6 Months Ended

Jun. 30, 2021

Intangible Assets

Summary of the components of intangible asset balances


	June 30,		December 31,
	2021		2020
	(unaudited)
Patents — in use	$	372,502	$	362,162
Patents — in process		78,123		69,733
Internally developed software — in use		872,218		872,253
Internally developed software — in process		342,887		261,622
Trademarks		27,697		27,247
		1,693,427		1,593,017
Accumulated amortization		(683,354)		(632,132)
Total	$	1,010,073	$	960,885

Schedule of expected annual amortization expense related to intangible assets (excludes in process intangible assets)


Six months ending December 31, 2021	$	50,513
2022	$	100,308
2023	$	99,797
2024	$	99,395
2025	$	96,225
2026	$	84,508

XML 38 R28.htm IDEA: XBRL DOCUMENT

Investments (Tables)

6 Months Ended

Jun. 30, 2021

Investments

Summary of available-for-sale securities


	June 30, 2021
			Gross		Gross
			Unrealized		Unrealized		Fair
	Cost		Gains		Losses		Value
U.S. corporate bonds	$	926,387	$	22,571	$	—	$	948,958


	December 31, 2020
			Gross		Gross
			Unrealized		Unrealized		Fair
	Cost		Gains		Losses		Value
U.S. corporate bonds	$	1,863,382	$	45,986	$	—	$	1,909,368

XML 39 R29.htm IDEA: XBRL DOCUMENT

Fair Value Measurements (Tables)

6 Months Ended

Jun. 30, 2021

Fair Value Measurements

Schedule of the fair value of assets and liabilities subject to recurring fair value measurements

Fair Value at June 30, 2021

Quoted Prices

Significant

in Active

Other

Significant

Market for

Observable

Unobservable

Fair

Identical Assets

Inputs

Value

(Level 1)

(Level 2)

(Level 3)

U.S. corporate bonds

948,958

—

948,958

—

Fair Value at December 31, 2020

Quoted Prices

Significant

in Active

Other

Significant

Market for

Observable

Unobservable

Fair

Identical Assets

Inputs

Value

(Level 1)

(Level 2)

(Level 3)

U.S. corporate bonds

1,909,368

—

1,909,368

—

XML 40 R30.htm IDEA: XBRL DOCUMENT

Accumulated Other Comprehensive Income (Loss) (Tables)

6 Months Ended

Jun. 30, 2021

Accumulated Other Comprehensive Income

Schedule of components of accumulated other comprehensive loss, net of tax

The components of accumulated other comprehensive income, net of tax, for the three months ended June 30, 2021 and 2020 are as follows:


	Unrealized (Losses)
	Gains on
	Available-For-Sale
	Securities
Balance at March 31, 2021	$	32,218
Gain on available-for-sale securities, net		1,790
Reclassification realized in net earnings		(9,829)
Balance at June 30, 2021	$	24,179

Balance at March 31, 2020	$	40,807
Gains on available-for-sale securities, net		19,797
Reclassification realized in net earnings		(6,662)
Balance at June 30, 2020	$	53,942

The components of accumulated other comprehensive income, net of tax, for the six months ended June 30, 2021 and 2020 are as follows:


	Unrealized (Losses)
	Gains on
	Available-For-Sale
	Securities
Balance at December 31, 2020	$	37,087
Loss on available-for-sale securities, net		(3,079)
Reclassification realized in net earnings		(9,829)
Balance at June 30, 2021	$	24,179

Balance at December 31, 2019	$	30,374
Gains on available-for-sale securities, net		30,230
Reclassification realized in net earnings		(6,662)
Balance at June 30, 2020	$	53,942

XML 41 R31.htm IDEA: XBRL DOCUMENT

Stock-Based Compensation (Tables)

6 Months Ended

Jun. 30, 2021

Stock-Based Compensation

Schedule of stock-based compensation


	Three Months Ended				Six Months Ended
	June 30,				June 30,
	2021		2020		2021		2020

	(unaudited)				(unaudited)
Cost of revenue	$	54,937	$	58,253	$	109,148	$	116,507
General and administrative		180,854		2,500,634		361,058		2,862,786
Sales and marketing		91,360		77,572		173,295		208,527
Research and development		30,861		22,173		62,252		39,770
Total	$	358,012	$	2,658,632	$	705,753	$	3,227,590

Summary of stock options and restricted stock units activity

The following table presents a summary of our stock-based compensation activity for the six months ended June 30, 2021 (shares):


			Performance
			Based
	Stock	Restricted	Restricted
	Options	Stock Units	Stock Units
Outstanding beginning of period	230,510	151,139	11,891
Awards granted	—	8,920	—
Awards exercised/vested	(2,375)	(8,443)	—
Awards canceled	—	(9,549)	(2,546)
Outstanding end of period	228,135	142,067	9,345

XML 42 R32.htm IDEA: XBRL DOCUMENT

Leases (Tables)

6 Months Ended

Jun. 30, 2021

Leases

Schedule of operating lease cost


	Three Months Ended					Six Months Ended
	June 30,				June 30,
	2021		2020		2021		2020

		(unaudited)				(unaudited)
Cost of revenue	$	51,094	$	46,535	$	102,189	$	93,070
General and administrative		53,406		46,044		103,962		92,088
Sales and marketing		2,860		2,603		5,719		5,208
Research and development		7,923		7,215		15,845		14,430
Total	$	115,283	$	102,397	$	227,715	$	204,796

Schedule of maturity of operating lease liability


Six months ending December 31, 2021	$	207,647
2022		415,294
2023		415,294
2024		415,294
2025		415,294
Thereafter		1,400,876
Total lease payments		3,269,699
Imputed interest		(655,348)
Present value of lease liability	$	2,614,351

XML 43 R33.htm IDEA: XBRL DOCUMENT

Basis of Presentation (Details)	6 Months Ended
Basis of Presentation (Details)	Jun. 30, 2021 segment
Basis of Presentation
Number of reportable segment	1

XML 44 R34.htm IDEA: XBRL DOCUMENT

Revenue Recognition - Information by geographic region (Details) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2021	Jun. 30, 2020	Jun. 30, 2021	Jun. 30, 2020
Contract Liabilities
Total revenue	$ 9,810,423	$ 6,794,692	$ 19,034,419	$ 15,472,233
United States
Contract Liabilities
Total revenue	8,043,156	4,642,916	15,315,986	10,965,022
International
Contract Liabilities
Total revenue	$ 1,767,267	$ 2,151,776	$ 3,718,433	$ 4,507,211

- Definition

Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 30
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 40
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e9031-108599

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 41
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e9038-108599

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 4
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=121604090&loc=SL49130543-203045

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 42
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e9054-108599

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=121604090&loc=SL49130545-203045

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 924
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SAB Topic 11.L)
-URI http://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856

+ Details

XML 45 R35.htm IDEA: XBRL DOCUMENT

Revenue Recognition - Information by Type (Details) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2021	Jun. 30, 2020	Jun. 30, 2021	Jun. 30, 2020
Disaggregation of Revenue
Total Devices revenue	$ 5,834,486	$ 3,802,632	$ 11,941,663	$ 9,086,981
Disposables, service and other	3,490,969	2,535,548	6,126,435	5,467,449
Amortization of extended warranty agreements	484,968	456,512	966,321	917,803
Total revenue	9,810,423	6,794,692	19,034,419	15,472,233
MRI Compatible IV Infusion Pump Systems
Disaggregation of Revenue
Total Devices revenue	2,456,767	1,875,159	5,960,114	4,539,993
MRI Compatible Patient Vital Signs Monitoring Systems
Disaggregation of Revenue
Total Devices revenue	$ 3,377,719	$ 1,927,473	$ 5,981,549	$ 4,546,988

- Definition

+ References

+ Details

XML 46 R36.htm IDEA: XBRL DOCUMENT

Revenue Recognition - Contract Liabilities (Details) - USD ($)	6 Months Ended
	Jun. 30, 2021	Jun. 30, 2020	Dec. 31, 2020
Deferred revenue
Advance payments from customers	$ 484,354		$ 85,590
Shipments in-transit	649,887		35,013
Extended warranty agreements	3,873,522		4,134,069
Total	5,007,763	$ 4,490,165	$ 4,254,672
Changes in contract liabilities
Contract liabilities at beginning of the year	4,254,672	4,301,887
Increases due to cash received from customers	2,426,575	1,236,658
Decreases due to recognition of revenue	(1,673,484)	(1,048,380)
Contract liabilities at end	$ 5,007,763	$ 4,490,165

XML 47 R37.htm IDEA: XBRL DOCUMENT

Revenue Recognition - Capitalized Contract Costs (Details) - USD ($)	Jun. 30, 2021	Dec. 31, 2020
Revenue Recognition
Capitalized contract costs	$ 353,942	$ 384,367

XML 48 R38.htm IDEA: XBRL DOCUMENT

Basic and Diluted Net Income per Share (Details) - USD ($)	3 Months Ended				6 Months Ended
	Jun. 30, 2021	Mar. 31, 2021	Jun. 30, 2020	Mar. 31, 2020	Jun. 30, 2021	Jun. 30, 2020
Basic and Diluted Net Income per Share
Net income (loss)	$ 1,469,694	$ 1,386,849	$ (2,112,270)	$ 1,769,211	$ 2,856,543	$ (343,059)
Weighted-average shares outstanding - Basic (in shares)	12,313,563		12,076,399		12,312,078	11,983,913
Effect of dilutive securities:
Stock Options	194,419				192,347
Restricted Stock Units	46,846				35,058
Weighted-average shares outstanding - Diluted (in shares)	12,554,828		12,076,399		12,539,483	11,983,913
Basic net income (loss) per share (in dollars per share)	$ 0.12		$ (0.17)		$ 0.23	$ (0.03)
Diluted net income (loss) per share (in dollars per share)	$ 0.12		$ (0.17)		$ 0.23	$ (0.03)
Anti-dilutive stock
Anti-dilutive stock options and restricted stock units	1,500		399,772		1,635	479,499

XML 49 R39.htm IDEA: XBRL DOCUMENT

Inventory (Details) - USD ($)	Jun. 30, 2021	Dec. 31, 2020
Inventory
Raw materials	$ 3,528,442	$ 3,210,815
Work in process	264,868	207,807
Finished goods	865,456	653,038
Inventory before allowance for excess and obsolete	4,658,766	4,071,660
Allowance for excess and obsolete	(190,651)	(137,673)
Total	$ 4,468,115	$ 3,933,987

XML 50 R40.htm IDEA: XBRL DOCUMENT

Property and Equipment (Details) - USD ($)	3 Months Ended		6 Months Ended
Property and Equipment (Details) - USD ($)	Jun. 30, 2021	Jun. 30, 2020	Jun. 30, 2021	Jun. 30, 2020	Dec. 31, 2020
Property and equipment
Property and equipment, gross	$ 4,688,051		$ 4,688,051		$ 4,456,556
Accumulated depreciation	(2,595,827)		(2,595,827)		(2,336,408)
Total	2,092,224		2,092,224		2,120,148
Depreciation and amortization expense of property and equipment	137,598	$ 127,945	264,737	$ 254,253
Computer software and hardware
Property and equipment
Property and equipment, gross	783,690		783,690		705,811
Furniture and fixtures
Property and equipment
Property and equipment, gross	1,233,749		1,233,749		1,226,113
Leasehold improvements
Property and equipment
Property and equipment, gross	230,351		230,351		230,351
Machinery and equipment
Property and equipment
Property and equipment, gross	2,044,479		2,044,479		1,823,835
Tooling in-process
Property and equipment
Property and equipment, gross	$ 395,782		$ 395,782		$ 470,446

XML 51 R41.htm IDEA: XBRL DOCUMENT

Property and Equipment - Geographic information (Details) - USD ($)	Jun. 30, 2021	Dec. 31, 2020
Property and equipment
Total property and equipment, net	$ 2,092,224	$ 2,120,148
United States
Property and equipment
Total property and equipment, net	1,839,405	1,832,894
International
Property and equipment
Total property and equipment, net	$ 252,819	$ 287,254

XML 52 R42.htm IDEA: XBRL DOCUMENT

Intangible Assets (Details) - USD ($)	3 Months Ended		6 Months Ended
Intangible Assets (Details) - USD ($)	Jun. 30, 2021	Jun. 30, 2020	Jun. 30, 2021	Jun. 30, 2020	Dec. 31, 2020
Intangible assets
Intangible Assets, gross	$ 1,693,427		$ 1,693,427		$ 1,593,017
Accumulated amortization	(683,354)		(683,354)		(632,132)
Total	1,010,073		1,010,073		960,885
Amortization expense of intangible assets	25,104	$ 22,999	51,222	$ 45,490
Expected annual amortization expense
Six months ending December 31, 2021	50,513		50,513
2022	100,308		100,308
2023	99,797		99,797
2024	99,395		99,395
2025	96,225		96,225
2026	84,508		84,508
Patents - in use
Intangible assets
Intangible Assets, gross	372,502		372,502		362,162
Patents - in process
Intangible assets
Intangible Assets, gross	78,123		78,123		69,733
Internally developed software - in use
Intangible assets
Intangible Assets, gross	872,218		872,218		872,253
Internally developed software - in process
Intangible assets
Intangible Assets, gross	342,887		342,887		261,622
Trademarks
Intangible assets
Intangible Assets, gross	$ 27,697		$ 27,697		$ 27,247

XML 53 R43.htm IDEA: XBRL DOCUMENT

Investments (Details) - U.S. corporations - USD ($)	6 Months Ended	12 Months Ended
Investments (Details) - U.S. corporations - USD ($)	Jun. 30, 2021	Dec. 31, 2020
Investments
Cost	$ 926,387	$ 1,863,382
Gross Unrealized Gains	22,571	45,986
Fair Value	$ 948,958	$ 1,909,368

XML 54 R44.htm IDEA: XBRL DOCUMENT

Fair Value Measurements (Details) - USD ($)	Jun. 30, 2021	Dec. 31, 2020
Fair Value Measurements
Fair value assets, amount transferred between measurement levels	$ 0	$ 0
Fair value liabilities, amount transferred between measurement levels	0	0
Recurring \| U.S. corporations
Fair Value Measurements
Total	948,958	1,909,368
Recurring \| Significant Other Observable Inputs (Level 2) \| U.S. corporations
Fair Value Measurements
Total	$ 948,958	$ 1,909,368

XML 55 R45.htm IDEA: XBRL DOCUMENT

Accumulated Other Comprehensive Income (Details) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2021	Jun. 30, 2020	Jun. 30, 2021	Jun. 30, 2020
Component of accumulated other comprehensive loss
Balance at the beginning	$ 32,218	$ 40,807	$ 37,087	$ 30,374
Gains (Loss) on available-for-sale securities, net	1,790	19,797	(3,079)	30,230
Reclassification realized in net earnings	(9,829)	(6,662)	(9,829)	(6,662)
Balance at the end	$ 24,179	$ 53,942	$ 24,179	$ 53,942

- Definition

Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.

+ References + Details

XML 56 R46.htm IDEA: XBRL DOCUMENT

Stock-Based Compensation (Details) - USD ($)	3 Months Ended		6 Months Ended
Stock-Based Compensation (Details) - USD ($)	Jun. 30, 2021	Jun. 30, 2020	Jun. 30, 2021	Jun. 30, 2020
Stock-Based Compensation
Total stock-based compensation expense	$ 358,012	$ 2,658,632	$ 705,753	$ 3,227,590
Cost of revenue
Stock-Based Compensation
Total stock-based compensation expense	54,937	58,253	109,148	116,507
General and administrative
Stock-Based Compensation
Total stock-based compensation expense	180,854	2,500,634	361,058	2,862,786
Sales and marketing
Stock-Based Compensation
Total stock-based compensation expense	91,360	77,572	173,295	208,527
Research and development
Stock-Based Compensation
Total stock-based compensation expense	$ 30,861	$ 22,173	$ 62,252	$ 39,770

XML 57 R47.htm IDEA: XBRL DOCUMENT

Stock-Based Compensation - Stock Options and Restricted Stock Units Activity (Details) - USD ($)	6 Months Ended
	Jun. 30, 2021
Stock Options
Stock Options
Outstanding beginning of period (in shares)	230,510
Options exercised (in shares)	(2,375)
Outstanding end of period (in shares)	228,135
Restricted Stock Units
Stock-Based Compensation
Unrecognized compensation cost related to unvested restricted stock units	$ 2,527,686
Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Period for Recognition	2 years 6 months
Stock Options
Outstanding beginning of period (in shares)	151,139
Options granted (in shares)	8,920
Options exercised (in shares)	(8,443)
Options cancelled (in shares)	(9,549)
Outstanding end of period (in shares)	142,067
Performance-Based Restricted Stock Units ("PSUs")
Stock-Based Compensation
Unrecognized compensation cost related to unvested restricted stock units	$ 224,090
Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Period for Recognition	2 years 4 months 24 days
Stock Options
Outstanding beginning of period (in shares)	11,891
Options cancelled (in shares)	(2,546)
Outstanding end of period (in shares)	9,345

XML 58 R48.htm IDEA: XBRL DOCUMENT

Income Taxes (Details) - USD ($)	3 Months Ended		6 Months Ended
Income Taxes (Details) - USD ($)	Jun. 30, 2021	Jun. 30, 2020	Jun. 30, 2021	Jun. 30, 2020
Reconciliation of the statutory U.S. federal tax rate to effective rate
Provision for income tax expense (benefit)	$ 387,727	$ (798,988)	$ 772,221	$ (1,732,462)
Effective tax rate (as a percent)	20.90%	27.40%	21.30%	83.50%

- Definition

Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.

+ References + Details

XML 59 R49.htm IDEA: XBRL DOCUMENT

Leases (Details)	1 Months Ended	6 Months Ended
Leases (Details)	Jan. 31, 2014 USD ($)	Jun. 30, 2021 item
Leases
Number of material lease contract outstanding \| item		1
Lessee, operating lease, existence of option to extend		true
Lessee, operating lease, existence of residual value guarantee		false
Susi, LLC \| Winter Springs, Florida Facility
Leases
Monthly base rent \| $	$ 34,133
Renewal term of lease beginning in 2019	5 years
Number of successive renewal terms of lease	1
Renewal term of lease beginning in 2024	5 years
Renewal term lease thereafter	1 year
Remaining lease term (in years)		7 years 10 months 24 days

XML 60 R50.htm IDEA: XBRL DOCUMENT

Leases - Operating Lease Cost (Details) - USD ($)	3 Months Ended		6 Months Ended
Leases - Operating Lease Cost (Details) - USD ($)	Jun. 30, 2021	Jun. 30, 2020	Jun. 30, 2021	Jun. 30, 2020
Leases
Operating lease cost	$ 115,283	$ 102,397	$ 227,715	$ 204,796
Cost of revenue
Leases
Operating lease cost	51,094	46,535	102,189	93,070
General and administrative
Leases
Operating lease cost	53,406	46,044	103,962	92,088
Sales and marketing
Leases
Operating lease cost	2,860	2,603	5,719	5,208
Research and development
Leases
Operating lease cost	$ 7,923	$ 7,215	$ 15,845	$ 14,430

XML 61 R51.htm IDEA: XBRL DOCUMENT

Leases - Maturity of Lease Liabilities (Details)	Jun. 30, 2021 USD ($)
Operating leases
Six months ending December 31, 2021	$ 207,647
2022	415,294
2023	415,294
2024	415,294
2025	415,294
Thereafter	1,400,876
Total lease payments	3,269,699
Imputed interest	(655,348)
Present value of lease liability	$ 2,614,351

XML 62 R52.htm IDEA: XBRL DOCUMENT

Commitments and Contingencies (Details) - USD ($)	Jun. 30, 2021	Dec. 31, 2020
Purchase commitments
Purchase commitments	$ 4,819,367	$ 3,089,103

EXCEL 63 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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
;9M.P.R/XRFZ% M<'G6")O-ZT;.I0J^?SL<:VH:_H9V(G52*V@L&NZE>+)O^XM-]BBM7,I,NN=. M4/Z=B8#E4LEK^3:E,< M!JZBX5U&68?#9U7$&_-_RJC7:YF*OD[WN5"NJJ,160&H[%;N;, 4ST4G.'1A M7*U8HAP4B0U5=2CH6UPIG'JXJJ[: :Y70W,C88<9KDIP.LC>9-Q/QO.DSWYT M1]UQ+V'S09(LYAY=B-"%EZ%CGZ;<"+^$$0(9?13D?-%=)'?)& GMVPR36;= MQ="#C!'(^#*0O7P9ROICT_AE,/,C/".3G M"U6R.Q^PVY$'^06!_$(+^8-;:9E>LZD1%KJ^GQ:_(FA?:=%FXE&HO6 SD>J- MDN_GZR8V83?IJY:63NG+;._$BHWA3$.5ZERPG? Q4:\0BV6HH().FV*QW_MY>[XA]\.LPA+6*)#.'KKS;%25G76D@F/ACFC1:Q.(K[ M:%W1Z0@)LT2+6!.W7!IVSS,8GW>"V[T1)WB8'UK$@NBFT&4/.V!H3MQ6&-;3 M.63OK5 6DJJ/B1FB1:R(N=/IPQ7,)H!9 +=22[%Y- BML/KC+;@O\31K<6L MT"+6P@B^;D/B:DD)%8)FA*. M!G.$.28B=LRYE/!:3A\3LTQ$;)E*S'7?Q0BS2D1LE3/RZPO'97:,B2Y@$8NE M3GY7;VN5/B8FEHA8+"CF\9#!+!,16Z8>LPAGAJ>.^9B892)BRYS!Y#OI>"9? M?$Q,-1&Q:O#0$_F8F'4B\J>5/Z&G;G1CIHF(37,N];QR^NO3F&EB8M.&.YC8J:)R=>U3L)9S0V/,>O$Q-8Y2F=U<)AK8F+7G(UG%:B/B;XN(78- M'L_\:2?&7!,3N^9\/"O+Z6-BKHF)77,6\XH5NWQ,S#4Q^6/-VY)3_NX,+_$'[(H!K=R O,W+U:@6-D$=]J"9OQ7BYA?VL1^^8-YQ]W>%"_C M(9=7H"/)ESXFYI$C(3*G>?447]@M==%/F6X5)R)\7 @]A M,GN/^R9OVV/:;+LT.AWVQS2O-CEWSR&DY28>FC1NNWB\7%FU_:')EV6_#EVS MW#7K&'0RF8;^YXSJ9?9SYFAQ[N)?)K:KU7897]OEYR$>\R^#PU?;[](FQER- M%DV_CGE>A=/^?CJ%ZT'&E\G5Z.UC7O5O'U*%TD$*05H^R"#(R@BOJK01Z*^JM!'HKZJT$>BOJK01Z*^JM!'HKZJT$>BOJK01Z&^IM!'H;ZFT$ M>AOJ;01ZVV"SA$!O0[V-0&]#O8U ;T.]C4!O0[V-0&]#O8U ;T.]C4!O1[V= M0&]'O9U ;T>]G4!O1[V=0&\?;'83Z.VHMQ/H[:BW$^CMJ+<3Z.VHMQ/H[:BW M$^A=H]XU@=XUZET3Z%VCWO5_ZIWR>1_3O>>VQN?_)]7YUW7VSI;#)^VUGRO6U5UGZ2+$.P#XSY;$F5]JFQ5,>1 MN7&5#O'1+9C5V4HOB(G!8,0R4P>J0S\T-9+I^(GF>EV&WO,VOO:%J2>)H](G MOVN:>5+NIC/FM_A4\_ 5!+ 0(4 Q0 ( !0X!E,'04UB@0 +$ 0 M " 0 !D;V-0&UL4$L! A0#% @ M%#@&4ZBVX13N *P( !$ ( !KP &1O8U!R;W!S+V-O M&UL4$L! A0#% @ %#@&4YE&PO=V]R:W-H965T&UL4$L! A0#% @ %#@&4[R+@S"@!@ S!D !@ M ("!=0T 'AL+W=O&PO=V]R:W-H965T&UL4$L! A0#% M @ %#@&4]FHWJW? P L0P !@ ("!#1T 'AL+W=O9@% "R$ &0 @($\/P >&PO=V]R:W-H965T&UL4$L! A0#% @ M%#@&4V,('K&J @ >@8 !D ("!>TD 'AL+W=O&PO=V]R:W-H965T&UL4$L! A0#% @ %#@&4QY"M^5:! $PP !D M ("!?%X 'AL+W=O&PO=V]R:W-H M965T&UL4$L! M A0#% @ %#@&4RY>QY?[ 0 K00 !D ("!YFX 'AL M+W=O&PO=V]R:W-H965T&UL4$L! A0#% @ %#@& M4]UU&$2& P ?0L !D ("!6G\ 'AL+W=O*P" !&PO=V]R:W-H965T<+X2 , ,D( 9 " @?J% !X;"]W;W)K M&UL4$L! A0#% @ %#@&4R V))59 P @D M !D ("!>8D 'AL+W=O&PO=V]R:W-H965T&UL4$L! A0#% @ %#@&4RP%2^HY P 7@H !D M ("!OI( 'AL+W=O4# #8"@ &0 @($NE@ >&PO=V]R:W-H965T M&UL4$L! A0# M% @ %#@&4QZB&PO=V]R:W-H965T&UL4$L! A0#% @ %#@&4U+.@BZD @ A@< !D M ("!I[$ 'AL+W=O&PO M=V]R:W-H965T[?9P( M #4' 9 " @&UL4$L! A0#% @ %#@&4[>9."Z=! $A4 !D ("! M:+L 'AL+W=O&PO=V]R:W-H965T3" !X;"]W;W)K&UL4$L! A0#% M @ %#@&4V!+1&PF P IPD !D ("!O<4 'AL+W=O&PO=V]R:W-H965T&UL4$L! A0#% @ %#@&4]>!F!G% M @ P@ !D ("!_M 'AL+W=O&PO=V]R:W-H965T&UL4$L! A0#% @ %#@&4[[5!P.? @ C0< !D M ("!)=L 'AL+W=O&PO=V]R M:W-H965T7!E&UL4$L%!@ \ #P 6Q -?L $! end XML 64 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 65 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 66 FilingSummary.xml IDEA: XBRL DOCUMENT 3.21.2 html 129 288 1 false 30 0 false 6 false false R1.htm 00090 - Document - Document and Entity Information Sheet http://www.iradimed.com/role/DocumentDocumentAndEntityInformation Document and Entity Information Cover 1 false false R2.htm 00100 - Statement - CONDENSED BALANCE SHEETS Sheet http://www.iradimed.com/role/StatementCondensedBalanceSheets CONDENSED BALANCE SHEETS Statements 2 false false R3.htm 00105 - Statement - CONDENSED BALANCE SHEETS (Parenthetical) Sheet http://www.iradimed.com/role/StatementCondensedBalanceSheetsParenthetical CONDENSED BALANCE SHEETS (Parenthetical) Statements 3 false false R4.htm 00200 - Statement - CONDENSED STATEMENTS OF OPERATIONS Sheet http://www.iradimed.com/role/StatementCondensedStatementsOfOperations CONDENSED STATEMENTS OF OPERATIONS Statements 4 false false R5.htm 00300 - Statement - CONDENSED STATEMENTS OF COMPREHENSIVE INCOME Sheet http://www.iradimed.com/role/StatementCondensedStatementsOfComprehensiveIncome CONDENSED STATEMENTS OF COMPREHENSIVE INCOME Statements 5 false false R6.htm 00305 - Statement - CONDENSED STATEMENTS OF COMPREHENSIVE INCOME (Parenthetical) Sheet http://www.iradimed.com/role/StatementCondensedStatementsOfComprehensiveIncomeParenthetical CONDENSED STATEMENTS OF COMPREHENSIVE INCOME (Parenthetical) Statements 6 false false R7.htm 00400 - Statement - CONDENSED STATEMENTS OF STOCKHOLDERS' EQUITY Sheet http://www.iradimed.com/role/StatementCondensedStatementsOfStockholdersEquity CONDENSED STATEMENTS OF STOCKHOLDERS' EQUITY Statements 7 false false R8.htm 00500 - Statement - CONDENSED STATEMENTS OF CASH FLOWS Sheet http://www.iradimed.com/role/StatementCondensedStatementsOfCashFlows CONDENSED STATEMENTS OF CASH FLOWS Statements 8 false false R9.htm 10101 - Disclosure - Basis of Presentation Sheet http://www.iradimed.com/role/DisclosureBasisOfPresentation Basis of Presentation Notes 9 false false R10.htm 10201 - Disclosure - Revenue Recognition Sheet http://www.iradimed.com/role/DisclosureRevenueRecognition Revenue Recognition Notes 10 false false R11.htm 10301 - Disclosure - Basic and Diluted Net Income per Share Sheet http://www.iradimed.com/role/DisclosureBasicAndDilutedNetIncomePerShare Basic and Diluted Net Income per Share Notes 11 false false R12.htm 10401 - Disclosure - Inventory Sheet http://www.iradimed.com/role/DisclosureInventory Inventory Notes 12 false false R13.htm 10501 - Disclosure - Property and Equipment Sheet http://www.iradimed.com/role/DisclosurePropertyAndEquipment Property and Equipment Notes 13 false false R14.htm 10601 - Disclosure - Intangible Assets Sheet http://www.iradimed.com/role/DisclosureIntangibleAssets Intangible Assets Notes 14 false false R15.htm 10701 - Disclosure - Investments Sheet http://www.iradimed.com/role/DisclosureInvestments Investments Notes 15 false false R16.htm 10801 - Disclosure - Fair Value Measurements Sheet http://www.iradimed.com/role/DisclosureFairValueMeasurements Fair Value Measurements Notes 16 false false R17.htm 10901 - Disclosure - Accumulated Other Comprehensive Income Sheet http://www.iradimed.com/role/DisclosureAccumulatedOtherComprehensiveIncome Accumulated Other Comprehensive Income Notes 17 false false R18.htm 11001 - Disclosure - Stock-Based Compensation Sheet http://www.iradimed.com/role/DisclosureStockBasedCompensation Stock-Based Compensation Notes 18 false false R19.htm 11101 - Disclosure - Income Taxes Sheet http://www.iradimed.com/role/DisclosureIncomeTaxes Income Taxes Notes 19 false false R20.htm 11201 - Disclosure - Leases Sheet http://www.iradimed.com/role/DisclosureLeases Leases Notes 20 false false R21.htm 11301 - Disclosure - Commitments and Contingencies Sheet http://www.iradimed.com/role/DisclosureCommitmentsAndContingencies Commitments and Contingencies Notes 21 false false R22.htm 20102 - Disclosure - Basis of Presentation (Policies) Sheet http://www.iradimed.com/role/DisclosureBasisOfPresentationPolicies Basis of Presentation (Policies) Policies 22 false false R23.htm 30203 - Disclosure - Revenue Recognition (Tables) Sheet http://www.iradimed.com/role/DisclosureRevenueRecognitionTables Revenue Recognition (Tables) Tables http://www.iradimed.com/role/DisclosureRevenueRecognition 23 false false R24.htm 30303 - Disclosure - Basic and Diluted Net Income per Share (Tables) Sheet http://www.iradimed.com/role/DisclosureBasicAndDilutedNetIncomePerShareTables Basic and Diluted Net Income per Share (Tables) Tables http://www.iradimed.com/role/DisclosureBasicAndDilutedNetIncomePerShare 24 false false R25.htm 30403 - Disclosure - Inventory (Tables) Sheet http://www.iradimed.com/role/DisclosureInventoryTables Inventory (Tables) Tables http://www.iradimed.com/role/DisclosureInventory 25 false false R26.htm 30503 - Disclosure - Property and Equipment (Tables) Sheet http://www.iradimed.com/role/DisclosurePropertyAndEquipmentTables Property and Equipment (Tables) Tables http://www.iradimed.com/role/DisclosurePropertyAndEquipment 26 false false R27.htm 30603 - Disclosure - Intangible Assets (Tables) Sheet http://www.iradimed.com/role/DisclosureIntangibleAssetsTables Intangible Assets (Tables) Tables http://www.iradimed.com/role/DisclosureIntangibleAssets 27 false false R28.htm 30703 - Disclosure - Investments (Tables) Sheet http://www.iradimed.com/role/DisclosureInvestmentsTables Investments (Tables) Tables http://www.iradimed.com/role/DisclosureInvestments 28 false false R29.htm 30803 - Disclosure - Fair Value Measurements (Tables) Sheet http://www.iradimed.com/role/DisclosureFairValueMeasurementsTables Fair Value Measurements (Tables) Tables http://www.iradimed.com/role/DisclosureFairValueMeasurements 29 false false R30.htm 30903 - Disclosure - Accumulated Other Comprehensive Income (Loss) (Tables) Sheet http://www.iradimed.com/role/DisclosureAccumulatedOtherComprehensiveIncomeLossTables Accumulated Other Comprehensive Income (Loss) (Tables) Tables http://www.iradimed.com/role/DisclosureAccumulatedOtherComprehensiveIncome 30 false false R31.htm 31003 - Disclosure - Stock-Based Compensation (Tables) Sheet http://www.iradimed.com/role/DisclosureStockBasedCompensationTables Stock-Based Compensation (Tables) Tables http://www.iradimed.com/role/DisclosureStockBasedCompensation 31 false false R32.htm 31203 - Disclosure - Leases (Tables) Sheet http://www.iradimed.com/role/DisclosureLeasesTables Leases (Tables) Tables http://www.iradimed.com/role/DisclosureLeases 32 false false R33.htm 40101 - Disclosure - Basis of Presentation (Details) Sheet http://www.iradimed.com/role/DisclosureBasisOfPresentationDetails Basis of Presentation (Details) Details http://www.iradimed.com/role/DisclosureBasisOfPresentationPolicies 33 false false R34.htm 40201 - Disclosure - Revenue Recognition - Information by geographic region (Details) Sheet http://www.iradimed.com/role/DisclosureRevenueRecognitionInformationByGeographicRegionDetails Revenue Recognition - Information by geographic region (Details) Details 34 false false R35.htm 40202 - Disclosure - Revenue Recognition - Information by Type (Details) Sheet http://www.iradimed.com/role/DisclosureRevenueRecognitionInformationByTypeDetails Revenue Recognition - Information by Type (Details) Details 35 false false R36.htm 40203 - Disclosure - Revenue Recognition - Contract Liabilities (Details) Sheet http://www.iradimed.com/role/DisclosureRevenueRecognitionContractLiabilitiesDetails Revenue Recognition - Contract Liabilities (Details) Details 36 false false R37.htm 40204 - Disclosure - Revenue Recognition - Capitalized Contract Costs (Details) Sheet http://www.iradimed.com/role/DisclosureRevenueRecognitionCapitalizedContractCostsDetails Revenue Recognition - Capitalized Contract Costs (Details) Details 37 false false R38.htm 40301 - Disclosure - Basic and Diluted Net Income per Share (Details) Sheet http://www.iradimed.com/role/DisclosureBasicAndDilutedNetIncomePerShareDetails Basic and Diluted Net Income per Share (Details) Details http://www.iradimed.com/role/DisclosureBasicAndDilutedNetIncomePerShareTables 38 false false R39.htm 40401 - Disclosure - Inventory (Details) Sheet http://www.iradimed.com/role/DisclosureInventoryDetails Inventory (Details) Details http://www.iradimed.com/role/DisclosureInventoryTables 39 false false R40.htm 40501 - Disclosure - Property and Equipment (Details) Sheet http://www.iradimed.com/role/DisclosurePropertyAndEquipmentDetails Property and Equipment (Details) Details http://www.iradimed.com/role/DisclosurePropertyAndEquipmentTables 40 false false R41.htm 40502 - Disclosure - Property and Equipment - Geographic information (Details) Sheet http://www.iradimed.com/role/DisclosurePropertyAndEquipmentGeographicInformationDetails Property and Equipment - Geographic information (Details) Details 41 false false R42.htm 40601 - Disclosure - Intangible Assets (Details) Sheet http://www.iradimed.com/role/DisclosureIntangibleAssetsDetails Intangible Assets (Details) Details http://www.iradimed.com/role/DisclosureIntangibleAssetsTables 42 false false R43.htm 40701 - Disclosure - Investments (Details) Sheet http://www.iradimed.com/role/DisclosureInvestmentsDetails Investments (Details) Details http://www.iradimed.com/role/DisclosureInvestmentsTables 43 false false R44.htm 40801 - Disclosure - Fair Value Measurements (Details) Sheet http://www.iradimed.com/role/DisclosureFairValueMeasurementsDetails Fair Value Measurements (Details) Details http://www.iradimed.com/role/DisclosureFairValueMeasurementsTables 44 false false R45.htm 40901 - Disclosure - Accumulated Other Comprehensive Income (Details) Sheet http://www.iradimed.com/role/DisclosureAccumulatedOtherComprehensiveIncomeDetails Accumulated Other Comprehensive Income (Details) Details http://www.iradimed.com/role/DisclosureAccumulatedOtherComprehensiveIncomeLossTables 45 false false R46.htm 41001 - Disclosure - Stock-Based Compensation (Details) Sheet http://www.iradimed.com/role/DisclosureStockBasedCompensationDetails Stock-Based Compensation (Details) Details http://www.iradimed.com/role/DisclosureStockBasedCompensationTables 46 false false R47.htm 41002 - Disclosure - Stock-Based Compensation - Stock Options and Restricted Stock Units Activity (Details) Sheet http://www.iradimed.com/role/DisclosureStockBasedCompensationStockOptionsAndRestrictedStockUnitsActivityDetails Stock-Based Compensation - Stock Options and Restricted Stock Units Activity (Details) Details 47 false false R48.htm 41101 - Disclosure - Income Taxes (Details) Sheet http://www.iradimed.com/role/DisclosureIncomeTaxesDetails Income Taxes (Details) Details http://www.iradimed.com/role/DisclosureIncomeTaxes 48 false false R49.htm 41201 - Disclosure - Leases (Details) Sheet http://www.iradimed.com/role/DisclosureLeasesDetails Leases (Details) Details http://www.iradimed.com/role/DisclosureLeasesTables 49 false false R50.htm 41202 - Disclosure - Leases - Operating Lease Cost (Details) Sheet http://www.iradimed.com/role/DisclosureLeasesOperatingLeaseCostDetails Leases - Operating Lease Cost (Details) Details 50 false false R51.htm 41203 - Disclosure - Leases - Maturity of Lease Liabilities (Details) Sheet http://www.iradimed.com/role/DisclosureLeasesMaturityOfLeaseLiabilitiesDetails Leases - Maturity of Lease Liabilities (Details) Details 51 false false R52.htm 41301 - Disclosure - Commitments and Contingencies (Details) Sheet http://www.iradimed.com/role/DisclosureCommitmentsAndContingenciesDetails Commitments and Contingencies (Details) Details http://www.iradimed.com/role/DisclosureCommitmentsAndContingencies 52 false false All Reports Book All Reports irmd-20210630x10q.htm irmd-20210630.xsd irmd-20210630_cal.xml irmd-20210630_def.xml irmd-20210630_lab.xml irmd-20210630_pre.xml irmd-20210630xex31d1.htm irmd-20210630xex31d2.htm irmd-20210630xex32d1.htm http://fasb.org/us-gaap/2020-01-31 http://fasb.org/srt/2020-01-31 http://xbrl.sec.gov/country/2020-01-31 http://xbrl.sec.gov/dei/2020-01-31 true true JSON 69 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "irmd-20210630x10q.htm": { "axisCustom": 0, "axisStandard": 11, "contextCount": 129, "dts": { "calculationLink": { "local": [ "irmd-20210630_cal.xml" ] }, "definitionLink": { "local": [ "irmd-20210630_def.xml" ], "remote": [ "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-eedm-def-2020-01-31.xml", "http://xbrl.fasb.org/srt/2020/elts/srt-eedm1-def-2020-01-31.xml" ] }, "inline": { "local": [ "irmd-20210630x10q.htm" ] }, "labelLink": { "local": [ "irmd-20210630_lab.xml" ], "remote": [ "https://xbrl.sec.gov/dei/2020/dei-doc-2020-01-31.xml", "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-doc-2020-01-31.xml" ] }, "presentationLink": { "local": [ "irmd-20210630_pre.xml" ] }, "referenceLink": { "remote": [ "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-ref-2020-01-31.xml", "https://xbrl.sec.gov/dei/2020/dei-ref-2020-01-31.xml" ] }, "schema": { "local": [ "irmd-20210630.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd", "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd", "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd", "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd", "http://xbrl.fasb.org/us-gaap/2020/elts/us-roles-2020-01-31.xsd", "http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://xbrl.fasb.org/srt/2020/elts/srt-types-2020-01-31.xsd", "http://xbrl.fasb.org/srt/2020/elts/srt-roles-2020-01-31.xsd", "https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd", "http://xbrl.fasb.org/us-gaap/2020/elts/us-types-2020-01-31.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd", "http://xbrl.fasb.org/us-gaap/2020/elts/us-parts-codification-2020-01-31.xsd" ] } }, "elementCount": 337, "entityCount": 1, "hidden": { "http://fasb.org/us-gaap/2020-01-31": 5, "http://www.iradimed.com/20210630": 2, "http://xbrl.sec.gov/dei/2020-01-31": 5, "total": 12 }, "keyCustom": 17, "keyStandard": 271, "memberCustom": 12, "memberStandard": 18, "nsprefix": "irmd", "nsuri": "http://www.iradimed.com/20210630", "report": { "R1": { "firstAnchor": { "ancestors": [ "p", "div", "div", "body", "html" ], "baseRef": "irmd-20210630x10q.htm", "contextRef": "Duration_1_1_2021_To_6_30_2021_OwYVSYPBn0CWKJGwfudFRw", "decimals": null, "first": true, "lang": "en-US", "name": "dei:EntityRegistrantName", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "00090 - Document - Document and Entity Information", "role": "http://www.iradimed.com/role/DocumentDocumentAndEntityInformation", "shortName": "Document and Entity Information", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "p", "div", "div", "body", "html" ], "baseRef": "irmd-20210630x10q.htm", "contextRef": "Duration_1_1_2021_To_6_30_2021_OwYVSYPBn0CWKJGwfudFRw", "decimals": null, "first": true, "lang": "en-US", "name": "dei:EntityRegistrantName", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R10": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "irmd-20210630x10q.htm", "contextRef": "Duration_1_1_2021_To_6_30_2021_OwYVSYPBn0CWKJGwfudFRw", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RevenueFromContractWithCustomerTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "10201 - Disclosure - Revenue Recognition", "role": "http://www.iradimed.com/role/DisclosureRevenueRecognition", "shortName": "Revenue Recognition", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "irmd-20210630x10q.htm", "contextRef": "Duration_1_1_2021_To_6_30_2021_OwYVSYPBn0CWKJGwfudFRw", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RevenueFromContractWithCustomerTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R11": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "irmd-20210630x10q.htm", "contextRef": "Duration_1_1_2021_To_6_30_2021_OwYVSYPBn0CWKJGwfudFRw", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:EarningsPerShareTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "10301 - Disclosure - Basic and Diluted Net Income per Share", "role": "http://www.iradimed.com/role/DisclosureBasicAndDilutedNetIncomePerShare", "shortName": "Basic and Diluted Net Income per Share", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "irmd-20210630x10q.htm", "contextRef": "Duration_1_1_2021_To_6_30_2021_OwYVSYPBn0CWKJGwfudFRw", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:EarningsPerShareTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R12": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "irmd-20210630x10q.htm", "contextRef": "Duration_1_1_2021_To_6_30_2021_OwYVSYPBn0CWKJGwfudFRw", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:InventoryDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "10401 - Disclosure - Inventory", "role": "http://www.iradimed.com/role/DisclosureInventory", "shortName": "Inventory", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "irmd-20210630x10q.htm", "contextRef": "Duration_1_1_2021_To_6_30_2021_OwYVSYPBn0CWKJGwfudFRw", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:InventoryDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R13": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "irmd-20210630x10q.htm", "contextRef": "Duration_1_1_2021_To_6_30_2021_OwYVSYPBn0CWKJGwfudFRw", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "10501 - Disclosure - Property and Equipment", "role": "http://www.iradimed.com/role/DisclosurePropertyAndEquipment", "shortName": "Property and Equipment", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "irmd-20210630x10q.htm", "contextRef": "Duration_1_1_2021_To_6_30_2021_OwYVSYPBn0CWKJGwfudFRw", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R14": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "irmd-20210630x10q.htm", "contextRef": "Duration_1_1_2021_To_6_30_2021_OwYVSYPBn0CWKJGwfudFRw", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IntangibleAssetsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "10601 - Disclosure - Intangible Assets", "role": "http://www.iradimed.com/role/DisclosureIntangibleAssets", "shortName": "Intangible Assets", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "irmd-20210630x10q.htm", "contextRef": "Duration_1_1_2021_To_6_30_2021_OwYVSYPBn0CWKJGwfudFRw", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IntangibleAssetsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R15": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "irmd-20210630x10q.htm", "contextRef": "Duration_1_1_2021_To_6_30_2021_OwYVSYPBn0CWKJGwfudFRw", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "10701 - Disclosure - Investments", "role": "http://www.iradimed.com/role/DisclosureInvestments", "shortName": "Investments", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "irmd-20210630x10q.htm", "contextRef": "Duration_1_1_2021_To_6_30_2021_OwYVSYPBn0CWKJGwfudFRw", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R16": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "irmd-20210630x10q.htm", "contextRef": "Duration_1_1_2021_To_6_30_2021_OwYVSYPBn0CWKJGwfudFRw", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "10801 - Disclosure - Fair Value Measurements", "role": "http://www.iradimed.com/role/DisclosureFairValueMeasurements", "shortName": "Fair Value Measurements", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "irmd-20210630x10q.htm", "contextRef": "Duration_1_1_2021_To_6_30_2021_OwYVSYPBn0CWKJGwfudFRw", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R17": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "irmd-20210630x10q.htm", "contextRef": "Duration_1_1_2021_To_6_30_2021_OwYVSYPBn0CWKJGwfudFRw", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ComprehensiveIncomeNoteTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "10901 - Disclosure - Accumulated Other Comprehensive Income", "role": "http://www.iradimed.com/role/DisclosureAccumulatedOtherComprehensiveIncome", "shortName": "Accumulated Other Comprehensive Income", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "irmd-20210630x10q.htm", "contextRef": "Duration_1_1_2021_To_6_30_2021_OwYVSYPBn0CWKJGwfudFRw", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ComprehensiveIncomeNoteTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R18": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "irmd-20210630x10q.htm", "contextRef": "Duration_1_1_2021_To_6_30_2021_OwYVSYPBn0CWKJGwfudFRw", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "11001 - Disclosure - Stock-Based Compensation", "role": "http://www.iradimed.com/role/DisclosureStockBasedCompensation", "shortName": "Stock-Based Compensation", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "irmd-20210630x10q.htm", "contextRef": "Duration_1_1_2021_To_6_30_2021_OwYVSYPBn0CWKJGwfudFRw", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R19": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "irmd-20210630x10q.htm", "contextRef": "Duration_1_1_2021_To_6_30_2021_OwYVSYPBn0CWKJGwfudFRw", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "11101 - Disclosure - Income Taxes", "role": "http://www.iradimed.com/role/DisclosureIncomeTaxes", "shortName": "Income Taxes", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "irmd-20210630x10q.htm", "contextRef": "Duration_1_1_2021_To_6_30_2021_OwYVSYPBn0CWKJGwfudFRw", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R2": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "irmd-20210630x10q.htm", "contextRef": "As_Of_6_30_2021_mm1hmareTUK-VJ05_XA1tg", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_AEl66n9kAE2uthQfuH8D7A", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "00100 - Statement - CONDENSED BALANCE SHEETS", "role": "http://www.iradimed.com/role/StatementCondensedBalanceSheets", "shortName": "CONDENSED BALANCE SHEETS", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "irmd-20210630x10q.htm", "contextRef": "As_Of_6_30_2021_mm1hmareTUK-VJ05_XA1tg", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_AEl66n9kAE2uthQfuH8D7A", "xsiNil": "false" } }, "R20": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "irmd-20210630x10q.htm", "contextRef": "Duration_1_1_2021_To_6_30_2021_OwYVSYPBn0CWKJGwfudFRw", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LesseeOperatingLeasesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "11201 - Disclosure - Leases", "role": "http://www.iradimed.com/role/DisclosureLeases", "shortName": "Leases", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "irmd-20210630x10q.htm", "contextRef": "Duration_1_1_2021_To_6_30_2021_OwYVSYPBn0CWKJGwfudFRw", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LesseeOperatingLeasesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R21": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "irmd-20210630x10q.htm", "contextRef": "Duration_1_1_2021_To_6_30_2021_OwYVSYPBn0CWKJGwfudFRw", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "11301 - Disclosure - Commitments and Contingencies", "role": "http://www.iradimed.com/role/DisclosureCommitmentsAndContingencies", "shortName": "Commitments and Contingencies", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "irmd-20210630x10q.htm", "contextRef": "Duration_1_1_2021_To_6_30_2021_OwYVSYPBn0CWKJGwfudFRw", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R22": { "firstAnchor": { "ancestors": [ "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock", "div", "div", "body", "html" ], "baseRef": "irmd-20210630x10q.htm", "contextRef": "Duration_1_1_2021_To_6_30_2021_OwYVSYPBn0CWKJGwfudFRw", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ConcentrationRiskCreditRisk", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "20102 - Disclosure - Basis of Presentation (Policies)", "role": "http://www.iradimed.com/role/DisclosureBasisOfPresentationPolicies", "shortName": "Basis of Presentation (Policies)", "subGroupType": "policies", "uniqueAnchor": { "ancestors": [ "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock", "div", "div", "body", "html" ], "baseRef": "irmd-20210630x10q.htm", "contextRef": "Duration_1_1_2021_To_6_30_2021_OwYVSYPBn0CWKJGwfudFRw", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ConcentrationRiskCreditRisk", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R23": { "firstAnchor": { "ancestors": [ "us-gaap:RevenueFromContractWithCustomerTextBlock", "div", "div", "body", "html" ], "baseRef": "irmd-20210630x10q.htm", "contextRef": "Duration_1_1_2021_To_6_30_2021_OwYVSYPBn0CWKJGwfudFRw", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisaggregationOfRevenueTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "30203 - Disclosure - Revenue Recognition (Tables)", "role": "http://www.iradimed.com/role/DisclosureRevenueRecognitionTables", "shortName": "Revenue Recognition (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:RevenueFromContractWithCustomerTextBlock", "div", "div", "body", "html" ], "baseRef": "irmd-20210630x10q.htm", "contextRef": "Duration_1_1_2021_To_6_30_2021_OwYVSYPBn0CWKJGwfudFRw", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisaggregationOfRevenueTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R24": { "firstAnchor": { "ancestors": [ "us-gaap:EarningsPerShareTextBlock", "div", "div", "body", "html" ], "baseRef": "irmd-20210630x10q.htm", "contextRef": "Duration_1_1_2021_To_6_30_2021_OwYVSYPBn0CWKJGwfudFRw", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "30303 - Disclosure - Basic and Diluted Net Income per Share (Tables)", "role": "http://www.iradimed.com/role/DisclosureBasicAndDilutedNetIncomePerShareTables", "shortName": "Basic and Diluted Net Income per Share (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:EarningsPerShareTextBlock", "div", "div", "body", "html" ], "baseRef": "irmd-20210630x10q.htm", "contextRef": "Duration_1_1_2021_To_6_30_2021_OwYVSYPBn0CWKJGwfudFRw", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R25": { "firstAnchor": { "ancestors": [ "us-gaap:InventoryDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "irmd-20210630x10q.htm", "contextRef": "Duration_1_1_2021_To_6_30_2021_OwYVSYPBn0CWKJGwfudFRw", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "30403 - Disclosure - Inventory (Tables)", "role": "http://www.iradimed.com/role/DisclosureInventoryTables", "shortName": "Inventory (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:InventoryDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "irmd-20210630x10q.htm", "contextRef": "Duration_1_1_2021_To_6_30_2021_OwYVSYPBn0CWKJGwfudFRw", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R26": { "firstAnchor": { "ancestors": [ "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "irmd-20210630x10q.htm", "contextRef": "Duration_1_1_2021_To_6_30_2021_OwYVSYPBn0CWKJGwfudFRw", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "30503 - Disclosure - Property and Equipment (Tables)", "role": "http://www.iradimed.com/role/DisclosurePropertyAndEquipmentTables", "shortName": "Property and Equipment (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "irmd-20210630x10q.htm", "contextRef": "Duration_1_1_2021_To_6_30_2021_OwYVSYPBn0CWKJGwfudFRw", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R27": { "firstAnchor": { "ancestors": [ "us-gaap:IntangibleAssetsDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "irmd-20210630x10q.htm", "contextRef": "Duration_1_1_2021_To_6_30_2021_OwYVSYPBn0CWKJGwfudFRw", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "30603 - Disclosure - Intangible Assets (Tables)", "role": "http://www.iradimed.com/role/DisclosureIntangibleAssetsTables", "shortName": "Intangible Assets (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:IntangibleAssetsDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "irmd-20210630x10q.htm", "contextRef": "Duration_1_1_2021_To_6_30_2021_OwYVSYPBn0CWKJGwfudFRw", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R28": { "firstAnchor": { "ancestors": [ "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "irmd-20210630x10q.htm", "contextRef": "Duration_1_1_2021_To_6_30_2021_OwYVSYPBn0CWKJGwfudFRw", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "30703 - Disclosure - Investments (Tables)", "role": "http://www.iradimed.com/role/DisclosureInvestmentsTables", "shortName": "Investments (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "irmd-20210630x10q.htm", "contextRef": "Duration_1_1_2021_To_6_30_2021_OwYVSYPBn0CWKJGwfudFRw", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R29": { "firstAnchor": { "ancestors": [ "us-gaap:FairValueDisclosuresTextBlock", "div", "div", "body", "html" ], "baseRef": "irmd-20210630x10q.htm", "contextRef": "Duration_1_1_2021_To_6_30_2021_OwYVSYPBn0CWKJGwfudFRw", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "30803 - Disclosure - Fair Value Measurements (Tables)", "role": "http://www.iradimed.com/role/DisclosureFairValueMeasurementsTables", "shortName": "Fair Value Measurements (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:FairValueDisclosuresTextBlock", "div", "div", "body", "html" ], "baseRef": "irmd-20210630x10q.htm", "contextRef": "Duration_1_1_2021_To_6_30_2021_OwYVSYPBn0CWKJGwfudFRw", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R3": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "irmd-20210630x10q.htm", "contextRef": "As_Of_6_30_2021_mm1hmareTUK-VJ05_XA1tg", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_AEl66n9kAE2uthQfuH8D7A", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "00105 - Statement - CONDENSED BALANCE SHEETS (Parenthetical)", "role": "http://www.iradimed.com/role/StatementCondensedBalanceSheetsParenthetical", "shortName": "CONDENSED BALANCE SHEETS (Parenthetical)", "subGroupType": "parenthetical", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "irmd-20210630x10q.htm", "contextRef": "As_Of_6_30_2021_mm1hmareTUK-VJ05_XA1tg", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_AEl66n9kAE2uthQfuH8D7A", "xsiNil": "false" } }, "R30": { "firstAnchor": { "ancestors": [ "us-gaap:ComprehensiveIncomeNoteTextBlock", "div", "div", "body", "html" ], "baseRef": "irmd-20210630x10q.htm", "contextRef": "Duration_1_1_2021_To_6_30_2021_OwYVSYPBn0CWKJGwfudFRw", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "30903 - Disclosure - Accumulated Other Comprehensive Income (Loss) (Tables)", "role": "http://www.iradimed.com/role/DisclosureAccumulatedOtherComprehensiveIncomeLossTables", "shortName": "Accumulated Other Comprehensive Income (Loss) (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:ComprehensiveIncomeNoteTextBlock", "div", "div", "body", "html" ], "baseRef": "irmd-20210630x10q.htm", "contextRef": "Duration_1_1_2021_To_6_30_2021_OwYVSYPBn0CWKJGwfudFRw", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R31": { "firstAnchor": { "ancestors": [ "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "div", "body", "html" ], "baseRef": "irmd-20210630x10q.htm", "contextRef": "Duration_1_1_2021_To_6_30_2021_OwYVSYPBn0CWKJGwfudFRw", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "31003 - Disclosure - Stock-Based Compensation (Tables)", "role": "http://www.iradimed.com/role/DisclosureStockBasedCompensationTables", "shortName": "Stock-Based Compensation (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "div", "body", "html" ], "baseRef": "irmd-20210630x10q.htm", "contextRef": "Duration_1_1_2021_To_6_30_2021_OwYVSYPBn0CWKJGwfudFRw", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R32": { "firstAnchor": { "ancestors": [ "ix:continuation", "div", "div", "body", "html" ], "baseRef": "irmd-20210630x10q.htm", "contextRef": "Duration_1_1_2021_To_6_30_2021_OwYVSYPBn0CWKJGwfudFRw", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LeaseCostTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "31203 - Disclosure - Leases (Tables)", "role": "http://www.iradimed.com/role/DisclosureLeasesTables", "shortName": "Leases (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "div", "div", "body", "html" ], "baseRef": "irmd-20210630x10q.htm", "contextRef": "Duration_1_1_2021_To_6_30_2021_OwYVSYPBn0CWKJGwfudFRw", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LeaseCostTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R33": { "firstAnchor": { "ancestors": [ "p", "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock", "div", "div", "body", "html" ], "baseRef": "irmd-20210630x10q.htm", "contextRef": "Duration_1_1_2021_To_6_30_2021_OwYVSYPBn0CWKJGwfudFRw", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:NumberOfReportableSegments", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_segment_1bs1OMgwb0yd18c9ak60OA", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "40101 - Disclosure - Basis of Presentation (Details)", "role": "http://www.iradimed.com/role/DisclosureBasisOfPresentationDetails", "shortName": "Basis of Presentation (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock", "div", "div", "body", "html" ], "baseRef": "irmd-20210630x10q.htm", "contextRef": "Duration_1_1_2021_To_6_30_2021_OwYVSYPBn0CWKJGwfudFRw", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:NumberOfReportableSegments", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_segment_1bs1OMgwb0yd18c9ak60OA", "xsiNil": "false" } }, "R34": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:DisaggregationOfRevenueTableTextBlock", "us-gaap:RevenueFromContractWithCustomerTextBlock", "div", "div", "body", "html" ], "baseRef": "irmd-20210630x10q.htm", "contextRef": "Duration_4_1_2021_To_6_30_2021_woYvM3aDH0yk3lQpUq6_ew", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "reportCount": 1, "unitRef": "Unit_Standard_USD_AEl66n9kAE2uthQfuH8D7A", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "40201 - Disclosure - Revenue Recognition - Information by geographic region (Details)", "role": "http://www.iradimed.com/role/DisclosureRevenueRecognitionInformationByGeographicRegionDetails", "shortName": "Revenue Recognition - Information by geographic region (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:DisaggregationOfRevenueTableTextBlock", "us-gaap:RevenueFromContractWithCustomerTextBlock", "div", "div", "body", "html" ], "baseRef": "irmd-20210630x10q.htm", "contextRef": "Duration_4_1_2021_To_6_30_2021_srt_StatementGeographicalAxis_country_US_6QX0OriUYkmbDxiQ1GbjUQ", "decimals": "0", "lang": null, "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_AEl66n9kAE2uthQfuH8D7A", "xsiNil": "false" } }, "R35": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:DisaggregationOfRevenueTableTextBlock", "us-gaap:RevenueFromContractWithCustomerTextBlock", "div", "div", "body", "html" ], "baseRef": "irmd-20210630x10q.htm", "contextRef": "Duration_4_1_2021_To_6_30_2021_woYvM3aDH0yk3lQpUq6_ew", "decimals": "0", "first": true, "lang": null, "name": "irmd:RevenueFromContractWithCustomerBeforeOtherIncomeExcludingAssessedTax", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_AEl66n9kAE2uthQfuH8D7A", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "40202 - Disclosure - Revenue Recognition - Information by Type (Details)", "role": "http://www.iradimed.com/role/DisclosureRevenueRecognitionInformationByTypeDetails", "shortName": "Revenue Recognition - Information by Type (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:DisaggregationOfRevenueTableTextBlock", "us-gaap:RevenueFromContractWithCustomerTextBlock", "div", "div", "body", "html" ], "baseRef": "irmd-20210630x10q.htm", "contextRef": "Duration_4_1_2021_To_6_30_2021_woYvM3aDH0yk3lQpUq6_ew", "decimals": "0", "first": true, "lang": null, "name": "irmd:RevenueFromContractWithCustomerBeforeOtherIncomeExcludingAssessedTax", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_AEl66n9kAE2uthQfuH8D7A", "xsiNil": "false" } }, "R36": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock", "us-gaap:RevenueFromContractWithCustomerTextBlock", "div", "div", "body", "html" ], "baseRef": "irmd-20210630x10q.htm", "contextRef": "As_Of_6_30_2021_mm1hmareTUK-VJ05_XA1tg", "decimals": "0", "first": true, "lang": null, "name": "irmd:AdvancePaymentsFromCustomers", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_AEl66n9kAE2uthQfuH8D7A", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "40203 - Disclosure - Revenue Recognition - Contract Liabilities (Details)", "role": "http://www.iradimed.com/role/DisclosureRevenueRecognitionContractLiabilitiesDetails", "shortName": "Revenue Recognition - Contract Liabilities (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock", "us-gaap:RevenueFromContractWithCustomerTextBlock", "div", "div", "body", "html" ], "baseRef": "irmd-20210630x10q.htm", "contextRef": "As_Of_6_30_2021_mm1hmareTUK-VJ05_XA1tg", "decimals": "0", "first": true, "lang": null, "name": "irmd:AdvancePaymentsFromCustomers", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_AEl66n9kAE2uthQfuH8D7A", "xsiNil": "false" } }, "R37": { "firstAnchor": { "ancestors": [ "p", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "irmd-20210630x10q.htm", "contextRef": "As_Of_6_30_2021_mm1hmareTUK-VJ05_XA1tg", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:CapitalizedContractCostNet", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_AEl66n9kAE2uthQfuH8D7A", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "40204 - Disclosure - Revenue Recognition - Capitalized Contract Costs (Details)", "role": "http://www.iradimed.com/role/DisclosureRevenueRecognitionCapitalizedContractCostsDetails", "shortName": "Revenue Recognition - Capitalized Contract Costs (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "irmd-20210630x10q.htm", "contextRef": "As_Of_6_30_2021_mm1hmareTUK-VJ05_XA1tg", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:CapitalizedContractCostNet", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_AEl66n9kAE2uthQfuH8D7A", "xsiNil": "false" } }, "R38": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "irmd-20210630x10q.htm", "contextRef": "Duration_4_1_2021_To_6_30_2021_woYvM3aDH0yk3lQpUq6_ew", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:NetIncomeLoss", "reportCount": 1, "unitRef": "Unit_Standard_USD_AEl66n9kAE2uthQfuH8D7A", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "40301 - Disclosure - Basic and Diluted Net Income per Share (Details)", "role": "http://www.iradimed.com/role/DisclosureBasicAndDilutedNetIncomePerShareDetails", "shortName": "Basic and Diluted Net Income per Share (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "us-gaap:EarningsPerShareTextBlock", "div", "div", "body", "html" ], "baseRef": "irmd-20210630x10q.htm", "contextRef": "Duration_4_1_2021_To_6_30_2021_woYvM3aDH0yk3lQpUq6_ew", "decimals": "INF", "lang": null, "name": "us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_shares_hUq5i33TbkyPFMGZ5Ha5bA", "xsiNil": "false" } }, "R39": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "us-gaap:InventoryDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "irmd-20210630x10q.htm", "contextRef": "As_Of_6_30_2021_mm1hmareTUK-VJ05_XA1tg", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:InventoryRawMaterials", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_AEl66n9kAE2uthQfuH8D7A", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "40401 - Disclosure - Inventory (Details)", "role": "http://www.iradimed.com/role/DisclosureInventoryDetails", "shortName": "Inventory (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "us-gaap:InventoryDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "irmd-20210630x10q.htm", "contextRef": "As_Of_6_30_2021_mm1hmareTUK-VJ05_XA1tg", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:InventoryRawMaterials", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_AEl66n9kAE2uthQfuH8D7A", "xsiNil": "false" } }, "R4": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "irmd-20210630x10q.htm", "contextRef": "Duration_4_1_2021_To_6_30_2021_woYvM3aDH0yk3lQpUq6_ew", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:Revenues", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_AEl66n9kAE2uthQfuH8D7A", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "00200 - Statement - CONDENSED STATEMENTS OF OPERATIONS", "role": "http://www.iradimed.com/role/StatementCondensedStatementsOfOperations", "shortName": "CONDENSED STATEMENTS OF OPERATIONS", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "irmd-20210630x10q.htm", "contextRef": "Duration_4_1_2021_To_6_30_2021_woYvM3aDH0yk3lQpUq6_ew", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:Revenues", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_AEl66n9kAE2uthQfuH8D7A", "xsiNil": "false" } }, "R40": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:PropertyPlantAndEquipmentTextBlock", "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "irmd-20210630x10q.htm", "contextRef": "As_Of_6_30_2021_mm1hmareTUK-VJ05_XA1tg", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:PropertyPlantAndEquipmentGross", "reportCount": 1, "unitRef": "Unit_Standard_USD_AEl66n9kAE2uthQfuH8D7A", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "40501 - Disclosure - Property and Equipment (Details)", "role": "http://www.iradimed.com/role/DisclosurePropertyAndEquipmentDetails", "shortName": "Property and Equipment (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:PropertyPlantAndEquipmentTextBlock", "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "irmd-20210630x10q.htm", "contextRef": "As_Of_12_31_2020_WrMjly_cCUSgewU5UvUjIQ", "decimals": "0", "lang": null, "name": "us-gaap:PropertyPlantAndEquipmentGross", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_AEl66n9kAE2uthQfuH8D7A", "xsiNil": "false" } }, "R41": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "irmd-20210630x10q.htm", "contextRef": "As_Of_6_30_2021_mm1hmareTUK-VJ05_XA1tg", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:PropertyPlantAndEquipmentNet", "reportCount": 1, "unitRef": "Unit_Standard_USD_AEl66n9kAE2uthQfuH8D7A", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "40502 - Disclosure - Property and Equipment - Geographic information (Details)", "role": "http://www.iradimed.com/role/DisclosurePropertyAndEquipmentGeographicInformationDetails", "shortName": "Property and Equipment - Geographic information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:LongLivedAssetsByGeographicAreasTableTextBlock", "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "irmd-20210630x10q.htm", "contextRef": "As_Of_6_30_2021_srt_StatementGeographicalAxis_country_US_oT1yz2A450eUBg2Xmg9AcQ", "decimals": "0", "lang": null, "name": "us-gaap:PropertyPlantAndEquipmentNet", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_AEl66n9kAE2uthQfuH8D7A", "xsiNil": "false" } }, "R42": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "us-gaap:IntangibleAssetsDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "irmd-20210630x10q.htm", "contextRef": "As_Of_6_30_2021_mm1hmareTUK-VJ05_XA1tg", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:FiniteLivedIntangibleAssetsGross", "reportCount": 1, "unitRef": "Unit_Standard_USD_AEl66n9kAE2uthQfuH8D7A", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "40601 - Disclosure - Intangible Assets (Details)", "role": "http://www.iradimed.com/role/DisclosureIntangibleAssetsDetails", "shortName": "Intangible Assets (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "us-gaap:IntangibleAssetsDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "irmd-20210630x10q.htm", "contextRef": "As_Of_12_31_2020_WrMjly_cCUSgewU5UvUjIQ", "decimals": "0", "lang": null, "name": "us-gaap:FiniteLivedIntangibleAssetsGross", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_AEl66n9kAE2uthQfuH8D7A", "xsiNil": "false" } }, "R43": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock", "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "irmd-20210630x10q.htm", "contextRef": "As_Of_6_30_2021_us-gaap_FinancialInstrumentAxis_us-gaap_DomesticCorporateDebtSecuritiesMember_fccGmyq8ykydfRSN4QcMpg", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:TradingSecuritiesDebtAmortizedCost", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_AEl66n9kAE2uthQfuH8D7A", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "40701 - Disclosure - Investments (Details)", "role": "http://www.iradimed.com/role/DisclosureInvestmentsDetails", "shortName": "Investments (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock", "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "irmd-20210630x10q.htm", "contextRef": "As_Of_6_30_2021_us-gaap_FinancialInstrumentAxis_us-gaap_DomesticCorporateDebtSecuritiesMember_fccGmyq8ykydfRSN4QcMpg", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:TradingSecuritiesDebtAmortizedCost", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_AEl66n9kAE2uthQfuH8D7A", "xsiNil": "false" } }, "R44": { "firstAnchor": { "ancestors": [ "p", "us-gaap:FairValueDisclosuresTextBlock", "div", "div", "body", "html" ], "baseRef": "irmd-20210630x10q.htm", "contextRef": "As_Of_6_30_2021_mm1hmareTUK-VJ05_XA1tg", "decimals": "0", "first": true, "lang": null, "name": "irmd:FairValueAssetsAmountTransferredBetweenMeasurementLevels", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_AEl66n9kAE2uthQfuH8D7A", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "40801 - Disclosure - Fair Value Measurements (Details)", "role": "http://www.iradimed.com/role/DisclosureFairValueMeasurementsDetails", "shortName": "Fair Value Measurements (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "us-gaap:FairValueDisclosuresTextBlock", "div", "div", "body", "html" ], "baseRef": "irmd-20210630x10q.htm", "contextRef": "As_Of_6_30_2021_mm1hmareTUK-VJ05_XA1tg", "decimals": "0", "first": true, "lang": null, "name": "irmd:FairValueAssetsAmountTransferredBetweenMeasurementLevels", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_AEl66n9kAE2uthQfuH8D7A", "xsiNil": "false" } }, "R45": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock", "us-gaap:ComprehensiveIncomeNoteTextBlock", "div", "div", "body", "html" ], "baseRef": "irmd-20210630x10q.htm", "contextRef": "As_Of_3_31_2021_LYuqZNP-K0qdqv7ZFsr6kA", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_AEl66n9kAE2uthQfuH8D7A", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "40901 - Disclosure - Accumulated Other Comprehensive Income (Details)", "role": "http://www.iradimed.com/role/DisclosureAccumulatedOtherComprehensiveIncomeDetails", "shortName": "Accumulated Other Comprehensive Income (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock", "us-gaap:ComprehensiveIncomeNoteTextBlock", "div", "div", "body", "html" ], "baseRef": "irmd-20210630x10q.htm", "contextRef": "As_Of_3_31_2021_LYuqZNP-K0qdqv7ZFsr6kA", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_AEl66n9kAE2uthQfuH8D7A", "xsiNil": "false" } }, "R46": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "div", "body", "html" ], "baseRef": "irmd-20210630x10q.htm", "contextRef": "Duration_4_1_2021_To_6_30_2021_woYvM3aDH0yk3lQpUq6_ew", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:AllocatedShareBasedCompensationExpense", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_AEl66n9kAE2uthQfuH8D7A", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "41001 - Disclosure - Stock-Based Compensation (Details)", "role": "http://www.iradimed.com/role/DisclosureStockBasedCompensationDetails", "shortName": "Stock-Based Compensation (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "div", "body", "html" ], "baseRef": "irmd-20210630x10q.htm", "contextRef": "Duration_4_1_2021_To_6_30_2021_woYvM3aDH0yk3lQpUq6_ew", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:AllocatedShareBasedCompensationExpense", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_AEl66n9kAE2uthQfuH8D7A", "xsiNil": "false" } }, "R47": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfShareBasedCompensationActivityTableTextBlock", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "irmd-20210630x10q.htm", "contextRef": "As_Of_12_31_2020_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_mWqUqJPUAk2cBzzhbYVYsw", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_shares_hUq5i33TbkyPFMGZ5Ha5bA", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "41002 - Disclosure - Stock-Based Compensation - Stock Options and Restricted Stock Units Activity (Details)", "role": "http://www.iradimed.com/role/DisclosureStockBasedCompensationStockOptionsAndRestrictedStockUnitsActivityDetails", "shortName": "Stock-Based Compensation - Stock Options and Restricted Stock Units Activity (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfShareBasedCompensationActivityTableTextBlock", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "irmd-20210630x10q.htm", "contextRef": "As_Of_12_31_2020_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_mWqUqJPUAk2cBzzhbYVYsw", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_shares_hUq5i33TbkyPFMGZ5Ha5bA", "xsiNil": "false" } }, "R48": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "irmd-20210630x10q.htm", "contextRef": "Duration_4_1_2021_To_6_30_2021_woYvM3aDH0yk3lQpUq6_ew", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:IncomeTaxExpenseBenefit", "reportCount": 1, "unitRef": "Unit_Standard_USD_AEl66n9kAE2uthQfuH8D7A", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "41101 - Disclosure - Income Taxes (Details)", "role": "http://www.iradimed.com/role/DisclosureIncomeTaxesDetails", "shortName": "Income Taxes (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "us-gaap:IncomeTaxDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "irmd-20210630x10q.htm", "contextRef": "Duration_4_1_2021_To_6_30_2021_woYvM3aDH0yk3lQpUq6_ew", "decimals": "3", "lang": null, "name": "us-gaap:EffectiveIncomeTaxRateContinuingOperations", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_pure_Ctp2r77KM0emrM8S8t4SfA", "xsiNil": "false" } }, "R49": { "firstAnchor": { "ancestors": [ "p", "us-gaap:LesseeOperatingLeasesTextBlock", "div", "div", "body", "html" ], "baseRef": "irmd-20210630x10q.htm", "contextRef": "As_Of_6_30_2021_mm1hmareTUK-VJ05_XA1tg", "decimals": "INF", "first": true, "lang": null, "name": "irmd:NumberOfMaterialLeaseContract", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_item_5bba7D2bfkaU7K2obeT-DA", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "41201 - Disclosure - Leases (Details)", "role": "http://www.iradimed.com/role/DisclosureLeasesDetails", "shortName": "Leases (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "us-gaap:LesseeOperatingLeasesTextBlock", "div", "div", "body", "html" ], "baseRef": "irmd-20210630x10q.htm", "contextRef": "As_Of_6_30_2021_mm1hmareTUK-VJ05_XA1tg", "decimals": "INF", "first": true, "lang": null, "name": "irmd:NumberOfMaterialLeaseContract", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_item_5bba7D2bfkaU7K2obeT-DA", "xsiNil": "false" } }, "R5": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "irmd-20210630x10q.htm", "contextRef": "Duration_4_1_2021_To_6_30_2021_woYvM3aDH0yk3lQpUq6_ew", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:NetIncomeLoss", "reportCount": 1, "unitRef": "Unit_Standard_USD_AEl66n9kAE2uthQfuH8D7A", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "00300 - Statement - CONDENSED STATEMENTS OF COMPREHENSIVE INCOME", "role": "http://www.iradimed.com/role/StatementCondensedStatementsOfComprehensiveIncome", "shortName": "CONDENSED STATEMENTS OF COMPREHENSIVE INCOME", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "irmd-20210630x10q.htm", "contextRef": "Duration_4_1_2021_To_6_30_2021_woYvM3aDH0yk3lQpUq6_ew", "decimals": "0", "lang": null, "name": "us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_AEl66n9kAE2uthQfuH8D7A", "xsiNil": "false" } }, "R50": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:LeaseCostTableTextBlock", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "irmd-20210630x10q.htm", "contextRef": "Duration_4_1_2021_To_6_30_2021_woYvM3aDH0yk3lQpUq6_ew", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:OperatingLeaseCost", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_AEl66n9kAE2uthQfuH8D7A", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "41202 - Disclosure - Leases - Operating Lease Cost (Details)", "role": "http://www.iradimed.com/role/DisclosureLeasesOperatingLeaseCostDetails", "shortName": "Leases - Operating Lease Cost (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:LeaseCostTableTextBlock", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "irmd-20210630x10q.htm", "contextRef": "Duration_4_1_2021_To_6_30_2021_woYvM3aDH0yk3lQpUq6_ew", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:OperatingLeaseCost", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_AEl66n9kAE2uthQfuH8D7A", "xsiNil": "false" } }, "R51": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "irmd-20210630x10q.htm", "contextRef": "As_Of_6_30_2021_mm1hmareTUK-VJ05_XA1tg", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_AEl66n9kAE2uthQfuH8D7A", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "41203 - Disclosure - Leases - Maturity of Lease Liabilities (Details)", "role": "http://www.iradimed.com/role/DisclosureLeasesMaturityOfLeaseLiabilitiesDetails", "shortName": "Leases - Maturity of Lease Liabilities (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "irmd-20210630x10q.htm", "contextRef": "As_Of_6_30_2021_mm1hmareTUK-VJ05_XA1tg", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_AEl66n9kAE2uthQfuH8D7A", "xsiNil": "false" } }, "R52": { "firstAnchor": { "ancestors": [ "p", "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "irmd-20210630x10q.htm", "contextRef": "As_Of_6_30_2021_mm1hmareTUK-VJ05_XA1tg", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:PurchaseObligation", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_AEl66n9kAE2uthQfuH8D7A", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "41301 - Disclosure - Commitments and Contingencies (Details)", "role": "http://www.iradimed.com/role/DisclosureCommitmentsAndContingenciesDetails", "shortName": "Commitments and Contingencies (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "irmd-20210630x10q.htm", "contextRef": "As_Of_6_30_2021_mm1hmareTUK-VJ05_XA1tg", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:PurchaseObligation", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_AEl66n9kAE2uthQfuH8D7A", "xsiNil": "false" } }, "R6": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "irmd-20210630x10q.htm", "contextRef": "Duration_4_1_2021_To_6_30_2021_woYvM3aDH0yk3lQpUq6_ew", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesTaxPortionAttributableToParent", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_AEl66n9kAE2uthQfuH8D7A", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "00305 - Statement - CONDENSED STATEMENTS OF COMPREHENSIVE INCOME (Parenthetical)", "role": "http://www.iradimed.com/role/StatementCondensedStatementsOfComprehensiveIncomeParenthetical", "shortName": "CONDENSED STATEMENTS OF COMPREHENSIVE INCOME (Parenthetical)", "subGroupType": "parenthetical", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "irmd-20210630x10q.htm", "contextRef": "Duration_4_1_2021_To_6_30_2021_woYvM3aDH0yk3lQpUq6_ew", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesTaxPortionAttributableToParent", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_AEl66n9kAE2uthQfuH8D7A", "xsiNil": "false" } }, "R7": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "irmd-20210630x10q.htm", "contextRef": "As_Of_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_7WJd4AaeWUKDBUtbhGuDxg", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:StockholdersEquity", "reportCount": 1, "unitRef": "Unit_Standard_USD_AEl66n9kAE2uthQfuH8D7A", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "00400 - Statement - CONDENSED STATEMENTS OF STOCKHOLDERS' EQUITY", "role": "http://www.iradimed.com/role/StatementCondensedStatementsOfStockholdersEquity", "shortName": "CONDENSED STATEMENTS OF STOCKHOLDERS' EQUITY", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "irmd-20210630x10q.htm", "contextRef": "Duration_1_1_2020_To_3_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_-nG8N1n9ekqca3cvZY-HDA", "decimals": "0", "lang": null, "name": "us-gaap:NetIncomeLoss", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_AEl66n9kAE2uthQfuH8D7A", "xsiNil": "false" } }, "R8": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "irmd-20210630x10q.htm", "contextRef": "Duration_1_1_2021_To_6_30_2021_OwYVSYPBn0CWKJGwfudFRw", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:ProfitLoss", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_AEl66n9kAE2uthQfuH8D7A", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "00500 - Statement - CONDENSED STATEMENTS OF CASH FLOWS", "role": "http://www.iradimed.com/role/StatementCondensedStatementsOfCashFlows", "shortName": "CONDENSED STATEMENTS OF CASH FLOWS", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "irmd-20210630x10q.htm", "contextRef": "Duration_1_1_2021_To_6_30_2021_OwYVSYPBn0CWKJGwfudFRw", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:ProfitLoss", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_AEl66n9kAE2uthQfuH8D7A", "xsiNil": "false" } }, "R9": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "irmd-20210630x10q.htm", "contextRef": "Duration_1_1_2021_To_6_30_2021_OwYVSYPBn0CWKJGwfudFRw", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "10101 - Disclosure - Basis of Presentation", "role": "http://www.iradimed.com/role/DisclosureBasisOfPresentation", "shortName": "Basis of Presentation", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "irmd-20210630x10q.htm", "contextRef": "Duration_1_1_2021_To_6_30_2021_OwYVSYPBn0CWKJGwfudFRw", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 30, "tag": { "country_US": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "U [S]", "terseLabel": "United States" } } }, "localname": "US", "nsuri": "http://xbrl.sec.gov/country/2020-01-31", "presentation": [ "http://www.iradimed.com/role/DisclosurePropertyAndEquipmentGeographicInformationDetails", "http://www.iradimed.com/role/DisclosureRevenueRecognitionInformationByGeographicRegionDetails" ], "xbrltype": "domainItemType" }, "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.iradimed.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.iradimed.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Document and Entity Information" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "xbrltype": "stringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.iradimed.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.iradimed.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.iradimed.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "gYearItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented. If there is no historical data in the report, use the filing date. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.iradimed.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "dateItemType" }, "dei_DocumentQuarterlyReport": { "auth_ref": [ "r422" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an quarterly report.", "label": "Document Quarterly Report" } } }, "localname": "DocumentQuarterlyReport", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.iradimed.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r423" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.iradimed.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.iradimed.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.iradimed.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.iradimed.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.iradimed.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.iradimed.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r424" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.iradimed.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock, Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.iradimed.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.iradimed.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "yesNoItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r424" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.iradimed.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.iradimed.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r424" ], "lang": { "en-us": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.iradimed.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.iradimed.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r425" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.iradimed.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "yesNoItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r424" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.iradimed.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r424" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.iradimed.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r424" ], "lang": { "en-us": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.iradimed.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r424" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.iradimed.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "employerIdItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.iradimed.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r420" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.iradimed.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r421" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.iradimed.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.iradimed.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "tradingSymbolItemType" }, "irmd_AdvancePaymentsFromCustomers": { "auth_ref": [], "calculation": { "http://www.iradimed.com/role/DisclosureRevenueRecognitionContractLiabilitiesDetails": { "order": 2.0, "parentTag": "us-gaap_ContractWithCustomerLiability", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due.", "label": "Advance Payments From Customers", "terseLabel": "Advance payments from customers" } } }, "localname": "AdvancePaymentsFromCustomers", "nsuri": "http://www.iradimed.com/20210630", "presentation": [ "http://www.iradimed.com/role/DisclosureRevenueRecognitionContractLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "irmd_AmortizationOfExtendedWarrantyAgreements": { "auth_ref": [], "calculation": { "http://www.iradimed.com/role/DisclosureRevenueRecognitionInformationByTypeDetails": { "order": 1.0, "parentTag": "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization of extended warranty agreements.", "label": "Amortization of Extended Warranty Agreements", "terseLabel": "Amortization of extended warranty agreements" } } }, "localname": "AmortizationOfExtendedWarrantyAgreements", "nsuri": "http://www.iradimed.com/20210630", "presentation": [ "http://www.iradimed.com/role/DisclosureRevenueRecognitionInformationByTypeDetails" ], "xbrltype": "monetaryItemType" }, "irmd_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "N/A", "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Abstract]", "verboseLabel": "Anti-dilutive stock" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAbstract", "nsuri": "http://www.iradimed.com/20210630", "presentation": [ "http://www.iradimed.com/role/DisclosureBasicAndDilutedNetIncomePerShareDetails" ], "xbrltype": "stringItemType" }, "irmd_ComputerSoftwareAndHardwareMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents information pertaining to collection of computer programs and related data that provide instructions to a computer and information about long lived, depreciable assets that are used in the creation, maintenance and utilization of information systems.", "label": "Computer Software And Hardware [Member]", "terseLabel": "Computer software and hardware" } } }, "localname": "ComputerSoftwareAndHardwareMember", "nsuri": "http://www.iradimed.com/20210630", "presentation": [ "http://www.iradimed.com/role/DisclosurePropertyAndEquipmentDetails" ], "xbrltype": "domainItemType" }, "irmd_ContractWithCustomerLiabilityDecreaseDueToRecognitionOfRevenue": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of decrease in contract liabilities due to recognition of revenue.", "label": "Contract with Customer, Liability, Decrease Due to Recognition of Revenue", "negatedLabel": "Decreases due to recognition of revenue" } } }, "localname": "ContractWithCustomerLiabilityDecreaseDueToRecognitionOfRevenue", "nsuri": "http://www.iradimed.com/20210630", "presentation": [ "http://www.iradimed.com/role/DisclosureRevenueRecognitionContractLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "irmd_ContractWithCustomerLiabilityIncreaseDueToCashReceivedFromCustomers": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase in contract liabilities due to cash received from customers.", "label": "Contract with Customer, Liability, Increase Due to Cash Received from Customers", "terseLabel": "Increases due to cash received from customers" } } }, "localname": "ContractWithCustomerLiabilityIncreaseDueToCashReceivedFromCustomers", "nsuri": "http://www.iradimed.com/20210630", "presentation": [ "http://www.iradimed.com/role/DisclosureRevenueRecognitionContractLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "irmd_DevicesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents information pertaining to devices of the entity.", "label": "Devices [Member]", "terseLabel": "Devices" } } }, "localname": "DevicesMember", "nsuri": "http://www.iradimed.com/20210630", "presentation": [ "http://www.iradimed.com/role/DisclosureRevenueRecognitionInformationByTypeDetails" ], "xbrltype": "domainItemType" }, "irmd_FairValueAssetsAmountTransferredBetweenMeasurementLevels": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Represents the amount of transfer of assets between the levels of fair value hierarchy.", "label": "Fair Value Assets Amount Transferred between Measurement Levels", "terseLabel": "Fair value assets, amount transferred between measurement levels" } } }, "localname": "FairValueAssetsAmountTransferredBetweenMeasurementLevels", "nsuri": "http://www.iradimed.com/20210630", "presentation": [ "http://www.iradimed.com/role/DisclosureFairValueMeasurementsDetails" ], "xbrltype": "monetaryItemType" }, "irmd_FairValueLiabilitiesAmountTransferredBetweenMeasurementLevels": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Represents the amount of transfer of liabilities between the levels of fair value hierarchy.", "label": "Fair Value Liabilities Amount Transferred between Measurement Levels", "terseLabel": "Fair value liabilities, amount transferred between measurement levels" } } }, "localname": "FairValueLiabilitiesAmountTransferredBetweenMeasurementLevels", "nsuri": "http://www.iradimed.com/20210630", "presentation": [ "http://www.iradimed.com/role/DisclosureFairValueMeasurementsDetails" ], "xbrltype": "monetaryItemType" }, "irmd_IncreaseDecreaseInWarrantyReserve": { "auth_ref": [], "calculation": { "http://www.iradimed.com/role/StatementCondensedStatementsOfCashFlows": { "order": 16.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Represents the increase (decrease) during the period in the carrying amount (including both current and noncurrent portions of the accrual) of the liability pertaining to warranty reserve.", "label": "Increase Decrease in Warranty Reserve", "terseLabel": "Warranty reserve" } } }, "localname": "IncreaseDecreaseInWarrantyReserve", "nsuri": "http://www.iradimed.com/20210630", "presentation": [ "http://www.iradimed.com/role/StatementCondensedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "irmd_IncrementalCommonSharesAttributableToDilutiveEffectOfRestrictedStockUnits": { "auth_ref": [], "calculation": { "http://www.iradimed.com/role/DisclosureBasicAndDilutedNetIncomePerShareDetails": { "order": 2.0, "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of restricted stock units arrangements using the treasury stock method.", "label": "Incremental Common Shares Attributable to Dilutive Effect of Restricted Stock Units", "terseLabel": "Restricted Stock Units" } } }, "localname": "IncrementalCommonSharesAttributableToDilutiveEffectOfRestrictedStockUnits", "nsuri": "http://www.iradimed.com/20210630", "presentation": [ "http://www.iradimed.com/role/DisclosureBasicAndDilutedNetIncomePerShareDetails" ], "xbrltype": "sharesItemType" }, "irmd_InternationalMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents information pertaining to International, a geographic region of the entity.", "label": "International [Member]", "terseLabel": "International" } } }, "localname": "InternationalMember", "nsuri": "http://www.iradimed.com/20210630", "presentation": [ "http://www.iradimed.com/role/DisclosurePropertyAndEquipmentGeographicInformationDetails", "http://www.iradimed.com/role/DisclosureRevenueRecognitionInformationByGeographicRegionDetails" ], "xbrltype": "domainItemType" }, "irmd_LesseeLeasingArrangementsOperatingLeasesRenewalTermBeginningInTwoThousandNineteen": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the term of the lessee's leasing arrangement renewal beginning in 2019, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Lessee Leasing Arrangements Operating Leases Renewal Term Beginning in Two Thousand Nineteen", "terseLabel": "Renewal term of lease beginning in 2019" } } }, "localname": "LesseeLeasingArrangementsOperatingLeasesRenewalTermBeginningInTwoThousandNineteen", "nsuri": "http://www.iradimed.com/20210630", "presentation": [ "http://www.iradimed.com/role/DisclosureLeasesDetails" ], "xbrltype": "durationItemType" }, "irmd_LesseeLeasingArrangementsOperatingLeasesRenewalTermBeginningInTwoThousandTwentyFour": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the term of the lessee's leasing arrangement renewal beginning in 2024, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Lessee Leasing Arrangements Operating Leases Renewal Term Beginning in Two Thousand Twenty Four", "terseLabel": "Renewal term of lease beginning in 2024" } } }, "localname": "LesseeLeasingArrangementsOperatingLeasesRenewalTermBeginningInTwoThousandTwentyFour", "nsuri": "http://www.iradimed.com/20210630", "presentation": [ "http://www.iradimed.com/role/DisclosureLeasesDetails" ], "xbrltype": "durationItemType" }, "irmd_LesseeLeasingArrangementsOperatingLeasesRenewalTermThereafter": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the term of the lessee's leasing arrangement renewal thereafter, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Lessee Leasing Arrangements Operating Leases Renewal Term Thereafter", "terseLabel": "Renewal term lease thereafter" } } }, "localname": "LesseeLeasingArrangementsOperatingLeasesRenewalTermThereafter", "nsuri": "http://www.iradimed.com/20210630", "presentation": [ "http://www.iradimed.com/role/DisclosureLeasesDetails" ], "xbrltype": "durationItemType" }, "irmd_MRICompatibleIVInfusionPumpsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents information pertaining to MRI compatible IV infusion pumps, a product of the entity.", "label": "M R I Compatible I V Infusion Pumps [Member]", "terseLabel": "MRI Compatible IV Infusion Pump Systems" } } }, "localname": "MRICompatibleIVInfusionPumpsMember", "nsuri": "http://www.iradimed.com/20210630", "presentation": [ "http://www.iradimed.com/role/DisclosureRevenueRecognitionInformationByTypeDetails" ], "xbrltype": "domainItemType" }, "irmd_MRICompatiblePatientVitalSignsMonitoringSystemsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents information pertaining to MRI compatible IV infusion pumps, a product of the entity.", "label": "M R I Compatible Patient Vital Signs Monitoring Systems [Member]", "terseLabel": "MRI Compatible Patient Vital Signs Monitoring Systems" } } }, "localname": "MRICompatiblePatientVitalSignsMonitoringSystemsMember", "nsuri": "http://www.iradimed.com/20210630", "presentation": [ "http://www.iradimed.com/role/DisclosureRevenueRecognitionInformationByTypeDetails" ], "xbrltype": "domainItemType" }, "irmd_MonthlyBaseRent": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Represents the monthly base rent amount during the term of the lease.", "label": "Monthly Base Rent", "terseLabel": "Monthly base rent" } } }, "localname": "MonthlyBaseRent", "nsuri": "http://www.iradimed.com/20210630", "presentation": [ "http://www.iradimed.com/role/DisclosureLeasesDetails" ], "xbrltype": "monetaryItemType" }, "irmd_NumberOfMaterialLeaseContract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The number of material lease contract.", "label": "Number of Material Lease Contract", "terseLabel": "Number of material lease contract outstanding" } } }, "localname": "NumberOfMaterialLeaseContract", "nsuri": "http://www.iradimed.com/20210630", "presentation": [ "http://www.iradimed.com/role/DisclosureLeasesDetails" ], "xbrltype": "integerItemType" }, "irmd_NumberOfSuccessiveRenewalTermOfLease": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the number of successive renewal term of lease.", "label": "Number of Successive Renewal Term of Lease", "terseLabel": "Number of successive renewal terms of lease" } } }, "localname": "NumberOfSuccessiveRenewalTermOfLease", "nsuri": "http://www.iradimed.com/20210630", "presentation": [ "http://www.iradimed.com/role/DisclosureLeasesDetails" ], "xbrltype": "integerItemType" }, "irmd_PatentsInProcessMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents information pertaining to exclusive legal right granted by the government to the owner of the patent to exploit an invention or a process for a period of time specified by law, which are in process.", "label": "Patents In Process [Member]", "terseLabel": "Patents - in process" } } }, "localname": "PatentsInProcessMember", "nsuri": "http://www.iradimed.com/20210630", "presentation": [ "http://www.iradimed.com/role/DisclosureIntangibleAssetsDetails" ], "xbrltype": "domainItemType" }, "irmd_PatentsInUseMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents information pertaining to exclusive legal right granted by the government to the owner of the patent to exploit an invention or a process for a period of time specified by law, which are in use.", "label": "Patents In Use [Member]", "terseLabel": "Patents - in use" } } }, "localname": "PatentsInUseMember", "nsuri": "http://www.iradimed.com/20210630", "presentation": [ "http://www.iradimed.com/role/DisclosureIntangibleAssetsDetails" ], "xbrltype": "domainItemType" }, "irmd_PerformanceBasedRestrictedStockUnitsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This member is stands for Performance-Based Restricted Stock Units.", "label": "Performance Based Restricted Stock Units [Member]", "terseLabel": "Performance-Based Restricted Stock Units (\"PSUs\")" } } }, "localname": "PerformanceBasedRestrictedStockUnitsMember", "nsuri": "http://www.iradimed.com/20210630", "presentation": [ "http://www.iradimed.com/role/DisclosureStockBasedCompensationStockOptionsAndRestrictedStockUnitsActivityDetails" ], "xbrltype": "domainItemType" }, "irmd_PurchaseCommitmentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Purchase Commitment [Abstract]", "terseLabel": "Purchase commitments" } } }, "localname": "PurchaseCommitmentAbstract", "nsuri": "http://www.iradimed.com/20210630", "presentation": [ "http://www.iradimed.com/role/DisclosureCommitmentsAndContingenciesDetails" ], "xbrltype": "stringItemType" }, "irmd_RevenueFromContractWithCustomerBeforeOtherIncomeExcludingAssessedTax": { "auth_ref": [], "calculation": { "http://www.iradimed.com/role/DisclosureRevenueRecognitionInformationByTypeDetails": { "order": 2.0, "parentTag": "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of revenue excluding tax, earned from contracts with customers before other income.", "label": "Revenue from Contract with Customer Before Other Income, Excluding Assessed Tax", "terseLabel": "Total Devices revenue" } } }, "localname": "RevenueFromContractWithCustomerBeforeOtherIncomeExcludingAssessedTax", "nsuri": "http://www.iradimed.com/20210630", "presentation": [ "http://www.iradimed.com/role/DisclosureRevenueRecognitionInformationByTypeDetails" ], "xbrltype": "monetaryItemType" }, "irmd_RevenueFromDisposablesAndServices": { "auth_ref": [], "calculation": { "http://www.iradimed.com/role/DisclosureRevenueRecognitionInformationByTypeDetails": { "order": 3.0, "parentTag": "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of revenue earned from disposables and services.", "label": "Revenue from Disposables and Services", "terseLabel": "Disposables, service and other" } } }, "localname": "RevenueFromDisposablesAndServices", "nsuri": "http://www.iradimed.com/20210630", "presentation": [ "http://www.iradimed.com/role/DisclosureRevenueRecognitionInformationByTypeDetails" ], "xbrltype": "monetaryItemType" }, "irmd_ShipmentsInTransit": { "auth_ref": [], "calculation": { "http://www.iradimed.com/role/DisclosureRevenueRecognitionContractLiabilitiesDetails": { "order": 3.0, "parentTag": "us-gaap_ContractWithCustomerLiability", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of revenue recognized that was previously included in balance of obligation to shipments in-transit.", "label": "Shipments in-Transit", "terseLabel": "Shipments in-transit" } } }, "localname": "ShipmentsInTransit", "nsuri": "http://www.iradimed.com/20210630", "presentation": [ "http://www.iradimed.com/role/DisclosureRevenueRecognitionContractLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "irmd_SoftwareDevelopmentInProcessMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents information pertaining to internally developed software in process.", "label": "Software Development In Process [Member]", "terseLabel": "Internally developed software - in process" } } }, "localname": "SoftwareDevelopmentInProcessMember", "nsuri": "http://www.iradimed.com/20210630", "presentation": [ "http://www.iradimed.com/role/DisclosureIntangibleAssetsDetails" ], "xbrltype": "domainItemType" }, "irmd_SoftwareDevelopmentInUseMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents information pertaining to internally developed software which are in use.", "label": "Software Development In Use [Member]", "terseLabel": "Internally developed software - in use" } } }, "localname": "SoftwareDevelopmentInUseMember", "nsuri": "http://www.iradimed.com/20210630", "presentation": [ "http://www.iradimed.com/role/DisclosureIntangibleAssetsDetails" ], "xbrltype": "domainItemType" }, "irmd_SusiLLCMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents details pertaining the Susi, LLC.", "label": "Susi L L C [Member]", "terseLabel": "Susi, LLC" } } }, "localname": "SusiLLCMember", "nsuri": "http://www.iradimed.com/20210630", "presentation": [ "http://www.iradimed.com/role/DisclosureLeasesDetails" ], "xbrltype": "domainItemType" }, "irmd_ToolingInProcessMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents information pertaining to tooling in process equipment.", "label": "Tooling In Process [Member]", "terseLabel": "Tooling in-process" } } }, "localname": "ToolingInProcessMember", "nsuri": "http://www.iradimed.com/20210630", "presentation": [ "http://www.iradimed.com/role/DisclosurePropertyAndEquipmentDetails" ], "xbrltype": "domainItemType" }, "irmd_WinterSpringsFloridaFacilityMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents information pertaining to the Winter Springs, Florida facility.", "label": "Winter Springs Florida Facility [Member]", "terseLabel": "Winter Springs, Florida Facility" } } }, "localname": "WinterSpringsFloridaFacilityMember", "nsuri": "http://www.iradimed.com/20210630", "presentation": [ "http://www.iradimed.com/role/DisclosureLeasesDetails" ], "xbrltype": "domainItemType" }, "srt_ProductOrServiceAxis": { "auth_ref": [ "r138", "r210", "r213", "r352", "r392", "r393" ], "lang": { "en-us": { "role": { "label": "Products and Services [Axis]" } } }, "localname": "ProductOrServiceAxis", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://www.iradimed.com/role/DisclosureRevenueRecognitionInformationByTypeDetails" ], "xbrltype": "stringItemType" }, "srt_ProductsAndServicesDomain": { "auth_ref": [ "r138", "r210", "r213", "r352", "r392", "r393" ], "lang": { "en-us": { "role": { "label": "Products And Services [Domain]", "terseLabel": "Products and Services [Domain]" } } }, "localname": "ProductsAndServicesDomain", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://www.iradimed.com/role/DisclosureRevenueRecognitionInformationByTypeDetails" ], "xbrltype": "domainItemType" }, "srt_SegmentGeographicalDomain": { "auth_ref": [ "r139", "r140", "r210", "r214", "r394", "r410", "r411", "r412", "r413", "r414", "r415", "r416", "r417" ], "lang": { "en-us": { "role": { "label": "Segment Geographical [Domain]", "terseLabel": "Geographical [Domain]" } } }, "localname": "SegmentGeographicalDomain", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://www.iradimed.com/role/DisclosurePropertyAndEquipmentGeographicInformationDetails", "http://www.iradimed.com/role/DisclosureRevenueRecognitionInformationByGeographicRegionDetails" ], "xbrltype": "domainItemType" }, "srt_StatementGeographicalAxis": { "auth_ref": [ "r139", "r140", "r210", "r214", "r394", "r406", "r410", "r411", "r412", "r413", "r414", "r415", "r416", "r417", "r418" ], "lang": { "en-us": { "role": { "label": "Geographical [Axis]" } } }, "localname": "StatementGeographicalAxis", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://www.iradimed.com/role/DisclosurePropertyAndEquipmentGeographicInformationDetails", "http://www.iradimed.com/role/DisclosureRevenueRecognitionInformationByGeographicRegionDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AOCIAttributableToParentNetOfTaxRollForward": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax [Roll Forward]", "terseLabel": "Component of accumulated other comprehensive loss" } } }, "localname": "AOCIAttributableToParentNetOfTaxRollForward", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.iradimed.com/role/DisclosureAccumulatedOtherComprehensiveIncomeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AccountsPayableCurrent": { "auth_ref": [ "r34" ], "calculation": { "http://www.iradimed.com/role/StatementCondensedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accounts Payable, Current", "terseLabel": "Accounts payable" } } }, "localname": "AccountsPayableCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.iradimed.com/role/StatementCondensedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccountsReceivableNetCurrent": { "auth_ref": [ "r4", "r17", "r143", "r144" ], "calculation": { "http://www.iradimed.com/role/StatementCondensedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.", "label": "Accounts Receivable, Net, Current", "terseLabel": "Accounts receivable, net of allowance for doubtful accounts of $45,578 as of June 30, 2021 and $46,484 as of December 31, 2020" } } }, "localname": "AccountsReceivableNetCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.iradimed.com/role/StatementCondensedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccrualForTaxesOtherThanIncomeTaxesCurrent": { "auth_ref": [ "r11", "r36", "r255" ], "calculation": { "http://www.iradimed.com/role/StatementCondensedBalanceSheets": { "order": 4.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable for real and property taxes. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accrual for Taxes Other than Income Taxes, Current", "terseLabel": "Other accrued taxes" } } }, "localname": "AccrualForTaxesOtherThanIncomeTaxesCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.iradimed.com/role/StatementCondensedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": { "auth_ref": [ "r32", "r186" ], "calculation": { "http://www.iradimed.com/role/DisclosurePropertyAndEquipmentDetails": { "order": 2.0, "parentTag": "us-gaap_PropertyPlantAndEquipmentNet", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.", "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment", "negatedLabel": "Accumulated depreciation" } } }, "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.iradimed.com/role/DisclosurePropertyAndEquipmentDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": { "auth_ref": [ "r20", "r46", "r48", "r49", "r381", "r399", "r400" ], "calculation": { "http://www.iradimed.com/role/StatementCondensedBalanceSheets": { "order": 4.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.", "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax", "periodEndLabel": "Balance at the end", "periodStartLabel": "Balance at the beginning", "terseLabel": "Accumulated other comprehensive income" } } }, "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.iradimed.com/role/DisclosureAccumulatedOtherComprehensiveIncomeDetails", "http://www.iradimed.com/role/StatementCondensedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeMember": { "auth_ref": [ "r45", "r49", "r52", "r90", "r91", "r92", "r281", "r395", "r396" ], "lang": { "en-us": { "role": { "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.", "label": "Accumulated Other Comprehensive Income [Member]", "terseLabel": "Accumulated Other Comprehensive (Loss) Income" } } }, "localname": "AccumulatedOtherComprehensiveIncomeMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.iradimed.com/role/StatementCondensedStatementsOfStockholdersEquity" ], "xbrltype": "domainItemType" }, "us-gaap_AdditionalPaidInCapital": { "auth_ref": [ "r18", "r250" ], "calculation": { "http://www.iradimed.com/role/StatementCondensedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders. Includes adjustments to additional paid in capital. Some examples of such adjustments include recording the issuance of debt with a beneficial conversion feature and certain tax consequences of equity instruments awarded to employees. Use this element for the aggregate amount of additional paid-in capital associated with common and preferred stock. For additional paid-in capital associated with only common stock, use the element additional paid in capital, common stock. For additional paid-in capital associated with only preferred stock, use the element additional paid in capital, preferred stock.", "label": "Additional Paid in Capital", "terseLabel": "Additional paid-in capital" } } }, "localname": "AdditionalPaidInCapital", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.iradimed.com/role/StatementCondensedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdditionalPaidInCapitalMember": { "auth_ref": [ "r90", "r91", "r92", "r247", "r248", "r249" ], "lang": { "en-us": { "role": { "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.", "label": "Additional Paid In Capital [Member]", "terseLabel": "Additional Paid-in Capital" } } }, "localname": "AdditionalPaidInCapitalMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.iradimed.com/role/StatementCondensedStatementsOfStockholdersEquity" ], "xbrltype": "domainItemType" }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": { "auth_ref": [ "r230", "r232", "r252", "r253" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.", "label": "Adjustments to Additional Paid in Capital, Share-based Compensation, Requisite Service Period Recognition", "verboseLabel": "Stock-based compensation expense" } } }, "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.iradimed.com/role/StatementCondensedStatementsOfStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]", "terseLabel": "Adjustments to reconcile net income (loss) to net cash provided by operating activities:" } } }, "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.iradimed.com/role/StatementCondensedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_AllocatedShareBasedCompensationExpense": { "auth_ref": [ "r232", "r243", "r251" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.", "label": "Allocated Share-based Compensation Expense", "terseLabel": "Total stock-based compensation expense" } } }, "localname": "AllocatedShareBasedCompensationExpense", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.iradimed.com/role/DisclosureStockBasedCompensationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent": { "auth_ref": [ "r24", "r145", "r157" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of allowance for credit loss on accounts receivable, classified as current.", "label": "Allowance for Doubtful Accounts Receivable, Current", "terseLabel": "Accounts receivable, allowance for doubtful accounts" } } }, "localname": "AllowanceForDoubtfulAccountsReceivableCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.iradimed.com/role/StatementCondensedBalanceSheetsParenthetical" ], "xbrltype": "monetaryItemType" }, "us-gaap_AmortizationOfIntangibleAssets": { "auth_ref": [ "r81", "r175", "r180" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.", "label": "Amortization of Intangible Assets", "terseLabel": "Amortization expense of intangible assets" } } }, "localname": "AmortizationOfIntangibleAssets", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.iradimed.com/role/DisclosureIntangibleAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": { "auth_ref": [ "r113" ], "lang": { "en-us": { "role": { "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.", "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount", "terseLabel": "Anti-dilutive stock options and restricted stock units" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.iradimed.com/role/DisclosureBasicAndDilutedNetIncomePerShareDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_Assets": { "auth_ref": [ "r86", "r127", "r130", "r136", "r155", "r276", "r282", "r295", "r369", "r380" ], "calculation": { "http://www.iradimed.com/role/StatementCondensedBalanceSheets": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets", "totalLabel": "Total assets" } } }, "localname": "Assets", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.iradimed.com/role/StatementCondensedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Assets [Abstract]", "terseLabel": "ASSETS" } } }, "localname": "AssetsAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.iradimed.com/role/StatementCondensedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_AssetsCurrent": { "auth_ref": [ "r6", "r8", "r44", "r86", "r155", "r276", "r282", "r295" ], "calculation": { "http://www.iradimed.com/role/StatementCondensedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets, Current", "totalLabel": "Total current assets" } } }, "localname": "AssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.iradimed.com/role/StatementCondensedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Assets, Current [Abstract]", "terseLabel": "Current assets:" } } }, "localname": "AssetsCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.iradimed.com/role/StatementCondensedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_AssetsFairValueDisclosure": { "auth_ref": [ "r287" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets, Fair Value Disclosure", "terseLabel": "Total" } } }, "localname": "AssetsFairValueDisclosure", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.iradimed.com/role/DisclosureFairValueMeasurementsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleSecuritiesDebtSecurities": { "auth_ref": [ "r147", "r149", "r164", "r371" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Available-for-sale Securities", "terseLabel": "Fair Value" } } }, "localname": "AvailableForSaleSecuritiesDebtSecurities", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.iradimed.com/role/DisclosureInvestmentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AwardTypeAxis": { "auth_ref": [ "r233", "r245" ], "lang": { "en-us": { "role": { "documentation": "Information by type of award under share-based payment arrangement.", "label": "Award Type [Axis]" } } }, "localname": "AwardTypeAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.iradimed.com/role/DisclosureStockBasedCompensationStockOptionsAndRestrictedStockUnitsActivityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_CapitalizedContractCostNet": { "auth_ref": [ "r174" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after accumulated amortization and accumulated impairment loss, of asset recognized from cost incurred to obtain or fulfill contract with customer.", "label": "Capitalized Contract Cost, Net", "terseLabel": "Capitalized contract costs" } } }, "localname": "CapitalizedContractCostNet", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.iradimed.com/role/DisclosureRevenueRecognitionCapitalizedContractCostsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashAndCashEquivalentsAtCarryingValue": { "auth_ref": [ "r2", "r30", "r83" ], "calculation": { "http://www.iradimed.com/role/StatementCondensedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.", "label": "Cash and Cash Equivalents, at Carrying Value", "terseLabel": "Cash and cash equivalents" } } }, "localname": "CashAndCashEquivalentsAtCarryingValue", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.iradimed.com/role/StatementCondensedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": { "auth_ref": [ "r78", "r83", "r85" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents", "periodEndLabel": "Cash and cash equivalents, end of period", "periodStartLabel": "Cash and cash equivalents, beginning of period" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.iradimed.com/role/StatementCondensedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": { "auth_ref": [ "r78", "r296" ], "calculation": { "http://www.iradimed.com/role/StatementCondensedStatementsOfCashFlows": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect", "totalLabel": "Net increase in cash and cash equivalents" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.iradimed.com/role/StatementCondensedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ChangeInContractWithCustomerLiabilityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Changes in contract liabilities" } } }, "localname": "ChangeInContractWithCustomerLiabilityAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.iradimed.com/role/DisclosureRevenueRecognitionContractLiabilitiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Commitments and Contingencies" } } }, "localname": "CommitmentsAndContingenciesDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": { "auth_ref": [ "r190", "r191", "r192", "r193" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for commitments and contingencies.", "label": "Commitments and Contingencies Disclosure [Text Block]", "terseLabel": "Commitments and Contingencies" } } }, "localname": "CommitmentsAndContingenciesDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.iradimed.com/role/DisclosureCommitmentsAndContingencies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CommonStockMember": { "auth_ref": [ "r90", "r91" ], "lang": { "en-us": { "role": { "documentation": "Stock that is subordinate to all other stock of the issuer.", "label": "Common Stock [Member]", "terseLabel": "Common Stock" } } }, "localname": "CommonStockMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.iradimed.com/role/StatementCondensedStatementsOfStockholdersEquity" ], "xbrltype": "domainItemType" }, "us-gaap_CommonStockParOrStatedValuePerShare": { "auth_ref": [ "r16" ], "lang": { "en-us": { "role": { "documentation": "Face amount or stated value per share of common stock.", "label": "Common Stock, Par or Stated Value Per Share", "terseLabel": "Common stock, par value (in dollars per share)" } } }, "localname": "CommonStockParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.iradimed.com/role/StatementCondensedBalanceSheetsParenthetical" ], "xbrltype": "perShareItemType" }, "us-gaap_CommonStockSharesAuthorized": { "auth_ref": [ "r16" ], "lang": { "en-us": { "role": { "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.", "label": "Common Stock, Shares Authorized", "terseLabel": "Common stock, shares authorized" } } }, "localname": "CommonStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.iradimed.com/role/StatementCondensedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesIssued": { "auth_ref": [ "r16" ], "lang": { "en-us": { "role": { "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.", "label": "Common Stock, Shares, Issued", "terseLabel": "Common stock, shares issued" } } }, "localname": "CommonStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.iradimed.com/role/StatementCondensedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesOutstanding": { "auth_ref": [ "r16", "r197" ], "lang": { "en-us": { "role": { "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.", "label": "Common Stock, Shares, Outstanding", "terseLabel": "Common stock, shares outstanding" } } }, "localname": "CommonStockSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.iradimed.com/role/StatementCondensedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockValue": { "auth_ref": [ "r16" ], "calculation": { "http://www.iradimed.com/role/StatementCondensedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "Common Stock, Value, Issued", "terseLabel": "Common stock; $0.0001 par value; 31,500,000 shares authorized; 12,317,036 shares issued and outstanding as of June 30, 2021 and 12,308,432 shares issued and outstanding as of December 31, 2020" } } }, "localname": "CommonStockValue", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.iradimed.com/role/StatementCondensedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_ComprehensiveIncomeNetOfTax": { "auth_ref": [ "r55", "r57", "r58", "r64", "r375", "r387" ], "calculation": { "http://www.iradimed.com/role/StatementCondensedStatementsOfComprehensiveIncome": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.", "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent", "totalLabel": "Comprehensive income (loss)" } } }, "localname": "ComprehensiveIncomeNetOfTax", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.iradimed.com/role/StatementCondensedStatementsOfComprehensiveIncome" ], "xbrltype": "monetaryItemType" }, "us-gaap_ComprehensiveIncomeNetOfTaxAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Accumulated Other Comprehensive Income", "verboseLabel": "Other comprehensive income:" } } }, "localname": "ComprehensiveIncomeNetOfTaxAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.iradimed.com/role/StatementCondensedStatementsOfComprehensiveIncome" ], "xbrltype": "stringItemType" }, "us-gaap_ComprehensiveIncomeNoteTextBlock": { "auth_ref": [ "r63", "r72", "r374", "r386" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for comprehensive income, which includes, but is not limited to, 1) the amount of income tax expense or benefit allocated to each component of other comprehensive income, including reclassification adjustments, 2) the reclassification adjustments for each classification of other comprehensive income and 3) the ending accumulated balances for each component of comprehensive income.", "label": "Comprehensive Income (Loss) Note [Text Block]", "terseLabel": "Accumulated Other Comprehensive Income" } } }, "localname": "ComprehensiveIncomeNoteTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.iradimed.com/role/DisclosureAccumulatedOtherComprehensiveIncome" ], "xbrltype": "textBlockItemType" }, "us-gaap_ConcentrationRiskCreditRisk": { "auth_ref": [ "r120", "r379" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for credit risk.", "label": "Concentration Risk, Credit Risk, Policy [Policy Text Block]", "terseLabel": "Certain Significant Risks and Uncertainties" } } }, "localname": "ConcentrationRiskCreditRisk", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.iradimed.com/role/DisclosureBasisOfPresentationPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_ContractWithCustomerAssetAndLiabilityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Deferred revenue" } } }, "localname": "ContractWithCustomerAssetAndLiabilityAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.iradimed.com/role/DisclosureRevenueRecognitionContractLiabilitiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock": { "auth_ref": [ "r201" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of receivable, contract asset, and contract liability from contract with customer. Includes, but is not limited to, change in contract asset and contract liability.", "label": "Contract with Customer, Asset and Liability [Table Text Block]", "terseLabel": "Schedule of contract liabilities and changes in the contract liabilities" } } }, "localname": "ContractWithCustomerAssetAndLiabilityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.iradimed.com/role/DisclosureRevenueRecognitionTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ContractWithCustomerLiability": { "auth_ref": [ "r199", "r200", "r211" ], "calculation": { "http://www.iradimed.com/role/DisclosureRevenueRecognitionContractLiabilitiesDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.", "label": "Contract With Customer Liability", "periodEndLabel": "Contract liabilities at end", "periodStartLabel": "Contract liabilities at beginning of the year", "totalLabel": "Total" } } }, "localname": "ContractWithCustomerLiability", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.iradimed.com/role/DisclosureRevenueRecognitionContractLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ContractWithCustomerLiabilityCurrent": { "auth_ref": [ "r199", "r200", "r211" ], "calculation": { "http://www.iradimed.com/role/StatementCondensedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.", "label": "Contract with Customer, Liability, Current", "terseLabel": "Deferred revenue" } } }, "localname": "ContractWithCustomerLiabilityCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.iradimed.com/role/StatementCondensedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_ContractWithCustomerLiabilityNoncurrent": { "auth_ref": [ "r199", "r200", "r211" ], "calculation": { "http://www.iradimed.com/role/StatementCondensedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as noncurrent.", "label": "Contract with Customer, Liability, Noncurrent", "terseLabel": "Deferred revenue" } } }, "localname": "ContractWithCustomerLiabilityNoncurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.iradimed.com/role/StatementCondensedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_CostOfRevenue": { "auth_ref": [ "r69", "r86", "r155", "r295" ], "calculation": { "http://www.iradimed.com/role/StatementCondensedStatementsOfOperations": { "order": 2.0, "parentTag": "us-gaap_GrossProfit", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate cost of goods produced and sold and services rendered during the reporting period.", "label": "Cost of Revenue.", "terseLabel": "Cost of revenue" } } }, "localname": "CostOfRevenue", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.iradimed.com/role/StatementCondensedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_CostOfSalesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Primary financial statement caption encompassing cost of sales.", "label": "Cost Of Sales [Member]", "terseLabel": "Cost of revenue" } } }, "localname": "CostOfSalesMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.iradimed.com/role/DisclosureLeasesOperatingLeaseCostDetails", "http://www.iradimed.com/role/DisclosureStockBasedCompensationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock": { "auth_ref": [ "r154" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Debt Securities, Available-for-sale [Table Text Block]", "terseLabel": "Summary of available-for-sale securities" } } }, "localname": "DebtSecuritiesAvailableForSaleTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.iradimed.com/role/DisclosureInvestmentsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_DebtSecuritiesCurrent": { "auth_ref": [], "calculation": { "http://www.iradimed.com/role/StatementCondensedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of investment in debt security measured at amortized cost (held-to-maturity), investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale) and investment in debt security measured at fair value with change in fair value recognized in net income (trading); classified as current.", "label": "Debt Securities, Current", "terseLabel": "Investments" } } }, "localname": "DebtSecuritiesCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.iradimed.com/role/StatementCondensedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtSecuritiesTradingUnrealizedGain": { "auth_ref": [ "r153" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of unrealized gain on investment in debt security measured at fair value with change in fair value recognized in net income (trading).", "label": "Debt Securities, Trading, Unrealized Gain", "terseLabel": "Gross Unrealized Gains" } } }, "localname": "DebtSecuritiesTradingUnrealizedGain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.iradimed.com/role/DisclosureInvestmentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredIncomeTaxAssetsNet": { "auth_ref": [ "r257", "r258" ], "calculation": { "http://www.iradimed.com/role/StatementCondensedBalanceSheets": { "order": 5.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, with jurisdictional netting.", "label": "Deferred Income Tax Assets, Net", "terseLabel": "Deferred income taxes, net" } } }, "localname": "DeferredIncomeTaxAssetsNet", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.iradimed.com/role/StatementCondensedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_Depreciation": { "auth_ref": [ "r81", "r184" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.", "label": "Depreciation", "terseLabel": "Depreciation and amortization expense of property and equipment" } } }, "localname": "Depreciation", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.iradimed.com/role/DisclosurePropertyAndEquipmentDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DepreciationDepletionAndAmortization": { "auth_ref": [ "r81", "r125" ], "calculation": { "http://www.iradimed.com/role/StatementCondensedStatementsOfCashFlows": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.", "label": "Depreciation, Depletion and Amortization", "terseLabel": "Depreciation and amortization" } } }, "localname": "DepreciationDepletionAndAmortization", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.iradimed.com/role/StatementCondensedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_DisaggregationOfRevenueLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Contract Liabilities", "terseLabel": "Disaggregation of Revenue", "verboseLabel": "Contract Liabilities" } } }, "localname": "DisaggregationOfRevenueLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.iradimed.com/role/DisclosureRevenueRecognitionInformationByGeographicRegionDetails", "http://www.iradimed.com/role/DisclosureRevenueRecognitionInformationByTypeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DisaggregationOfRevenueTable": { "auth_ref": [ "r210", "r213", "r214", "r215", "r216", "r217", "r218", "r219" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.", "label": "Disaggregation of Revenue [Table]" } } }, "localname": "DisaggregationOfRevenueTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.iradimed.com/role/DisclosureRevenueRecognitionInformationByGeographicRegionDetails", "http://www.iradimed.com/role/DisclosureRevenueRecognitionInformationByTypeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DisaggregationOfRevenueTableTextBlock": { "auth_ref": [ "r210" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.", "label": "Disaggregation of Revenue [Table Text Block]", "terseLabel": "Schedule of disaggregation of revenue by geographic region and revenue type" } } }, "localname": "DisaggregationOfRevenueTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.iradimed.com/role/DisclosureRevenueRecognitionTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": { "auth_ref": [ "r254" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for share-based payment arrangement.", "label": "Disclosure of Compensation Related Costs, Share-based Payments [Text Block]", "terseLabel": "Stock-Based Compensation" } } }, "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.iradimed.com/role/DisclosureStockBasedCompensation" ], "xbrltype": "textBlockItemType" }, "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Stock-Based Compensation" } } }, "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_DomesticCorporateDebtSecuritiesMember": { "auth_ref": [ "r148", "r221", "r229" ], "lang": { "en-us": { "role": { "documentation": "Debt security issued by corporation domiciled in United States of America (US).", "label": "Domestic Corporate Debt Securities [Member]", "terseLabel": "U.S. corporations" } } }, "localname": "DomesticCorporateDebtSecuritiesMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.iradimed.com/role/DisclosureFairValueMeasurementsDetails", "http://www.iradimed.com/role/DisclosureInvestmentsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_EarningsPerShareAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Basic and Diluted Net Income per Share" } } }, "localname": "EarningsPerShareAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_EarningsPerShareBasic": { "auth_ref": [ "r65", "r95", "r96", "r97", "r98", "r99", "r103", "r105", "r110", "r111", "r112", "r116", "r117", "r376", "r388" ], "lang": { "en-us": { "role": { "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.", "label": "Earnings Per Share, Basic", "terseLabel": "Basic net income (loss) per share (in dollars per share)", "verboseLabel": "Basic (in dollars per share)" } } }, "localname": "EarningsPerShareBasic", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.iradimed.com/role/DisclosureBasicAndDilutedNetIncomePerShareDetails", "http://www.iradimed.com/role/StatementCondensedStatementsOfOperations" ], "xbrltype": "perShareItemType" }, "us-gaap_EarningsPerShareBasicAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Earnings Per Share, Basic [Abstract]", "terseLabel": "Net income (loss) per share:" } } }, "localname": "EarningsPerShareBasicAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.iradimed.com/role/StatementCondensedStatementsOfOperations" ], "xbrltype": "stringItemType" }, "us-gaap_EarningsPerShareDiluted": { "auth_ref": [ "r65", "r95", "r96", "r97", "r98", "r99", "r105", "r110", "r111", "r112", "r116", "r117", "r376", "r388" ], "lang": { "en-us": { "role": { "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.", "label": "Earnings Per Share, Diluted", "terseLabel": "Diluted net income (loss) per share (in dollars per share)", "verboseLabel": "Diluted (in dollars per share)" } } }, "localname": "EarningsPerShareDiluted", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.iradimed.com/role/DisclosureBasicAndDilutedNetIncomePerShareDetails", "http://www.iradimed.com/role/StatementCondensedStatementsOfOperations" ], "xbrltype": "perShareItemType" }, "us-gaap_EarningsPerShareTextBlock": { "auth_ref": [ "r113", "r114", "r115", "r118" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for earnings per share.", "label": "Earnings Per Share [Text Block]", "terseLabel": "Basic and Diluted Net Income per Share" } } }, "localname": "EarningsPerShareTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.iradimed.com/role/DisclosureBasicAndDilutedNetIncomePerShare" ], "xbrltype": "textBlockItemType" }, "us-gaap_EffectiveIncomeTaxRateContinuingOperations": { "auth_ref": [ "r260" ], "lang": { "en-us": { "role": { "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.", "label": "Effective Income Tax Rate Reconciliation, Percent", "terseLabel": "Effective tax rate (as a percent)" } } }, "localname": "EffectiveIncomeTaxRateContinuingOperations", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.iradimed.com/role/DisclosureIncomeTaxesDetails" ], "xbrltype": "percentItemType" }, "us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Effective Income Tax Rate Reconciliation, Percent [Abstract]", "terseLabel": "Reconciliation of the statutory U.S. federal tax rate to effective rate" } } }, "localname": "EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.iradimed.com/role/DisclosureIncomeTaxesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_EmployeeRelatedLiabilitiesCurrent": { "auth_ref": [ "r36" ], "calculation": { "http://www.iradimed.com/role/StatementCondensedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Employee-related Liabilities, Current", "terseLabel": "Accrued payroll and benefits" } } }, "localname": "EmployeeRelatedLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.iradimed.com/role/StatementCondensedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]", "terseLabel": "Stock-Based Compensation" } } }, "localname": "EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.iradimed.com/role/DisclosureStockBasedCompensationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": { "auth_ref": [ "r244" ], "lang": { "en-us": { "role": { "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Period for Recognition" } } }, "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.iradimed.com/role/DisclosureStockBasedCompensationStockOptionsAndRestrictedStockUnitsActivityDetails" ], "xbrltype": "durationItemType" }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions": { "auth_ref": [ "r244" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cost to be recognized for option under share-based payment arrangement.", "label": "Employee Service Share-based Compensation, Nonvested Awards, Compensation Not yet Recognized, Stock Options", "terseLabel": "Unrecognized compensation cost related to unvested restricted stock units" } } }, "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.iradimed.com/role/DisclosureStockBasedCompensationStockOptionsAndRestrictedStockUnitsActivityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_EmployeeStockOptionMember": { "auth_ref": [ "r241" ], "lang": { "en-us": { "role": { "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time.", "label": "Employee Stock Option [Member]", "terseLabel": "Stock Options" } } }, "localname": "EmployeeStockOptionMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.iradimed.com/role/DisclosureStockBasedCompensationStockOptionsAndRestrictedStockUnitsActivityDetails" ], "xbrltype": "domainItemType" }, "us-gaap_EquityComponentDomain": { "auth_ref": [ "r90", "r91", "r92", "r94", "r100", "r102", "r119", "r156", "r197", "r198", "r247", "r248", "r249", "r264", "r265", "r297", "r298", "r299", "r300", "r301", "r303", "r395", "r396", "r397" ], "lang": { "en-us": { "role": { "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.", "label": "Equity Component [Domain]", "terseLabel": "Equity Component [Domain]" } } }, "localname": "EquityComponentDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.iradimed.com/role/StatementCondensedStatementsOfStockholdersEquity" ], "xbrltype": "domainItemType" }, "us-gaap_ExtendedProductWarrantyAccrual": { "auth_ref": [ "r196" ], "calculation": { "http://www.iradimed.com/role/DisclosureRevenueRecognitionContractLiabilitiesDetails": { "order": 1.0, "parentTag": "us-gaap_ContractWithCustomerLiability", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount as of the balance sheet date of the aggregate extended product warranty liability. Does not include the ending balance for the standard product warranty liability.", "label": "Extended Product Warranty Accrual", "terseLabel": "Extended warranty agreements" } } }, "localname": "ExtendedProductWarrantyAccrual", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.iradimed.com/role/DisclosureRevenueRecognitionContractLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]", "terseLabel": "Fair Value Measurements" } } }, "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.iradimed.com/role/DisclosureFairValueMeasurementsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": { "auth_ref": [ "r287", "r288", "r289", "r293" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis.", "label": "Fair Value Measurements, Recurring and Nonrecurring [Table]" } } }, "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.iradimed.com/role/DisclosureFairValueMeasurementsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueByFairValueHierarchyLevelAxis": { "auth_ref": [ "r221", "r222", "r223", "r224", "r225", "r226", "r227", "r229", "r288", "r325", "r326", "r327" ], "lang": { "en-us": { "role": { "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.", "label": "Fair Value, Hierarchy [Axis]" } } }, "localname": "FairValueByFairValueHierarchyLevelAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.iradimed.com/role/DisclosureFairValueMeasurementsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueByMeasurementFrequencyAxis": { "auth_ref": [ "r287", "r288", "r290", "r291", "r294" ], "lang": { "en-us": { "role": { "documentation": "Information by measurement frequency.", "label": "Measurement Frequency [Axis]" } } }, "localname": "FairValueByMeasurementFrequencyAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.iradimed.com/role/DisclosureFairValueMeasurementsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueDisclosuresAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Fair Value Measurements" } } }, "localname": "FairValueDisclosuresAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_FairValueDisclosuresTextBlock": { "auth_ref": [ "r292" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.", "label": "Fair Value Disclosures [Text Block]", "terseLabel": "Fair Value Measurements" } } }, "localname": "FairValueDisclosuresTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.iradimed.com/role/DisclosureFairValueMeasurements" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValueInputsLevel2Member": { "auth_ref": [ "r221", "r222", "r227", "r229", "r288", "r326" ], "lang": { "en-us": { "role": { "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.", "label": "Fair Value Inputs Level2 [Member]", "terseLabel": "Significant Other Observable Inputs (Level 2)" } } }, "localname": "FairValueInputsLevel2Member", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.iradimed.com/role/DisclosureFairValueMeasurementsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueMeasurementFrequencyDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Measurement frequency.", "label": "Fair Value Measurement Frequency [Domain]", "terseLabel": "Fair Value, Measurement Frequency [Domain]" } } }, "localname": "FairValueMeasurementFrequencyDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.iradimed.com/role/DisclosureFairValueMeasurementsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": { "auth_ref": [ "r221", "r222", "r223", "r224", "r225", "r226", "r227", "r229", "r325", "r326", "r327" ], "lang": { "en-us": { "role": { "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.", "label": "Fair Value Measurements Fair Value Hierarchy [Domain]", "terseLabel": "Fair Value Hierarchy [Domain]" } } }, "localname": "FairValueMeasurementsFairValueHierarchyDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.iradimed.com/role/DisclosureFairValueMeasurementsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueMeasurementsRecurringMember": { "auth_ref": [ "r292", "r294" ], "lang": { "en-us": { "role": { "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value.", "label": "Fair Value Measurements Recurring [Member]", "terseLabel": "Recurring" } } }, "localname": "FairValueMeasurementsRecurringMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.iradimed.com/role/DisclosureFairValueMeasurementsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FinancialInstrumentAxis": { "auth_ref": [ "r150", "r151", "r158", "r160", "r161", "r162", "r163", "r165", "r166", "r167", "r168", "r322", "r323", "r324", "r325", "r326", "r327", "r328", "r329", "r330", "r331", "r332", "r333", "r334", "r335", "r336", "r337", "r338", "r339", "r340", "r341", "r342", "r343", "r344", "r345", "r346", "r347", "r348", "r349", "r350", "r351" ], "lang": { "en-us": { "role": { "documentation": "Information by type of financial instrument.", "label": "Financial Instrument [Axis]" } } }, "localname": "FinancialInstrumentAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.iradimed.com/role/DisclosureFairValueMeasurementsDetails", "http://www.iradimed.com/role/DisclosureInvestmentsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization": { "auth_ref": [ "r179" ], "calculation": { "http://www.iradimed.com/role/DisclosureIntangibleAssetsDetails": { "order": 2.0, "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.", "label": "Finite-Lived Intangible Assets, Accumulated Amortization", "negatedLabel": "Accumulated amortization" } } }, "localname": "FiniteLivedIntangibleAssetsAccumulatedAmortization", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.iradimed.com/role/DisclosureIntangibleAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths": { "auth_ref": [ "r181" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Finite-Lived Intangible Assets, Amortization Expense, Next Twelve Months", "terseLabel": "2022" } } }, "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.iradimed.com/role/DisclosureIntangibleAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in remainder of current fiscal year.", "label": "Finite-Lived Intangible Assets, Amortization Expense, Remainder of Fiscal Year", "terseLabel": "Six months ending December 31, 2021" } } }, "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.iradimed.com/role/DisclosureIntangibleAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive": { "auth_ref": [ "r181" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Finite-Lived Intangible Assets, Amortization Expense, Year Five", "terseLabel": "2026" } } }, "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFive", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.iradimed.com/role/DisclosureIntangibleAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour": { "auth_ref": [ "r181" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Finite-Lived Intangible Assets, Amortization Expense, Year Four", "terseLabel": "2025" } } }, "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFour", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.iradimed.com/role/DisclosureIntangibleAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree": { "auth_ref": [ "r181" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Finite-Lived Intangible Assets, Amortization Expense, Year Three", "terseLabel": "2024" } } }, "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearThree", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.iradimed.com/role/DisclosureIntangibleAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo": { "auth_ref": [ "r181" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Finite-Lived Intangible Assets, Amortization Expense, Year Two", "terseLabel": "2023" } } }, "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.iradimed.com/role/DisclosureIntangibleAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis": { "auth_ref": [ "r176", "r177", "r179", "r182", "r353", "r354" ], "lang": { "en-us": { "role": { "documentation": "Information by major type or class of finite-lived intangible assets.", "label": "Finite-Lived Intangible Assets by Major Class [Axis]" } } }, "localname": "FiniteLivedIntangibleAssetsByMajorClassAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.iradimed.com/role/DisclosureIntangibleAssetsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Finite-Lived Intangible Assets, Net, Amortization Expense, Fiscal Year Maturity [Abstract]", "terseLabel": "Expected annual amortization expense" } } }, "localname": "FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.iradimed.com/role/DisclosureIntangibleAssetsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FiniteLivedIntangibleAssetsGross": { "auth_ref": [ "r179", "r354" ], "calculation": { "http://www.iradimed.com/role/DisclosureIntangibleAssetsDetails": { "order": 1.0, "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.", "label": "Finite-Lived Intangible Assets, Gross", "terseLabel": "Intangible Assets, gross" } } }, "localname": "FiniteLivedIntangibleAssetsGross", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.iradimed.com/role/DisclosureIntangibleAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Finite-Lived Intangible Assets [Line Items]", "terseLabel": "Intangible assets" } } }, "localname": "FiniteLivedIntangibleAssetsLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.iradimed.com/role/DisclosureIntangibleAssetsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain": { "auth_ref": [ "r176", "r178" ], "lang": { "en-us": { "role": { "documentation": "The major class of finite-lived intangible asset (for example, patents, trademarks, copyrights, etc.) A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company.", "label": "Finite Lived Intangible Assets Major Class Name [Domain]", "terseLabel": "Finite-Lived Intangible Assets, Major Class Name [Domain]" } } }, "localname": "FiniteLivedIntangibleAssetsMajorClassNameDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.iradimed.com/role/DisclosureIntangibleAssetsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FiniteLivedIntangibleAssetsNet": { "auth_ref": [ "r179", "r353" ], "calculation": { "http://www.iradimed.com/role/DisclosureIntangibleAssetsDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.iradimed.com/role/StatementCondensedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.", "label": "Finite-Lived Intangible Assets, Net", "terseLabel": "Intangible assets, net", "totalLabel": "Total" } } }, "localname": "FiniteLivedIntangibleAssetsNet", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.iradimed.com/role/DisclosureIntangibleAssetsDetails", "http://www.iradimed.com/role/StatementCondensedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_FurnitureAndFixturesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities. Examples include, but are not limited to, desks, chairs, tables, and bookcases.", "label": "Furniture And Fixtures [Member]", "terseLabel": "Furniture and fixtures" } } }, "localname": "FurnitureAndFixturesMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.iradimed.com/role/DisclosurePropertyAndEquipmentDetails" ], "xbrltype": "domainItemType" }, "us-gaap_GeneralAndAdministrativeExpense": { "auth_ref": [ "r70" ], "calculation": { "http://www.iradimed.com/role/StatementCondensedStatementsOfOperations": { "order": 1.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.", "label": "General and Administrative Expense", "terseLabel": "General and administrative" } } }, "localname": "GeneralAndAdministrativeExpense", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.iradimed.com/role/StatementCondensedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_GeneralAndAdministrativeExpenseMember": { "auth_ref": [ "r66" ], "lang": { "en-us": { "role": { "documentation": "Primary financial statement caption encompassing general and administrative expense.", "label": "General And Administrative Expense [Member]", "terseLabel": "General and administrative" } } }, "localname": "GeneralAndAdministrativeExpenseMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.iradimed.com/role/DisclosureLeasesOperatingLeaseCostDetails", "http://www.iradimed.com/role/DisclosureStockBasedCompensationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Intangible Assets" } } }, "localname": "GoodwillAndIntangibleAssetsDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_GrossProfit": { "auth_ref": [ "r68", "r86", "r127", "r129", "r132", "r135", "r137", "r155", "r295" ], "calculation": { "http://www.iradimed.com/role/StatementCondensedStatementsOfOperations": { "order": 1.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity.", "label": "Gross Profit", "totalLabel": "Gross profit" } } }, "localname": "GrossProfit", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.iradimed.com/role/StatementCondensedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": { "auth_ref": [ "r61", "r127", "r129", "r132", "r135", "r137", "r367", "r372", "r377", "r389" ], "calculation": { "http://www.iradimed.com/role/StatementCondensedStatementsOfOperations": { "order": 1.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.", "label": "Income (Loss) from Continuing Operations before Income Taxes, Extraordinary Items, Noncontrolling Interest", "totalLabel": "Income (loss) before provision for income taxes" } } }, "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.iradimed.com/role/StatementCondensedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeStatementAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "CONDENSED STATEMENTS OF OPERATIONS" } } }, "localname": "IncomeStatementAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_IncomeStatementLocationAxis": { "auth_ref": [ "r188" ], "lang": { "en-us": { "role": { "documentation": "Information by location in the income statement.", "label": "Income Statement Location [Axis]" } } }, "localname": "IncomeStatementLocationAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.iradimed.com/role/DisclosureLeasesOperatingLeaseCostDetails", "http://www.iradimed.com/role/DisclosureStockBasedCompensationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_IncomeStatementLocationDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Location in the income statement.", "label": "Income Statement Location [Domain]", "terseLabel": "Income Statement Location [Domain]" } } }, "localname": "IncomeStatementLocationDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.iradimed.com/role/DisclosureLeasesOperatingLeaseCostDetails", "http://www.iradimed.com/role/DisclosureStockBasedCompensationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_IncomeTaxDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Income Taxes" } } }, "localname": "IncomeTaxDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_IncomeTaxDisclosureTextBlock": { "auth_ref": [ "r261", "r262", "r263", "r266", "r268", "r270", "r271", "r272" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.", "label": "Income Tax Disclosure [Text Block]", "terseLabel": "Income Taxes" } } }, "localname": "IncomeTaxDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.iradimed.com/role/DisclosureIncomeTaxes" ], "xbrltype": "textBlockItemType" }, "us-gaap_IncomeTaxExpenseBenefit": { "auth_ref": [ "r87", "r101", "r102", "r126", "r259", "r267", "r269", "r390" ], "calculation": { "http://www.iradimed.com/role/StatementCondensedStatementsOfOperations": { "order": 2.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.", "label": "Income Tax Expense (Benefit)", "terseLabel": "Provision for income tax expense (benefit)" } } }, "localname": "IncomeTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.iradimed.com/role/DisclosureIncomeTaxesDetails", "http://www.iradimed.com/role/StatementCondensedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeTaxesPaidNet": { "auth_ref": [ "r84" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income, net of any cash received during the current period as refunds for the overpayment of taxes.", "label": "Income Taxes Paid, Net", "terseLabel": "Cash paid for income taxes" } } }, "localname": "IncomeTaxesPaidNet", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.iradimed.com/role/StatementCondensedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccountsPayable": { "auth_ref": [ "r80" ], "calculation": { "http://www.iradimed.com/role/StatementCondensedStatementsOfCashFlows": { "order": 13.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.", "label": "Increase (Decrease) in Accounts Payable", "terseLabel": "Accounts payable" } } }, "localname": "IncreaseDecreaseInAccountsPayable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.iradimed.com/role/StatementCondensedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccountsReceivable": { "auth_ref": [ "r80" ], "calculation": { "http://www.iradimed.com/role/StatementCondensedStatementsOfCashFlows": { "order": 7.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.", "label": "Increase (Decrease) in Accounts Receivable", "negatedLabel": "Accounts receivable" } } }, "localname": "IncreaseDecreaseInAccountsReceivable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.iradimed.com/role/StatementCondensedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable": { "auth_ref": [ "r80" ], "calculation": { "http://www.iradimed.com/role/StatementCondensedStatementsOfCashFlows": { "order": 18.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the period in the amount due for taxes based on the reporting entity's earnings or attributable to the entity's income earning process (business presence) within a given jurisdiction.", "label": "Increase (Decrease) in Income Taxes Payable", "terseLabel": "Prepaid income taxes" } } }, "localname": "IncreaseDecreaseInAccruedIncomeTaxesPayable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.iradimed.com/role/StatementCondensedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInContractWithCustomerLiability": { "auth_ref": [ "r80" ], "calculation": { "http://www.iradimed.com/role/StatementCondensedStatementsOfCashFlows": { "order": 17.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable.", "label": "Increase (Decrease) in Contract with Customer, Liability", "terseLabel": "Deferred revenue" } } }, "localname": "IncreaseDecreaseInContractWithCustomerLiability", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.iradimed.com/role/StatementCondensedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInDeferredIncomeTaxes": { "auth_ref": [ "r80" ], "calculation": { "http://www.iradimed.com/role/StatementCondensedStatementsOfCashFlows": { "order": 11.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the account that represents the temporary difference that results from Income or Loss that is recognized for accounting purposes but not for tax purposes and vice versa.", "label": "Increase (Decrease) in Deferred Income Taxes", "negatedLabel": "Deferred income taxes, net" } } }, "localname": "IncreaseDecreaseInDeferredIncomeTaxes", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.iradimed.com/role/StatementCondensedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities": { "auth_ref": [ "r80" ], "calculation": { "http://www.iradimed.com/role/StatementCondensedStatementsOfCashFlows": { "order": 14.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the aggregate amount of obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits.", "label": "Increase (Decrease) in Employee Related Liabilities", "terseLabel": "Accrued payroll and benefits" } } }, "localname": "IncreaseDecreaseInEmployeeRelatedLiabilities", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.iradimed.com/role/StatementCondensedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInInventories": { "auth_ref": [ "r80" ], "calculation": { "http://www.iradimed.com/role/StatementCondensedStatementsOfCashFlows": { "order": 8.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.", "label": "Increase (Decrease) in Inventories", "negatedLabel": "Inventory" } } }, "localname": "IncreaseDecreaseInInventories", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.iradimed.com/role/StatementCondensedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Increase (Decrease) in Operating Capital [Abstract]", "terseLabel": "Changes in operating assets and liabilities:" } } }, "localname": "IncreaseDecreaseInOperatingCapitalAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.iradimed.com/role/StatementCondensedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_IncreaseDecreaseInOtherCurrentLiabilities": { "auth_ref": [ "r80" ], "calculation": { "http://www.iradimed.com/role/StatementCondensedStatementsOfCashFlows": { "order": 12.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in current liabilities classified as other.", "label": "Increase (Decrease) in Other Current Liabilities", "terseLabel": "Other current liability" } } }, "localname": "IncreaseDecreaseInOtherCurrentLiabilities", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.iradimed.com/role/StatementCondensedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInOtherOperatingAssets": { "auth_ref": [ "r80" ], "calculation": { "http://www.iradimed.com/role/StatementCondensedStatementsOfCashFlows": { "order": 10.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in operating assets classified as other.", "label": "Increase (Decrease) in Other Operating Assets", "negatedLabel": "Other assets" } } }, "localname": "IncreaseDecreaseInOtherOperatingAssets", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.iradimed.com/role/StatementCondensedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": { "auth_ref": [ "r80" ], "calculation": { "http://www.iradimed.com/role/StatementCondensedStatementsOfCashFlows": { "order": 9.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other.", "label": "Increase (Decrease) in Prepaid Expense and Other Assets", "negatedLabel": "Prepaid expenses and other current assets" } } }, "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.iradimed.com/role/StatementCondensedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInPropertyAndOtherTaxesPayable": { "auth_ref": [ "r80" ], "calculation": { "http://www.iradimed.com/role/StatementCondensedStatementsOfCashFlows": { "order": 15.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the period in the amount of cash payments due to taxing authorities for non-income-related taxes.", "label": "Increase (Decrease) in Property and Other Taxes Payable", "terseLabel": "Other accrued taxes" } } }, "localname": "IncreaseDecreaseInPropertyAndOtherTaxesPayable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.iradimed.com/role/StatementCondensedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Increase (Decrease) in Stockholders' Equity" } } }, "localname": "IncreaseDecreaseInStockholdersEquityRollForward", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.iradimed.com/role/StatementCondensedStatementsOfStockholdersEquity" ], "xbrltype": "stringItemType" }, "us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements": { "auth_ref": [ "r106", "r107", "r108", "r112" ], "calculation": { "http://www.iradimed.com/role/DisclosureBasicAndDilutedNetIncomePerShareDetails": { "order": 3.0, "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of share based payment arrangements using the treasury stock method.", "label": "Incremental Common Shares Attributable to Dilutive Effect of Share-based Payment Arrangements", "terseLabel": "Stock Options" } } }, "localname": "IncrementalCommonSharesAttributableToShareBasedPaymentArrangements", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.iradimed.com/role/DisclosureBasicAndDilutedNetIncomePerShareDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_IntangibleAssetsDisclosureTextBlock": { "auth_ref": [ "r183" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for all or part of the information related to intangible assets.", "label": "Intangible Assets Disclosure [Text Block]", "terseLabel": "Intangible Assets" } } }, "localname": "IntangibleAssetsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.iradimed.com/role/DisclosureIntangibleAssets" ], "xbrltype": "textBlockItemType" }, "us-gaap_InventoryAdjustments": { "auth_ref": [ "r43", "r169" ], "calculation": { "http://www.iradimed.com/role/DisclosureInventoryDetails": { "order": 2.0, "parentTag": "us-gaap_InventoryNet", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of inventory reserves for last-in first-out (LIFO) and other inventory valuation methods.", "label": "Inventory Adjustments", "negatedLabel": "Allowance for excess and obsolete" } } }, "localname": "InventoryAdjustments", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.iradimed.com/role/DisclosureInventoryDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Inventory" } } }, "localname": "InventoryDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_InventoryDisclosureTextBlock": { "auth_ref": [ "r171" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory.", "label": "Inventory Disclosure [Text Block]", "terseLabel": "Inventory" } } }, "localname": "InventoryDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.iradimed.com/role/DisclosureInventory" ], "xbrltype": "textBlockItemType" }, "us-gaap_InventoryFinishedGoods": { "auth_ref": [ "r39" ], "calculation": { "http://www.iradimed.com/role/DisclosureInventoryDetails": { "order": 2.0, "parentTag": "us-gaap_InventoryGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before valuation and LIFO reserves of completed merchandise or goods expected to be sold within one year or operating cycle, if longer.", "label": "Inventory, Finished Goods, Gross", "terseLabel": "Finished goods" } } }, "localname": "InventoryFinishedGoods", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.iradimed.com/role/DisclosureInventoryDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryGross": { "auth_ref": [ "r42" ], "calculation": { "http://www.iradimed.com/role/DisclosureInventoryDetails": { "order": 1.0, "parentTag": "us-gaap_InventoryNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Gross amount, as of the balance sheet date, of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.", "label": "Inventory, Gross", "totalLabel": "Inventory before allowance for excess and obsolete" } } }, "localname": "InventoryGross", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.iradimed.com/role/DisclosureInventoryDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryNet": { "auth_ref": [ "r3", "r42" ], "calculation": { "http://www.iradimed.com/role/DisclosureInventoryDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.iradimed.com/role/StatementCondensedBalanceSheets": { "order": 4.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.", "label": "Inventory, Net", "terseLabel": "Inventory, net", "totalLabel": "Total" } } }, "localname": "InventoryNet", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.iradimed.com/role/DisclosureInventoryDetails", "http://www.iradimed.com/role/StatementCondensedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryRawMaterials": { "auth_ref": [ "r41" ], "calculation": { "http://www.iradimed.com/role/DisclosureInventoryDetails": { "order": 1.0, "parentTag": "us-gaap_InventoryGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before valuation and LIFO reserves of raw materials expected to be sold, or consumed within one year or operating cycle, if longer.", "label": "Inventory, Raw Materials, Gross", "terseLabel": "Raw materials" } } }, "localname": "InventoryRawMaterials", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.iradimed.com/role/DisclosureInventoryDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryWorkInProcess": { "auth_ref": [ "r40" ], "calculation": { "http://www.iradimed.com/role/DisclosureInventoryDetails": { "order": 3.0, "parentTag": "us-gaap_InventoryGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before valuation and LIFO reserves of merchandise or goods in the production process expected to be completed within one year or operating cycle, if longer.", "label": "Inventory, Work in Process, Gross", "terseLabel": "Work in process" } } }, "localname": "InventoryWorkInProcess", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.iradimed.com/role/DisclosureInventoryDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryWriteDown": { "auth_ref": [ "r170" ], "calculation": { "http://www.iradimed.com/role/StatementCondensedStatementsOfCashFlows": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of loss from reductions in inventory due to subsequent measurement adjustments, including, but not limited to, physical deterioration, obsolescence, or changes in price levels.", "label": "Inventory Write-down", "terseLabel": "Change in provision for excess and obsolete inventory" } } }, "localname": "InventoryWriteDown", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.iradimed.com/role/StatementCondensedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_InvestmentHoldingsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Investment Holdings [Line Items]", "terseLabel": "Investments" } } }, "localname": "InvestmentHoldingsLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.iradimed.com/role/DisclosureInvestmentsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_InvestmentHoldingsTable": { "auth_ref": [ "r401", "r402", "r403", "r404" ], "lang": { "en-us": { "role": { "documentation": "The investment holdings table is used for any listing of investments. The \"Investment [Axis]\" identifies the investment for which the line items apply. The other axes are used for categorizing the investments and creating useful subtotals. These axes cover different categorizations. The appropriate axes are expected to be used. Additional axes can be added for alternative categorizations.", "label": "Investment Holdings [Table]" } } }, "localname": "InvestmentHoldingsTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.iradimed.com/role/DisclosureInvestmentsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Investments" } } }, "localname": "InvestmentsDebtAndEquitySecuritiesAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock": { "auth_ref": [ "r154", "r368", "r378", "r405" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for investments in certain debt and equity securities.", "label": "Investments in Debt and Marketable Equity Securities (and Certain Trading Assets) Disclosure [Text Block]", "terseLabel": "Investments" } } }, "localname": "InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.iradimed.com/role/DisclosureInvestments" ], "xbrltype": "textBlockItemType" }, "us-gaap_LeaseCostTableTextBlock": { "auth_ref": [ "r314" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.", "label": "Lease, Cost [Table Text Block]", "terseLabel": "Schedule of operating lease cost" } } }, "localname": "LeaseCostTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.iradimed.com/role/DisclosureLeasesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_LeaseholdImprovementsMember": { "auth_ref": [ "r185" ], "lang": { "en-us": { "role": { "documentation": "Additions or improvements to assets held under a lease arrangement.", "label": "Leasehold Improvements [Member]", "terseLabel": "Leasehold improvements" } } }, "localname": "LeaseholdImprovementsMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.iradimed.com/role/DisclosurePropertyAndEquipmentDetails" ], "xbrltype": "domainItemType" }, "us-gaap_LeasesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Leases" } } }, "localname": "LeasesAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_LesseeLeaseDescriptionLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Lessee, Lease, Description [Line Items]", "terseLabel": "Leases" } } }, "localname": "LesseeLeaseDescriptionLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.iradimed.com/role/DisclosureLeasesDetails", "http://www.iradimed.com/role/DisclosureLeasesOperatingLeaseCostDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LesseeLeaseDescriptionTable": { "auth_ref": [ "r310" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about lessee's leases.", "label": "Lessee, Lease, Description [Table]" } } }, "localname": "LesseeLeaseDescriptionTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.iradimed.com/role/DisclosureLeasesDetails", "http://www.iradimed.com/role/DisclosureLeasesOperatingLeaseCostDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend": { "auth_ref": [ "r308" ], "lang": { "en-us": { "role": { "documentation": "Indicates (true false) whether lessee has option to extend operating lease.", "label": "Lessee, Operating Lease, Existence of Option to Extend [true false]", "terseLabel": "Lessee, operating lease, existence of option to extend" } } }, "localname": "LesseeOperatingLeaseExistenceOfOptionToExtend", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.iradimed.com/role/DisclosureLeasesDetails" ], "xbrltype": "booleanItemType" }, "us-gaap_LesseeOperatingLeaseExistenceOfResidualValueGuarantee": { "auth_ref": [ "r309" ], "lang": { "en-us": { "role": { "documentation": "Indicates (true false) whether lessee provided residual value guarantee for operating lease.", "label": "Lessee, Operating Lease, Existence of Residual Value Guarantee [true false]", "terseLabel": "Lessee, operating lease, existence of residual value guarantee" } } }, "localname": "LesseeOperatingLeaseExistenceOfResidualValueGuarantee", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.iradimed.com/role/DisclosureLeasesDetails" ], "xbrltype": "booleanItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": { "auth_ref": [ "r315" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.", "label": "Lessee, Operating Lease, Liability, Maturity [Table Text Block]", "terseLabel": "Schedule of maturity of operating lease liability" } } }, "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.iradimed.com/role/DisclosureLeasesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": { "auth_ref": [ "r315" ], "calculation": { "http://www.iradimed.com/role/DisclosureLeasesMaturityOfLeaseLiabilitiesDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.iradimed.com/role/DisclosureLeasesMaturityOfLeaseLiabilitiesDetailsCalc2": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease.", "label": "Lessee, Operating Lease, Liability, Payments, Due", "totalLabel": "Total lease payments" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDue", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.iradimed.com/role/DisclosureLeasesMaturityOfLeaseLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive": { "auth_ref": [ "r315" ], "calculation": { "http://www.iradimed.com/role/DisclosureLeasesMaturityOfLeaseLiabilitiesDetails": { "order": 6.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease due after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Lessee, Operating Lease, Liability, Payments, Due after Year Five", "terseLabel": "Thereafter" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.iradimed.com/role/DisclosureLeasesMaturityOfLeaseLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": { "auth_ref": [ "r315" ], "calculation": { "http://www.iradimed.com/role/DisclosureLeasesMaturityOfLeaseLiabilitiesDetails": { "order": 2.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Lessee, Operating Lease, Liability, Payments, Due Next Twelve Months", "terseLabel": "2022" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.iradimed.com/role/DisclosureLeasesMaturityOfLeaseLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": { "auth_ref": [ "r315" ], "calculation": { "http://www.iradimed.com/role/DisclosureLeasesMaturityOfLeaseLiabilitiesDetails": { "order": 5.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Lessee, Operating Lease, Liability, Payments, Due Year Four", "terseLabel": "2025" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.iradimed.com/role/DisclosureLeasesMaturityOfLeaseLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": { "auth_ref": [ "r315" ], "calculation": { "http://www.iradimed.com/role/DisclosureLeasesMaturityOfLeaseLiabilitiesDetails": { "order": 4.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Lessee, Operating Lease, Liability, Payments, Due Year Three", "terseLabel": "2024" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.iradimed.com/role/DisclosureLeasesMaturityOfLeaseLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": { "auth_ref": [ "r315" ], "calculation": { "http://www.iradimed.com/role/DisclosureLeasesMaturityOfLeaseLiabilitiesDetails": { "order": 3.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Lessee, Operating Lease, Liability, Payments, Due Year Two", "terseLabel": "2023" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.iradimed.com/role/DisclosureLeasesMaturityOfLeaseLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear": { "auth_ref": [ "r315" ], "calculation": { "http://www.iradimed.com/role/DisclosureLeasesMaturityOfLeaseLiabilitiesDetails": { "order": 1.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease having initial or remaining lease term in excess of one year to be paid in remainder of current fiscal year.", "label": "Lessee, Operating Lease, Liability, Payments, Remainder of Fiscal Year", "terseLabel": "Six months ending December 31, 2021" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.iradimed.com/role/DisclosureLeasesMaturityOfLeaseLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": { "auth_ref": [ "r315" ], "calculation": { "http://www.iradimed.com/role/DisclosureLeasesMaturityOfLeaseLiabilitiesDetailsCalc2": { "order": 1.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.", "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount", "negatedLabel": "Imputed interest" } } }, "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.iradimed.com/role/DisclosureLeasesMaturityOfLeaseLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseRemainingLeaseTerm": { "auth_ref": [ "r307" ], "lang": { "en-us": { "role": { "documentation": "Remaining lease term of operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Lessee Operating Lease Remaining Lease Term", "terseLabel": "Remaining lease term (in years)" } } }, "localname": "LesseeOperatingLeaseRemainingLeaseTerm", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.iradimed.com/role/DisclosureLeasesDetails" ], "xbrltype": "durationItemType" }, "us-gaap_LesseeOperatingLeasesTextBlock": { "auth_ref": [ "r317" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.", "label": "Lessee, Operating Leases [Text Block]", "terseLabel": "Leases" } } }, "localname": "LesseeOperatingLeasesTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.iradimed.com/role/DisclosureLeases" ], "xbrltype": "textBlockItemType" }, "us-gaap_Liabilities": { "auth_ref": [ "r35", "r86", "r131", "r155", "r277", "r282", "r283", "r295" ], "calculation": { "http://www.iradimed.com/role/StatementCondensedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.", "label": "Liabilities", "totalLabel": "Total liabilities" } } }, "localname": "Liabilities", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.iradimed.com/role/StatementCondensedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquity": { "auth_ref": [ "r23", "r86", "r155", "r295", "r370", "r383" ], "calculation": { "http://www.iradimed.com/role/StatementCondensedBalanceSheets": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.", "label": "Liabilities and Equity", "totalLabel": "Total liabilities and stockholders' equity" } } }, "localname": "LiabilitiesAndStockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.iradimed.com/role/StatementCondensedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Liabilities and Equity [Abstract]", "terseLabel": "LIABILITIES AND STOCKHOLDERS' EQUITY" } } }, "localname": "LiabilitiesAndStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.iradimed.com/role/StatementCondensedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_LiabilitiesCurrent": { "auth_ref": [ "r37", "r86", "r155", "r277", "r282", "r283", "r295" ], "calculation": { "http://www.iradimed.com/role/StatementCondensedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.", "label": "Liabilities, Current", "totalLabel": "Total current liabilities" } } }, "localname": "LiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.iradimed.com/role/StatementCondensedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Liabilities, Current [Abstract]", "terseLabel": "Current liabilities:" } } }, "localname": "LiabilitiesCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.iradimed.com/role/StatementCondensedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_LongLivedAssetsByGeographicAreasTableTextBlock": { "auth_ref": [ "r141" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of long-lived assets, excluding financial instruments, long-term customer relationships of a financial institution, mortgage rights, deferred policy acquisition costs, and deferred tax assets, by geographic areas located in the entity's country of domicile and foreign countries in which the entity holds assets.", "label": "Long-lived Assets by Geographic Areas [Table Text Block]", "terseLabel": "Schedule of property and equipment, net, information by geographic region" } } }, "localname": "LongLivedAssetsByGeographicAreasTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.iradimed.com/role/DisclosurePropertyAndEquipmentTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_MachineryAndEquipmentMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tangible personal property used to produce goods and services, including, but is not limited to, tools, dies and molds, computer and office equipment.", "label": "Machinery And Equipment [Member]", "terseLabel": "Machinery and equipment" } } }, "localname": "MachineryAndEquipmentMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.iradimed.com/role/DisclosurePropertyAndEquipmentDetails" ], "xbrltype": "domainItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivities": { "auth_ref": [ "r78" ], "calculation": { "http://www.iradimed.com/role/StatementCondensedStatementsOfCashFlows": { "order": 3.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.", "label": "Net Cash Provided by (Used in) Financing Activities, Continuing Operations", "totalLabel": "Net cash used in financing activities" } } }, "localname": "NetCashProvidedByUsedInFinancingActivities", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.iradimed.com/role/StatementCondensedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Financing Activities, Continuing Operations [Abstract]", "terseLabel": "Financing activities:" } } }, "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.iradimed.com/role/StatementCondensedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivities": { "auth_ref": [ "r78" ], "calculation": { "http://www.iradimed.com/role/StatementCondensedStatementsOfCashFlows": { "order": 2.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.", "label": "Net Cash Provided by (Used in) Investing Activities", "totalLabel": "Net cash provided by investing activities" } } }, "localname": "NetCashProvidedByUsedInInvestingActivities", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.iradimed.com/role/StatementCondensedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Investing Activities, Continuing Operations [Abstract]", "terseLabel": "Investing activities:" } } }, "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.iradimed.com/role/StatementCondensedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivities": { "auth_ref": [ "r78", "r79", "r82" ], "calculation": { "http://www.iradimed.com/role/StatementCondensedStatementsOfCashFlows": { "order": 1.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.", "label": "Net Cash Provided by (Used in) Operating Activities, Continuing Operations", "totalLabel": "Net cash provided by operating activities" } } }, "localname": "NetCashProvidedByUsedInOperatingActivities", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.iradimed.com/role/StatementCondensedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Operating Activities, Continuing Operations [Abstract]", "terseLabel": "Operating activities:" } } }, "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.iradimed.com/role/StatementCondensedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetIncomeLoss": { "auth_ref": [ "r0", "r53", "r56", "r62", "r82", "r86", "r93", "r95", "r96", "r97", "r98", "r101", "r102", "r109", "r127", "r129", "r132", "r135", "r137", "r155", "r295", "r373", "r385" ], "calculation": { "http://www.iradimed.com/role/StatementCondensedStatementsOfComprehensiveIncome": { "order": 2.0, "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0 }, "http://www.iradimed.com/role/StatementCondensedStatementsOfOperations": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.", "label": "Net Income (Loss) Attributable to Parent", "terseLabel": "Net income (loss)", "totalLabel": "Net income (loss)" } } }, "localname": "NetIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.iradimed.com/role/DisclosureBasicAndDilutedNetIncomePerShareDetails", "http://www.iradimed.com/role/StatementCondensedStatementsOfComprehensiveIncome", "http://www.iradimed.com/role/StatementCondensedStatementsOfOperations", "http://www.iradimed.com/role/StatementCondensedStatementsOfStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.", "label": "New Accounting Pronouncements, Policy [Policy Text Block]", "terseLabel": "Recent Accounting Pronouncements" } } }, "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.iradimed.com/role/DisclosureBasisOfPresentationPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_NonoperatingIncomeExpense": { "auth_ref": [ "r71" ], "calculation": { "http://www.iradimed.com/role/StatementCondensedStatementsOfOperations": { "order": 2.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).", "label": "Nonoperating Income (Expense)", "terseLabel": "Other income, net" } } }, "localname": "NonoperatingIncomeExpense", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.iradimed.com/role/StatementCondensedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_NumberOfReportableSegments": { "auth_ref": [ "r122" ], "lang": { "en-us": { "role": { "documentation": "Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements.", "label": "Number of Reportable Segments", "terseLabel": "Number of reportable segment" } } }, "localname": "NumberOfReportableSegments", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.iradimed.com/role/DisclosureBasisOfPresentationDetails" ], "xbrltype": "integerItemType" }, "us-gaap_OperatingExpenses": { "auth_ref": [], "calculation": { "http://www.iradimed.com/role/StatementCondensedStatementsOfOperations": { "order": 2.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.", "label": "Operating Expenses", "totalLabel": "Total operating expenses" } } }, "localname": "OperatingExpenses", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.iradimed.com/role/StatementCondensedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingExpensesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Operating Expenses [Abstract]", "terseLabel": "Operating expenses:" } } }, "localname": "OperatingExpensesAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.iradimed.com/role/StatementCondensedStatementsOfOperations" ], "xbrltype": "stringItemType" }, "us-gaap_OperatingIncomeLoss": { "auth_ref": [ "r127", "r129", "r132", "r135", "r137" ], "calculation": { "http://www.iradimed.com/role/StatementCondensedStatementsOfOperations": { "order": 1.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The net result for the period of deducting operating expenses from operating revenues.", "label": "Operating Income (Loss)", "totalLabel": "Income (loss) from operations" } } }, "localname": "OperatingIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.iradimed.com/role/StatementCondensedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseCost": { "auth_ref": [ "r311", "r316" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.", "label": "Operating Lease cost", "terseLabel": "Operating lease cost" } } }, "localname": "OperatingLeaseCost", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.iradimed.com/role/DisclosureLeasesOperatingLeaseCostDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Operating Lease Liabilities, Payments Due [Abstract]", "terseLabel": "Operating leases" } } }, "localname": "OperatingLeaseLiabilitiesPaymentsDueAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.iradimed.com/role/DisclosureLeasesMaturityOfLeaseLiabilitiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_OperatingLeaseLiability": { "auth_ref": [ "r305" ], "calculation": { "http://www.iradimed.com/role/DisclosureLeasesMaturityOfLeaseLiabilitiesDetailsCalc2": { "order": 2.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease.", "label": "Operating Lease, Liability", "verboseLabel": "Present value of lease liability" } } }, "localname": "OperatingLeaseLiability", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.iradimed.com/role/DisclosureLeasesMaturityOfLeaseLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiabilityCurrent": { "auth_ref": [ "r305" ], "calculation": { "http://www.iradimed.com/role/StatementCondensedBalanceSheets": { "order": 6.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.", "label": "Operating Lease, Liability, Current", "terseLabel": "Current portion of operating lease liability" } } }, "localname": "OperatingLeaseLiabilityCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.iradimed.com/role/StatementCondensedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiabilityNoncurrent": { "auth_ref": [ "r305" ], "calculation": { "http://www.iradimed.com/role/StatementCondensedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.", "label": "Operating Lease, Liability, Noncurrent", "terseLabel": "Operating lease liability, less current portion" } } }, "localname": "OperatingLeaseLiabilityNoncurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.iradimed.com/role/StatementCondensedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeasePayments": { "auth_ref": [ "r306", "r312" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.", "label": "Operating Lease, Payments", "terseLabel": "Operating and short-term lease payments recorded within cash flow provided by operating activities" } } }, "localname": "OperatingLeasePayments", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.iradimed.com/role/StatementCondensedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseRightOfUseAsset": { "auth_ref": [ "r304" ], "calculation": { "http://www.iradimed.com/role/StatementCondensedBalanceSheets": { "order": 4.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's right to use underlying asset under operating lease.", "label": "Operating Lease, Right-of-Use Asset", "terseLabel": "Operating lease right-of-use asset, net" } } }, "localname": "OperatingLeaseRightOfUseAsset", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.iradimed.com/role/StatementCondensedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Basis of Presentation" } } }, "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock": { "auth_ref": [ "r1", "r89", "r121", "r286" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for the organization, consolidation and basis of presentation of financial statements disclosure, and significant accounting policies of the reporting entity. May be provided in more than one note to the financial statements, as long as users are provided with an understanding of (1) the significant judgments and assumptions made by an enterprise in determining whether it must consolidate a VIE and/or disclose information about its involvement with a VIE, (2) the nature of restrictions on a consolidated VIE's assets reported by an enterprise in its statement of financial position, including the carrying amounts of such assets, (3) the nature of, and changes in, the risks associated with an enterprise's involvement with the VIE, and (4) how an enterprise's involvement with the VIE affects the enterprise's financial position, financial performance, and cash flows. Describes procedure if disclosures are provided in more than one note to the financial statements.", "label": "Organization, Consolidation and Presentation of Financial Statements Disclosure and Significant Accounting Policies [Text Block]", "terseLabel": "Basis of Presentation" } } }, "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.iradimed.com/role/DisclosureBasisOfPresentation" ], "xbrltype": "textBlockItemType" }, "us-gaap_OtherAssetsNoncurrent": { "auth_ref": [ "r33" ], "calculation": { "http://www.iradimed.com/role/StatementCondensedBalanceSheets": { "order": 6.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of noncurrent assets classified as other.", "label": "Other Assets, Noncurrent", "terseLabel": "Other assets" } } }, "localname": "OtherAssetsNoncurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.iradimed.com/role/StatementCondensedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent": { "auth_ref": [ "r274", "r275", "r280" ], "calculation": { "http://www.iradimed.com/role/StatementCondensedStatementsOfComprehensiveIncome": { "order": 2.0, "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after tax and reclassification adjustments, of appreciation (loss) in value of unsold available-for-sale securities, attributable to parent entity. Excludes amounts related to other than temporary impairment (OTTI) loss.", "label": "Other Comprehensive Income (Loss), Available-for-sale Securities Adjustment, Net of Tax, Portion Attributable to Parent", "terseLabel": "Change in fair value of available-for-sale securities, net of tax expense (benefit) of $5,772 and $4,227 for the three months ended June 30, 2021 and 2020, respectively, and $(7,331) and $7,669 for the six months ended June 30, 2021 and 2020, respectively", "verboseLabel": "Gains (Loss) on available-for-sale securities, net" } } }, "localname": "OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.iradimed.com/role/DisclosureAccumulatedOtherComprehensiveIncomeDetails", "http://www.iradimed.com/role/StatementCondensedStatementsOfComprehensiveIncome" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesTaxPortionAttributableToParent": { "auth_ref": [ "r274", "r275", "r280" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of tax expense (benefit), after reclassification adjustments, of appreciation (loss) in value of unsold available-for-sale securities, attributable to parent entity. Excludes amounts related to other than temporary impairment (OTTI) loss.", "label": "Other Comprehensive Income (Loss), Available-for-sale Securities, Tax, Portion Attributable to Parent", "terseLabel": "Change in fair value of available-for-sale securities, net of tax expense" } } }, "localname": "OtherComprehensiveIncomeAvailableforsaleSecuritiesTaxPortionAttributableToParent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.iradimed.com/role/StatementCondensedStatementsOfComprehensiveIncomeParenthetical" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossNetOfTax": { "auth_ref": [ "r54", "r57", "r59", "r63", "r197", "r297", "r302", "r303", "r374", "r386" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after tax and reclassification adjustments of other comprehensive income (loss).", "label": "Other Comprehensive Income (Loss), Net of Tax", "verboseLabel": "Other comprehensive income (loss)" } } }, "localname": "OtherComprehensiveIncomeLossNetOfTax", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.iradimed.com/role/StatementCondensedStatementsOfStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent": { "auth_ref": [ "r54", "r57", "r274", "r275", "r280" ], "calculation": { "http://www.iradimed.com/role/StatementCondensedStatementsOfComprehensiveIncome": { "order": 1.0, "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after tax of other comprehensive income (loss) attributable to parent entity.", "label": "Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent", "totalLabel": "Other comprehensive income" } } }, "localname": "OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.iradimed.com/role/StatementCondensedStatementsOfComprehensiveIncome" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax": { "auth_ref": [ "r46", "r50", "r51", "r152" ], "calculation": { "http://www.iradimed.com/role/StatementCondensedStatementsOfComprehensiveIncome": { "order": 1.0, "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after tax of reclassification adjustment from accumulated other comprehensive income for unrealized gain (loss) realized upon the sale of available-for-sale securities.", "label": "Other Comprehensive Income (Loss), Reclassification Adjustment from AOCI for Sale of Securities, Net of Tax", "negatedLabel": "Realized gain on available-for-sale securities reclassified to net income, net of tax expense of $3,176 and $2,199 for the three months ended June 30, 2021 and 2020, respectively, and $3,176 and $2,199 for the six months ended June 30, 2021 and 2020, respectively" } } }, "localname": "OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.iradimed.com/role/StatementCondensedStatementsOfComprehensiveIncome" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesTax": { "auth_ref": [ "r47", "r152" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of tax expense (benefit) of reclassification adjustment from accumulated other comprehensive income for unrealized gain (loss) realized upon the sale of available-for-sale securities.", "label": "Other Comprehensive Income (Loss), Reclassification Adjustment from AOCI for Sale of Securities, Tax", "terseLabel": "Realized gain on available-for-sale securities reclassified to net income, net of tax expense (benefit)" } } }, "localname": "OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesTax", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.iradimed.com/role/StatementCondensedStatementsOfComprehensiveIncomeParenthetical" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherLiabilitiesCurrent": { "auth_ref": [ "r9", "r10", "r36" ], "calculation": { "http://www.iradimed.com/role/StatementCondensedBalanceSheets": { "order": 7.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.", "label": "Other Liabilities, Current", "terseLabel": "Other current liabilities" } } }, "localname": "OtherLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.iradimed.com/role/StatementCondensedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation": { "auth_ref": [ "r76" ], "calculation": { "http://www.iradimed.com/role/StatementCondensedStatementsOfCashFlows": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash outflow to satisfy grantee's tax withholding obligation for award under share-based payment arrangement.", "label": "Payments Related to Tax Withholding for Share-based Compensation", "terseLabel": "Taxes paid related to the net share settlement of equity awards" } } }, "localname": "PaymentsRelatedToTaxWithholdingForShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.iradimed.com/role/StatementCondensedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquireOtherProductiveAssets": { "auth_ref": [ "r74" ], "calculation": { "http://www.iradimed.com/role/StatementCondensedStatementsOfCashFlows": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash outflow for the purchase of or improvements to tangible or intangible assets, used to produce goods or deliver services, classified as other.", "label": "Payments to Acquire Other Productive Assets", "negatedLabel": "Capitalized intangible assets" } } }, "localname": "PaymentsToAcquireOtherProductiveAssets", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.iradimed.com/role/StatementCondensedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": { "auth_ref": [ "r74" ], "calculation": { "http://www.iradimed.com/role/StatementCondensedStatementsOfCashFlows": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.", "label": "Payments to Acquire Property, Plant, and Equipment", "negatedLabel": "Purchases of property and equipment" } } }, "localname": "PaymentsToAcquirePropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.iradimed.com/role/StatementCondensedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": { "auth_ref": [ "r6", "r28", "r29" ], "calculation": { "http://www.iradimed.com/role/StatementCondensedBalanceSheets": { "order": 5.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.", "label": "Prepaid Expense and Other Assets, Current", "terseLabel": "Prepaid expenses and other current assets" } } }, "localname": "PrepaidExpenseAndOtherAssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.iradimed.com/role/StatementCondensedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_PrepaidTaxes": { "auth_ref": [ "r5", "r7", "r172", "r173" ], "calculation": { "http://www.iradimed.com/role/StatementCondensedBalanceSheets": { "order": 6.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of asset related to consideration paid in advance for income and other taxes that provide economic benefits within a future period of one year or the normal operating cycle, if longer.", "label": "Prepaid Taxes", "terseLabel": "Prepaid income taxes" } } }, "localname": "PrepaidTaxes", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.iradimed.com/role/StatementCondensedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments": { "auth_ref": [ "r73" ], "calculation": { "http://www.iradimed.com/role/StatementCondensedStatementsOfCashFlows": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow associated with the sale, maturity and collection of all investments such as debt, security and so forth during the period.", "label": "Proceeds from Sale, Maturity and Collection of Investments", "terseLabel": "Proceeds from maturity of investments" } } }, "localname": "ProceedsFromSaleMaturityAndCollectionsOfInvestments", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.iradimed.com/role/StatementCondensedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromStockOptionsExercised": { "auth_ref": [ "r75", "r246" ], "calculation": { "http://www.iradimed.com/role/StatementCondensedStatementsOfCashFlows": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement.", "label": "Proceeds from Stock Options Exercised", "terseLabel": "Proceeds from exercises of stock options" } } }, "localname": "ProceedsFromStockOptionsExercised", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.iradimed.com/role/StatementCondensedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProductWarrantyAccrualClassifiedCurrent": { "auth_ref": [ "r36", "r194", "r195" ], "calculation": { "http://www.iradimed.com/role/StatementCondensedBalanceSheets": { "order": 5.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for estimated claims under standard and extended warranty protection rights granted to customers. For classified balance sheets, represents the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Product Warranty Accrual, Current", "terseLabel": "Warranty reserve" } } }, "localname": "ProductWarrantyAccrualClassifiedCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.iradimed.com/role/StatementCondensedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProfitLoss": { "auth_ref": [ "r0", "r53", "r56", "r77", "r86", "r93", "r101", "r102", "r127", "r129", "r132", "r135", "r137", "r155", "r274", "r278", "r279", "r284", "r285", "r295", "r377" ], "calculation": { "http://www.iradimed.com/role/StatementCondensedStatementsOfCashFlows": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.", "label": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest", "verboseLabel": "Net income (loss)" } } }, "localname": "ProfitLoss", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.iradimed.com/role/StatementCondensedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Property and Equipment" } } }, "localname": "PropertyPlantAndEquipmentAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_PropertyPlantAndEquipmentByTypeAxis": { "auth_ref": [ "r32", "r187" ], "lang": { "en-us": { "role": { "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale.", "label": "Property, Plant and Equipment, Type [Axis]" } } }, "localname": "PropertyPlantAndEquipmentByTypeAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.iradimed.com/role/DisclosureLeasesDetails", "http://www.iradimed.com/role/DisclosurePropertyAndEquipmentDetails" ], "xbrltype": "stringItemType" }, "us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock": { "auth_ref": [ "r189", "r407", "r408", "r409" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.", "label": "Property, Plant and Equipment Disclosure [Text Block]", "terseLabel": "Property and Equipment" } } }, "localname": "PropertyPlantAndEquipmentDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.iradimed.com/role/DisclosurePropertyAndEquipment" ], "xbrltype": "textBlockItemType" }, "us-gaap_PropertyPlantAndEquipmentGross": { "auth_ref": [ "r31", "r185" ], "calculation": { "http://www.iradimed.com/role/DisclosurePropertyAndEquipmentDetails": { "order": 1.0, "parentTag": "us-gaap_PropertyPlantAndEquipmentNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.", "label": "Property, Plant and Equipment, Gross", "terseLabel": "Property and equipment, gross" } } }, "localname": "PropertyPlantAndEquipmentGross", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.iradimed.com/role/DisclosurePropertyAndEquipmentDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Property, Plant and Equipment [Line Items]", "terseLabel": "Property and equipment" } } }, "localname": "PropertyPlantAndEquipmentLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.iradimed.com/role/DisclosurePropertyAndEquipmentDetails", "http://www.iradimed.com/role/DisclosurePropertyAndEquipmentGeographicInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_PropertyPlantAndEquipmentNet": { "auth_ref": [ "r13", "r14", "r187", "r384" ], "calculation": { "http://www.iradimed.com/role/DisclosurePropertyAndEquipmentDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.iradimed.com/role/StatementCondensedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.", "label": "Property, Plant and Equipment, Net", "terseLabel": "Property and equipment, net", "totalLabel": "Total", "verboseLabel": "Total property and equipment, net" } } }, "localname": "PropertyPlantAndEquipmentNet", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.iradimed.com/role/DisclosurePropertyAndEquipmentDetails", "http://www.iradimed.com/role/DisclosurePropertyAndEquipmentGeographicInformationDetails", "http://www.iradimed.com/role/StatementCondensedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentTextBlock": { "auth_ref": [ "r13", "r187" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.", "label": "Property, Plant and Equipment [Table Text Block]", "terseLabel": "Schedule of property and equipment" } } }, "localname": "PropertyPlantAndEquipmentTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.iradimed.com/role/DisclosurePropertyAndEquipmentTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_PropertyPlantAndEquipmentTypeDomain": { "auth_ref": [ "r13", "r185" ], "lang": { "en-us": { "role": { "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.", "label": "Property Plant And Equipment Type [Domain]", "terseLabel": "Property, Plant and Equipment, Type [Domain]" } } }, "localname": "PropertyPlantAndEquipmentTypeDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.iradimed.com/role/DisclosureLeasesDetails", "http://www.iradimed.com/role/DisclosurePropertyAndEquipmentDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ProvisionForDoubtfulAccounts": { "auth_ref": [ "r67", "r159" ], "calculation": { "http://www.iradimed.com/role/StatementCondensedStatementsOfCashFlows": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of expense (reversal of expense) for expected credit loss on accounts receivable.", "label": "Provision for Doubtful Accounts", "verboseLabel": "Change in allowance for doubtful accounts" } } }, "localname": "ProvisionForDoubtfulAccounts", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.iradimed.com/role/StatementCondensedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PurchaseObligation": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Minimum amount of purchase arrangement in which the entity has agreed to expend funds to procure goods or services from a supplier.", "label": "Purchase Obligation", "terseLabel": "Purchase commitments" } } }, "localname": "PurchaseObligation", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.iradimed.com/role/DisclosureCommitmentsAndContingenciesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RealizedInvestmentGainsLosses": { "auth_ref": [ "r391" ], "calculation": { "http://www.iradimed.com/role/StatementCondensedStatementsOfCashFlows": { "order": 6.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of realized gain (loss) on investment.", "label": "Realized Investment Gains (Losses)", "negatedLabel": "Gain on maturities of investments" } } }, "localname": "RealizedInvestmentGainsLosses", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.iradimed.com/role/StatementCondensedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent": { "auth_ref": [ "r49", "r59" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after tax of reclassification adjustments of other comprehensive income (loss) attributable to parent.", "label": "Reclassification from Accumulated Other Comprehensive Income, Current Period, Net of Tax", "negatedLabel": "Reclassification realized in net earnings" } } }, "localname": "ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.iradimed.com/role/DisclosureAccumulatedOtherComprehensiveIncomeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RelatedPartyDomain": { "auth_ref": [ "r228", "r318", "r319" ], "lang": { "en-us": { "role": { "documentation": "Related parties include affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.", "label": "Related Party [Domain]", "terseLabel": "Related Party [Domain]" } } }, "localname": "RelatedPartyDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.iradimed.com/role/DisclosureLeasesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": { "auth_ref": [ "r228", "r318", "r321", "r355", "r356", "r357", "r358", "r359", "r360", "r361", "r362", "r363", "r364", "r365", "r366" ], "lang": { "en-us": { "role": { "documentation": "Information by type of related party. Related parties include, but not limited to, affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.", "label": "Related Party [Axis]" } } }, "localname": "RelatedPartyTransactionsByRelatedPartyAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.iradimed.com/role/DisclosureLeasesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ResearchAndDevelopmentExpense": { "auth_ref": [ "r256", "r419" ], "calculation": { "http://www.iradimed.com/role/StatementCondensedStatementsOfOperations": { "order": 3.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.", "label": "Research and Development Expense", "terseLabel": "Research and development" } } }, "localname": "ResearchAndDevelopmentExpense", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.iradimed.com/role/StatementCondensedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_ResearchAndDevelopmentExpenseMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included.", "label": "Research And Development Expense [Member]", "terseLabel": "Research and development" } } }, "localname": "ResearchAndDevelopmentExpenseMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.iradimed.com/role/DisclosureLeasesOperatingLeaseCostDetails", "http://www.iradimed.com/role/DisclosureStockBasedCompensationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number, after shares used to satisfy grantee's tax withholding obligation for award under share-based payment arrangement, of restricted shares issued. Excludes cash used to satisfy grantee's tax withholding obligation.", "label": "Restricted Stock, Shares Issued Net of Shares for Tax Withholdings", "verboseLabel": "Net share settlement of restricted stock units (in shares)" } } }, "localname": "RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.iradimed.com/role/StatementCondensedStatementsOfStockholdersEquity" ], "xbrltype": "sharesItemType" }, "us-gaap_RestrictedStockUnitsRSUMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met.", "label": "Restricted Stock Units R S U [Member]", "terseLabel": "Restricted Stock Units" } } }, "localname": "RestrictedStockUnitsRSUMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.iradimed.com/role/DisclosureStockBasedCompensationStockOptionsAndRestrictedStockUnitsActivityDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RestrictedStockValueSharesIssuedNetOfTaxWithholdings": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value, after value of shares used to satisfy grantee's tax withholding obligation for award under share-based payment arrangement, of restricted shares issued. Excludes cash used to satisfy grantee's tax withholding obligation.", "label": "Restricted Stock, Value, Shares Issued Net of Tax Withholdings", "terseLabel": "Net share settlement of restricted stock units" } } }, "localname": "RestrictedStockValueSharesIssuedNetOfTaxWithholdings", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.iradimed.com/role/StatementCondensedStatementsOfStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_RetainedEarningsAccumulatedDeficit": { "auth_ref": [ "r19", "r198", "r250", "r382", "r398", "r400" ], "calculation": { "http://www.iradimed.com/role/StatementCondensedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Retained Earnings (Accumulated Deficit)", "terseLabel": "Retained earnings" } } }, "localname": "RetainedEarningsAccumulatedDeficit", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.iradimed.com/role/StatementCondensedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_RetainedEarningsMember": { "auth_ref": [ "r90", "r91", "r92", "r94", "r100", "r102", "r156", "r247", "r248", "r249", "r264", "r265", "r395", "r397" ], "lang": { "en-us": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Retained Earnings [Member]", "terseLabel": "Retained Earnings" } } }, "localname": "RetainedEarningsMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.iradimed.com/role/StatementCondensedStatementsOfStockholdersEquity" ], "xbrltype": "domainItemType" }, "us-gaap_RevenueFromContractWithCustomerAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Revenue Recognition" } } }, "localname": "RevenueFromContractWithCustomerAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": { "auth_ref": [ "r123", "r124", "r128", "r133", "r134", "r138", "r139", "r142", "r209", "r210", "r352" ], "calculation": { "http://www.iradimed.com/role/DisclosureRevenueRecognitionInformationByTypeDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.", "label": "Revenue from Contract with Customer, Excluding Assessed Tax", "terseLabel": "Total revenue", "totalLabel": "Total revenue" } } }, "localname": "RevenueFromContractWithCustomerExcludingAssessedTax", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.iradimed.com/role/DisclosureRevenueRecognitionInformationByGeographicRegionDetails", "http://www.iradimed.com/role/DisclosureRevenueRecognitionInformationByTypeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RevenueFromContractWithCustomerTextBlock": { "auth_ref": [ "r201", "r202", "r203", "r204", "r205", "r206", "r207", "r208", "r212", "r220" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts.", "label": "Revenue from Contract with Customer [Text Block]", "terseLabel": "Revenue Recognition" } } }, "localname": "RevenueFromContractWithCustomerTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.iradimed.com/role/DisclosureRevenueRecognition" ], "xbrltype": "textBlockItemType" }, "us-gaap_Revenues": { "auth_ref": [ "r60", "r86", "r123", "r124", "r128", "r133", "r134", "r138", "r139", "r142", "r155", "r295", "r377" ], "calculation": { "http://www.iradimed.com/role/StatementCondensedStatementsOfOperations": { "order": 1.0, "parentTag": "us-gaap_GrossProfit", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).", "label": "Revenues", "terseLabel": "Revenue" } } }, "localname": "Revenues", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.iradimed.com/role/StatementCondensedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability": { "auth_ref": [ "r313", "r316" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase in right-of-use asset obtained in exchange for operating lease liability.", "label": "Right-of-Use Asset Obtained in Exchange for Operating Lease Liability", "terseLabel": "Right-of-use asset recognized in exchange for a new lease obligation" } } }, "localname": "RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.iradimed.com/role/StatementCondensedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock": { "auth_ref": [ "r49", "r302", "r303" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the components of accumulated other comprehensive income (loss).", "label": "Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block]", "verboseLabel": "Schedule of components of accumulated other comprehensive loss, net of tax" } } }, "localname": "ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.iradimed.com/role/DisclosureAccumulatedOtherComprehensiveIncomeLossTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": { "auth_ref": [ "r113" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.", "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]", "verboseLabel": "Schedule of stock options and restricted stock units excluded from the calculation of diluted net income per share" } } }, "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.iradimed.com/role/DisclosureBasicAndDilutedNetIncomePerShareTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": { "auth_ref": [ "r112" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.", "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]", "terseLabel": "Schedule of computation of basic and diluted net income per share" } } }, "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.iradimed.com/role/DisclosureBasicAndDilutedNetIncomePerShareTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable": { "auth_ref": [ "r232", "r242", "r251" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about amount recognized for award under share-based payment arrangement. Includes, but is not limited to, amount expensed in statement of income or comprehensive income, amount capitalized in statement of financial position, and corresponding reporting line item in financial statements.", "label": "Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table]" } } }, "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.iradimed.com/role/DisclosureStockBasedCompensationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": { "auth_ref": [ "r232", "r242", "r251" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.", "label": "Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table Text Block]", "terseLabel": "Schedule of stock-based compensation" } } }, "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.iradimed.com/role/DisclosureStockBasedCompensationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock": { "auth_ref": [ "r287", "r288" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).", "label": "Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]", "terseLabel": "Schedule of the fair value of assets and liabilities subject to recurring fair value measurements" } } }, "localname": "ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.iradimed.com/role/DisclosureFairValueMeasurementsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable": { "auth_ref": [ "r176", "r178", "r353" ], "lang": { "en-us": { "role": { "documentation": "Schedule of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.", "label": "Schedule of Finite-Lived Intangible Assets [Table]" } } }, "localname": "ScheduleOfFiniteLivedIntangibleAssetsTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.iradimed.com/role/DisclosureIntangibleAssetsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock": { "auth_ref": [ "r176", "r178" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance with a finite life, by either major class or business segment.", "label": "Schedule of Finite-Lived Intangible Assets [Table Text Block]", "terseLabel": "Summary of the components of intangible asset balances" } } }, "localname": "ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.iradimed.com/role/DisclosureIntangibleAssetsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfInventoryCurrentTableTextBlock": { "auth_ref": [ "r12", "r25", "r26", "r27" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.", "label": "Schedule of Inventory, Current [Table Text Block]", "terseLabel": "Schedule of inventory" } } }, "localname": "ScheduleOfInventoryCurrentTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.iradimed.com/role/DisclosureInventoryTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": { "auth_ref": [ "r32", "r187" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.", "label": "Property, Plant and Equipment [Table]" } } }, "localname": "ScheduleOfPropertyPlantAndEquipmentTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.iradimed.com/role/DisclosurePropertyAndEquipmentDetails", "http://www.iradimed.com/role/DisclosurePropertyAndEquipmentGeographicInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable": { "auth_ref": [ "r88", "r320", "r321" ], "lang": { "en-us": { "role": { "documentation": "Schedule of quantitative and qualitative information pertaining to related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.", "label": "Schedule of Related Party Transactions, by Related Party [Table]" } } }, "localname": "ScheduleOfRelatedPartyTransactionsByRelatedPartyTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.iradimed.com/role/DisclosureCommitmentsAndContingenciesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock": { "auth_ref": [ "r238", "r239", "r240" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of activity for award under share-based payment arrangement. Includes, but is not limited to, outstanding award at beginning and end of year, granted, exercised, forfeited, and weighted-average grant date fair value.", "label": "Schedule of Share-based Compensation, Activity [Table Text Block]", "terseLabel": "Summary of stock options and restricted stock units activity" } } }, "localname": "ScheduleOfShareBasedCompensationActivityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.iradimed.com/role/DisclosureStockBasedCompensationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": { "auth_ref": [ "r233", "r245" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about share-based payment arrangement.", "label": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]" } } }, "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.iradimed.com/role/DisclosureStockBasedCompensationStockOptionsAndRestrictedStockUnitsActivityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock": { "auth_ref": [ "r178" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the amount of amortization expense expected to be recorded in succeeding fiscal years for finite-lived intangible assets.", "label": "Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block]", "terseLabel": "Schedule of expected annual amortization expense related to intangible assets (excludes in process intangible assets)" } } }, "localname": "ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.iradimed.com/role/DisclosureIntangibleAssetsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_SellingAndMarketingExpense": { "auth_ref": [], "calculation": { "http://www.iradimed.com/role/StatementCondensedStatementsOfOperations": { "order": 2.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate total amount of expenses directly related to the marketing or selling of products or services.", "label": "Selling and Marketing Expense", "terseLabel": "Sales and marketing" } } }, "localname": "SellingAndMarketingExpense", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.iradimed.com/role/StatementCondensedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_SellingAndMarketingExpenseMember": { "auth_ref": [ "r66" ], "lang": { "en-us": { "role": { "documentation": "Primary financial statement caption encompassing selling and marketing expense.", "label": "Selling And Marketing Expense [Member]", "terseLabel": "Sales and marketing" } } }, "localname": "SellingAndMarketingExpenseMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.iradimed.com/role/DisclosureLeasesOperatingLeaseCostDetails", "http://www.iradimed.com/role/DisclosureStockBasedCompensationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ShareBasedCompensation": { "auth_ref": [ "r80" ], "calculation": { "http://www.iradimed.com/role/StatementCondensedStatementsOfCashFlows": { "order": 5.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of noncash expense for share-based payment arrangement.", "label": "Share-based Compensation", "terseLabel": "Stock-based compensation" } } }, "localname": "ShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.iradimed.com/role/StatementCondensedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]", "terseLabel": "Stock-Based Compensation" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.iradimed.com/role/DisclosureStockBasedCompensationStockOptionsAndRestrictedStockUnitsActivityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": { "auth_ref": [ "r237" ], "lang": { "en-us": { "role": { "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period", "negatedLabel": "Options cancelled (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.iradimed.com/role/DisclosureStockBasedCompensationStockOptionsAndRestrictedStockUnitsActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Gross number of share options (or share units) granted during the period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross", "terseLabel": "Options granted (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.iradimed.com/role/DisclosureStockBasedCompensationStockOptionsAndRestrictedStockUnitsActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": { "auth_ref": [ "r235", "r245" ], "lang": { "en-us": { "role": { "documentation": "Number of options outstanding, including both vested and non-vested options.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number", "periodEndLabel": "Outstanding end of period (in shares)", "periodStartLabel": "Outstanding beginning of period (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.iradimed.com/role/DisclosureStockBasedCompensationStockOptionsAndRestrictedStockUnitsActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]", "terseLabel": "Stock Options" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.iradimed.com/role/DisclosureStockBasedCompensationStockOptionsAndRestrictedStockUnitsActivityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": { "auth_ref": [ "r231", "r234" ], "lang": { "en-us": { "role": { "documentation": "Award under share-based payment arrangement.", "label": "Share Based Compensation Arrangements By Share Based Payment Award Award Type And Plan Name [Domain]", "terseLabel": "Equity Award [Domain]" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.iradimed.com/role/DisclosureStockBasedCompensationStockOptionsAndRestrictedStockUnitsActivityDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of shares issued which are neither cancelled nor held in the treasury.", "label": "Shares, Outstanding", "periodEndLabel": "Balance (in shares)", "periodStartLabel": "Balance (in shares)" } } }, "localname": "SharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.iradimed.com/role/StatementCondensedStatementsOfStockholdersEquity" ], "xbrltype": "sharesItemType" }, "us-gaap_StatementEquityComponentsAxis": { "auth_ref": [ "r38", "r90", "r91", "r92", "r94", "r100", "r102", "r119", "r156", "r197", "r198", "r247", "r248", "r249", "r264", "r265", "r297", "r298", "r299", "r300", "r301", "r303", "r395", "r396", "r397" ], "lang": { "en-us": { "role": { "documentation": "Information by component of equity.", "label": "Equity Components [Axis]" } } }, "localname": "StatementEquityComponentsAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.iradimed.com/role/StatementCondensedStatementsOfStockholdersEquity" ], "xbrltype": "stringItemType" }, "us-gaap_StatementLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Statement [Line Items]", "verboseLabel": "Statement" } } }, "localname": "StatementLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.iradimed.com/role/StatementCondensedStatementsOfStockholdersEquity" ], "xbrltype": "stringItemType" }, "us-gaap_StatementOfCashFlowsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "CONDENSED STATEMENTS OF CASH FLOWS" } } }, "localname": "StatementOfCashFlowsAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementOfFinancialPositionAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "CONDENSED BALANCE SHEETS" } } }, "localname": "StatementOfFinancialPositionAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "CONDENSED STATEMENTS OF COMPREHENSIVE INCOME" } } }, "localname": "StatementOfIncomeAndComprehensiveIncomeAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementOfStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "CONDENSED STATEMENTS OF STOCKHOLDERS' EQUITY" } } }, "localname": "StatementOfStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementTable": { "auth_ref": [ "r90", "r91", "r92", "r119", "r352" ], "lang": { "en-us": { "role": { "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.", "label": "Statement [Table]" } } }, "localname": "StatementTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.iradimed.com/role/StatementCondensedStatementsOfStockholdersEquity" ], "xbrltype": "stringItemType" }, "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": { "auth_ref": [ "r15", "r16", "r197", "r198", "r236" ], "lang": { "en-us": { "role": { "documentation": "Number of share options (or share units) exercised during the current period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period", "negatedLabel": "Options exercised (in shares)", "verboseLabel": "Exercise of stock options (in Shares)" } } }, "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.iradimed.com/role/DisclosureStockBasedCompensationStockOptionsAndRestrictedStockUnitsActivityDetails", "http://www.iradimed.com/role/StatementCondensedStatementsOfStockholdersEquity" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": { "auth_ref": [ "r38", "r197", "r198" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value of stock issued as a result of the exercise of stock options.", "label": "Stock Issued During Period, Value, Stock Options Exercised", "terseLabel": "Exercise of stock options" } } }, "localname": "StockIssuedDuringPeriodValueStockOptionsExercised", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.iradimed.com/role/StatementCondensedStatementsOfStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquity": { "auth_ref": [ "r16", "r21", "r22", "r86", "r146", "r155", "r295" ], "calculation": { "http://www.iradimed.com/role/StatementCondensedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.", "label": "Stockholders' Equity Attributable to Parent", "periodEndLabel": "Balances", "periodStartLabel": "Balances", "totalLabel": "Total stockholders' equity" } } }, "localname": "StockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.iradimed.com/role/StatementCondensedBalanceSheets", "http://www.iradimed.com/role/StatementCondensedStatementsOfStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Stockholders' Equity Attributable to Parent [Abstract]", "terseLabel": "Stockholders' equity:" } } }, "localname": "StockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.iradimed.com/role/StatementCondensedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_SupplementalCashFlowInformationAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Supplemental Cash Flow Information [Abstract]", "terseLabel": "Supplemental disclosure of cash flow information:" } } }, "localname": "SupplementalCashFlowInformationAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.iradimed.com/role/StatementCondensedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_TrademarksMember": { "auth_ref": [ "r273" ], "lang": { "en-us": { "role": { "documentation": "Rights acquired through registration of a trademark to gain or protect exclusive use of a business name, symbol or other device or style.", "label": "Trademarks [Member]", "terseLabel": "Trademarks" } } }, "localname": "TrademarksMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.iradimed.com/role/DisclosureIntangibleAssetsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_TradingSecuritiesDebtAmortizedCost": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amortized cost of investments in debt securities classified as trading.", "label": "Debt Securities, Trading, Amortized Cost", "terseLabel": "Cost" } } }, "localname": "TradingSecuritiesDebtAmortizedCost", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.iradimed.com/role/DisclosureInvestmentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": { "auth_ref": [ "r150", "r151", "r322", "r323", "r324", "r325", "r326", "r327", "r328", "r329", "r330", "r331", "r332", "r333", "r334", "r335", "r336", "r337", "r338", "r339", "r340", "r341", "r342", "r343", "r344", "r345", "r346", "r347", "r348", "r349", "r350", "r351" ], "lang": { "en-us": { "role": { "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms.", "label": "Transfers And Servicing Of Financial Instruments Types Of Financial Instruments [Domain]", "terseLabel": "Major Types of Debt and Equity Securities [Domain] (Deprecated 2018-01-31)" } } }, "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.iradimed.com/role/DisclosureFairValueMeasurementsDetails", "http://www.iradimed.com/role/DisclosureInvestmentsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Incremental Weighted Average Shares Attributable to Dilutive Effect [Abstract]", "terseLabel": "Effect of dilutive securities:" } } }, "localname": "WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.iradimed.com/role/DisclosureBasicAndDilutedNetIncomePerShareDetails" ], "xbrltype": "stringItemType" }, "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": { "auth_ref": [ "r104", "r112" ], "calculation": { "http://www.iradimed.com/role/DisclosureBasicAndDilutedNetIncomePerShareDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "lang": { "en-us": { "role": { "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.", "label": "Weighted Average Number of Shares Outstanding, Diluted", "totalLabel": "Weighted-average shares outstanding - Diluted (in shares)", "verboseLabel": "Diluted (in shares)" } } }, "localname": "WeightedAverageNumberOfDilutedSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.iradimed.com/role/DisclosureBasicAndDilutedNetIncomePerShareDetails", "http://www.iradimed.com/role/StatementCondensedStatementsOfOperations" ], "xbrltype": "sharesItemType" }, "us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Weighted Average Number of Shares Outstanding, Diluted [Abstract]", "terseLabel": "Weighted average shares outstanding:" } } }, "localname": "WeightedAverageNumberOfSharesOutstandingAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.iradimed.com/role/StatementCondensedStatementsOfOperations" ], "xbrltype": "stringItemType" }, "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": { "auth_ref": [ "r103", "r112" ], "calculation": { "http://www.iradimed.com/role/DisclosureBasicAndDilutedNetIncomePerShareDetails": { "order": 1.0, "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.", "label": "Weighted Average Number of Shares Outstanding, Basic", "terseLabel": "Weighted-average shares outstanding - Basic (in shares)", "verboseLabel": "Basic (in shares)" } } }, "localname": "WeightedAverageNumberOfSharesOutstandingBasic", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.iradimed.com/role/DisclosureBasicAndDilutedNetIncomePerShareDetails", "http://www.iradimed.com/role/StatementCondensedStatementsOfOperations" ], "xbrltype": "sharesItemType" } }, "unitCount": 6 } }, "std_ref": { "r0": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760" }, "r1": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "205", "URI": "http://asc.fasb.org/topic&trid=2122149" }, "r10": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6911-107765" }, "r100": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22644-107794" }, "r101": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22658-107794" }, "r102": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22663-107794" }, "r103": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1448-109256" }, "r104": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1505-109256" }, "r105": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1252-109256" }, "r106": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1707-109256" }, "r107": { "Name": "Accounting Standards Codification", "Paragraph": "23", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1757-109256" }, "r108": { "Name": "Accounting Standards Codification", "Paragraph": "28A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1500-109256" }, "r109": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=SL5780133-109256" }, "r11": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6935-107765" }, "r110": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=SL5780133-109256" }, "r111": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1337-109256" }, "r112": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257" }, "r113": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257" }, "r114": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3630-109257" }, "r115": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=109243012&loc=SL65017193-207537" }, "r116": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=120380238&loc=d3e3842-109258" }, "r117": { "Name": "Accounting Standards Codification", "Paragraph": "52", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=120380238&loc=d3e4984-109258" }, "r118": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "260", "URI": "http://asc.fasb.org/topic&trid=2144383" }, "r119": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "272", "URI": "http://asc.fasb.org/extlink&oid=6828210&loc=d3e70191-108054" }, "r12": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6361739&loc=d3e7789-107766" }, "r120": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592" }, "r121": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "275", "URI": "http://asc.fasb.org/topic&trid=2134479" }, "r122": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8672-108599" }, "r123": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599" }, "r124": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599" }, "r125": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599" }, "r126": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599" }, "r127": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599" }, "r128": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599" }, "r129": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599" }, "r13": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(13))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r130": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599" }, "r131": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599" }, "r132": { "Name": "Accounting Standards Codification", "Paragraph": "31", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8924-108599" }, "r133": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599" }, "r134": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599" }, "r135": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599" }, "r136": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599" }, "r137": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599" }, "r138": { "Name": "Accounting Standards Codification", "Paragraph": "40", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e9031-108599" }, "r139": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e9038-108599" }, "r14": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(14))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r140": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e9038-108599" }, "r141": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "b", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e9038-108599" }, "r142": { "Name": "Accounting Standards Codification", "Paragraph": "42", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e9054-108599" }, "r143": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=121593590&loc=d3e4428-111522" }, "r144": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=121593590&loc=d3e4531-111522" }, "r145": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=121611835&loc=d3e5074-111524" }, "r146": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 4.E)", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=27010918&loc=d3e74512-122707" }, "r147": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=121553693&loc=d3e26610-111562" }, "r148": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=SL6283291-111563" }, "r149": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(aa)", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27161-111563" }, "r15": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(28))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r150": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27232-111563" }, "r151": { "Name": "Accounting Standards Codification", "Paragraph": "5A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=SL120269820-111563" }, "r152": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27357-111563" }, "r153": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27357-111563" }, "r154": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "320", "URI": "http://asc.fasb.org/topic&trid=2196928" }, "r155": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "323", "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571" }, "r156": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=121646688&loc=SL121648383-210437" }, "r157": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=121599878&loc=SL82895884-210446" }, "r158": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=121599337&loc=SL82919244-210447" }, "r159": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=121599337&loc=SL82919249-210447" }, "r16": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(29))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r160": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=121599337&loc=SL82919249-210447" }, "r161": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=121599337&loc=SL82919253-210447" }, "r162": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=121599337&loc=SL82919258-210447" }, "r163": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=121599337&loc=SL82919230-210447" }, "r164": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=121558606&loc=SL82898722-210454" }, "r165": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=121582814&loc=SL82922888-210455" }, "r166": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=121582814&loc=SL82922895-210455" }, "r167": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=121582814&loc=SL82922900-210455" }, "r168": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "30", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=121590138&loc=SL82922954-210456" }, "r169": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "330", "URI": "http://asc.fasb.org/extlink&oid=116847112&loc=d3e4492-108314" }, "r17": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(3))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r170": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "330", "URI": "http://asc.fasb.org/extlink&oid=116847112&loc=d3e4542-108314" }, "r171": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "330", "URI": "http://asc.fasb.org/topic&trid=2126998" }, "r172": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "05", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "340", "URI": "http://asc.fasb.org/extlink&oid=68074540&loc=d3e5879-108316" }, "r173": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "340", "URI": "http://asc.fasb.org/extlink&oid=6387103&loc=d3e6435-108320" }, "r174": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Subparagraph": "(a)", "Topic": "340", "URI": "http://asc.fasb.org/extlink&oid=68051541&loc=SL49131252-203054" }, "r175": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=6388964&loc=d3e16225-109274" }, "r176": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275" }, "r177": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275" }, "r178": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r179": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(1)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r18": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(1))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r180": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(2)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r181": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(3)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r182": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r183": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "350", "URI": "http://asc.fasb.org/topic&trid=2144416" }, "r184": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r185": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r186": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r187": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r188": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230" }, "r189": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "360", "URI": "http://asc.fasb.org/topic&trid=2155823" }, "r19": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(3))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r190": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "440", "URI": "http://asc.fasb.org/extlink&oid=121559207&loc=d3e25336-109308" }, "r191": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "440", "URI": "http://asc.fasb.org/extlink&oid=121559207&loc=d3e25336-109308" }, "r192": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "440", "URI": "http://asc.fasb.org/topic&trid=2144648" }, "r193": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "450", "URI": "http://asc.fasb.org/topic&trid=2127136" }, "r194": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "25", "SubTopic": "10", "Topic": "460", "URI": "http://asc.fasb.org/extlink&oid=68070138&loc=d3e11281-110244" }, "r195": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "460", "URI": "http://asc.fasb.org/extlink&oid=68068213&loc=d3e12524-110249" }, "r196": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1),(c)(5)", "Topic": "460", "URI": "http://asc.fasb.org/extlink&oid=68068213&loc=d3e12565-110249" }, "r197": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21463-112644" }, "r198": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.3-04)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770" }, "r199": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121556615&loc=SL49130531-203044" }, "r2": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765" }, "r20": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(4))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r200": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121556615&loc=SL49130532-203044" }, "r201": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130551-203045" }, "r202": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130554-203045" }, "r203": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130554-203045" }, "r204": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130554-203045" }, "r205": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130554-203045" }, "r206": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130554-203045" }, "r207": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(2)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130556-203045" }, "r208": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130558-203045" }, "r209": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130543-203045" }, "r21": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r210": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130545-203045" }, "r211": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130549-203045" }, "r212": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130550-203045" }, "r213": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121551570&loc=SL49130690-203046-203046" }, "r214": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121551570&loc=SL49130690-203046-203046" }, "r215": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121551570&loc=SL49130690-203046-203046" }, "r216": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121551570&loc=SL49130690-203046-203046" }, "r217": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121551570&loc=SL49130690-203046-203046" }, "r218": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121551570&loc=SL49130690-203046-203046" }, "r219": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121551570&loc=SL49130690-203046-203046" }, "r22": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(31))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r220": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "606", "URI": "http://asc.fasb.org/topic&trid=49130388" }, "r221": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(ii)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r222": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(01)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r223": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r224": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(A)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r225": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(B)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r226": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(C)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r227": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(03)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r228": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(n)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r229": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118257860&loc=d3e4179-114921" }, "r23": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(32))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r230": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "35", "SubTopic": "10", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121326096&loc=d3e4534-113899" }, "r231": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901" }, "r232": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901" }, "r233": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901" }, "r234": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a),(g)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r235": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(i)-(ii)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r236": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r237": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(3)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r238": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r239": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r24": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(4)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r240": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r241": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r242": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r243": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(1)(i)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r244": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(i)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r245": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r246": { "Name": "Accounting Standards Codification", "Paragraph": "2A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=SL79508275-113901" }, "r247": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r248": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r249": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r25": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(a))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r250": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(g)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r251": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 14.F)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=115993241&loc=d3e301413-122809" }, "r252": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120383193&loc=d3e11149-113907" }, "r253": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120383193&loc=d3e11178-113907" }, "r254": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "718", "URI": "http://asc.fasb.org/topic&trid=2228938" }, "r255": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "720", "URI": "http://asc.fasb.org/extlink&oid=6419918&loc=d3e35281-107843" }, "r256": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "730", "URI": "http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373" }, "r257": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=120406818&loc=d3e31917-109318" }, "r258": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=120406818&loc=d3e31931-109318" }, "r259": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32672-109319" }, "r26": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(b))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r260": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32687-109319" }, "r261": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32705-109319" }, "r262": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32809-109319" }, "r263": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32857-109319" }, "r264": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(2)", "Topic": "740" }, "r265": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(3)", "Topic": "740" }, "r266": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 6.I.5.Q1)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817" }, "r267": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 6.I.7)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817" }, "r268": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.C)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330215-122817" }, "r269": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=120385591&loc=d3e38679-109324" }, "r27": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(c))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r270": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "270", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338" }, "r271": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331" }, "r272": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "740", "URI": "http://asc.fasb.org/topic&trid=2144680" }, "r273": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=121598580&loc=d3e5263-128473" }, "r274": { "Name": "Accounting Standards Codification", "Paragraph": "19", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4569616-111683" }, "r275": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4569643-111683" }, "r276": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988" }, "r277": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988" }, "r278": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684" }, "r279": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684" }, "r28": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(7))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r280": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(3)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684" }, "r281": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c),(3)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684" }, "r282": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bb)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=121559654&loc=d3e5710-111685" }, "r283": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=121559654&loc=d3e5710-111685" }, "r284": { "Name": "Accounting Standards Codification", "Paragraph": "4J", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=120409616&loc=SL4591551-111686" }, "r285": { "Name": "Accounting Standards Codification", "Paragraph": "4K", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=120409616&loc=SL4591552-111686" }, "r286": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "810", "URI": "http://asc.fasb.org/topic&trid=2197479" }, "r287": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258" }, "r288": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258" }, "r289": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bb)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258" }, "r29": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(8))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r290": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bbb)(1)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258" }, "r291": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bbb)(2)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258" }, "r292": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258" }, "r293": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19279-110258" }, "r294": { "Name": "Accounting Standards Codification", "Paragraph": "6A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=SL6742756-110258" }, "r295": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=75031198&loc=d3e14064-108612" }, "r296": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "230", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=98513438&loc=d3e33268-110906" }, "r297": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900" }, "r298": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r299": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r3": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765" }, "r30": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.1)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r300": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(c)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r301": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r302": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r303": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901" }, "r304": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=121603541&loc=SL77918627-209977" }, "r305": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=121603541&loc=SL77918627-209977" }, "r306": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=121603541&loc=SL77918643-209977" }, "r307": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(1)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918673-209980" }, "r308": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(3)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918673-209980" }, "r309": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(4)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918673-209980" }, "r31": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.13)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r310": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918673-209980" }, "r311": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980" }, "r312": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(1)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980" }, "r313": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(2)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980" }, "r314": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980" }, "r315": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918701-209980" }, "r316": { "Name": "Accounting Standards Codification", "Paragraph": "53", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=121568110&loc=SL77918982-209971" }, "r317": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "SubTopic": "20", "Topic": "842", "URI": "http://asc.fasb.org/subtopic&trid=77888251" }, "r318": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r319": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r32": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.14)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r320": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r321": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864" }, "r322": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)(i)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r323": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)(ii)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r324": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r325": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r326": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r327": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r328": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r329": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r33": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.17)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r330": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r331": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r332": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r333": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r334": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r335": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=66007379&loc=d3e113888-111728" }, "r336": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=109249958&loc=SL34722452-111729" }, "r337": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122625-111746" }, "r338": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122625-111746" }, "r339": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122625-111746" }, "r34": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19(a))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r340": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(4)(i)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122625-111746" }, "r341": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746" }, "r342": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746" }, "r343": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746" }, "r344": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(4)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746" }, "r345": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(5)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746" }, "r346": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(6)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746" }, "r347": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(7)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746" }, "r348": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(b)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746" }, "r349": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(e)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746" }, "r35": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19-26)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r350": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(e)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746" }, "r351": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(e)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746" }, "r352": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.L)", "Topic": "924", "URI": "http://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856" }, "r353": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "926", "URI": "http://asc.fasb.org/extlink&oid=120154696&loc=d3e54445-107959" }, "r354": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "340", "Topic": "928", "URI": "http://asc.fasb.org/extlink&oid=6473545&loc=d3e61844-108004" }, "r355": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e61929-109447" }, "r356": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e61929-109447" }, "r357": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62059-109447" }, "r358": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62059-109447" }, "r359": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62395-109447" }, "r36": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.20)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r360": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62395-109447" }, "r361": { "Name": "Accounting Standards Codification", "Paragraph": "33", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62479-109447" }, "r362": { "Name": "Accounting Standards Codification", "Paragraph": "33", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62479-109447" }, "r363": { "Name": "Accounting Standards Codification", "Paragraph": "35A", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=SL6807758-109447" }, "r364": { "Name": "Accounting Standards Codification", "Paragraph": "35A", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=SL6807758-109447" }, "r365": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(c)(1)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e61872-109447" }, "r366": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(c)(2)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e61872-109447" }, "r367": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "25", "SubTopic": "20", "Topic": "940", "URI": "http://asc.fasb.org/extlink&oid=68072869&loc=d3e41242-110953" }, "r368": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "SubTopic": "320", "Topic": "940", "URI": "http://asc.fasb.org/subtopic&trid=2176304" }, "r369": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(11))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r37": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.21)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r370": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(23))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r371": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(6))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r372": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(15))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r373": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(22))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r374": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(23))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r375": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(26))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r376": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(27))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r377": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "235", "Subparagraph": "(SX 210.9-05(b)(2))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884" }, "r378": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "SubTopic": "320", "Topic": "942", "URI": "http://asc.fasb.org/subtopic&trid=2209399" }, "r379": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "825", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=108315417&loc=d3e61044-112788" }, "r38": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29-31)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r380": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(12))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r381": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r382": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r383": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(25))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r384": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(8))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r385": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(18))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r386": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(19))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r387": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(22))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r388": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(23))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r389": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(8))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r39": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.6(a)(1))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r390": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(9))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r391": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04.3(a))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r392": { "Name": "Accounting Standards Codification", "Paragraph": "4H", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=116884468&loc=SL65671331-158438" }, "r393": { "Name": "Accounting Standards Codification", "Paragraph": "13H", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Subparagraph": "(a)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121639165&loc=SL117783719-158441" }, "r394": { "Name": "Accounting Standards Codification", "Paragraph": "13H", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Subparagraph": "(b)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121639165&loc=SL117783719-158441" }, "r395": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641" }, "r396": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(1)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641" }, "r397": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(2)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641" }, "r398": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(i)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641" }, "r399": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(ii)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641" }, "r4": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765" }, "r40": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.6(a)(3))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r400": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(h)(2)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641" }, "r401": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12)", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611133-123010" }, "r402": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B)", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611197-123010" }, "r403": { "Name": "Accounting Standards Codification", "Paragraph": "5D", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-13D)", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=SL120429264-123010" }, "r404": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-14)", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611322-123010" }, "r405": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "SubTopic": "320", "Topic": "946", "URI": "http://asc.fasb.org/subtopic&trid=2324412" }, "r406": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "310", "Subparagraph": "(SX 210.12-29(Footnote 4))", "Topic": "948", "URI": "http://asc.fasb.org/extlink&oid=120402547&loc=d3e617274-123014" }, "r407": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Subparagraph": "(d)", "Topic": "958", "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=d3e99779-112916" }, "r408": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Topic": "958", "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=d3e99893-112916" }, "r409": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Topic": "958", "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=SL120174063-112916" }, "r41": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.6(a)(4))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r410": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column B))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r411": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column C))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r412": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column D))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r413": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column E))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r414": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column F))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r415": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column G))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r416": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column H))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r417": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column I))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r418": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Footnote 2))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r419": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "985", "URI": "http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756" }, "r42": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.6(a))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r420": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r421": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r422": { "Name": "Form 10-Q", "Number": "240", "Publisher": "SEC", "Section": "308", "Subsection": "a" }, "r423": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1" }, "r424": { "Name": "Regulation 12B", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r425": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405" }, "r43": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.6(b))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r44": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.9)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r45": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669646-108580" }, "r46": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=d3e637-108580" }, "r47": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=d3e640-108580" }, "r48": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=d3e681-108580" }, "r49": { "Name": "Accounting Standards Codification", "Paragraph": "14A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669686-108580" }, "r5": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(g)(4)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765" }, "r50": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=d3e689-108580" }, "r51": { "Name": "Accounting Standards Codification", "Paragraph": "17A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL34724391-108580" }, "r52": { "Name": "Accounting Standards Codification", "Paragraph": "17B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL34724394-108580" }, "r53": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669619-108580" }, "r54": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669619-108580" }, "r55": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669619-108580" }, "r56": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669625-108580" }, "r57": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669625-108580" }, "r58": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=d3e557-108580" }, "r59": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121640130&loc=d3e1436-108581" }, "r6": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765" }, "r60": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(1))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227" }, "r61": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(10))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227" }, "r62": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(20))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227" }, "r63": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(21))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227" }, "r64": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(24))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227" }, "r65": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(25))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227" }, "r66": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(4))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227" }, "r67": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(5))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227" }, "r68": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.1,2)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227" }, "r69": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.2)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227" }, "r7": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6787-107765" }, "r70": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.4)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227" }, "r71": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.7)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227" }, "r72": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "220", "URI": "http://asc.fasb.org/topic&trid=2134417" }, "r73": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3179-108585" }, "r74": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3213-108585" }, "r75": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3255-108585" }, "r76": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3291-108585" }, "r77": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3000-108585" }, "r78": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3521-108585" }, "r79": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3536-108585" }, "r8": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6801-107765" }, "r80": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585" }, "r81": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585" }, "r82": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585" }, "r83": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3044-108585" }, "r84": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121583591&loc=d3e4297-108586" }, "r85": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121583591&loc=SL98516268-108586" }, "r86": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r87": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(h))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r88": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(k))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r89": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "235", "URI": "http://asc.fasb.org/topic&trid=2122369" }, "r9": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6904-107765" }, "r90": { "Name": "Accounting Standards Codification", "Paragraph": "23", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=115929471&loc=d3e21914-107793" }, "r91": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=115929471&loc=d3e21930-107793" }, "r92": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=115929471&loc=d3e21711-107793" }, "r93": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(2)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794" }, "r94": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(3)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794" }, "r95": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794" }, "r96": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794" }, "r97": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22583-107794" }, "r98": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22595-107794" }, "r99": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22644-107794" } }, "version": "2.1" } ZIP 70 0001104659-21-101081-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001104659-21-101081-xbrl.zip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�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end